{"6ca62443152264ac3bc401ba0f92dd3748367e8d": [["Although the CNS lacks lymphatics, displays low levels of major histocompatibility complex (MHC) molecules and is uniquely shielded from free diffusion of molecular and cellular components by the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier, the immune response in the brain can be impressive if not spectacular, as is the case in meningitis.", [["CNS", "ANATOMY", 13, 16], ["lymphatics", "ANATOMY", 23, 33], ["cellular", "ANATOMY", 169, 177], ["blood-brain barrier", "ANATOMY", 196, 215], ["BBB", "ANATOMY", 217, 220], ["blood", "ANATOMY", 230, 235], ["cerebrospinal fluid", "ANATOMY", 236, 255], ["brain", "ANATOMY", 298, 303], ["meningitis", "DISEASE", 360, 370], ["CNS", "ANATOMICAL_SYSTEM", 13, 16], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 23, 33], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 58, 90], ["cellular", "CELL", 169, 177], ["blood", "MULTI-TISSUE_STRUCTURE", 196, 201], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 202, 215], ["BBB", "MULTI-TISSUE_STRUCTURE", 217, 220], ["blood", "ORGANISM_SUBSTANCE", 230, 235], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 236, 255], ["CSF", "ORGANISM_SUBSTANCE", 257, 260], ["brain", "ORGAN", 298, 303], ["major histocompatibility complex (MHC) molecules", "PROTEIN", 58, 106], ["the blood", "TEST", 192, 201], ["the blood-cerebrospinal fluid (CSF) barrier", "TEST", 226, 269], ["the immune response", "TEST", 271, 290], ["meningitis", "PROBLEM", 360, 370], ["CNS", "ANATOMY", 13, 16], ["lymphatics", "ANATOMY", 23, 33], ["low levels", "OBSERVATION_MODIFIER", 44, 54], ["cellular components", "OBSERVATION", 169, 188], ["brain", "ANATOMY", 202, 207], ["blood", "ANATOMY", 230, 235], ["cerebrospinal", "ANATOMY", 236, 249], ["fluid", "OBSERVATION", 250, 255], ["brain", "ANATOMY", 298, 303], ["meningitis", "OBSERVATION", 360, 370]]], ["By contrast, loss of immunity is often highlighted by cerebral infections.", [["cerebral", "ANATOMY", 54, 62], ["loss of immunity", "DISEASE", 13, 29], ["cerebral infections", "DISEASE", 54, 73], ["cerebral", "ORGAN", 54, 62], ["loss of immunity", "PROBLEM", 13, 29], ["cerebral infections", "PROBLEM", 54, 73], ["cerebral", "ANATOMY", 54, 62], ["infections", "OBSERVATION", 63, 73]]], ["To protect this vital system, the healthy brain and spinal cord are under continual immune surveillance to detect and eliminate potential mediators of infection and damage.", [["brain", "ANATOMY", 42, 47], ["spinal cord", "ANATOMY", 52, 63], ["infection", "DISEASE", 151, 160], ["brain", "ORGAN", 42, 47], ["spinal cord", "ORGAN", 52, 63], ["this vital system", "TEST", 11, 28], ["the healthy brain and spinal cord", "PROBLEM", 30, 63], ["continual immune surveillance", "TEST", 74, 103], ["infection", "PROBLEM", 151, 160], ["damage", "PROBLEM", 165, 171], ["brain", "ANATOMY", 42, 47], ["spinal cord", "ANATOMY", 52, 63], ["infection", "OBSERVATION", 151, 160]]], ["Both resident microglia and immune cells from the general circulation function as primary guardians of the CNS, and their sentinel duties contribute to the maintenance of homeostasis and thus optimal functioning of the brain and spinal cord.", [["microglia", "ANATOMY", 14, 23], ["immune cells", "ANATOMY", 28, 40], ["CNS", "ANATOMY", 107, 110], ["brain", "ANATOMY", 219, 224], ["spinal cord", "ANATOMY", 229, 240], ["microglia", "CELL", 14, 23], ["immune cells", "CELL", 28, 40], ["CNS", "ANATOMICAL_SYSTEM", 107, 110], ["brain", "ORGAN", 219, 224], ["spinal cord", "ORGAN", 229, 240], ["resident microglia", "CELL_TYPE", 5, 23], ["immune cells", "CELL_TYPE", 28, 40], ["immune cells", "OBSERVATION", 28, 40], ["CNS", "ANATOMY", 107, 110], ["brain", "ANATOMY", 219, 224], ["spinal cord", "ANATOMY", 229, 240]]]], "9954a2f76ec85f5990c8693e8aa8feb24ee21175": [["subsistence consumers rely on their families and extended social networks when deciding to trust and adopt new targeted innovations (Chikweche & Fletcher, 2009; Hasan et al., 2019; Viswanathan & Sreekumar, 2019) , indicating that subjective norms can influence how they engage with such technologies (Agarwal et al., 2020; .", [["social networks", "MULTI-TISSUE_STRUCTURE", 58, 73]]]], "b313b3a2d9c3fab1e226effee6f849f09c529e36": [["Available online at www.sciencedirect.comLucas C Reineke and Richard E LloydViruses have adapted a broad range of unique mechanisms to modulate the cellular translational machinery to ensure viral translation at the expense of cellular protein synthesis.", [["cellular", "ANATOMY", 148, 156], ["cellular", "ANATOMY", 227, 235], ["cellular", "CELL", 148, 156], ["cellular", "CELL", 227, 235], ["Richard E LloydViruses", "TREATMENT", 61, 83], ["viral translation", "PROBLEM", 191, 208], ["cellular protein synthesis", "PROBLEM", 227, 253], ["viral translation", "OBSERVATION", 191, 208], ["cellular protein synthesis", "OBSERVATION", 227, 253]]], ["Many of these promote virus-specific translation by use of molecular tags on viral mRNA such as internal ribosome entry sites (IRES) and genome-linked viral proteins (VPg) that bind translation machinery components in unusual ways and promote RNA circularization.", [["genome-linked viral proteins", "GENE_OR_GENE_PRODUCT", 137, 165], ["VPg", "GENE_OR_GENE_PRODUCT", 167, 170], ["viral mRNA", "RNA", 77, 87], ["internal ribosome entry sites", "DNA", 96, 125], ["IRES", "DNA", 127, 131], ["viral proteins", "PROTEIN", 151, 165], ["VPg", "PROTEIN", 167, 170], ["these promote virus", "PROBLEM", 8, 27], ["molecular tags", "PROBLEM", 59, 73], ["viral mRNA", "TREATMENT", 77, 87], ["internal ribosome entry sites", "TREATMENT", 96, 125], ["linked viral proteins", "PROBLEM", 144, 165], ["RNA circularization", "TREATMENT", 243, 262], ["virus", "OBSERVATION", 22, 27], ["viral mRNA", "OBSERVATION", 77, 87], ["viral proteins", "OBSERVATION", 151, 165], ["RNA circularization", "OBSERVATION", 243, 262]]], ["This review describes recent advances in understanding some of the mechanisms in which animal virus mRNAs gain an advantage over cellular transcripts, including new structural and biochemical insights into IRES function and novel proteins that function as alternate met-tRNA i met carriers in translation initiation.", [["cellular", "ANATOMY", 129, 137], ["cellular", "CELL", 129, 137], ["animal virus mRNAs", "RNA", 87, 105], ["cellular transcripts", "RNA", 129, 149], ["IRES", "DNA", 206, 210], ["animal virus mRNAs", "PROBLEM", 87, 105]]], ["Comparisons between animal and plant virus mechanisms that promote translation of viral mRNAs are discussed.IntroductionViruses use diverse mechanisms to outcompete cellular mRNAs for translation machinery and minimal genome sizes (summarized in Table 1 ).", [["cellular", "ANATOMY", 165, 173], ["plant virus", "ORGANISM", 31, 42], ["cellular", "CELL", 165, 173], ["viral mRNAs", "RNA", 82, 93], ["cellular mRNAs", "RNA", 165, 179], ["animal and plant virus mechanisms", "PROBLEM", 20, 53], ["viral mRNAs", "TREATMENT", 82, 93], ["IntroductionViruses", "TREATMENT", 108, 127], ["translation machinery", "TREATMENT", 184, 205], ["viral mRNAs", "OBSERVATION", 82, 93], ["minimal", "OBSERVATION_MODIFIER", 210, 217], ["sizes", "OBSERVATION_MODIFIER", 225, 230]]], ["This review will focus on only three of many categories of viral translation control mechanisms, thus readers are referred to a more comprehensive review of the other mechanisms [1 ] .IntroductionViruses generally exploit the dependence of the host translation machinery on the m 7 G cap structure at the 5 0 end of the mRNA.", [["m 7 G cap structure", "RNA", 278, 297], ["5 0 end", "RNA", 305, 312], ["mRNA", "RNA", 320, 324], ["viral translation control mechanisms", "TREATMENT", 59, 95], ["the m 7 G cap structure", "TREATMENT", 274, 297]]], ["The 5 0 cap is recognized by the eukaryotic initiation factor 4F protein complex (eIF4F; Figure 1 ).", [["eukaryotic initiation factor 4F", "GENE_OR_GENE_PRODUCT", 33, 64], ["eIF4F; Figure 1", "GENE_OR_GENE_PRODUCT", 82, 97], ["5 0 cap", "DNA", 4, 11], ["eukaryotic initiation factor 4F protein complex", "PROTEIN", 33, 80], ["eIF4F", "PROTEIN", 82, 87], ["Figure 1", "PROTEIN", 89, 97], ["The 5 0 cap", "TREATMENT", 0, 11]]], ["The 43S complex is recruited through interactions between the eIF4G moiety of eIF4F and the 40Sbound eIF3 to form the 48S preinitiation complex ( Figure 1 ).", [["43S", "GENE_OR_GENE_PRODUCT", 4, 7], ["eIF4G", "GENE_OR_GENE_PRODUCT", 62, 67], ["eIF4F", "GENE_OR_GENE_PRODUCT", 78, 83], ["eIF3", "GENE_OR_GENE_PRODUCT", 101, 105], ["43S complex", "PROTEIN", 4, 15], ["eIF4G moiety", "PROTEIN", 62, 74], ["eIF4F", "PROTEIN", 78, 83], ["40Sbound eIF3", "PROTEIN", 92, 105], ["48S preinitiation complex", "PROTEIN", 118, 143], ["Figure 1", "PROTEIN", 146, 154], ["the eIF4G moiety of eIF4F", "TREATMENT", 58, 83], ["the 40Sbound eIF3", "TREATMENT", 88, 105]]], ["The 40S ribosome then scans for the AUG initiator codon where the 60S ribosome subunit joins to initiate translation.", [["60S", "CELLULAR_COMPONENT", 66, 69], ["40S ribosome", "RNA", 4, 16], ["AUG initiator codon", "DNA", 36, 55], ["60S ribosome subunit", "PROTEIN", 66, 86], ["scans", "TEST", 22, 27], ["the AUG initiator codon", "TREATMENT", 32, 55]]], ["Interactions between cap-bound eIF4G and the poly(A)-bound poly(A) binding protein produce a closed loop mRNP that enhances cap-dependent translation [2, 3] .", [["eIF4G", "GENE_OR_GENE_PRODUCT", 31, 36], ["poly(A) binding protein", "GENE_OR_GENE_PRODUCT", 59, 82], ["eIF4G", "PROTEIN", 31, 36], ["poly(A)-bound poly(A) binding protein", "PROTEIN", 45, 82], ["closed loop mRNP", "PROTEIN", 93, 109], ["the poly(A)-bound poly(A) binding protein", "TREATMENT", 41, 82], ["a closed loop mRNP", "TREATMENT", 91, 109]]], ["Although the precise explanation for mRNA circularization is unknown, it is hypothesized to increase binding affinity of eIF4F for the cap and the efficiency of ribosome recycling for subsequent translation initiation events [4] [5] [6] .IntroductionMany plant and animal virus mRNAs are differentiated from host mRNAs by being uncapped, and therefore cannot recruit eIF4F by canonical means.", [["ribosome", "ANATOMY", 161, 169], ["eIF4F", "GENE_OR_GENE_PRODUCT", 121, 126], ["ribosome", "CELLULAR_COMPONENT", 161, 169], ["eIF4F", "GENE_OR_GENE_PRODUCT", 367, 372], ["eIF4F", "PROTEIN", 121, 126], ["plant and animal virus mRNAs", "RNA", 255, 283], ["host mRNAs", "RNA", 308, 318], ["eIF4F", "PROTEIN", 367, 372], ["mRNA circularization", "PROBLEM", 37, 57], ["the cap", "PROBLEM", 131, 138], ["ribosome recycling", "TREATMENT", 161, 179], ["subsequent translation initiation events", "TREATMENT", 184, 224], ["animal virus mRNAs", "TREATMENT", 265, 283], ["host mRNAs", "OBSERVATION", 308, 318]]], ["Viruses inhibit cap-dependent translation through many mechanisms, including cleavage of translation initiation factors (reviewed in [7] ).", [["cap", "GENE_OR_GENE_PRODUCT", 16, 19], ["translation initiation factors", "PROTEIN", 89, 119], ["Viruses inhibit cap", "PROBLEM", 0, 19], ["cap", "OBSERVATION_MODIFIER", 16, 19], ["dependent", "OBSERVATION_MODIFIER", 20, 29]]], ["This affords virus mRNAs a competitive advantage by increasing availability of translational machinery for cap-independent translation.", [["virus mRNAs", "RNA", 13, 24], ["translational machinery", "TREATMENT", 79, 102]]], ["While many animal viruses cleave initiation factors to promote viral translation, this mechanism is not conserved in plant viruses, as a translation factor-specific protease has not been identified.New concepts for IRES-mediated translation initiation in animal virusesA lack of dependence on 5 0 cap structures is a major mechanism exploited by many viruses to functionally distinguish and promote virus mRNA translation.", [["plant viruses", "ORGANISM", 117, 130], ["initiation factors", "PROTEIN", 33, 51], ["translation factor", "PROTEIN", 137, 155], ["protease", "PROTEIN", 165, 173], ["IRES", "DNA", 215, 219], ["virus mRNA", "RNA", 399, 409], ["viral translation", "PROBLEM", 63, 80], ["plant viruses", "PROBLEM", 117, 130], ["a translation factor", "TEST", 135, 155], ["specific protease", "PROBLEM", 156, 173], ["IRES-mediated translation initiation", "TREATMENT", 215, 251], ["animal viruses", "PROBLEM", 255, 269], ["5 0 cap structures", "TREATMENT", 293, 311], ["many viruses", "PROBLEM", 346, 358], ["viruses", "OBSERVATION", 18, 25], ["viral translation", "OBSERVATION", 63, 80], ["viruses", "OBSERVATION", 123, 130], ["viruses", "OBSERVATION", 351, 358]]], ["IRES elements are RNA sequence or structures that function in lieu of the cap to recruit required translation factors and ribosomal subunits to the vicinity of the start codon.", [["ribosomal", "CELLULAR_COMPONENT", 122, 131], ["IRES elements", "DNA", 0, 13], ["RNA sequence", "DNA", 18, 30], ["translation factors", "PROTEIN", 98, 117], ["ribosomal subunits", "PROTEIN", 122, 140], ["start codon", "DNA", 164, 175], ["RNA sequence", "TEST", 18, 30], ["the cap", "PROBLEM", 70, 77], ["translation factors", "TREATMENT", 98, 117], ["ribosomal subunits", "TREATMENT", 122, 140]]], ["Capindependent translation using IRESs was first observed in the poliovirus (PV) and EMCV genomic RNAs, and has since been characterized in many viral and cellular mRNAs including all picornaviruses, hepatitis C virus and pestiviruses, c-myc, p53 and the yeast URE2 IRES element [8] [9] [10] [11] [12] .", [["cellular", "ANATOMY", 155, 163], ["hepatitis C", "DISEASE", 200, 211], ["IRESs", "GENE_OR_GENE_PRODUCT", 33, 38], ["poliovirus", "ORGANISM", 65, 75], ["EMCV", "ORGANISM", 85, 89], ["cellular", "CELL", 155, 163], ["hepatitis C virus", "ORGANISM", 200, 217], ["pestiviruses", "GENE_OR_GENE_PRODUCT", 222, 234], ["c-myc", "GENE_OR_GENE_PRODUCT", 236, 241], ["p53", "GENE_OR_GENE_PRODUCT", 243, 246], ["IRESs", "DNA", 33, 38], ["poliovirus (PV) and EMCV genomic RNAs", "RNA", 65, 102], ["viral and cellular mRNAs", "RNA", 145, 169], ["p53", "PROTEIN", 243, 246], ["yeast URE2 IRES element", "DNA", 255, 278], ["hepatitis C virus", "SPECIES", 200, 217], ["yeast", "SPECIES", 255, 260], ["PV", "SPECIES", 77, 79], ["EMCV", "SPECIES", 85, 89], ["hepatitis C virus", "SPECIES", 200, 217], ["yeast", "SPECIES", 255, 260], ["IRESs", "TREATMENT", 33, 38], ["the poliovirus (PV) and EMCV genomic RNAs", "PROBLEM", 61, 102], ["many viral and cellular mRNAs", "PROBLEM", 140, 169], ["all picornaviruses", "PROBLEM", 180, 198], ["hepatitis C virus", "PROBLEM", 200, 217], ["pestiviruses", "PROBLEM", 222, 234], ["-myc", "TEST", 237, 241], ["the yeast URE2 IRES element", "TEST", 251, 278], ["genomic RNAs", "OBSERVATION", 90, 102], ["viral", "OBSERVATION", 145, 150], ["cellular mRNAs", "OBSERVATION", 155, 169]]], ["Even DNA viruses such as Kaposi's Sarcoma Associated Herpes Virus, Epstein-Barr Virus and Herpes simplex virus utilize IRES elements, the latter for production of thymidine kinase, which is associated with pathogenicity and drug resistance [13] .", [["Kaposi's Sarcoma", "DISEASE", 25, 41], ["Herpes Virus", "DISEASE", 53, 65], ["Epstein-Barr Virus", "DISEASE", 67, 85], ["Herpes simplex virus", "DISEASE", 90, 110], ["thymidine", "CHEMICAL", 163, 172], ["thymidine", "CHEMICAL", 163, 172], ["DNA", "CELLULAR_COMPONENT", 5, 8], ["Kaposi's Sarcoma Associated Herpes Virus", "ORGANISM", 25, 65], ["Epstein-Barr Virus", "ORGANISM", 67, 85], ["Herpes simplex virus", "ORGANISM", 90, 110], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 163, 179], ["IRES elements", "DNA", 119, 132], ["thymidine kinase", "PROTEIN", 163, 179], ["Herpes Virus", "SPECIES", 53, 65], ["Herpes simplex virus", "SPECIES", 90, 110], ["Epstein-Barr Virus", "SPECIES", 67, 85], ["Herpes simplex virus", "SPECIES", 90, 110], ["DNA viruses", "PROBLEM", 5, 16], ["Kaposi's Sarcoma", "PROBLEM", 25, 41], ["Herpes Virus", "PROBLEM", 53, 65], ["Epstein", "PROBLEM", 67, 74], ["Barr Virus", "PROBLEM", 75, 85], ["Herpes simplex virus", "PROBLEM", 90, 110], ["production of thymidine kinase", "PROBLEM", 149, 179], ["pathogenicity", "PROBLEM", 206, 219], ["DNA viruses", "OBSERVATION", 5, 16], ["Sarcoma", "OBSERVATION", 34, 41], ["Herpes Virus", "OBSERVATION", 53, 65], ["Barr Virus", "OBSERVATION", 75, 85], ["associated with", "UNCERTAINTY", 190, 205]]], ["IRES RNA structures are typically situated upstream of the initiating AUG codon, however HIV and eIF4GI contain IRES elements within the open reading frame [14] [15] [16] .", [["eIF4GI", "GENE_OR_GENE_PRODUCT", 97, 103], ["IRES RNA structures", "RNA", 0, 19], ["initiating AUG codon", "DNA", 59, 79], ["eIF4GI", "DNA", 97, 103], ["IRES elements", "DNA", 112, 125], ["open reading frame", "DNA", 137, 155], ["HIV", "SPECIES", 89, 92], ["IRES RNA structures", "PROBLEM", 0, 19], ["AUG codon", "TREATMENT", 70, 79], ["HIV and eIF4GI contain IRES elements", "PROBLEM", 89, 125], ["AUG codon", "OBSERVATION", 70, 79]]], ["Animal virus IRES elements are analogous to plant virus 3 0 cap-independent translation enhancers (3 0 CITEs; reviewed in companion article), which function as bipartite pseudo-IRES elements to recruit initiation factors.", [["Animal virus IRES elements", "DNA", 0, 26], ["plant virus 3 0 cap-independent translation enhancers", "DNA", 44, 97], ["bipartite pseudo-IRES elements", "DNA", 160, 190], ["initiation factors", "PROTEIN", 202, 220], ["Animal virus", "SPECIES", 0, 12], ["Animal virus IRES elements", "PROBLEM", 0, 26], ["plant virus", "TREATMENT", 44, 55], ["virus", "OBSERVATION", 7, 12]]], ["A crucial feature of IRES-mediated translation allows continued or enhanced expression of virus proteins during cell stress when cap-dependent translation is repressed.New concepts for IRES-mediated translation initiation in animal virusesVirus IRES elements are currently grouped into classes based on their requirement for canonical translation initiation factors (as outlined in [17]).", [["cell", "ANATOMY", 112, 116], ["cell", "CELL", 112, 116], ["animal viruses", "ORGANISM", 225, 239], ["IRES", "DNA", 21, 25], ["virus proteins", "PROTEIN", 90, 104], ["IRES", "DNA", 185, 189], ["Virus IRES elements", "DNA", 239, 258], ["canonical translation initiation factors", "PROTEIN", 325, 365], ["virus proteins", "PROBLEM", 90, 104], ["IRES-mediated translation initiation", "TREATMENT", 185, 221], ["animal viruses", "PROBLEM", 225, 239], ["Virus IRES elements", "PROBLEM", 239, 258], ["viruses", "OBSERVATION", 232, 239]]], ["Type 1 and 2 IRES elements, in which type 2 lack a scanning step after ribosome binding, require several canonical initiation factors, including the C-terminus of eIF4G (a product of viral proteases) that recruits the 40S subunit via interaction with eIF3 (note similarity to cap-dependent translation; Figure 2 Recently a new report on the understudied HIV IRESs indicates they may straddle Type 2 and 3 IRES classifications.", [["C", "CHEMICAL", 149, 150], ["Type 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["eIF4G", "GENE_OR_GENE_PRODUCT", 163, 168], ["eIF3", "GENE_OR_GENE_PRODUCT", 251, 255], ["HIV", "ORGANISM", 354, 357], ["Type 1 and 2 IRES elements", "DNA", 0, 26], ["canonical initiation factors", "PROTEIN", 105, 133], ["C-terminus", "PROTEIN", 149, 159], ["eIF4G", "PROTEIN", 163, 168], ["viral proteases", "PROTEIN", 183, 198], ["40S subunit", "PROTEIN", 218, 229], ["eIF3", "PROTEIN", 251, 255], ["HIV", "SPECIES", 354, 357], ["Type 1 and 2 IRES elements", "PROBLEM", 0, 26], ["ribosome binding", "PROBLEM", 71, 87], ["the C-terminus of eIF4G", "TREATMENT", 145, 168], ["viral proteases", "PROBLEM", 183, 198]]], ["A conserved core stem loop structure located in HIV-1, HIV-2 and SIV-IRESs was found to bind eIF3 and 40S ribosomes, similar to Type 3 IRESs ( Figure 2 ).", [["stem loop", "ANATOMY", 17, 26], ["HIV-1", "ORGANISM", 48, 53], ["HIV-2", "ORGANISM", 55, 60], ["SIV", "ORGANISM", 65, 68], ["IRESs", "GENE_OR_GENE_PRODUCT", 69, 74], ["eIF3", "GENE_OR_GENE_PRODUCT", 93, 97], ["HIV-1, HIV-2 and SIV-IRESs", "DNA", 48, 74], ["eIF3", "PROTEIN", 93, 97], ["40S ribosomes", "PROTEIN", 102, 115], ["Type 3 IRESs", "PROTEIN", 128, 140], ["HIV-1", "SPECIES", 48, 53], ["HIV-", "SPECIES", 55, 59], ["HIV-1", "SPECIES", 48, 53], ["HIV-2", "SPECIES", 55, 60], ["A conserved core stem loop structure", "PROBLEM", 0, 36], ["HIV", "TEST", 48, 51], ["HIV", "TEST", 55, 58], ["core", "OBSERVATION_MODIFIER", 12, 16], ["stem loop", "OBSERVATION", 17, 26], ["40S ribosomes", "OBSERVATION", 102, 115]]], ["However, analysis of stalled initiation complexes on these IRESs showed they contain all canonical initiation factors except eIF4E and eIF1.", [["IRESs", "GENE_OR_GENE_PRODUCT", 59, 64], ["eIF4E", "GENE_OR_GENE_PRODUCT", 125, 130], ["eIF1", "GENE_OR_GENE_PRODUCT", 135, 139], ["stalled initiation complexes", "PROTEIN", 21, 49], ["IRESs", "PROTEIN", 59, 64], ["canonical initiation factors", "PROTEIN", 89, 117], ["eIF4E", "PROTEIN", 125, 130], ["eIF1", "PROTEIN", 135, 139], ["stalled initiation complexes", "PROBLEM", 21, 49], ["these IRESs", "TEST", 53, 64], ["eIF4E and eIF1", "TREATMENT", 125, 139]]], ["The latter is surprising since eIF1 normally binds 40S subunits in conjunction with eIF5, eIF1A, and eIF3.", [["eIF1", "GENE_OR_GENE_PRODUCT", 31, 35], ["40S subunits", "GENE_OR_GENE_PRODUCT", 51, 63], ["eIF5", "GENE_OR_GENE_PRODUCT", 84, 88], ["eIF1A", "GENE_OR_GENE_PRODUCT", 90, 95], ["eIF3", "GENE_OR_GENE_PRODUCT", 101, 105], ["eIF1", "PROTEIN", 31, 35], ["40S subunits", "PROTEIN", 51, 63], ["eIF5", "PROTEIN", 84, 88], ["eIF1A", "PROTEIN", 90, 95], ["eIF3", "PROTEIN", 101, 105], ["eIF3", "TREATMENT", 101, 105]]], ["This result suggests the HIV IRES uses pools of 40S subunits containing only eIF3 to assemble initiation complexes [37].Use of alternative factors for initiator tRNA deliveryAnimal RNA virus infection often produces double stranded RNA and cell stress responses that activate eIF2a kinases PKR or HRI, respectively, which Animal virus translation schemes Reineke and Lloyd 365 Schematic depiction of translation initiation and the eIF2 nucleotide exchange cycle.", [["cell", "ANATOMY", 240, 244], ["infection", "DISEASE", 191, 200], ["nucleotide", "CHEMICAL", 436, 446], ["nucleotide", "CHEMICAL", 436, 446], ["HIV", "ORGANISM", 25, 28], ["40S subunits", "GENE_OR_GENE_PRODUCT", 48, 60], ["eIF3", "GENE_OR_GENE_PRODUCT", 77, 81], ["cell", "CELL", 240, 244], ["eIF2a", "GENE_OR_GENE_PRODUCT", 276, 281], ["PKR", "GENE_OR_GENE_PRODUCT", 290, 293], ["HRI", "GENE_OR_GENE_PRODUCT", 297, 300], ["eIF2", "GENE_OR_GENE_PRODUCT", 431, 435], ["HIV IRES", "DNA", 25, 33], ["40S subunits", "PROTEIN", 48, 60], ["eIF3", "PROTEIN", 77, 81], ["initiation complexes", "PROTEIN", 94, 114], ["eIF2a kinases", "PROTEIN", 276, 289], ["PKR", "PROTEIN", 290, 293], ["HRI", "PROTEIN", 297, 300], ["eIF2", "PROTEIN", 431, 435], ["HIV", "SPECIES", 25, 28], ["the HIV IRES", "PROBLEM", 21, 33], ["pools of 40S subunits", "TREATMENT", 39, 60], ["alternative factors", "TREATMENT", 127, 146], ["initiator tRNA delivery", "TREATMENT", 151, 174], ["Animal RNA virus infection", "PROBLEM", 174, 200], ["double stranded RNA", "PROBLEM", 216, 235], ["cell stress responses", "PROBLEM", 240, 261], ["PKR", "TEST", 290, 293], ["HRI", "TEST", 297, 300], ["translation initiation", "TREATMENT", 400, 422], ["the eIF2 nucleotide exchange cycle", "TREATMENT", 427, 461], ["RNA virus infection", "OBSERVATION", 181, 200], ["double stranded RNA", "OBSERVATION_MODIFIER", 216, 235], ["cell", "OBSERVATION", 240, 244]]], ["Eukaryotic initiation factor 4F, which consists of the cap binding protein (eIF4E), a scaffolding protein (eIF4G) and an RNA helicase (eIF4A), recognizes the m 7 G cap structure.", [["Eukaryotic initiation factor 4F", "GENE_OR_GENE_PRODUCT", 0, 31], ["cap binding protein", "GENE_OR_GENE_PRODUCT", 55, 74], ["eIF4E", "GENE_OR_GENE_PRODUCT", 76, 81], ["eIF4G", "GENE_OR_GENE_PRODUCT", 107, 112], ["eIF4A", "GENE_OR_GENE_PRODUCT", 135, 140], ["Eukaryotic initiation factor 4F", "PROTEIN", 0, 31], ["cap binding protein", "PROTEIN", 55, 74], ["eIF4E", "PROTEIN", 76, 81], ["scaffolding protein", "PROTEIN", 86, 105], ["eIF4G", "PROTEIN", 107, 112], ["RNA helicase", "PROTEIN", 121, 133], ["eIF4A", "PROTEIN", 135, 140], ["m 7 G cap structure", "PROTEIN", 158, 177], ["Eukaryotic initiation factor 4F", "PROBLEM", 0, 31], ["the cap binding protein", "TEST", 51, 74], ["a scaffolding protein (eIF4G", "TREATMENT", 84, 112], ["an RNA helicase (eIF4A", "TREATMENT", 118, 140], ["factor 4F", "OBSERVATION_MODIFIER", 22, 31]]], ["The mRNA can circularize in accordance with the closed-loop model via interaction between PABP at the 3 0 terminus and eIF4G complexed with the 5 0 cap.", [["PABP", "GENE_OR_GENE_PRODUCT", 90, 94], ["eIF4G", "GENE_OR_GENE_PRODUCT", 119, 124], ["mRNA", "RNA", 4, 8], ["PABP", "PROTEIN", 90, 94], ["3 0 terminus", "PROTEIN", 102, 114], ["eIF4G", "PROTEIN", 119, 124], ["5 0 cap", "DNA", 144, 151], ["PABP", "TEST", 90, 94]]], ["Next, the 43S preinitiation complex, composed of the 40S small ribosomal subunit and initiation factors eIF1, eIF1A, heterotrimeric eIF2(a,b,g), eIF5 and multisubunit eIF3, can bind the mRNA via interaction between eIF3 and eIF4G to form the 48S complex. eIF2 delivers the initiator methionyl tRNA as a ternary complex, comprised of eIF2\u00c1GTP\u00c1met-tRNA i met .", [["methionyl", "CHEMICAL", 283, 292], ["43S", "GENE_OR_GENE_PRODUCT", 10, 13], ["eIF1", "GENE_OR_GENE_PRODUCT", 104, 108], ["eIF1A", "GENE_OR_GENE_PRODUCT", 110, 115], ["heterotrimeric eIF2(a,b,g)", "GENE_OR_GENE_PRODUCT", 117, 143], ["eIF5", "GENE_OR_GENE_PRODUCT", 145, 149], ["eIF3", "GENE_OR_GENE_PRODUCT", 167, 171], ["eIF3", "GENE_OR_GENE_PRODUCT", 215, 219], ["eIF4G", "GENE_OR_GENE_PRODUCT", 224, 229], ["48S", "GENE_OR_GENE_PRODUCT", 242, 245], ["eIF2", "GENE_OR_GENE_PRODUCT", 255, 259], ["43S preinitiation complex", "PROTEIN", 10, 35], ["40S small ribosomal subunit", "PROTEIN", 53, 80], ["initiation factors", "PROTEIN", 85, 103], ["eIF1", "PROTEIN", 104, 108], ["eIF1A", "PROTEIN", 110, 115], ["heterotrimeric eIF2(a,b,g)", "PROTEIN", 117, 143], ["eIF5", "PROTEIN", 145, 149], ["multisubunit eIF3", "PROTEIN", 154, 171], ["mRNA", "RNA", 186, 190], ["eIF3", "PROTEIN", 215, 219], ["eIF4G", "PROTEIN", 224, 229], ["48S complex", "PROTEIN", 242, 253], ["eIF2", "PROTEIN", 255, 259], ["initiator methionyl tRNA", "PROTEIN", 273, 297], ["ternary complex", "PROTEIN", 303, 318], ["eIF2\u00c1GTP\u00c1met", "PROTEIN", 333, 345], ["eIF1A", "TREATMENT", 110, 115], ["heterotrimeric eIF2", "TREATMENT", 117, 136], ["eIF5", "TREATMENT", 145, 149], ["multisubunit eIF3", "TREATMENT", 154, 171], ["eIF3 and eIF4G", "TREATMENT", 215, 229], ["the initiator methionyl tRNA", "TREATMENT", 269, 297], ["a ternary complex", "PROBLEM", 301, 318], ["ribosomal subunit", "OBSERVATION", 63, 80], ["methionyl tRNA", "OBSERVATION", 283, 297]]], ["The 40S ribosomal subunit then scans to locate the AUG codon where the 60S joins, some factors are ejected including eIF2, and the 80S ribosome enters the elongation phase of protein synthesis (reviewed in [109] ). eIF2 activity relies on GTP hydrolysis and the guanine nucleotide exchange factor eIF2B must recycle GTP\u00c1eIF2 before it can be used in subsequent rounds of translation initiation (depicted by the eIF2:GTP exchange cycle).", [["GTP", "CHEMICAL", 239, 242], ["guanine nucleotide", "CHEMICAL", 262, 280], ["GTP", "CHEMICAL", 239, 242], ["guanine nucleotide", "CHEMICAL", 262, 280], ["GTP", "CHEMICAL", 416, 419], ["eIF2", "GENE_OR_GENE_PRODUCT", 117, 121], ["80S", "CELLULAR_COMPONENT", 131, 134], ["ribosome", "CELLULAR_COMPONENT", 135, 143], ["eIF2", "GENE_OR_GENE_PRODUCT", 215, 219], ["GTP", "SIMPLE_CHEMICAL", 239, 242], ["eIF2B", "GENE_OR_GENE_PRODUCT", 297, 302], ["GTP\u00c1eIF2", "GENE_OR_GENE_PRODUCT", 316, 324], ["eIF2", "GENE_OR_GENE_PRODUCT", 411, 415], ["GTP", "SIMPLE_CHEMICAL", 416, 419], ["40S ribosomal subunit", "PROTEIN", 4, 25], ["AUG codon", "DNA", 51, 60], ["eIF2", "PROTEIN", 117, 121], ["80S ribosome", "PROTEIN", 131, 143], ["eIF2", "PROTEIN", 215, 219], ["guanine nucleotide exchange factor", "PROTEIN", 262, 296], ["eIF2B", "PROTEIN", 297, 302], ["GTP\u00c1eIF2", "PROTEIN", 316, 324], ["eIF2", "PROTEIN", 411, 415], ["scans", "TEST", 31, 36], ["the AUG codon", "PROBLEM", 47, 60], ["eIF2", "TEST", 117, 121], ["protein synthesis", "TEST", 175, 192], ["GTP hydrolysis", "TREATMENT", 239, 253], ["the guanine nucleotide exchange factor eIF2B", "TREATMENT", 258, 302], ["GTP exchange cycle", "TREATMENT", 416, 434], ["AUG codon", "OBSERVATION", 51, 60], ["elongation", "OBSERVATION_MODIFIER", 155, 165], ["phase", "OBSERVATION_MODIFIER", 166, 171]]], ["Several kinases have been identified that act on eIF2 to inhibit met-tRNA i met delivery by phosphorylating eIF2a, which include: PKR, a double-stranded RNA-dependent protein kinase typically activated during infection by RNA viruses in animals, PERK, which is activated in response to ER stress, HRI, a heme-sensing molecule, and GCN2, which senses nutrient availability.Use of alternative factors for initiator tRNA deliveryphosphorylate the alpha subunit of eIF2 (reviewed in [38] ) and result in repression of global translation by depleting the ternary complex ( Figure 1; [39] ).", [["infection", "DISEASE", 209, 218], ["eIF2", "GENE_OR_GENE_PRODUCT", 49, 53], ["eIF2a", "GENE_OR_GENE_PRODUCT", 108, 113], ["PKR", "GENE_OR_GENE_PRODUCT", 130, 133], ["PERK", "GENE_OR_GENE_PRODUCT", 246, 250], ["ER", "GENE_OR_GENE_PRODUCT", 286, 288], ["HRI", "GENE_OR_GENE_PRODUCT", 297, 300], ["GCN2", "GENE_OR_GENE_PRODUCT", 331, 335], ["eIF2", "GENE_OR_GENE_PRODUCT", 461, 465], ["kinases", "PROTEIN", 8, 15], ["eIF2", "PROTEIN", 49, 53], ["eIF2a", "PROTEIN", 108, 113], ["PKR", "PROTEIN", 130, 133], ["double-stranded RNA-dependent protein kinase", "PROTEIN", 137, 181], ["PERK", "PROTEIN", 246, 250], ["ER", "PROTEIN", 286, 288], ["HRI", "PROTEIN", 297, 300], ["heme-sensing molecule", "PROTEIN", 304, 325], ["GCN2", "PROTEIN", 331, 335], ["alternative factors", "PROTEIN", 379, 398], ["initiator tRNA", "PROTEIN", 403, 417], ["alpha subunit", "PROTEIN", 444, 457], ["eIF2", "PROTEIN", 461, 465], ["ternary complex", "PROTEIN", 550, 565], ["PKR", "TEST", 130, 133], ["a double-stranded RNA", "TEST", 135, 156], ["dependent protein kinase", "PROBLEM", 157, 181], ["RNA viruses", "PROBLEM", 222, 233], ["ER stress", "TEST", 286, 295], ["GCN2", "PROBLEM", 331, 335], ["alternative factors", "TREATMENT", 379, 398], ["initiator tRNA deliveryphosphorylate", "TREATMENT", 403, 439], ["global translation", "PROBLEM", 514, 532]]], ["Some viruses evade the antiviral activation of PKR through interesting antagonistic mechanisms (reviewed in [40,41]).", [["PKR", "GENE_OR_GENE_PRODUCT", 47, 50], ["PKR", "PROTEIN", 47, 50], ["Some viruses", "PROBLEM", 0, 12], ["viruses", "OBSERVATION", 5, 12], ["antiviral activation", "OBSERVATION", 23, 43]]], ["Viruses also encode proteins to directly deal with limited ternary complexes.", [["ternary complexes", "PROTEIN", 59, 76], ["Viruses", "PROBLEM", 0, 7], ["encode proteins", "PROBLEM", 13, 28], ["limited ternary complexes", "PROBLEM", 51, 76], ["ternary complexes", "OBSERVATION", 59, 76]]], ["For instance, Herpes simplex virus protein ICP34.5 recruits protein phosphatase P1, known to dephosphorylate eIF2a, to reactivate translation after an initial phase of inhibition [42, 43] .", [["Herpes simplex", "DISEASE", 14, 28], ["Herpes simplex virus", "ORGANISM", 14, 34], ["ICP34.5", "GENE_OR_GENE_PRODUCT", 43, 50], ["protein phosphatase P1", "GENE_OR_GENE_PRODUCT", 60, 82], ["eIF2a", "GENE_OR_GENE_PRODUCT", 109, 114], ["Herpes simplex virus protein", "PROTEIN", 14, 42], ["ICP34.5", "PROTEIN", 43, 50], ["protein phosphatase P1", "PROTEIN", 60, 82], ["eIF2a", "PROTEIN", 109, 114], ["Herpes simplex virus", "SPECIES", 14, 34], ["Herpes simplex virus", "SPECIES", 14, 34], ["Herpes simplex virus protein", "TEST", 14, 42], ["protein phosphatase P1", "TEST", 60, 82], ["dephosphorylate eIF2a", "TREATMENT", 93, 114]]], ["This mechanism is recapitulated during coronavirus and African swine fever virus by Gene 7 and DP71L, respectively 366 Virus replication in animals and plants [44,45].", [["swine fever", "DISEASE", 63, 74], ["coronavirus", "ORGANISM", 39, 50], ["African swine fever virus", "ORGANISM", 55, 80], ["Gene 7", "GENE_OR_GENE_PRODUCT", 84, 90], ["DP71L", "GENE_OR_GENE_PRODUCT", 95, 100], ["Gene 7", "DNA", 84, 90], ["coronavirus", "SPECIES", 39, 50], ["swine fever virus", "SPECIES", 63, 80], ["African swine fever virus", "SPECIES", 55, 80], ["coronavirus", "PROBLEM", 39, 50], ["African swine fever virus", "PROBLEM", 55, 80]]], ["Alternatively, several viruses have evolved alternate pathways to avoid the requirement for eIF2 ternary complex binding to 40S ribosomes to support viral translation during eIF2 phosphorylation.", [["eIF2", "GENE_OR_GENE_PRODUCT", 92, 96], ["40S", "GENE_OR_GENE_PRODUCT", 124, 127], ["eIF2", "GENE_OR_GENE_PRODUCT", 174, 178], ["eIF2 ternary complex", "PROTEIN", 92, 112], ["40S ribosomes", "RNA", 124, 137], ["eIF2", "PROTEIN", 174, 178], ["several viruses", "PROBLEM", 15, 30], ["eIF2 ternary complex binding", "PROBLEM", 92, 120], ["40S ribosomes", "TREATMENT", 124, 137], ["viral translation", "PROBLEM", 149, 166], ["eIF2 phosphorylation", "TREATMENT", 174, 194], ["viruses", "OBSERVATION", 23, 30]]], ["The Dicistroviridae class of viruses (including CrPV) contain IGR IRES elements resembling tRNAs, which efficiently bind the P-site of the ribosome and promote initiation often at an alanine codon [18, 46] .", [["ribosome", "ANATOMY", 139, 147], ["alanine", "CHEMICAL", 183, 190], ["alanine", "CHEMICAL", 183, 190], ["CrPV", "GENE_OR_GENE_PRODUCT", 48, 52], ["ribosome", "CELLULAR_COMPONENT", 139, 147], ["alanine", "AMINO_ACID", 183, 190], ["IGR IRES elements", "DNA", 62, 79], ["P-site", "DNA", 125, 131], ["The Dicistroviridae class of viruses", "TREATMENT", 0, 36], ["CrPV)", "TREATMENT", 48, 53], ["IGR IRES elements", "TREATMENT", 62, 79], ["tRNAs", "TREATMENT", 91, 96], ["the ribosome", "TREATMENT", 135, 147], ["viruses", "OBSERVATION", 29, 36], ["IGR IRES", "OBSERVATION", 62, 70]]], ["This circumvents the need for translation initiation using met-tRNA i met since translation is initiated using elongator tRNAs.Use of alternative factors for initiator tRNA deliveryRecent reports have emerged of a resistance strategy unique to animal viruses to cope with eIF2a phosphorylation; the use of alternative proteins for initiator tRNA delivery.", [["eIF2a", "GENE_OR_GENE_PRODUCT", 272, 277], ["elongator tRNAs", "RNA", 111, 126], ["eIF2a", "PROTEIN", 272, 277], ["alternative proteins", "PROTEIN", 306, 326], ["translation initiation", "TREATMENT", 30, 52], ["met-tRNA i", "TREATMENT", 59, 69], ["elongator tRNAs", "TREATMENT", 111, 126], ["alternative factors", "TREATMENT", 134, 153], ["initiator tRNA delivery", "TREATMENT", 158, 181], ["a resistance strategy", "TREATMENT", 212, 233], ["animal viruses", "PROBLEM", 244, 258], ["eIF2a phosphorylation", "TREATMENT", 272, 293], ["alternative proteins", "TREATMENT", 306, 326], ["initiator tRNA delivery", "TREATMENT", 331, 354]]], ["These include eukaryotic initiation factor 2A, a single polypeptide unrelated to the heterotrimeric complex eIF2 [47, 48] , Ligatin (also known as eIF2D; [49,50 ]), MCT1/DENR [50 ], and eukaryotic initiation 5B (eIF5B) (Figure 3; [51,52] ).", [["eukaryotic initiation factor 2A", "GENE_OR_GENE_PRODUCT", 14, 45], ["eIF2 [47, 48]", "GENE_OR_GENE_PRODUCT", 108, 121], ["Ligatin", "GENE_OR_GENE_PRODUCT", 124, 131], ["eIF2D", "GENE_OR_GENE_PRODUCT", 147, 152], ["MCT1", "GENE_OR_GENE_PRODUCT", 165, 169], ["DENR [50 ]", "GENE_OR_GENE_PRODUCT", 170, 180], ["eukaryotic initiation 5B", "GENE_OR_GENE_PRODUCT", 186, 210], ["eIF5B", "GENE_OR_GENE_PRODUCT", 212, 217], ["eukaryotic initiation factor 2A", "PROTEIN", 14, 45], ["heterotrimeric complex", "PROTEIN", 85, 107], ["eIF2", "PROTEIN", 108, 112], ["Ligatin", "PROTEIN", 124, 131], ["eIF2D", "PROTEIN", 147, 152], ["MCT1", "PROTEIN", 165, 169], ["DENR", "PROTEIN", 170, 174], ["eukaryotic initiation 5B", "PROTEIN", 186, 210], ["eIF5B", "PROTEIN", 212, 217], ["a single polypeptide", "TREATMENT", 47, 67]]], ["Identification of these proteins indicates a more diverse repertoire of pathways exists for translation initiation than previously thought, and highlights the need to investigate translation initiation of other viruses displaying eIF2-independent translation.Use of alternative factors for initiator tRNA deliveryeIF2A was first identified based on its ability to direct binding of met-tRNA i met with 40S ribosomal subunits in an AUG codon-dependent manner [48] .", [["deliveryeIF2A", "CHEMICAL", 305, 318], ["eIF2", "GENE_OR_GENE_PRODUCT", 230, 234], ["eIF2", "PROTEIN", 230, 234], ["initiator tRNA deliveryeIF2A", "PROTEIN", 290, 318], ["40S ribosomal subunits", "PROTEIN", 402, 424], ["AUG codon", "DNA", 431, 440], ["these proteins", "PROBLEM", 18, 32], ["alternative factors", "TREATMENT", 266, 285], ["initiator tRNA deliveryeIF2A", "TREATMENT", 290, 318], ["40S ribosomal subunits", "TREATMENT", 402, 424]]], ["In yeast, eIF2A was shown to act as a suppressor of cap-independent initiation on the URE2, PABP and GIC1 IRES elements [53, 54] .", [["eIF2A", "GENE_OR_GENE_PRODUCT", 10, 15], ["cap", "GENE_OR_GENE_PRODUCT", 52, 55], ["URE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["PABP", "GENE_OR_GENE_PRODUCT", 92, 96], ["GIC1", "GENE_OR_GENE_PRODUCT", 101, 105], ["eIF2A", "PROTEIN", 10, 15], ["URE2, PABP and GIC1 IRES elements", "DNA", 86, 119], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8], ["a suppressor of cap", "TREATMENT", 36, 55]]], ["The authors hypothesized that kinetic limitations of the eIF2A-dependent pathway for met-tRNA i met delivery inhibit initiation while eIF2 is active (perhaps because of overlapping binding sites on the ribosome).", [["ribosome", "ANATOMY", 202, 210], ["eIF2A", "GENE_OR_GENE_PRODUCT", 57, 62], ["eIF2", "GENE_OR_GENE_PRODUCT", 134, 138], ["ribosome", "CELLULAR_COMPONENT", 202, 210], ["eIF2A", "PROTEIN", 57, 62], ["eIF2", "PROTEIN", 134, 138], ["overlapping binding sites", "DNA", 169, 194], ["the eIF2A-dependent pathway", "TREATMENT", 53, 80], ["met-tRNA i met delivery", "TREATMENT", 85, 108], ["overlapping binding sites", "PROBLEM", 169, 194], ["active", "OBSERVATION_MODIFIER", 142, 148]]], ["However, when eIF2 is inactivated, translation can still proceed on IRES-containing transcripts at a slower rate.", [["eIF2", "GENE_OR_GENE_PRODUCT", 14, 18], ["eIF2", "PROTEIN", 14, 18], ["IRES", "DNA", 68, 72], ["IRES", "TREATMENT", 68, 72]]], ["This hypothesis has yet to be directly tested, but positions eIF2A as an important stress-responsive protein for translation of RNA viruses.", [["eIF2A", "GENE_OR_GENE_PRODUCT", 61, 66], ["eIF2A", "PROTEIN", 61, 66], ["RNA viruses", "PROBLEM", 128, 139], ["RNA viruses", "OBSERVATION", 128, 139]]], ["Consistent with this hypothesis, eIF2A is important for ongoing Sindbis virus translation when high levels of eIF2a phosphorylation are observed [55] .", [["eIF2A", "GENE_OR_GENE_PRODUCT", 33, 38], ["Sindbis virus", "ORGANISM", 64, 77], ["eIF2a", "GENE_OR_GENE_PRODUCT", 110, 115], ["eIF2A", "PROTEIN", 33, 38], ["eIF2a", "PROTEIN", 110, 115], ["Sindbis virus", "SPECIES", 64, 77], ["this hypothesis", "PROBLEM", 16, 31], ["ongoing Sindbis virus translation", "TREATMENT", 56, 89], ["eIF2a phosphorylation", "TREATMENT", 110, 131]]], ["New data indicate that eIF2A can mediate delivery of met-tRNA i met to the 40S subunit to form 48S complexes on the HCV IRES element using purified components [56 ] .", [["eIF2A", "CHEMICAL", 23, 28], ["eIF2A", "GENE_OR_GENE_PRODUCT", 23, 28], ["48S", "GENE_OR_GENE_PRODUCT", 95, 98], ["eIF2A", "PROTEIN", 23, 28], ["40S subunit", "PROTEIN", 75, 86], ["48S complexes", "PROTEIN", 95, 108], ["HCV IRES element", "DNA", 116, 132], ["HCV", "SPECIES", 116, 119], ["the HCV IRES element", "TREATMENT", 112, 132]]], ["Furthermore, domain IIId of the HCV IRES was shown to interact with eIF2A directly.", [["HCV", "ORGANISM", 32, 35], ["eIF2A", "GENE_OR_GENE_PRODUCT", 68, 73], ["domain IIId", "PROTEIN", 13, 24], ["HCV IRES", "DNA", 32, 40], ["eIF2A", "PROTEIN", 68, 73], ["HCV", "SPECIES", 32, 35], ["the HCV IRES", "TREATMENT", 28, 40]]], ["These results suggest a mechanism wherein the IRES recruits the eIF2A:met-tRNA i met complex to the ribosome rather than the ribosome recruiting the eIF2A:met-tRNA i met complex, at least on some mRNAs.", [["ribosome", "ANATOMY", 100, 108], ["ribosome", "ANATOMY", 125, 133], ["eIF2A", "GENE_OR_GENE_PRODUCT", 64, 69], ["ribosome", "CELLULAR_COMPONENT", 100, 108], ["ribosome", "CELLULAR_COMPONENT", 125, 133], ["eIF2A", "GENE_OR_GENE_PRODUCT", 149, 154], ["IRES", "DNA", 46, 50], ["eIF2A", "PROTEIN", 64, 69], ["eIF2A:met-tRNA i met complex", "PROTEIN", 149, 177], ["mRNAs", "RNA", 196, 201], ["tRNA i met complex", "PROBLEM", 159, 177]]], ["Kinetics of eIF2A expression and activity during eIF2a phosphorylation, the precise mechanism of action for met-tRNA i met delivery by eIF2A, and validation of additional mRNA targets must be investigated to conclusively demonstrate a role for eIF2A at this step of translation initiation.Use of alternative factors for initiator tRNA deliveryIn an attempt to further characterize the role of eIF2A, Dmitriev et al. discovered an important role for ligatin (B) Mammalian eIF5B contains the C-terminal half that is homologous to archaeal IF2 and a N-terminal regulatory domain whose structure is unknown that is removed by PV 3Cpro cleavage.", [["C", "CHEMICAL", 490, 491], ["N", "CHEMICAL", 547, 548], ["eIF2A", "GENE_OR_GENE_PRODUCT", 12, 17], ["eIF2a", "GENE_OR_GENE_PRODUCT", 49, 54], ["eIF2A", "GENE_OR_GENE_PRODUCT", 135, 140], ["eIF2A", "GENE_OR_GENE_PRODUCT", 244, 249], ["eIF2A", "GENE_OR_GENE_PRODUCT", 393, 398], ["ligatin (B)", "GENE_OR_GENE_PRODUCT", 449, 460], ["eIF5B", "GENE_OR_GENE_PRODUCT", 471, 476], ["IF2", "GENE_OR_GENE_PRODUCT", 537, 540], ["eIF2A", "PROTEIN", 12, 17], ["eIF2a", "PROTEIN", 49, 54], ["eIF2A", "PROTEIN", 135, 140], ["mRNA targets", "RNA", 171, 183], ["eIF2A", "PROTEIN", 244, 249], ["eIF2A", "PROTEIN", 393, 398], ["ligatin (B) Mammalian eIF5B", "PROTEIN", 449, 476], ["C-terminal half", "PROTEIN", 490, 505], ["archaeal IF2", "PROTEIN", 528, 540], ["N-terminal regulatory domain", "PROTEIN", 547, 575], ["3Cpro", "PROTEIN", 625, 630], ["eIF2A expression", "TREATMENT", 12, 28], ["activity during eIF2a phosphorylation", "TREATMENT", 33, 70], ["additional mRNA targets", "TREATMENT", 160, 183], ["eIF2A", "TREATMENT", 244, 249], ["translation initiation", "TREATMENT", 266, 288], ["alternative factors", "TREATMENT", 296, 315], ["initiator tRNA delivery", "TREATMENT", 320, 343], ["ligatin (B) Mammalian eIF5B", "TREATMENT", 449, 476], ["the C-terminal half", "TREATMENT", 486, 505], ["archaeal IF2", "TREATMENT", 528, 540], ["a N-terminal regulatory domain", "TREATMENT", 545, 575]]], ["(C) Infection and stress activate eIF2a kinases that reduce concentrations of eIF2\u00c1GTP\u00c1met-tRNA i met ternary complex, inhibiting translation from viral IRES elements.", [["eIF2a", "GENE_OR_GENE_PRODUCT", 34, 39], ["eIF2\u00c1GTP\u00c1met", "GENE_OR_GENE_PRODUCT", 78, 90], ["eIF2a kinases", "PROTEIN", 34, 47], ["eIF2\u00c1GTP\u00c1met", "PROTEIN", 78, 90], ["ternary complex", "PROTEIN", 102, 117], ["viral IRES elements", "DNA", 147, 166], ["Infection", "PROBLEM", 4, 13], ["stress activate eIF2a kinases", "TREATMENT", 18, 47], ["eIF2\u00c1GTP\u00c1met", "TEST", 78, 90], ["tRNA i met ternary complex", "PROBLEM", 91, 117], ["Infection", "OBSERVATION", 4, 13], ["viral IRES", "OBSERVATION", 147, 157]]], ["PV and HCV may overcome this restriction by recruiting alternate proteins to help deliver met-tRNA i met in GTP-dependent or GTP-independent mechanisms.Use of alternative factors for initiator tRNA deliveryin 48S complex formation on the HCV IRES element ( Figure 3C; [49] ).", [["GTP", "CHEMICAL", 108, 111], ["GTP", "CHEMICAL", 125, 128], ["GTP", "CHEMICAL", 108, 111], ["HCV", "ORGANISM", 7, 10], ["GTP", "SIMPLE_CHEMICAL", 108, 111], ["GTP", "SIMPLE_CHEMICAL", 125, 128], ["tRNA deliveryin 48S complex", "GENE_OR_GENE_PRODUCT", 193, 220], ["initiator tRNA", "PROTEIN", 183, 197], ["48S complex", "PROTEIN", 209, 220], ["HCV IRES element", "DNA", 238, 254], ["PV", "SPECIES", 0, 2], ["HCV", "SPECIES", 7, 10], ["HCV", "SPECIES", 238, 241], ["HCV", "PROBLEM", 7, 10], ["this restriction", "TREATMENT", 24, 40], ["recruiting alternate proteins", "TREATMENT", 44, 73], ["alternative factors", "TREATMENT", 159, 178], ["initiator tRNA deliveryin", "TREATMENT", 183, 208], ["HCV", "OBSERVATION", 7, 10]]], ["Interestingly, ligatin, which they termed eIF2D, can promote 48S complex formation using phenylalanine-tRNA on the HCV IRES element when the initiating AUG is mutated to a UUU codon.", [["phenylalanine-tRNA", "CHEMICAL", 89, 107], ["phenylalanine", "CHEMICAL", 89, 102], ["ligatin", "GENE_OR_GENE_PRODUCT", 15, 22], ["eIF2D", "GENE_OR_GENE_PRODUCT", 42, 47], ["48S complex", "GENE_OR_GENE_PRODUCT", 61, 72], ["phenylalanine-tRNA", "SIMPLE_CHEMICAL", 89, 107], ["ligatin", "PROTEIN", 15, 22], ["eIF2D", "PROTEIN", 42, 47], ["48S complex", "PROTEIN", 61, 72], ["HCV IRES element", "DNA", 115, 131], ["AUG", "DNA", 152, 155], ["UUU codon", "DNA", 172, 181], ["HCV", "SPECIES", 115, 118], ["phenylalanine", "TREATMENT", 89, 102], ["tRNA", "TREATMENT", 103, 107], ["the HCV IRES element", "TREATMENT", 111, 131]]], ["This result suggests alternative initiation codons may be used to produce proteins with altered functions or half-lives.", [["alternative initiation codons", "TREATMENT", 21, 50], ["altered functions", "PROBLEM", 88, 105]]], ["Skabkin et al. extended these findings to show Ligatin can promote formation of 48S complexes on the CSFV IRES element and the Sindbis virus 26S RNA [50 ] .", [["Ligatin", "CHEMICAL", 47, 54], ["Ligatin", "SIMPLE_CHEMICAL", 47, 54], ["48S", "GENE_OR_GENE_PRODUCT", 80, 83], ["Sindbis virus", "ORGANISM", 127, 140], ["Ligatin", "PROTEIN", 47, 54], ["48S complexes", "PROTEIN", 80, 93], ["CSFV IRES element", "DNA", 101, 118], ["CSFV", "SPECIES", 101, 105], ["Sindbis virus", "SPECIES", 127, 140], ["Ligatin", "TREATMENT", 47, 54], ["48S complexes", "PROBLEM", 80, 93], ["the CSFV IRES element", "TREATMENT", 97, 118], ["the Sindbis virus 26S RNA", "PROBLEM", 123, 148], ["CSFV", "OBSERVATION", 101, 105]]], ["Interestingly, the proteins MCT1 and DENR, which are homologous to the N and C-termini of ligatin, respectively, can work simultaneously to promote 48S complex formation ( Figure 3C ).", [["N", "CHEMICAL", 71, 72], ["C", "CHEMICAL", 77, 78], ["MCT1", "GENE_OR_GENE_PRODUCT", 28, 32], ["DENR", "GENE_OR_GENE_PRODUCT", 37, 41], ["ligatin", "GENE_OR_GENE_PRODUCT", 90, 97], ["48S complex", "GENE_OR_GENE_PRODUCT", 148, 159], ["MCT1", "PROTEIN", 28, 32], ["DENR", "PROTEIN", 37, 41], ["N and C-termini", "PROTEIN", 71, 86], ["ligatin", "PROTEIN", 90, 97], ["48S complex", "PROTEIN", 148, 159], ["the proteins MCT1", "TEST", 15, 32], ["C-termini of ligatin", "TREATMENT", 77, 97]]], ["Further work is necessary to delineate in vivo activity of ligatin in translation initiation of these viral mRNAs.Use of alternative factors for initiator tRNA deliveryEukaryotic initiation factor 5B is the eukaryotic homolog of bacterial initiation factor 2 (IF2; [57] ).", [["ligatin", "GENE_OR_GENE_PRODUCT", 59, 66], ["Eukaryotic initiation factor 5B", "GENE_OR_GENE_PRODUCT", 168, 199], ["bacterial initiation factor 2", "GENE_OR_GENE_PRODUCT", 229, 258], ["IF2", "GENE_OR_GENE_PRODUCT", 260, 263], ["ligatin", "PROTEIN", 59, 66], ["viral mRNAs", "RNA", 102, 113], ["Eukaryotic initiation factor 5B", "PROTEIN", 168, 199], ["bacterial initiation factor 2", "PROTEIN", 229, 258], ["IF2", "PROTEIN", 260, 263], ["ligatin", "TREATMENT", 59, 66], ["these viral mRNAs", "PROBLEM", 96, 113], ["alternative factors", "TREATMENT", 121, 140], ["initiator tRNA delivery", "TREATMENT", 145, 168], ["viral mRNAs", "OBSERVATION", 102, 113]]], ["The domain architecture of mammalian eIF5B is highly reminiscent of archaeal eIF5B with the exception of a large Nterminal extension on mammalian eIF5B that may regulate met-tRNA i met binding (compare Figure 3A and B; [58] ).", [["eIF5B", "GENE_OR_GENE_PRODUCT", 37, 42], ["eIF5B", "GENE_OR_GENE_PRODUCT", 77, 82], ["Nterminal", "GENE_OR_GENE_PRODUCT", 113, 122], ["eIF5B", "GENE_OR_GENE_PRODUCT", 146, 151], ["mammalian eIF5B", "PROTEIN", 27, 42], ["archaeal eIF5B", "PROTEIN", 68, 82], ["mammalian eIF5B", "PROTEIN", 136, 151], ["a large Nterminal extension", "PROBLEM", 105, 132], ["mammalian eIF5B", "TREATMENT", 136, 151], ["mammalian eIF5B", "OBSERVATION", 27, 42], ["archaeal eIF5B", "OBSERVATION", 68, 82], ["large", "OBSERVATION_MODIFIER", 107, 112], ["Nterminal", "OBSERVATION_MODIFIER", 113, 122], ["extension", "OBSERVATION", 123, 132]]], ["Indeed, archaeal eIF5B can directly bind met-tRNA i met , although S. cerevisiae eIF5B has a relatively low affinity [59] .", [["eIF5B", "GENE_OR_GENE_PRODUCT", 17, 22], ["S. cerevisiae", "ORGANISM", 67, 80], ["eIF5B", "ORGANISM", 81, 86], ["archaeal eIF5B", "PROTEIN", 8, 22], ["S. cerevisiae eIF5B", "PROTEIN", 67, 86], ["S. cerevisiae", "SPECIES", 67, 80], ["S. cerevisiae", "SPECIES", 67, 80], ["a relatively low affinity", "PROBLEM", 91, 116]]], ["These results suggest the Nterminus of mammalian eIF5B must be removed in order for it to function as a met-tRNA i met carrier molecule.", [["eIF5B", "GENE_OR_GENE_PRODUCT", 49, 54], ["Nterminus", "PROTEIN", 26, 35], ["mammalian eIF5B", "PROTEIN", 39, 54], ["carrier molecule", "PROTEIN", 119, 135], ["mammalian eIF5B", "TREATMENT", 39, 54]]], ["Consistent with this hypothesis, poliovirus 3C proteinase cleaves eIF5B during infection liberating the C-terminal fragment and potentiating its use in met-tRNA i met delivery [60] .", [["infection", "DISEASE", 79, 88], ["C", "CHEMICAL", 104, 105], ["poliovirus 3C proteinase", "GENE_OR_GENE_PRODUCT", 33, 57], ["eIF5B", "GENE_OR_GENE_PRODUCT", 66, 71], ["poliovirus 3C proteinase", "PROTEIN", 33, 57], ["eIF5B", "PROTEIN", 66, 71], ["C-terminal fragment", "DNA", 104, 123], ["poliovirus 3C", "SPECIES", 33, 46], ["this hypothesis", "PROBLEM", 16, 31], ["poliovirus 3C proteinase cleaves", "TREATMENT", 33, 65], ["infection", "PROBLEM", 79, 88], ["the C-terminal fragment", "PROBLEM", 100, 123], ["infection", "OBSERVATION", 79, 88], ["terminal fragment", "OBSERVATION", 106, 123]]], ["The C-terminus is then capable of enhancing IRES-mediated translation of PV when ternary complex is depleted [52] .", [["C-terminus", "GENE_OR_GENE_PRODUCT", 4, 14], ["PV", "GENE_OR_GENE_PRODUCT", 73, 75], ["C-terminus", "PROTEIN", 4, 14], ["IRES", "DNA", 44, 48], ["PV", "PROTEIN", 73, 75], ["ternary complex", "PROTEIN", 81, 96], ["enhancing IRES", "PROBLEM", 34, 48]]], ["Interestingly, HCV and CSFV have also been shown to act in an eIF2-independent mode using eIF5B to assemble initiation complexes [51, 61] .", [["HCV", "ORGANISM", 15, 18], ["CSFV", "ORGANISM", 23, 27], ["eIF2", "GENE_OR_GENE_PRODUCT", 62, 66], ["eIF5B", "GENE_OR_GENE_PRODUCT", 90, 95], ["eIF2", "PROTEIN", 62, 66], ["eIF5B", "PROTEIN", 90, 95], ["initiation complexes", "PROTEIN", 108, 128], ["HCV", "SPECIES", 15, 18], ["CSFV", "SPECIES", 23, 27], ["HCV", "PROBLEM", 15, 18], ["CSFV", "PROBLEM", 23, 27], ["HCV", "OBSERVATION", 15, 18]]], ["In the cases of the HCV and CSFV IRES elements, eIF5B can function in the presence of the N-terminal extension.", [["N-", "CHEMICAL", 90, 92], ["HCV", "ORGANISM", 20, 23], ["CSFV", "ORGANISM", 28, 32], ["eIF5B", "GENE_OR_GENE_PRODUCT", 48, 53], ["HCV and CSFV IRES elements", "DNA", 20, 46], ["eIF5B", "DNA", 48, 53], ["HCV", "SPECIES", 20, 23], ["CSFV", "SPECIES", 28, 32], ["the HCV and CSFV IRES elements", "PROBLEM", 16, 46], ["the N-terminal extension", "PROBLEM", 86, 110], ["HCV", "OBSERVATION", 20, 23], ["CSFV IRES", "OBSERVATION", 28, 37], ["terminal", "OBSERVATION_MODIFIER", 92, 100]]], ["Therefore, it will be of interest to delineate the role of the N-terminus in regulating met-tRNA i met delivery, and determine whether either cleavage or posttranslational modification contribute to this function during viral infection.Use of alternative factors for initiator tRNA deliveryAlthough viruses differ in the route to efficient initiation of protein synthesis, many plus sense RNA viruses can employ similar strategies to enable ongoing protein synthesis during global translation inhibition by eIF2 phosphorylation.", [["viral infection", "DISEASE", 220, 235], ["N", "CHEMICAL", 63, 64], ["met-tRNA i", "GENE_OR_GENE_PRODUCT", 88, 98], ["eIF2", "GENE_OR_GENE_PRODUCT", 507, 511], ["N-terminus", "PROTEIN", 63, 73], ["eIF2", "PROTEIN", 507, 511], ["the N-terminus", "TREATMENT", 59, 73], ["delivery", "TREATMENT", 103, 111], ["posttranslational modification", "PROBLEM", 154, 184], ["this function", "PROBLEM", 199, 212], ["viral infection", "PROBLEM", 220, 235], ["alternative factors", "TREATMENT", 243, 262], ["initiator tRNA delivery", "TREATMENT", 267, 290], ["viruses", "PROBLEM", 299, 306], ["protein synthesis", "TREATMENT", 354, 371], ["many plus sense RNA viruses", "PROBLEM", 373, 400], ["ongoing protein synthesis", "PROBLEM", 441, 466], ["global translation inhibition", "TREATMENT", 474, 503], ["eIF2 phosphorylation", "TREATMENT", 507, 527], ["infection", "OBSERVATION", 226, 235], ["viruses", "OBSERVATION", 299, 306]]], ["Interestingly, plant viruses do not contend with robust eIF2 phosphorylation despite the presence of PKR in plant cells [62] ; these viruses clearly have a different set of parameters to enable expression of viral proteins.", [["cells", "ANATOMY", 114, 119], ["eIF2", "GENE_OR_GENE_PRODUCT", 56, 60], ["PKR", "GENE_OR_GENE_PRODUCT", 101, 104], ["plant cells", "CELL", 108, 119], ["eIF2", "PROTEIN", 56, 60], ["PKR", "PROTEIN", 101, 104], ["plant cells", "CELL_TYPE", 108, 119], ["viral proteins", "PROTEIN", 208, 222], ["robust eIF2 phosphorylation", "TREATMENT", 49, 76], ["PKR in plant cells", "PROBLEM", 101, 119], ["these viruses", "PROBLEM", 127, 140], ["viral proteins", "PROBLEM", 208, 222], ["viruses", "OBSERVATION", 21, 28], ["plant cells", "OBSERVATION", 108, 119], ["viral proteins", "OBSERVATION", 208, 222]]], ["Perhaps activity of alternative met-tRNA i met delivery proteins is higher on plant virus RNAs thereby making them more competitive with ongoing cellular protein synthesis.Long-range RNA interactions that increase translation competitivenessAnimal viruses with capped genomes or mRNAs must also compete for translational machinery, but must navigate downregulation of cap-dependent translation that is often associated with infection.", [["cellular", "ANATOMY", 145, 153], ["infection", "DISEASE", 424, 433], ["cellular", "CELL", 145, 153], ["cap", "GENE_OR_GENE_PRODUCT", 368, 371], ["plant virus RNAs", "RNA", 78, 94], ["capped genomes", "DNA", 261, 275], ["mRNAs", "RNA", 279, 284], ["alternative met-tRNA i met delivery proteins", "TREATMENT", 20, 64], ["plant virus RNAs", "TREATMENT", 78, 94], ["ongoing cellular protein synthesis", "PROBLEM", 137, 171], ["Long-range RNA interactions", "PROBLEM", 172, 199], ["Animal viruses", "PROBLEM", 241, 255], ["translational machinery", "TREATMENT", 307, 330], ["cap-dependent translation", "PROBLEM", 368, 393], ["infection", "PROBLEM", 424, 433], ["protein synthesis", "OBSERVATION", 154, 171], ["viruses", "OBSERVATION", 248, 255], ["cap", "OBSERVATION_MODIFIER", 368, 371], ["often associated with", "UNCERTAINTY", 402, 423], ["infection", "OBSERVATION", 424, 433]]], ["Closed loop structures mediated by long range RNA:RNA kissing interactions are a common paradigm in plant viruses that have rarely been described in animal viruses.", [["long range RNA", "RNA", 35, 49], ["Closed loop structures", "PROBLEM", 0, 22], ["RNA kissing interactions", "PROBLEM", 50, 74], ["a common paradigm in plant viruses", "PROBLEM", 79, 113], ["loop", "OBSERVATION", 7, 11], ["long", "OBSERVATION_MODIFIER", 35, 39], ["RNA kissing", "OBSERVATION", 50, 61], ["plant viruses", "OBSERVATION", 100, 113], ["viruses", "OBSERVATION", 156, 163]]], ["However, in animal viruses the 3 0 UTRs can enhance viral IRESmediated translation, though precise mechanisms are lacking [63] [64] [65] [66] [67] [68] [69] [70] .Long-range RNA interactions that increase translation competitivenessOne example of the influence of the 3 0 UTR on translation of a 5 0 capped, non-polyadenylated animal virus is observed in the Dengue virus (DEN) mRNA.", [["Dengue", "DISEASE", 359, 365], ["[63] [64] [65] [66] [67] [68] [69] [70]", "SIMPLE_CHEMICAL", 122, 161], ["Dengue virus", "ORGANISM", 359, 371], ["DEN", "ORGANISM", 373, 376], ["3 0 UTRs", "DNA", 31, 39], ["3 0 UTR", "DNA", 268, 275], ["Dengue virus (DEN) mRNA", "RNA", 359, 382], ["Dengue virus", "SPECIES", 359, 371], ["Dengue virus", "SPECIES", 359, 371], ["viral IRESmediated translation", "PROBLEM", 52, 82], ["Long-range RNA interactions", "PROBLEM", 163, 190], ["a 5 0 capped", "TREATMENT", 294, 306], ["non-polyadenylated animal virus", "PROBLEM", 308, 339], ["the Dengue virus", "PROBLEM", 355, 371], ["virus", "OBSERVATION", 334, 339], ["Dengue virus", "OBSERVATION", 359, 371]]], ["Two conserved dumbbell-shaped RNA structures within the 3 0 UTR not only form local pseudoknots important for RNA replication, but also work cooperatively to stimulate translation [71] .", [["3 0 UTR", "DNA", 56, 63], ["Two conserved dumbbell-shaped RNA structures", "PROBLEM", 0, 44], ["RNA replication", "TREATMENT", 110, 125], ["dumbbell", "OBSERVATION_MODIFIER", 14, 22], ["shaped", "OBSERVATION_MODIFIER", 23, 29], ["RNA structures", "OBSERVATION", 30, 44], ["local pseudoknots", "OBSERVATION", 78, 95]]], ["DEN can switch from capdependent to a non-canonical cap-independent translation mode when eIF4E is limiting.", [["DEN", "CHEMICAL", 0, 3], ["DEN", "CHEMICAL", 0, 3], ["DEN", "SIMPLE_CHEMICAL", 0, 3], ["eIF4E", "GENE_OR_GENE_PRODUCT", 90, 95], ["eIF4E", "PROTEIN", 90, 95], ["a non-canonical cap", "TREATMENT", 36, 55]]], ["The mechanism does not involve an IRES, but requires a closed loop [72] .", [["IRES", "DNA", 34, 38], ["a closed loop", "TREATMENT", 53, 66], ["does not involve", "UNCERTAINTY", 14, 30], ["IRES", "OBSERVATION", 34, 38]]], ["The details of this mechanism are unclear but probably involves RNA:RNA hybridization through the cyclization sequence (CS) and the upstream AUG region (UAR) [73, 74 ] .", [["cyclization sequence", "PROTEIN", 98, 118], ["upstream AUG region", "DNA", 132, 151], ["RNA hybridization", "TEST", 68, 85], ["the cyclization sequence", "TEST", 94, 118]]], ["PABP may stimulate translation by enhancing closed loop formation by binding the 3 0 UTR [74 ] and eIF4F simultaneously, despite the lack of a poly(A) tail.", [["PABP", "GENE_OR_GENE_PRODUCT", 0, 4], ["eIF4F", "GENE_OR_GENE_PRODUCT", 99, 104], ["poly(A) tail", "GENE_OR_GENE_PRODUCT", 143, 155], ["PABP", "PROTEIN", 0, 4], ["3 0 UTR [74", "DNA", 81, 92], ["eIF4F", "PROTEIN", 99, 104], ["poly(A) tail", "PROTEIN", 143, 155], ["PABP", "TREATMENT", 0, 4], ["enhancing closed loop formation", "TREATMENT", 34, 65], ["enhancing", "OBSERVATION_MODIFIER", 34, 43], ["closed loop", "OBSERVATION", 44, 55], ["tail", "ANATOMY", 151, 155]]], ["The dumbbell structures in the 3 0 UTR may also help to recruit trans-acting or initiation factors to stimulate translation.", [["dumbbell structures", "ANATOMY", 4, 23], ["3 0 UTR", "DNA", 31, 38], ["initiation factors", "PROTEIN", 80, 98], ["dumbbell structures", "OBSERVATION", 4, 23]]], ["The 3 0 UTR of DEN mRNA has been demonstrated to interact with typical ITAFs PTB, La, and YB-1 [75] [76] [77] , which could function to enhance DEN translation in a manner similar to their influence in IRES-mediated translation.", [["DEN", "CHEMICAL", 15, 18], ["DEN", "ORGANISM", 15, 18], ["ITAFs PTB", "GENE_OR_GENE_PRODUCT", 71, 80], ["YB-1", "GENE_OR_GENE_PRODUCT", 90, 94], ["DEN", "SIMPLE_CHEMICAL", 144, 147], ["3 0 UTR", "DNA", 4, 11], ["DEN mRNA", "RNA", 15, 23], ["ITAFs", "PROTEIN", 71, 76], ["PTB", "PROTEIN", 77, 80], ["La", "PROTEIN", 82, 84], ["YB", "PROTEIN", 90, 92], ["IRES", "DNA", 202, 206], ["La", "TEST", 82, 84], ["YB", "TEST", 90, 92]]], ["Overall, the RNA elements in the DEN 3 0 UTR may function similarly to many plant viruses with 3 0 UTR CITEs (see companion review in this issue) to stimulate translation when eIF4E becomes limited from stress or innate immunity activation.", [["eIF4E", "GENE_OR_GENE_PRODUCT", 176, 181], ["RNA elements", "DNA", 13, 25], ["DEN 3 0 UTR", "DNA", 33, 44], ["0 UTR CITEs", "DNA", 97, 108], ["eIF4E", "PROTEIN", 176, 181], ["stress", "PROBLEM", 203, 209], ["innate immunity activation", "PROBLEM", 213, 239], ["RNA elements", "OBSERVATION", 13, 25], ["plant viruses", "OBSERVATION", 76, 89]]], ["It will be important to further elucidate host factors that interact with the sequences in the 3 0 UTR and identify their precise mechanisms of translational regulation.Long-range RNA interactions that increase translation competitivenessLong range RNA kissing interactions have also been described for HCV, where the RNA domain 5BSL3.2 within the 3 0 region of the NS5B ORF base pairs with a portion of the HCV IRES.", [["HCV", "ORGANISM", 303, 306], ["NS5B", "GENE_OR_GENE_PRODUCT", 366, 370], ["3 0 UTR", "DNA", 95, 102], ["3 0 region", "DNA", 348, 358], ["NS5B ORF base pairs", "DNA", 366, 385], ["HCV IRES", "DNA", 408, 416], ["HCV", "SPECIES", 303, 306], ["HCV", "SPECIES", 408, 411], ["host factors", "PROBLEM", 42, 54], ["translational regulation", "TREATMENT", 144, 168], ["Long-range RNA interactions", "PROBLEM", 169, 196], ["Long range RNA kissing interactions", "PROBLEM", 238, 273], ["HCV", "PROBLEM", 303, 306], ["the RNA domain 5BSL", "TEST", 314, 333], ["the NS5B ORF base pairs", "PROBLEM", 362, 385], ["NS5B", "OBSERVATION", 366, 370], ["base", "ANATOMY_MODIFIER", 375, 379], ["HCV IRES", "OBSERVATION", 408, 416]]], ["Unlike DEN, this RNA:RNA interaction downregulates HCV IRES translation and may play a role in directing viral RNA to switch from translation to RNA replication [78 ] .", [["DEN", "CHEMICAL", 7, 10], ["DEN", "CHEMICAL", 7, 10], ["DEN", "SIMPLE_CHEMICAL", 7, 10], ["HCV", "ORGANISM", 51, 54], ["viral RNA", "RNA", 105, 114], ["HCV", "SPECIES", 51, 54], ["HCV IRES translation", "TREATMENT", 51, 71], ["viral RNA", "TREATMENT", 105, 114], ["RNA replication", "TREATMENT", 145, 160]]], ["Further, PCBP2, which functions as an ITAF in PV translation, binds both HCV 5 0 and 3 UTR.", [["PCBP2", "GENE_OR_GENE_PRODUCT", 9, 14], ["ITAF", "GENE_OR_GENE_PRODUCT", 38, 42], ["PV", "GENE_OR_GENE_PRODUCT", 46, 48], ["HCV 5", "ORGANISM", 73, 78], ["PCBP2", "PROTEIN", 9, 14], ["ITAF", "PROTEIN", 38, 42], ["HCV 5 0 and 3 UTR", "DNA", 73, 90], ["PCBP2", "TEST", 9, 14]]], ["Electron microscopy demonstrated that PCBP2, probably via dimerization, converted RNA from linear to circular forms.", [["PCBP2", "GENE_OR_GENE_PRODUCT", 38, 43], ["PCBP2", "PROTEIN", 38, 43], ["Electron microscopy", "TEST", 0, 19], ["PCBP2", "TEST", 38, 43], ["dimerization", "OBSERVATION", 58, 70]]], ["Interaction of PCBP2 with HCV replicons stimulated translation, perhaps via formation of closed loops, though the mechanism was not determined [79] .", [["PCBP2", "GENE_OR_GENE_PRODUCT", 15, 20], ["HCV", "ORGANISM", 26, 29], ["PCBP2", "PROTEIN", 15, 20], ["HCV replicons", "DNA", 26, 39], ["HCV", "SPECIES", 26, 29], ["PCBP2", "TREATMENT", 15, 20], ["HCV replicons stimulated translation", "TREATMENT", 26, 62], ["closed loops", "PROBLEM", 89, 101], ["closed loops", "OBSERVATION", 89, 101]]], ["These results indicate that HCV circularization modulates translation in multiple, possibly temporal ways.Long-range RNA interactions that increase translation competitivenessLong range RNA interactions linking the 5 0 and 3 0 UTR have otherwise only been described in the FMDV viral RNA [80] .", [["HCV", "ORGANISM", 28, 31], ["5 0 and 3 0 UTR", "DNA", 215, 230], ["FMDV viral RNA", "RNA", 273, 287], ["FMDV", "SPECIES", 273, 277], ["HCV", "SPECIES", 28, 31], ["FMDV", "SPECIES", 273, 277], ["HCV circularization modulates translation", "PROBLEM", 28, 69], ["Long-range RNA interactions", "PROBLEM", 106, 133], ["Long range RNA interactions", "PROBLEM", 175, 202], ["HCV circularization", "OBSERVATION", 28, 47], ["possibly", "UNCERTAINTY", 83, 91], ["temporal", "ANATOMY_MODIFIER", 92, 100]]], ["Despite a known importance for the 3 0 UTR of FMDV in stimulating IRES-mediated translation [68] , the functional relevance of this interaction is only speculative.", [["FMDV", "ORGANISM", 46, 50], ["3 0 UTR", "DNA", 35, 42], ["IRES", "DNA", 66, 70], ["FMDV", "SPECIES", 46, 50], ["FMDV", "SPECIES", 46, 50], ["FMDV in stimulating IRES", "TREATMENT", 46, 70]]], ["More studies dedicated to understanding the functional relevance of interactions between the 5 0 and 3 0 UTRs, or possibly 3 0 coding regions, of animal viruses may highlight important roles in recruiting translation factors, similar to the paradigm in plant CITEs.", [["5 0 and 3 0 UTRs", "DNA", 93, 109], ["3 0 coding regions", "DNA", 123, 141], ["translation factors", "PROTEIN", 205, 224], ["animal viruses", "PROBLEM", 146, 160], ["viruses", "OBSERVATION", 153, 160], ["plant CITEs", "OBSERVATION", 253, 264]]], ["Studies of plant RNA virus translation systems may identify additional, noncanonical proteins that are important for efficient competition with cellular mRNAs for the translational machinery.Perspectives and future directionsAnimal and plant viruses have evolved cunning mechanisms to ensure competition with cellular mRNAs for the translation machinery.", [["cellular", "ANATOMY", 144, 152], ["cellular", "ANATOMY", 309, 317], ["cellular", "CELL", 144, 152], ["cellular", "CELL", 309, 317], ["noncanonical proteins", "PROTEIN", 72, 93], ["cellular mRNAs", "RNA", 144, 158], ["cellular mRNAs", "RNA", 309, 323], ["plant RNA virus translation systems", "TEST", 11, 46], ["cellular mRNAs", "TREATMENT", 144, 158], ["Animal and plant viruses", "PROBLEM", 225, 249], ["cellular mRNAs", "TREATMENT", 309, 323], ["plant viruses", "OBSERVATION", 236, 249]]], ["IRESs share key functions with the 3 0 CITEs prevalent in plant virus systems, including the emerging theme of tRNA mimicry; however, no animal virus has yet been found with a 3 0 CITE.", [["IRESs", "GENE_OR_GENE_PRODUCT", 0, 5], ["CITEs", "GENE_OR_GENE_PRODUCT", 39, 44], ["IRESs", "PROTEIN", 0, 5], ["tRNA mimicry", "PROBLEM", 111, 123], ["animal virus", "PROBLEM", 137, 149]]], ["This is despite the recurring animal virus theme of 5 0 -3 0 closed loop mRNA structures that in principle could allow ribosome recruitment to 3 0 structures in spatial proximity to nearby 5 0 initiator codons.", [["ribosome", "ANATOMY", 119, 127], ["5 0 -3 0 closed loop mRNA structures", "RNA", 52, 88], ["5 0 initiator codons", "DNA", 189, 209], ["the recurring animal virus theme", "PROBLEM", 16, 48], ["closed loop mRNA structures", "TREATMENT", 61, 88], ["ribosome recruitment", "TREATMENT", 119, 139], ["virus", "OBSERVATION", 37, 42], ["loop mRNA", "OBSERVATION_MODIFIER", 68, 77], ["ribosome recruitment", "OBSERVATION", 119, 139]]], ["The principle of complex recruitment to one end of the RNA and transfer to the other end exists in enteroviruses, where the negative strand RNA replication complex assembles on a 5 0 cloverleaf structure that, within a closed loop, positions the replicase near the 3 0 end of the template to initiate replication on the other end of the template (reviewed in [81, 82] ).", [["negative strand RNA replication complex", "PROTEIN", 124, 163], ["5 0 cloverleaf structure", "DNA", 179, 203], ["3 0 end", "DNA", 265, 272], ["the RNA", "PROBLEM", 51, 58], ["enteroviruses", "PROBLEM", 99, 112], ["a 5 0 cloverleaf structure", "TREATMENT", 177, 203], ["a closed loop", "TREATMENT", 217, 230], ["the replicase", "TREATMENT", 242, 255], ["the template", "TREATMENT", 276, 288], ["replication", "TREATMENT", 301, 312], ["complex", "OBSERVATION_MODIFIER", 17, 24], ["recruitment", "OBSERVATION", 25, 36], ["enteroviruses", "OBSERVATION", 99, 112], ["closed loop", "OBSERVATION", 219, 230], ["replication", "OBSERVATION", 301, 312]]], ["It is unclear whether this paradigm exists for translation in animal cells, but it may partly emerge with further study of flaviviruses such as DEN.", [["cells", "ANATOMY", 69, 74], ["flaviviruses", "DISEASE", 123, 135], ["DEN", "CHEMICAL", 144, 147], ["DEN", "CHEMICAL", 144, 147], ["cells", "CELL", 69, 74], ["flaviviruses", "ORGANISM", 123, 135], ["DEN", "SIMPLE_CHEMICAL", 144, 147], ["animal cells", "CELL_TYPE", 62, 74], ["translation in animal cells", "PROBLEM", 47, 74], ["further study", "TEST", 106, 119], ["flaviviruses", "PROBLEM", 123, 135], ["unclear whether", "UNCERTAINTY", 6, 21]]], ["Avoidance of innate immunity and stress responses could explain the sharp divergence between plant and animal systems regarding these responses and how viruses must adapt.", [["stress responses", "PROBLEM", 33, 49], ["the sharp divergence between plant and animal systems", "PROBLEM", 64, 117]]], ["This is highlighted in the novel responses to stress inhibition of translation where animal viruses employ different cellular proteins to deliver met-tRNA i met to the ribosome.", [["cellular", "ANATOMY", 117, 125], ["ribosome", "ANATOMY", 168, 176], ["cellular", "CELL", 117, 125], ["ribosome", "CELLULAR_COMPONENT", 168, 176], ["cellular proteins", "PROTEIN", 117, 134], ["stress inhibition of translation", "TREATMENT", 46, 78], ["animal viruses", "PROBLEM", 85, 99]]], ["The differences between plant and animal virus translation, and translation of cellular mRNAs indicate that themes are paralleled between the mRNA templates with slight variations to account for organism-specific translational regulation.", [["cellular", "ANATOMY", 79, 87], ["cellular", "CELL", 79, 87], ["cellular mRNAs", "RNA", 79, 93], ["mRNA templates", "RNA", 142, 156], ["animal virus translation", "TREATMENT", 34, 58], ["slight variations", "PROBLEM", 162, 179], ["organism", "PROBLEM", 195, 203], ["virus translation", "OBSERVATION", 41, 58], ["cellular mRNAs", "OBSERVATION", 79, 93], ["mRNA templates", "OBSERVATION", 142, 156], ["slight", "OBSERVATION_MODIFIER", 162, 168]]], ["Additional mechanistic insights could be gained if more attention is devoted towards bridging common translational control mechanisms in the animal and plant virus kingdoms.", [["virus kingdoms", "OBSERVATION", 158, 172]]]], "PMC7267560": [["Maintaining safe distance between colleagues, not examining the mouth or oropharynx without full personal protection equipment (PPE) which includes a full facial visor, an approved face mask, apron and gloves are clearly important, as is regular handwashing for at least 20 seconds.", [["mouth", "ANATOMY", 64, 69], ["oropharynx", "ANATOMY", 73, 83], ["facial", "ANATOMY", 155, 161], ["face", "ANATOMY", 181, 185], ["mouth", "ORGANISM_SUBDIVISION", 64, 69], ["oropharynx", "ORGAN", 73, 83], ["a full facial visor", "TREATMENT", 148, 167], ["an approved face mask", "TREATMENT", 169, 190], ["apron and gloves", "TREATMENT", 192, 208], ["mouth", "ANATOMY", 64, 69], ["oropharynx", "ANATOMY", 73, 83]]], ["Nasendoscopy is not recommended at the current time unless absolutely necessary.", [["Nasendoscopy", "TREATMENT", 0, 12]]], ["Similarly, aerosol\u2010inducing treatments including the use of dental burs can significantly raise the risk of COVD\u201019 infection.", [["COVD", "DISEASE", 108, 112], ["infection", "DISEASE", 116, 125], ["aerosol\u2010inducing treatments", "TREATMENT", 11, 38], ["dental burs", "TREATMENT", 60, 71], ["COVD\u201019 infection", "PROBLEM", 108, 125], ["infection", "OBSERVATION", 116, 125]]], ["Two useful links about COVID\u201019, published by UK Specialty Associations, are available.6,7These provide clear information for colleagues who manage oral cancer and work in and around the oral cavity.", [["oral cancer", "ANATOMY", 148, 159], ["oral cavity", "ANATOMY", 187, 198], ["oral cancer", "DISEASE", 148, 159], ["oral cancer", "CANCER", 148, 159], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 187, 198], ["oral cancer", "PROBLEM", 148, 159], ["cancer", "OBSERVATION", 153, 159], ["oral cavity", "ANATOMY", 187, 198]]], ["Our UK specialty associations advise that examination of the oral cavity is regarded as high risk and fully protective measures should be used.GUIDELINES ON COVID\u201019Even when not at work, we should be extra careful.", [["oral cavity", "ANATOMY", 61, 72], ["oral cavity", "ORGANISM_SUBDIVISION", 61, 72], ["examination of the oral cavity", "TEST", 42, 72], ["fully protective measures", "TREATMENT", 102, 127]]], ["Coronavirus can live for up to 72 hours on some surfaces such as stainless steel and some plastics, and therefore, we are at risk from petrol pumps, ATM machines and supermarket trolleys to name just a few potential sources of transmission.RESEARCH ACTIVITYWith many colleagues around the world working from home, this crisis might provide some with the time and opportunity to complete an overdue research manuscript.", [["Coronavirus", "CHEMICAL", 0, 11], ["Coronavirus", "PROBLEM", 0, 11], ["some plastics", "TREATMENT", 85, 98], ["petrol pumps", "TREATMENT", 135, 147], ["ATM machines", "TREATMENT", 149, 161]]]], "2f52e5fd70a1dffd39054577ee06760c0f69f8b1": [["Chemoinformatics mainly emerged due to the enormous amount of data that has been generated by recent drug discovery attempts, including high-throughput screening and combinatorial chemistry methodologies (Russo 2002) .", [["Chemoinformatics", "TEST", 0, 16], ["combinatorial chemistry methodologies", "TEST", 166, 203]]], ["Chemoinformatics include several modeling approaches aiming at successful drug design.", [["several modeling approaches", "TREATMENT", 25, 52]]], ["For instance, the development of quantitative relationships between the observed biological activities and the chemical structures through construction of quantitative structure-activity relationships (QSARs) models and the prediction of ligand-protein structures via docking approaches are among the most widely used techniques.", [["docking approaches", "TREATMENT", 268, 286]]], ["It is important to highlight that the methods employed in chemoinformatics are usually developed to handle large sets of chemical structures and their different properties (usually referred as molecular descriptors) and thus should be appropriate for big data analysis.IntroductionThrough the course of the years, the development of chemoinformatics approaches has been greatly assisted by data mining tools and open-source software.", [["big data analysis", "TEST", 251, 268], ["chemoinformatics approaches", "TREATMENT", 333, 360]]], ["The recently released curated small-molecule databases are valuable assets for testing and validating chemoinformatics algorithms and tools (Hu and Bajorath 2012) .", [["testing", "TEST", 79, 86], ["validating chemoinformatics algorithms", "TEST", 91, 129], ["small", "OBSERVATION_MODIFIER", 30, 35]]], ["There are many databases (either publicly available or proprietary) containing a number of chemical substances.", [["chemical substances", "OBSERVATION", 91, 110]]], ["The size of typical databases ranges between tens of thousands and millions of compound entries (Leach and Gillet 2007) .", [["size", "OBSERVATION_MODIFIER", 4, 8], ["typical", "OBSERVATION_MODIFIER", 12, 19], ["databases", "OBSERVATION", 20, 29], ["ranges", "OBSERVATION_MODIFIER", 30, 36], ["thousands", "OBSERVATION_MODIFIER", 53, 62], ["millions", "OBSERVATION_MODIFIER", 67, 75], ["compound entries", "OBSERVATION", 79, 95]]], ["ZINC contains the three-dimensional structures of commercially available compounds, which were constructed to be used in structurebased virtual screening, while PubChem, BindingDB, and ChEMBL also include (bio)activity information.", [["ZINC", "PROTEIN", 0, 4], ["ZINC", "TREATMENT", 0, 4], ["structurebased virtual screening", "TEST", 121, 153]]], ["Additionally, PubChem provides screening information data sets (SIDS) and the three-dimensional structures of the majority of the compounds, and in BindingDB and ChEMBL databases the activities of compounds can be assembled into relevant classes.", [["compounds", "OBSERVATION", 130, 139]]], ["Activity classes are of particular usefulness toward benchmarking of new computational methodologies (Hu and Bajorath 2012) .IntroductionRecently, virtual databases have been built.", [["virtual databases", "TEST", 147, 164]]], ["This broader consideration allows for the construction of even larger virtual libraries containing billions of compounds (Leach and Gillet 2007) .IntroductionThe release of these important sources of information that can be systematically explored have boosted the development of many software tools for chemoinformatics that make extensive use of datasets.", [["chemoinformatics", "TREATMENT", 304, 320]]], ["Among others, software tools have been particularly emerged to tackle research practices, such as data mining, virtual screening and machine learning, molecular selectivity analysis, and visualization of structure-activity relationships (SARs) .IntroductionIn this chapter, we briefly review some of the most popular chemoinformatics tools with particular emphasis on programs that are either publicly available or at least free for academic purposes.", [["virtual screening", "TEST", 111, 128], ["molecular selectivity analysis", "TEST", 151, 181]]], ["Since KNIME is the most widely used, freely available platform for chemoinformatics applications, we will specifically present tools that have been integrated into KNIME and are offered as KNIME nodes to execute several important tasks for chemoinformatics analysis.", [["KNIME", "DNA", 164, 169], ["chemoinformatics applications", "TREATMENT", 67, 96], ["chemoinformatics analysis", "TEST", 240, 265]]], ["Such applications include CDK, Indigo, RDKit, Vernalis, CACTVS, Enalos, Lhasa, OpenBabel, OCHEM, Chemical Identifier Resolver, ErlWood, EMBL-EBI Nodes, and CheS-Mapper.", [["CDK", "GENE_OR_GENE_PRODUCT", 26, 29], ["CDK", "PROBLEM", 26, 29], ["Indigo", "TEST", 31, 37], ["RDKit", "TEST", 39, 44], ["Vernalis", "TEST", 46, 54], ["EBI Nodes", "OBSERVATION", 141, 150]]], ["Konstanz Information Miner (KNIME) is an open-source analytics platform, which is the leading tool for wide-ranging data processing, integration, analysis, and exploration (Berthold et al. 2008) .", [["analysis", "TEST", 146, 154], ["exploration", "TEST", 160, 171]]], ["It enables the visual creation of data flows (so-called pipelines), the selective execution of specified analysis steps, and the presentation of the results via interactive views on models and data.", [["interactive views", "TEST", 161, 178], ["models and data", "TEST", 182, 197]]], ["KNIME offers intuitive use and high level of scalability, which currently render it the most popular platform for chemoinformatics applications.", [["KNIME", "CHEMICAL", 0, 5], ["chemoinformatics applications", "TREATMENT", 114, 143]]], ["Therefore, as already mentioned, this chapter will be mostly devoted to the description of software tools that employ KNIME to accomplish their functions.Popular Software Tools for ChemoinformaticsThe Chemistry Development Kit (CDK) is an open-source and development chemoinformatics software (Steinbeck et al. 2003) .", [["KNIME", "PROTEIN", 118, 123], ["CDK", "PROTEIN", 228, 231], ["Chemoinformatics", "TEST", 181, 197], ["The Chemistry", "TEST", 197, 210]]], ["In collaboration with the KNIME group, the CDK nodes for KNIME have been recently developed.", [["KNIME", "CHEMICAL", 57, 62], ["CDK", "GENE_OR_GENE_PRODUCT", 43, 46], ["CDK", "PROTEIN", 43, 46], ["KNIME", "PROTEIN", 57, 62], ["the CDK nodes", "TEST", 39, 52], ["CDK nodes", "OBSERVATION", 43, 52]]], ["These nodes provide features regarding chemical compound handling, such as several file conversion applications for molecules, calculation and drawing of 2D and 3D structures, symmetry group calculations, fingerprint calculation, proper handling of hydrogen atoms, and molecular property estimations, among others.Popular Software Tools for ChemoinformaticsIndigo (developed by GGA Software Services LLC) is a software tool for organic chemistry (http://lifescience.opensource.epam.com/indigo/).", [["nodes", "ANATOMY", 6, 11], ["ChemoinformaticsIndigo", "CHEMICAL", 341, 363], ["hydrogen", "CHEMICAL", 249, 257], ["nodes", "MULTI-TISSUE_STRUCTURE", 6, 11], ["hydrogen atoms", "SIMPLE_CHEMICAL", 249, 263], ["calculation and drawing of 2D and 3D structures", "TEST", 127, 174], ["group calculations", "TEST", 185, 203], ["fingerprint calculation", "TEST", 205, 228], ["hydrogen atoms", "TREATMENT", 249, 263], ["organic chemistry", "TEST", 428, 445], ["nodes", "OBSERVATION", 6, 11], ["hydrogen atoms", "OBSERVATION", 249, 263]]], ["Manipulation and functionality of organic structures with the Indigo nodes for KNIME can be obtained through conversions to Kekul\u00e9 and aromatic states, handling of hydrogen, molecular properties generation, fingerprint comparison, R-group decomposition, stereochemistry calculation, and component separation.", [["KNIME", "CHEMICAL", 79, 84], ["hydrogen", "CHEMICAL", 164, 172], ["hydrogen", "CHEMICAL", 164, 172], ["KNIME", "SIMPLE_CHEMICAL", 79, 84], ["Kekul\u00e9", "SIMPLE_CHEMICAL", 124, 130], ["hydrogen", "SIMPLE_CHEMICAL", 164, 172], ["the Indigo nodes", "TEST", 58, 74], ["hydrogen", "TREATMENT", 164, 172], ["fingerprint comparison", "TEST", 207, 229], ["R-group decomposition", "TREATMENT", 231, 252], ["stereochemistry calculation", "TEST", 254, 281], ["component separation", "TREATMENT", 287, 307], ["nodes", "OBSERVATION", 69, 74], ["component", "OBSERVATION_MODIFIER", 287, 296], ["separation", "OBSERVATION_MODIFIER", 297, 307]]], ["Additional functionalities include file conversions among SDF, SMILES, and CML formats; detection of drawing errors in structures; 2D structure generation; and structure matching.Popular Software Tools for ChemoinformaticsRDKit (http://www.rdkit.org/) also provides chemoinformatics applications through KNIME, for instance, substructure filtering and searching, 2D and 3D structure generation, chemical reactions, molecular fingerprinting, salt separation from compounds, and R-group decomposition.Popular Software Tools for ChemoinformaticsVernalis Research (http://www.vernalis.com/research) employs its KNIME nodes to assist structure-based and fragment-based drug discovery.", [["CML", "ANATOMY", 75, 78], ["CML", "DISEASE", 75, 78], ["CML", "CANCER", 75, 78], ["salt", "SIMPLE_CHEMICAL", 441, 445], ["SDF", "PROTEIN", 58, 61], ["KNIME nodes", "DNA", 607, 618], ["CML formats", "TEST", 75, 86], ["drawing errors in structures", "PROBLEM", 101, 129], ["2D structure generation", "PROBLEM", 131, 154], ["ChemoinformaticsRDKit", "TEST", 206, 227], ["2D and 3D structure generation", "TREATMENT", 363, 393], ["chemical reactions", "PROBLEM", 395, 413], ["molecular fingerprinting", "PROBLEM", 415, 439], ["salt separation from compounds", "PROBLEM", 441, 471], ["R-group decomposition", "TREATMENT", 477, 498], ["ChemoinformaticsVernalis Research (http://www.vernalis.com/research)", "TREATMENT", 526, 594], ["its KNIME nodes", "PROBLEM", 603, 618], ["CML", "OBSERVATION", 75, 78], ["chemical reactions", "OBSERVATION", 395, 413], ["salt separation", "OBSERVATION", 441, 456]]], ["It includes several functionalities, such as flow control, PDB and sequence tools, I/O applications, matched molecular pairs, and fingerprint properties.Popular Software Tools for ChemoinformaticsLhasa Limited nodes for KNIME offer additional operations on the evaluation of binary classification models and table manipulation (http://www.lhasalimited.org/).Popular Software Tools for ChemoinformaticsThe OpenBabel chemoinformatics package (http://openbabel.org/) is primarily a file converter toolbox (KNIME chemistry nodes).", [["KNIME", "DNA", 220, 225], ["flow control", "TREATMENT", 45, 57], ["PDB and sequence tools", "TEST", 59, 81], ["additional operations", "TREATMENT", 232, 253], ["the evaluation", "TEST", 257, 271], ["table manipulation", "TEST", 308, 326], ["Chemoinformatics", "TEST", 385, 401], ["The OpenBabel chemoinformatics package", "TREATMENT", 401, 439], ["several", "OBSERVATION_MODIFIER", 12, 19], ["functionalities", "OBSERVATION", 20, 35], ["nodes", "OBSERVATION", 210, 215], ["nodes", "OBSERVATION", 519, 524]]], ["It can also filter molecular files with SMARTS and has a wide applicability in analyzing molecular modeling and bioinformatics data (O'Boyle et al. 2011) .Popular Software Tools for ChemoinformaticsThe Online Chemical Modeling Environment (OCHEM) is a platform, which aims to simplify the procedures for performing QSAR calculations (Sushko et al. 2011) .", [["SMARTS", "PROTEIN", 40, 46], ["bioinformatics data", "TEST", 112, 131], ["Chemoinformatics", "TEST", 182, 198], ["the procedures", "TREATMENT", 285, 299], ["QSAR calculations", "TEST", 315, 332]]], ["This is achieved through combination of experimental results taken from a database and a modeling procedure.", [["a modeling procedure", "TREATMENT", 87, 107]]], ["The database contains thousands of entries and a user-friendly application environment.", [["thousands", "OBSERVATION_MODIFIER", 22, 31]]], ["The use of current KNIME nodes for OCHEM is restricted to some running predictions and the data export/import.", [["KNIME nodes", "MULTI-TISSUE_STRUCTURE", 19, 30], ["current KNIME nodes", "TREATMENT", 11, 30], ["nodes", "OBSERVATION", 25, 30]]], ["KNIME nodes development from ErlWood also offers interpretation and handling of structure-activity relationship data, as well as various compound viewing facilities (https://tech.knime.org/community/erlwood).Popular Software Tools for ChemoinformaticsThe European Bioinformatics Institute (www.ebi.ac.uk) provides the EMBL-EBI KNIME nodes, which make use of the Chemical Entities of Biological Interest (ChEBI) database to obtain database files via ChEBI IDs, substructure, or keyword searches.", [["KNIME nodes", "ANATOMY", 0, 11], ["KNIME nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["ChEBI IDs", "DNA", 449, 458], ["KNIME nodes development", "PROBLEM", 0, 23], ["Chemoinformatics", "TEST", 235, 251], ["nodes", "OBSERVATION", 6, 11], ["nodes", "OBSERVATION", 333, 338]]], ["ChEBI is a publicly available depository of small chemical molecules.Popular Software Tools for ChemoinformaticsThe visualization node CheS-Mapper (Gutlein et al. 2012 ) employs the characteristics of small molecule structures to perform clustering according to feature similarity criteria.", [["node", "ANATOMY", 130, 134], ["ChEBI", "CHEMICAL", 0, 5], ["small chemical molecules", "PROBLEM", 44, 68], ["Chemoinformatics", "TEST", 96, 112], ["small molecule structures", "PROBLEM", 201, 226], ["small", "OBSERVATION_MODIFIER", 44, 49], ["chemical molecules", "OBSERVATION", 50, 68], ["node", "OBSERVATION", 130, 134], ["small molecule", "OBSERVATION", 201, 215]]], ["3D structure depiction and embedding of compound datasets are also supported.Popular Software Tools for ChemoinformaticsThe Chemical Identifier Resolver (CIR, developed by the CADD group at the National Cancer Institute) nodes for KNIME enable the recognition of a chemical structure provided that an identifier is known (http://cactus.nci.nih.gov/chemical/ Fig. 1 Freely available Enalos KNIME nodes structure).", [["Cancer", "DISEASE", 203, 209], ["KNIME nodes", "MULTI-TISSUE_STRUCTURE", 389, 400], ["KNIME", "PROTEIN", 231, 236], ["Chemoinformatics", "TEST", 104, 120], ["compound datasets", "OBSERVATION", 40, 57]]], ["CIR is a resolver for various structure identifiers and can also convert a particular structure identifier into another one.Popular Software Tools for ChemoinformaticsFinally, the functionality of the Enalos KNIME nodes (https://tech.knime. org/community/enalos-nodes) developed by NovaMechanics Ltd will be briefly described.", [["enalos-nodes", "ANATOMY", 255, 267], ["nodes", "MULTI-TISSUE_STRUCTURE", 262, 267], ["Enalos KNIME nodes", "DNA", 201, 219], ["ChemoinformaticsFinally", "TEST", 151, 174], ["org", "TEST", 241, 244], ["nodes", "OBSERVATION", 262, 267]]], ["Enalos nodes for the KNIME platform are associated with several important aspects regarding data analysis and curation for chemoinformatics and nanoinformatics.", [["Enalos nodes", "MULTI-TISSUE_STRUCTURE", 0, 12], ["data analysis", "TEST", 92, 105], ["chemoinformatics", "TEST", 123, 139], ["nanoinformatics", "TREATMENT", 144, 159]]], ["The Enalos nodes ( Fig. 1 ) among others provide (1) domainsimilarity based on (i) euclidean distances or (ii) leverages, (2) fit quality and predictive power of a QSAR model with the Model Acceptability Criteria node, (3) the newly developed fast generation of all possible substitutions of a lead compound, and (4) calculation of important molecular descriptors with the Mold2 node.", [["Enalos nodes", "ANATOMY", 4, 16], ["Mold2 node", "ANATOMY", 373, 383], ["Enalos nodes", "MULTI-TISSUE_STRUCTURE", 4, 16], ["Mold2 node", "MULTI-TISSUE_STRUCTURE", 373, 383], ["The Enalos nodes ( Fig.", "TREATMENT", 0, 23], ["a QSAR model", "TEST", 162, 174], ["a lead compound", "PROBLEM", 292, 307], ["the Mold2 node", "PROBLEM", 369, 383], ["nodes", "OBSERVATION", 11, 16], ["node", "OBSERVATION", 213, 217], ["Mold2 node", "OBSERVATION", 373, 383]]], ["Mold2 is able to evaluate large and diverse sets of molecular descriptors from two-dimensional chemical structure information (Hong et al. 2008) .", [["Mold2", "SIMPLE_CHEMICAL", 0, 5], ["Mold2", "PROTEIN", 0, 5]]], ["Comparison of Mold2 descriptors with descriptors calculated from commercial software on several published datasets showed that Mold2 descriptors yield models with higher quality than other packages and also produce sufficient structural information.Popular Software Tools for ChemoinformaticsIn the following section, we present three case studies of in silico approaches developed by our group that involve the utilization of Enalos KNIME nodes for building predictive models.Chemoinformatics Studies Using the Enalos KNIME Nodes and Enalos Cloud PlatformThe KNIME analytics platform contains a multitude of processing nodes for data I/O, modeling, analysis, and data mining.", [["Mold2", "DNA", 14, 19], ["Mold2", "PROTEIN", 127, 132], ["Chemoinformatics Studies", "TEST", 477, 501], ["modeling, analysis", "TEST", 640, 658], ["nodes", "OBSERVATION", 620, 625]]], ["Over the last 30 years, a vast amount of data has been generated within the areas of chemo-, bio-, and nanoinformatics.", [["chemo-", "TREATMENT", 85, 91], ["nanoinformatics", "TEST", 103, 118]]], ["KNIME has emerged as one of the most reliable open-source data mining tools for the prediction of chemical properties and applications, such as virtual screening of chemicals and nanoparticles (NPs), chemical library enumeration, virtual library creation, building QSAR/QSPR, ADMET, and pharmacokinetics models, as well as prediction of various biological effects of organic compounds and NPs.Chemoinformatics Studies Using the Enalos KNIME Nodes and Enalos Cloud PlatformIn this section, we present three case studies that involve the use of Enalos KNIME nodes in predicting (i) the toxicity of iron oxide NPs, (ii) the cellular uptake of organic NPs (virtual screening is also demonstrated), and (iii) the inhibitory potency of organic substances against corrosion.Chemoinformatics Studies Using the Enalos KNIME Nodes and Enalos Cloud PlatformIn the first two case studies Enalos InSilico platform is also introduced.", [["cellular", "ANATOMY", 621, 629], ["KNIME", "CHEMICAL", 0, 5], ["toxicity", "DISEASE", 584, 592], ["iron oxide", "CHEMICAL", 596, 606], ["organic NPs", "CHEMICAL", 640, 651], ["corrosion", "DISEASE", 757, 766], ["iron oxide", "CHEMICAL", 596, 606], ["nanoparticles", "SIMPLE_CHEMICAL", 179, 192], ["NPs", "SIMPLE_CHEMICAL", 194, 197], ["organic compounds", "SIMPLE_CHEMICAL", 367, 384], ["NPs", "SIMPLE_CHEMICAL", 389, 392], ["iron oxide NPs", "SIMPLE_CHEMICAL", 596, 610], ["cellular", "CELL", 621, 629], ["organic NPs", "SIMPLE_CHEMICAL", 640, 651], ["virtual screening", "TEST", 144, 161], ["virtual library creation", "TREATMENT", 230, 254], ["building QSAR", "TEST", 256, 269], ["ADMET", "TREATMENT", 276, 281], ["pharmacokinetics models", "TREATMENT", 287, 310], ["organic compounds", "TREATMENT", 367, 384], ["NPs", "TREATMENT", 389, 392], ["Chemoinformatics Studies", "TEST", 393, 417], ["iron oxide NPs", "TREATMENT", 596, 610], ["organic NPs", "TEST", 640, 651], ["virtual screening", "TEST", 653, 670], ["organic substances", "TREATMENT", 730, 748], ["Chemoinformatics Studies", "TEST", 767, 791], ["the Enalos KNIME Nodes", "TREATMENT", 798, 820], ["Enalos InSilico platform", "TREATMENT", 876, 900], ["organic compounds", "OBSERVATION", 367, 384]]], ["Enalos InSilico platform is a Cloud platform built to host a variety of predictive models to address the need for risk assessment and virtual screening.", [["risk assessment", "TEST", 114, 129], ["virtual screening", "TEST", 134, 151]]], ["Predictive workflows are available in a user-friendly format and include toxicity, biological activity, and property evaluation models.Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformNanoparticles (NPs) are known for their unique optical, electronic, and mechanical properties, which have led to the rapid evolution of nanotechnology materials being applied in a wide range of commercial, technological, and therapeutic applications in fields such as environment, industry, defense, electronics, and biomedicine.", [["toxicity", "DISEASE", 73, 81], ["Toxicity", "DISEASE", 164, 172], ["Iron Oxide", "CHEMICAL", 187, 197], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 187, 211], ["Enalos InSilicoNano Cloud PlatformNanoparticles", "SIMPLE_CHEMICAL", 220, 267], ["toxicity", "PROBLEM", 73, 81], ["property evaluation models", "TEST", 108, 134], ["the Toxicity", "PROBLEM", 160, 172], ["Iron Oxide Nanoparticles", "TREATMENT", 187, 211], ["Enalos InSilicoNano Cloud PlatformNanoparticles (NPs", "TREATMENT", 220, 272], ["nanotechnology materials", "TREATMENT", 390, 414], ["therapeutic applications", "TREATMENT", 479, 503]]], ["The latter has enjoyed great scientific, technological, and commercial progress in different NP applications (Gajewicz et al. 2012; Cohen et al. 2013) .Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformAlong with the apparent increasing use of NPs, concerns on their effect upon the environment and human health have been raised.", [["Toxicity", "DISEASE", 181, 189], ["Iron", "CHEMICAL", 204, 208], ["NPs", "CHEMICAL", 313, 316], ["Iron Oxide", "CHEMICAL", 204, 214], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 204, 228], ["human", "ORGANISM", 368, 373], ["human", "SPECIES", 368, 373], ["human", "SPECIES", 368, 373], ["the Toxicity", "PROBLEM", 177, 189], ["Iron Oxide Nanoparticles", "TREATMENT", 204, 228], ["NPs", "TREATMENT", 313, 316]]], ["Since toxicity assessment of NPs via traditional experimental routes often require expensive and time-consuming procedures, computational approaches such as quantitative nanostructure-activity relationships (QNARs) have been successfully used to predict the toxic effects of NPs (Vrontaki et al. 2015; Kleandrova et al. 2014a, b; Speck-Planche et al. 2015; Winkler et al. 2013 Winkler et al. , 2014 Shao et al. 2013; Toropov et al. 2013) .", [["toxicity", "DISEASE", 6, 14], ["NPs", "SIMPLE_CHEMICAL", 29, 32], ["NPs", "SIMPLE_CHEMICAL", 275, 278], ["toxicity assessment", "TEST", 6, 25], ["NPs", "TREATMENT", 29, 32], ["procedures", "TREATMENT", 112, 122], ["computational approaches", "TREATMENT", 124, 148]]], ["However, the computational investigation of NP toxicity is seriously hindered by the lack of available NP descriptors, organized datasets, and systematic experimental data for NPs.", [["toxicity", "DISEASE", 47, 55], ["NPs", "SIMPLE_CHEMICAL", 176, 179], ["NP toxicity", "PROBLEM", 44, 55], ["NPs", "TREATMENT", 176, 179]]], ["Only few organized datasets on NP toxicity are available so far.", [["toxicity", "DISEASE", 34, 42], ["NP toxicity", "PROBLEM", 31, 42], ["few", "OBSERVATION_MODIFIER", 5, 8], ["organized", "OBSERVATION_MODIFIER", 9, 18], ["datasets", "OBSERVATION", 19, 27]]], ["Among these toxicity datasets on nanostructures, metal oxide NP data have been investigated in several computational studies (Fourches et al. 2010; Liu et al. 2011 Liu et al. , 2013a Puzyn et al. 2011; Zhang et al. 2012) .Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformA fully validated QNAR model is presented, which was constructed based on toxicity data of iron oxide NPs with different core, coating, and surface modifications Shaw et al. 2008; Liu et al. 2013 ).", [["surface", "ANATOMY", 481, 488], ["toxicity", "DISEASE", 12, 20], ["metal oxide", "CHEMICAL", 49, 60], ["Toxicity", "DISEASE", 251, 259], ["Iron", "CHEMICAL", 274, 278], ["toxicity", "DISEASE", 415, 423], ["iron oxide", "CHEMICAL", 432, 442], ["metal oxide", "CHEMICAL", 49, 60], ["Iron Oxide", "CHEMICAL", 274, 284], ["iron oxide", "CHEMICAL", 432, 442], ["metal oxide", "SIMPLE_CHEMICAL", 49, 60], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 274, 298], ["iron oxide NPs", "SIMPLE_CHEMICAL", 432, 446], ["these toxicity datasets", "PROBLEM", 6, 29], ["metal oxide NP data", "TREATMENT", 49, 68], ["the Toxicity", "PROBLEM", 247, 259], ["Iron Oxide Nanoparticles", "TREATMENT", 274, 298], ["Enalos InSilicoNano", "TREATMENT", 307, 326], ["iron oxide NPs", "TREATMENT", 432, 446], ["different core, coating", "TREATMENT", 452, 475]]], ["The initial dataset was constructed with 44 iron oxide NPs that comprised a core with either Fe 2 O 3 or Fe 3 O 4 coating, including cross-linked dextran, PVA, or other, and various surface modifications (Shaw et al. 2008; Liu et al. 2013) .", [["surface", "ANATOMY", 182, 189], ["iron oxide", "CHEMICAL", 44, 54], ["Fe", "CHEMICAL", 93, 95], ["Fe", "CHEMICAL", 105, 107], ["dextran", "CHEMICAL", 146, 153], ["PVA", "CHEMICAL", 155, 158], ["iron oxide", "CHEMICAL", 44, 54], ["Fe 2 O 3", "CHEMICAL", 93, 101], ["Fe 3 O 4", "CHEMICAL", 105, 113], ["PVA", "CHEMICAL", 155, 158], ["iron oxide NPs", "SIMPLE_CHEMICAL", 44, 58], ["Fe 2 O 3", "SIMPLE_CHEMICAL", 93, 101], ["Fe 3 O 4 coating", "SIMPLE_CHEMICAL", 105, 121], ["dextran", "SIMPLE_CHEMICAL", 146, 153], ["PVA", "SIMPLE_CHEMICAL", 155, 158], ["44 iron oxide NPs", "TREATMENT", 41, 58], ["cross-linked dextran", "TREATMENT", 133, 153], ["PVA", "TREATMENT", 155, 158]]], ["Values for descriptors such as the size, R1 and R2 relaxivities, and zeta potential along with a coating-indicative parameter were considered as independent variables for the model development.", [["the size", "TEST", 31, 39], ["a coating-indicative parameter", "TREATMENT", 95, 125], ["size", "OBSERVATION_MODIFIER", 35, 39]]], ["The values of the input variables for each NP and the corresponding toxicity class are shown in Table 1 .", [["toxicity", "DISEASE", 68, 76], ["each NP", "TREATMENT", 38, 45]]], ["(Liu et al. 2011; Epa et al. 2012) c R1: spin-lattice relaxivity; R2: spin-spin relaxivity d NHit: the number of hits identified for each NP across the 64 bioactivity measures (4 cell lines X 4 assays X 4 concentrations) NPs were evaluated with different assays in various cell types and concentrations that produced a 64-component vectorial metric.", [["cell lines", "ANATOMY", 179, 189], ["cell", "ANATOMY", 273, 277], ["NPs", "SIMPLE_CHEMICAL", 221, 224], ["cell", "CELL", 273, 277], ["each NP across the 64 bioactivity measures (4 cell lines", "TREATMENT", 133, 189], ["NPs", "TREATMENT", 221, 224]]], ["Each NP was characterized either active or inactive according to the number of hits obtained across the 64 bioactivity measures.", [["the 64 bioactivity measures", "TREATMENT", 100, 127], ["active", "OBSERVATION_MODIFIER", 33, 39]]], ["For the QNAR developed KNIME workflow, the following steps have been integrated: (1) data preprocessing, (2) variable selection, (3) model development and (4) validation, and (5) determination of domain of applicability [via the Enalos Domain -Similarity node that defines applicability domain (APD) based on euclidean distances].", [["Enalos Domain", "PROTEIN", 229, 242], ["the Enalos Domain", "TREATMENT", 225, 242], ["Similarity node", "PROBLEM", 244, 259], ["node", "OBSERVATION", 255, 259]]], ["The publicly available set of Enalos KNIME nodes can be accessed through either the KNIME Community or NovaMechanics website (www. novamechanics.com/knime.php or www.insilicotox.com/index.php/products/ enalos-knime-nodes-community-contributions/) (Melagraki and Afantitis 2013) .Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformBefore model running, the available data were separated into training set and test set with the partitioning node in KNIME.", [["node", "ANATOMY", 507, 511], ["Toxicity", "DISEASE", 308, 316], ["Iron Oxide", "CHEMICAL", 331, 341], ["KNIME nodes", "MULTI-TISSUE_STRUCTURE", 37, 48], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 331, 355], ["Enalos KNIME nodes", "TREATMENT", 30, 48], ["insilicotox.com", "TEST", 166, 181], ["index.php", "PROBLEM", 182, 191], ["the Toxicity", "PROBLEM", 304, 316], ["Iron Oxide Nanoparticles", "TREATMENT", 331, 355], ["Enalos InSilicoNano Cloud PlatformBefore model running", "TREATMENT", 364, 418], ["test", "TEST", 476, 480], ["nodes", "OBSERVATION", 215, 220], ["node", "OBSERVATION", 507, 511]]], ["The NPs used in the validation set were not further employed during model development.", [["The NPs", "TREATMENT", 0, 7]]], ["The proposed predictive model was validated internally and externally regarding goodness-of-fit, robustness, and predictivity, thus totally meeting the criteria recommended by the Organization for Economic Cooperation and Development (OECD).Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformTo validate the performance of the model, the following parameters were considered ( Additionally, the Y-randomization test demonstrated the robustness and the statistical significance of the predictive model.Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformThe ability to perform virtual screening of NPs that were not originally included in the dataset is particularly important, especially if there is an indication on its reliability.", [["Toxicity", "DISEASE", 270, 278], ["Toxicity", "DISEASE", 598, 606], ["Iron", "CHEMICAL", 621, 625], ["Iron Oxide", "CHEMICAL", 293, 303], ["Iron Oxide", "CHEMICAL", 621, 631], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 293, 317], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 621, 645], ["NPs", "CANCER", 732, 735], ["the Toxicity", "PROBLEM", 266, 278], ["Iron Oxide Nanoparticles", "TREATMENT", 293, 317], ["the Y-randomization test", "TEST", 459, 483], ["the Toxicity", "PROBLEM", 594, 606], ["Iron Oxide Nanoparticles", "TREATMENT", 621, 645], ["virtual screening of NPs", "TEST", 711, 735]]], ["This will identify NPs that are excluded from the area of reliable predictions of the proposed model.Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformIn this work, the Enalos Domain-Similarity node calculated the domain of applicability using euclidean distances to estimate the similarity between NPs belonging to the training and test sets.", [["Toxicity", "DISEASE", 130, 138], ["Iron", "CHEMICAL", 153, 157], ["Iron Oxide", "CHEMICAL", 153, 163], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 153, 177], ["NPs", "TREATMENT", 19, 22], ["the Toxicity", "PROBLEM", 126, 138], ["Iron Oxide Nanoparticles", "TREATMENT", 153, 177], ["the Enalos Domain", "TREATMENT", 234, 251], ["test sets", "TEST", 402, 411], ["node", "OBSERVATION", 263, 267]]], ["More details on the domain of applicability calculation can be found elsewhere (Melagraki and Afantitis 2013; Afantitis et al. 2008; Tropsha 2010) .Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformBased on the reported toxicity data for the 44 iron oxide NPs used in this study, 31 compounds were included in the training set while the other 13 in the test set.", [["Toxicity", "DISEASE", 177, 185], ["Iron", "CHEMICAL", 200, 204], ["toxicity", "DISEASE", 289, 297], ["iron oxide", "CHEMICAL", 314, 324], ["Iron Oxide", "CHEMICAL", 200, 210], ["iron oxide", "CHEMICAL", 314, 324], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 200, 224], ["iron oxide NPs", "SIMPLE_CHEMICAL", 314, 328], ["applicability calculation", "TEST", 30, 55], ["the Toxicity", "PROBLEM", 173, 185], ["Iron Oxide Nanoparticles", "TREATMENT", 200, 224], ["the 44 iron oxide NPs", "TREATMENT", 307, 328], ["this study", "TEST", 337, 347]]], ["For the NPs, experimental parameters such as the size, R1 and R2 relaxivities, and zeta potential were combined with a coating-specific parameter and were used as inputs for the model development.", [["the NPs", "TEST", 4, 11], ["experimental parameters", "TEST", 13, 36], ["R1 and R2 relaxivities", "TREATMENT", 55, 77], ["a coating-specific parameter", "TREATMENT", 117, 145], ["size", "OBSERVATION_MODIFIER", 49, 53]]], ["The three coating categories which have been considered are: PVA, cross-linked dextran, and other.", [["PVA", "CHEMICAL", 61, 64], ["dextran", "CHEMICAL", 79, 86], ["PVA", "CHEMICAL", 61, 64], ["PVA", "SIMPLE_CHEMICAL", 61, 64], ["cross-linked dextran", "SIMPLE_CHEMICAL", 66, 86]]], ["Among the above descriptors, the subset that best describes the variation of toxicity with NP properties (as demonstrated by the variable selection algorithm) includes the R1 and R2 relaxivities and coating.Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformAfter the model development from the training data was achieved, the toxicity prediction for the test set followed.", [["toxicity", "DISEASE", 77, 85], ["Toxicity", "DISEASE", 236, 244], ["Iron", "CHEMICAL", 259, 263], ["toxicity", "DISEASE", 395, 403], ["Iron Oxide", "CHEMICAL", 259, 269], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 259, 283], ["NP properties", "TREATMENT", 91, 104], ["the variable selection algorithm", "TEST", 125, 157], ["the R1 and R2 relaxivities", "TREATMENT", 168, 194], ["the Toxicity", "PROBLEM", 232, 244], ["Iron Oxide Nanoparticles", "TREATMENT", 259, 283], ["Enalos InSilicoNano", "TREATMENT", 292, 311], ["the training data", "TEST", 359, 376], ["the toxicity prediction", "TEST", 391, 414], ["the test set", "TEST", 419, 431]]], ["Confusion matrices for the training and the test sets are shown in Tables 2 and 3, respectively.", [["Confusion", "DISEASE", 0, 9], ["Confusion matrices", "PROBLEM", 0, 18], ["the training", "TREATMENT", 23, 35], ["the test sets", "TEST", 40, 53]]], ["The evaluation of the performance of the training set yielded: precision D 80 %, sensitivity D 100 %, specificity D 73.3 %, and accuracy D 87.1 %.", [["The evaluation", "TEST", 0, 14], ["specificity D", "TEST", 102, 115], ["accuracy D", "TEST", 128, 138]]], ["Regarding the test set, the respective parameters are: precision D 87.5 %, sensitivity D 87.5 %, specificity D 80 %, and accuracy D 84.6 %.Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformThe applicability domain was defined for NPs within the test set and the cutoff value was estimated to be 0.906.", [["Toxicity", "DISEASE", 168, 176], ["Iron Oxide", "CHEMICAL", 191, 201], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 191, 215], ["the test set", "TEST", 10, 22], ["precision D", "TEST", 55, 66], ["sensitivity D", "TEST", 75, 88], ["specificity", "TEST", 97, 108], ["accuracy D", "TEST", 121, 131], ["Risk Assessment", "TEST", 139, 154], ["the Toxicity", "PROBLEM", 164, 176], ["Iron Oxide Nanoparticles", "TREATMENT", 191, 215], ["NPs", "TREATMENT", 299, 302], ["the test set", "TEST", 310, 322], ["the cutoff value", "TEST", 327, 343]]], ["For all structures of the test set, values range from 0 to 0.448, therefore, all predictions are considered reliable.", [["the test set", "TEST", 22, 34]]], ["The above set of validation measurements highlights the accuracy, significance, and robustness of the produced model.Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformThe predictive workflow is publicly available via the Enalos Cloud platform.", [["Toxicity", "DISEASE", 146, 154], ["Iron", "CHEMICAL", 169, 173], ["Iron Oxide", "CHEMICAL", 169, 179], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 169, 193], ["validation measurements", "TEST", 17, 40], ["the Toxicity", "PROBLEM", 142, 154], ["Iron Oxide Nanoparticles", "TREATMENT", 169, 193]]], ["In silico design and screening may be performed through the Enalos Cloud platform by visiting the iron oxide model web page (enalos.insilicotox.com/QNAR_IronOxide_ Toxicity/).", [["iron oxide", "CHEMICAL", 98, 108], ["iron oxide", "CHEMICAL", 98, 108], ["iron oxide", "SIMPLE_CHEMICAL", 98, 108], ["screening", "TEST", 21, 30], ["the iron oxide", "TREATMENT", 94, 108]]], ["The user can initiate a prediction by either manually entering the selected NP properties (e.g., zeta potential, size etc.) or by importing a CSV file (.csv) with NP properties for high-throughput virtual screening (HTVS) (Scheme 1).Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformWhen properties are uploaded for a set of NPs and the input values have been included, the predictive model is used and a prediction is obtained.", [["Toxicity", "DISEASE", 262, 270], ["Iron Oxide", "CHEMICAL", 285, 295], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 285, 309], ["NP properties", "TREATMENT", 163, 176], ["virtual screening", "TEST", 197, 214], ["the Toxicity", "PROBLEM", 258, 270], ["Iron Oxide Nanoparticles", "TREATMENT", 285, 309], ["a set of NPs", "TREATMENT", 385, 397], ["the input values", "TEST", 402, 418]]], ["The generated Scheme 1 Screenshot of Enalos iron oxide platform input page Scheme 2 Screenshot of Enalos QNAR iron oxide toxicity platform results output provides a summary of the results in a pdf-like format or a CSV file, which contains all relevant information for further analysis (Scheme 2).", [["iron oxide", "CHEMICAL", 44, 54], ["iron oxide", "CHEMICAL", 110, 120], ["toxicity", "DISEASE", 121, 129], ["iron oxide", "CHEMICAL", 44, 54], ["iron oxide", "CHEMICAL", 110, 120], ["Enalos iron oxide", "SIMPLE_CHEMICAL", 37, 54], ["iron oxide", "SIMPLE_CHEMICAL", 110, 120], ["The generated Scheme", "TREATMENT", 0, 20], ["Enalos iron oxide", "TREATMENT", 37, 54], ["Enalos QNAR iron oxide toxicity", "TREATMENT", 98, 129], ["a pdf", "TEST", 191, 196], ["a CSV file", "TEST", 212, 222], ["further analysis", "TEST", 268, 284]]], ["The results include predicted values for each nanostructure and a notification on the reliability of predictions based on the domain of applicability limits.Risk Assessment Tool for the Toxicity Prediction of Iron Oxide Nanoparticles Through Enalos InSilicoNano Cloud PlatformAs already mentioned, the Enalos Cloud platform allows the performance of a preliminary in silico testing by virtually screening a set of NPs, based on the validated model.", [["Toxicity", "DISEASE", 186, 194], ["Iron Oxide", "CHEMICAL", 209, 219], ["Iron Oxide Nanoparticles", "SIMPLE_CHEMICAL", 209, 233], ["the Toxicity", "PROBLEM", 182, 194], ["Iron Oxide Nanoparticles", "TREATMENT", 209, 233], ["silico testing", "TEST", 367, 381], ["NPs", "TREATMENT", 414, 417]]], ["The predictive QNAR model described here can be accessed at the web page of Enalos QNAR Iron Oxide Toxicity Platform (http://enalos.insilicotox. com/QNAR_IronOxide_Toxicity/).", [["insilicotox", "CHEMICAL", 132, 143], ["Iron Oxide", "CHEMICAL", 88, 98], ["insilicotox", "SIMPLE_CHEMICAL", 132, 143], ["Enalos", "TREATMENT", 76, 82], ["Iron Oxide Toxicity", "TREATMENT", 88, 107], ["Platform (http://enalos", "TREATMENT", 108, 131], ["insilicotox", "PROBLEM", 132, 143], ["QNAR_IronOxide_Toxicity", "TREATMENT", 149, 172]]], ["This study outlines Enalos InSilico platform as a useful tool to facilitate the computer-aided NP design by acting as a source of toxicity prediction for novel NPs.Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformIn this section, a validated quantitative nanostructure-activity relationships (QNAR) model that can predict the cellular uptake of organic nanoparticles is presented (Melagraki and Afantitis 2014) .", [["Cellular", "ANATOMY", 164, 172], ["cellular", "ANATOMY", 375, 383], ["toxicity", "DISEASE", 130, 138], ["cellular", "CELL", 375, 383], ["This study", "TEST", 0, 10], ["novel NPs", "TREATMENT", 154, 163], ["Cellular Uptake Prediction", "TEST", 164, 190], ["Virtual Screening", "TEST", 195, 212], ["Nanoparticles", "TREATMENT", 216, 229], ["organic nanoparticles", "PROBLEM", 394, 415], ["Uptake Prediction", "OBSERVATION", 173, 190], ["organic nanoparticles", "OBSERVATION", 394, 415]]], ["The model is publicly available through Enalos InSilico Cloud platform in the QNAR_PaCa2 web page (http://enalos. insilicotox.com/QNAR_PaCa2/) and can be used for new-structure predictions that are designed and/or uploaded to the server.", [["QNAR_PaCa2", "PROTEIN", 130, 140]]], ["The Enalos InSilico web service functionality was successfully used for the virtual screening of a set of PubChem structures, which were selected to recognize structures similar to that of a known active compound.", [["the virtual screening", "TEST", 72, 93], ["a known active compound", "PROBLEM", 189, 212], ["active", "OBSERVATION_MODIFIER", 197, 203], ["compound", "OBSERVATION", 204, 212]]], ["The model was based on Mold2 descriptors and the k-nearest neighbors (kNN) algorithm.Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformThe selected engineered NPs (ENPs) used for model development, possess the same metal core but different organic coating (Weissleder et al. 2005) .", [["Cellular", "ANATOMY", 85, 93], ["ENPs", "CHEMICAL", 212, 216], ["ENPs", "SIMPLE_CHEMICAL", 212, 216], ["Cellular Uptake Prediction", "TEST", 85, 111], ["Virtual Screening", "TEST", 116, 133], ["of Nanoparticles", "TREATMENT", 134, 150], ["The selected engineered NPs (ENPs)", "TREATMENT", 183, 217], ["Uptake Prediction", "OBSERVATION", 94, 111], ["organic coating", "OBSERVATION", 288, 303]]], ["The model building was based on a KNIME workflow, especially designed for this purpose.", [["a KNIME workflow", "TEST", 32, 48]]], ["Initially, for the development of the model, all data including organic molecules and cellular uptake values were preprocessed and randomly divided into training set (89 compounds, which were used in the model development) and validation (25 compounds) set.", [["cellular", "ANATOMY", 86, 94], ["cellular", "CELL", 86, 94], ["organic molecules", "PROBLEM", 64, 81], ["cellular uptake values", "TEST", 86, 108], ["validation", "TEST", 227, 237], ["uptake values", "OBSERVATION", 95, 108]]], ["The Enalos Mold2 KNIME node was used for the calculation of 777 descriptors for each compound.", [["Enalos Mold2 KNIME node", "DNA", 4, 27], ["The Enalos Mold2 KNIME node", "TREATMENT", 0, 27], ["node", "OBSERVATION", 23, 27]]], ["During the correlation analysis some descriptors were eliminated, thus leaving 382 of them to be used as inputs for the QNAR model development.Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformNext, the CfsSubset variable selection with BestFirst evaluator method was applied to identify nine descriptors as the most representatives of the structural features that define the biological profile of the studied NPs.Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformThe nine descriptors are: (D461) Geary topological structure autocorrelation length-7 weighted by atomic van der Waals volume, (D467) Geary topological structure autocorrelation length-5 weighted by atomic Sanderson electronegativities, (D599) number of total quaternary C-sp3, (D649) number of group secondary aliphatic amines, (D712) number of group donor atoms for hydrogen bonds, (D714) number of group CH 3 R and CH 4 , (D753) number of group phenol or enol or carboxyl OH, (D758) number of group Al 2 -NH, and (D775) hydrophilic factor index.", [["Cellular", "ANATOMY", 143, 151], ["Cellular", "ANATOMY", 462, 470], ["aliphatic amines", "CHEMICAL", 871, 887], ["D712", "CHEMICAL", 890, 894], ["phenol", "CHEMICAL", 1008, 1014], ["enol", "CHEMICAL", 1018, 1022], ["carboxyl OH", "CHEMICAL", 1026, 1037], ["Al 2 -NH", "CHEMICAL", 1062, 1070], ["C-sp3", "CHEMICAL", 831, 836], ["secondary aliphatic amines", "CHEMICAL", 861, 887], ["hydrogen", "CHEMICAL", 928, 936], ["CH 3 R", "CHEMICAL", 967, 973], ["CH", "CHEMICAL", 978, 980], ["phenol", "CHEMICAL", 1008, 1014], ["enol", "CHEMICAL", 1018, 1022], ["carboxyl OH", "CHEMICAL", 1026, 1037], ["Al 2 -NH", "CHEMICAL", 1062, 1070], ["NPs", "CANCER", 458, 461], ["C-sp3", "SIMPLE_CHEMICAL", 831, 836], ["secondary aliphatic amines", "SIMPLE_CHEMICAL", 861, 887], ["hydrogen bonds", "SIMPLE_CHEMICAL", 928, 942], ["phenol", "SIMPLE_CHEMICAL", 1008, 1014], ["enol", "SIMPLE_CHEMICAL", 1018, 1022], ["carboxyl OH", "SIMPLE_CHEMICAL", 1026, 1037], ["Al 2 -NH", "SIMPLE_CHEMICAL", 1062, 1070], ["the correlation analysis", "TEST", 7, 31], ["the QNAR model development", "TREATMENT", 116, 142], ["Cellular Uptake Prediction", "TEST", 143, 169], ["Virtual Screening", "TEST", 174, 191], ["Nanoparticles", "TREATMENT", 195, 208], ["Enalos InSilicoNano PlatformNext", "TREATMENT", 213, 245], ["the CfsSubset variable selection", "TREATMENT", 247, 279], ["BestFirst evaluator method", "TREATMENT", 285, 311], ["Cellular Uptake Prediction", "TEST", 462, 488], ["Virtual Screening", "TEST", 493, 510], ["Nanoparticles via Enalos", "TREATMENT", 514, 538], ["length", "TEST", 637, 643], ["atomic van der Waals volume", "TEST", 658, 685], ["length", "TEST", 738, 744], ["total quaternary C-sp3", "TREATMENT", 814, 836], ["group secondary aliphatic amines", "TREATMENT", 855, 887], ["hydrogen bonds", "PROBLEM", 928, 942], ["group phenol", "TREATMENT", 1002, 1014], ["enol or carboxyl OH", "TREATMENT", 1018, 1037], ["hydrophilic factor index", "TEST", 1083, 1107], ["Uptake Prediction", "OBSERVATION", 152, 169], ["Uptake Prediction", "OBSERVATION", 471, 488]]], ["The optimized value of k within kNN application was 2 (Franco-Lopez et al. 2001 ).Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformThe proposed model was successfully validated with the methodology applied in the previous section.", [["Cellular", "ANATOMY", 82, 90], ["Cellular Uptake Prediction", "TEST", 82, 108], ["Virtual Screening", "TEST", 113, 130], ["of Nanoparticles", "TREATMENT", 131, 147], ["the methodology", "TREATMENT", 231, 246], ["the previous section", "TREATMENT", 258, 278], ["Uptake Prediction", "OBSERVATION", 91, 108]]], ["The validation results are shown in Fig. 2 .Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformThe R 2 LOO was calculated to be 0.74.", [["The validation", "TEST", 0, 14], ["Cellular Uptake Prediction", "TEST", 44, 70], ["Virtual Screening", "TEST", 75, 92], ["Nanoparticles", "TEST", 96, 109], ["Uptake Prediction", "OBSERVATION", 53, 70]]], ["Also, the Y-randomization test verified the model's robustness and statistical significance.", [["the Y-randomization test", "TEST", 6, 30]]], ["The decreased values of the correlation coefficient indicate the low possibility of chance correlation.Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformAfter the model was validated, the reliability of a given prediction was suggested through domain of applicability calculations (cutoff value D 2.153) (Mouchlis et al. Zhang et al. 1995; Papa et al. 2009 ).", [["Cellular", "ANATOMY", 103, 111], ["Cellular Uptake Prediction", "TEST", 103, 129], ["Virtual Screening", "TEST", 134, 151], ["Nanoparticles", "TREATMENT", 155, 168], ["Enalos", "TREATMENT", 173, 179], ["applicability calculations", "TEST", 302, 328], ["decreased", "OBSERVATION_MODIFIER", 4, 13], ["Uptake Prediction", "OBSERVATION", 112, 129]]], ["Thus, the model could be considered a useful tool toward cellular uptake determination of NPs.Cellular Uptake Prediction and Virtual Screening of Nanoparticles via Enalos InSilicoNano PlatformThe model was made available online through Enalos InSilico platform for fast in silico predictions for a set of given compounds.", [["cellular", "ANATOMY", 57, 65], ["Cellular", "ANATOMY", 94, 102], ["cellular", "CELL", 57, 65], ["NPs", "SIMPLE_CHEMICAL", 90, 93], ["Cellular Uptake Prediction", "TEST", 94, 120], ["Virtual Screening", "TEST", 125, 142], ["of Nanoparticles", "TREATMENT", 143, 159], ["Uptake Prediction", "OBSERVATION", 103, 120]]], ["Screenshots of the Enalos InSilico web service and the results page are presented in Schemes 3 and 4.Scheme 3 Screenshot of Enalos InSilico platform input page for QNAR_PaCa2 modelScheme 4 Screenshot of Enalos InSilico platform results for QNAR_PaCa2 model As shown in Schemes 3 and 4, the user can design or enter a chemical structure and obtain a prediction.", [["PaCa2", "PROTEIN", 245, 250], ["QNAR_PaCa2 modelScheme", "TREATMENT", 164, 186], ["QNAR_PaCa2 model", "TREATMENT", 240, 256]]], ["The aforementioned workflow will calculate the descriptors and the output will be rapidly generated (within seconds).", [["the output", "TEST", 63, 73]]], ["One may experiment with different scaffolds and structures and observe the structural features that induce a certain effect.", [["different scaffolds", "TREATMENT", 24, 43], ["the structural features", "PROBLEM", 71, 94], ["different scaffolds", "OBSERVATION_MODIFIER", 24, 43]]], ["Also, the user can exploit the proposed QNAR model and then scan specific structures for a preliminary in silico testing.", [["QNAR model", "CELL_LINE", 40, 50], ["a preliminary in silico testing", "TEST", 89, 120]]], ["It was recently pointed out (Tetko 2012 ) that the use of predictive models as software tools will probably increase in the future, and this will activate the reuse of knowledge, which in turn will result in further developments.Scheme 3 Screenshot of Enalos InSilico platform input page for QNAR_PaCa2 modelAs already mentioned, the proposed model and web platform can be used in virtual screening studies for the prioritization of new compounds.", [["QNAR_PaCa2 model", "TREATMENT", 292, 308], ["virtual screening studies", "TEST", 381, 406]]], ["To demonstrate the usefulness of the produced model, potent compounds from the PubChem database were identified using similarity calculations based on molecular quantum numbers (MQNs) (Melagraki and Afantitis 2014) .", [["the PubChem database", "TEST", 75, 95], ["similarity calculations", "TEST", 118, 141], ["molecular quantum numbers", "TEST", 151, 176]]], ["The virtual screening procedure was employed for the recognition of the first 1000 neighbors of compound 36 (isatoic ahydride), in terms of chemical similarity.", [["isatoic ahydride", "CHEMICAL", 109, 125], ["isatoic ahydride", "CHEMICAL", 109, 125], ["isatoic ahydride", "SIMPLE_CHEMICAL", 109, 125], ["The virtual screening procedure", "TREATMENT", 0, 31]]], ["The 1000 resulting compounds were tested with the online tool through Enalos InSilico platform (via an sdf file, which contains all the structures) regarding their cellular uptake.", [["cellular", "ANATOMY", 164, 172], ["cellular", "CELL", 164, 172], ["an sdf file", "TEST", 100, 111], ["cellular uptake", "OBSERVATION", 164, 179]]], ["Compounds were next classified by increasing potency and the most promising ones were selected for screening.", [["screening", "TEST", 99, 108]]], ["The predictions for the first 20 compounds are shown in Table 4 .Scheme 3 Screenshot of Enalos InSilico platform input page for QNAR_PaCa2 modelWithin the proposed framework, the Enalos InSilico platform emerges as an invaluable application for the evaluation of novel NPs, which have not been experimentally tested or synthesized.", [["the Enalos InSilico platform emerges", "TREATMENT", 175, 211], ["the evaluation", "TEST", 245, 259], ["novel NPs", "TREATMENT", 263, 272]]], ["An additional, important aspect of the approach is that the above tools can be further expanded and applied to polymer-NP structures that are currently gaining increasing attention.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesOne of the most efficient ways to prevent metal corrosion in acidic media is the development of novel corrosion inhibitors (Ebenso et al. 2012) .", [["polymer-NP structures", "TREATMENT", 111, 132], ["Organic Materials", "TREATMENT", 199, 216], ["Corrosion Inhibitors", "TREATMENT", 220, 240], ["Enalos", "TREATMENT", 250, 256], ["metal corrosion in acidic media", "PROBLEM", 310, 341], ["novel corrosion inhibitors", "TREATMENT", 364, 390], ["Organic Materials", "OBSERVATION", 199, 216], ["metal corrosion", "OBSERVATION", 310, 325], ["acidic media", "OBSERVATION", 329, 341]]], ["Organic inhibitors, which contain heteroatoms (e.g., oxygen, nitrogen, sulfur) and possess multiple bonds, have been considered for various corrosion systems, metals, and alloys.", [["oxygen", "CHEMICAL", 53, 59], ["sulfur", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 53, 59], ["nitrogen", "CHEMICAL", 61, 69], ["sulfur", "CHEMICAL", 71, 77], ["oxygen", "SIMPLE_CHEMICAL", 53, 59], ["nitrogen", "SIMPLE_CHEMICAL", 61, 69], ["sulfur", "SIMPLE_CHEMICAL", 71, 77], ["metals", "SIMPLE_CHEMICAL", 159, 165], ["Organic inhibitors", "TREATMENT", 0, 18], ["heteroatoms", "TREATMENT", 34, 45], ["oxygen", "TREATMENT", 53, 59], ["nitrogen", "TREATMENT", 61, 69], ["sulfur", "TREATMENT", 71, 77], ["various corrosion systems", "PROBLEM", 132, 157], ["heteroatoms", "OBSERVATION", 34, 45]]], ["Inhibition is obtained with creation of physical and/or chemical absorption film on the surface of the metal (El Ashry et al. 2012).", [["surface", "ANATOMY", 88, 95], ["chemical absorption film", "TEST", 56, 80]]], ["The planarity of heterocycles and the presence of lone electron pairs on the heteroatoms are crucial factors that control the absorption of these compounds on the metallic surface.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesOne drawback regarding the design of corrosion inhibitors is the time-consuming and costly nature of the process.", [["heterocycles", "CHEMICAL", 17, 29], ["electron", "SIMPLE_CHEMICAL", 55, 63], ["surface", "CELLULAR_COMPONENT", 172, 179], ["heterocycles", "TREATMENT", 17, 29], ["lone electron pairs", "PROBLEM", 50, 69], ["the heteroatoms", "TREATMENT", 73, 88], ["crucial factors", "PROBLEM", 93, 108], ["Organic Materials", "TREATMENT", 198, 215], ["Corrosion Inhibitors", "TREATMENT", 219, 239], ["corrosion inhibitors", "TREATMENT", 304, 324], ["planarity", "OBSERVATION_MODIFIER", 4, 13], ["compounds", "OBSERVATION_MODIFIER", 146, 155], ["metallic", "OBSERVATION_MODIFIER", 163, 171], ["surface", "OBSERVATION_MODIFIER", 172, 179], ["Organic Materials", "OBSERVATION", 198, 215]]], ["On the other hand, computational techniques, such as the quantitative structure-property relationships (QSPR) methodology has greatly advanced the efficient modeling and prediction of new or modified corrosion inhibitors (Lee et al. 2012; Toropov et al. 2012 ).", [["computational techniques", "TEST", 19, 43], ["modified corrosion inhibitors", "TREATMENT", 191, 220]]], ["In this study, the modeling and prediction of corrosion inhibition for steel in acidic environment through the development of QSPR with the aid of the Enalos KNIME nodes is described (Berthold et al. 2008; Melagraki and Afantitis 2013) .", [["KNIME nodes", "MULTI-TISSUE_STRUCTURE", 158, 169], ["this study", "TEST", 3, 13], ["corrosion inhibition", "TREATMENT", 46, 66], ["steel in acidic environment", "TREATMENT", 71, 98], ["QSPR", "PROBLEM", 126, 130]]], ["The development of a predictive kNN model was realized by first calculating Mold2 molecular descriptors for the organic inhibitors with the Enalos Mold2 KNIME node.", [["a predictive kNN model", "PROBLEM", 19, 41], ["the organic inhibitors", "TREATMENT", 108, 130]]], ["The predictive model was assessed with the Enalos Model Acceptability Criteria KNIME node.", [["node", "OBSERVATION", 85, 89]]], ["The domain of model applicability was determined using the Enalos Domain KNIME nodes.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesCorrosion inhibition data for steel in acidic medium from various organic chemicals were collected from the literature (El Ashry et al. 2012) and were assembled in a single database.", [["the Enalos Domain KNIME nodes", "TREATMENT", 55, 84], ["Organic Materials", "TREATMENT", 103, 120], ["Corrosion Inhibitors", "TREATMENT", 124, 144], ["Enalos", "TREATMENT", 154, 160], ["inhibition data", "TEST", 182, 197], ["steel in acidic medium", "PROBLEM", 202, 224], ["various organic chemicals", "PROBLEM", 230, 255], ["Organic Materials", "OBSERVATION", 103, 120]]], ["Inhibitors involve triazole, oxadiazole, and thiadiazole derivatives; aromatic hydrazides and Schiff bases; benzimidazole and 2-substituted derivatives; as well as pyridine derivatives.", [["triazole", "CHEMICAL", 19, 27], ["oxadiazole", "CHEMICAL", 29, 39], ["thiadiazole", "CHEMICAL", 45, 56], ["aromatic hydrazides", "CHEMICAL", 70, 89], ["Schiff bases", "CHEMICAL", 94, 106], ["benzimidazole", "CHEMICAL", 108, 121], ["2-substituted", "CHEMICAL", 126, 139], ["pyridine", "CHEMICAL", 164, 172], ["triazole", "CHEMICAL", 19, 27], ["oxadiazole", "CHEMICAL", 29, 39], ["thiadiazole", "CHEMICAL", 45, 56], ["aromatic hydrazides", "CHEMICAL", 70, 89], ["Schiff bases", "CHEMICAL", 94, 106], ["benzimidazole", "CHEMICAL", 108, 121], ["pyridine", "CHEMICAL", 164, 172], ["triazole", "SIMPLE_CHEMICAL", 19, 27], ["oxadiazole", "SIMPLE_CHEMICAL", 29, 39], ["thiadiazole derivatives", "SIMPLE_CHEMICAL", 45, 68], ["aromatic hydrazides", "SIMPLE_CHEMICAL", 70, 89], ["Schiff bases", "SIMPLE_CHEMICAL", 94, 106], ["benzimidazole", "SIMPLE_CHEMICAL", 108, 121], ["2-substituted derivatives", "SIMPLE_CHEMICAL", 126, 151], ["pyridine derivatives", "SIMPLE_CHEMICAL", 164, 184], ["Inhibitors", "TREATMENT", 0, 10], ["triazole", "TREATMENT", 19, 27], ["oxadiazole", "TREATMENT", 29, 39], ["thiadiazole derivatives", "TREATMENT", 45, 68], ["aromatic hydrazides and Schiff bases", "TREATMENT", 70, 106], ["benzimidazole", "TREATMENT", 108, 121], ["2-substituted derivatives", "TREATMENT", 126, 151], ["pyridine derivatives", "TREATMENT", 164, 184]]], ["A set of 55 organic inhibitors in different concentrations yielded a total of 186 inhibition data.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe structural features of the studied corrosion inhibitors were evaluated with the Mold2 software.", [["55 organic inhibitors", "TREATMENT", 9, 30], ["Organic Materials", "TREATMENT", 116, 133], ["Corrosion Inhibitors", "TREATMENT", 137, 157], ["the studied corrosion inhibitors", "TREATMENT", 212, 244], ["Organic Materials", "OBSERVATION", 116, 133]]], ["From these, only 320 descriptors were used as possible inputs for the construction of the QSPR model, since the remaining descriptors were filtered out due to poor discrimination power (Ojha and Roy 2011) .Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesAmong the different modeling methodologies screened in KNIME platform, the k-nearest neighbors (kNN) technique (with an optimized value k D 3) was selected as the most appropriate for the specific data (Hall et al. 2009 ).", [["the QSPR model", "TREATMENT", 86, 100], ["Organic Materials", "TREATMENT", 224, 241], ["Corrosion Inhibitors", "TREATMENT", 245, 265], ["Enalos", "TREATMENT", 275, 281], ["Organic Materials", "OBSERVATION", 224, 241]]], ["Details on the kNN algorithm and methodology can be found elsewhere (Franco-Lopez et al. 2001 ).Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe predictive model was validated internally and externally according to the standards of QSAR model acceptance, as imposed by the OECD.", [["the kNN algorithm", "TEST", 11, 28], ["Organic Materials", "TREATMENT", 114, 131], ["Corrosion Inhibitors", "TREATMENT", 135, 155], ["Organic Materials", "OBSERVATION", 114, 131]]], ["The complete dataset was randomly split into 70:30 ratio (training set: validation set) with the partitioning KNIME node.", [["KNIME node", "ANATOMY", 110, 120], ["KNIME node", "MULTI-TISSUE_STRUCTURE", 110, 120], ["node", "OBSERVATION", 116, 120]]], ["The combinations in the test set did not participate in the training procedure.", [["the training procedure", "TREATMENT", 56, 78]]], ["The statistical criteria that were used to determine the robustness, reliability, and predictive ability of the model are: the coefficient of determination between experimental values and predicted values (R 2 ), validation via external test set, leave-one-out cross validation procedure and quality of fit and predictive ability of a continuous QSAR model based on Tropsha's tests (Tropsha 2010) .", [["experimental values", "TEST", 164, 183], ["validation via external test set", "TEST", 213, 245], ["cross validation procedure", "TREATMENT", 261, 287], ["a continuous QSAR model", "TREATMENT", 333, 356], ["Tropsha's tests", "TEST", 366, 381]]], ["The statistics of the validation procedure are shown in Table 5 .", [["the validation procedure", "TREATMENT", 18, 42]]], ["The predictive scheme included a KNIME workflow, which operated the following actions:Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME Nodes1.", [["Organic Materials", "TREATMENT", 104, 121], ["Corrosion Inhibitors", "TREATMENT", 125, 145]]], ["Compounds along with corrosion inhibition data were uploaded and preprocessed.", [["corrosion inhibition data", "TEST", 21, 46]]], ["The calculation and selection of descriptors was realized.", [["The calculation", "TEST", 0, 15]]], ["The kNN methodology was carried out.", [["The kNN methodology", "TEST", 0, 19]]], ["The domain of applicability was determined.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe initial dataset of 186 corrosion inhibitors was randomly divided into 131 training set compounds and 55 validation set compounds (ratio 70:30).", [["Organic Materials", "TREATMENT", 61, 78], ["Corrosion Inhibitors", "TREATMENT", 82, 102], ["corrosion inhibitors", "TREATMENT", 157, 177], ["Organic Materials", "OBSERVATION", 61, 78]]], ["As mentioned above, only compounds from the training set were used to develop the QSPR models, and 320 descriptors were selected as possible inputs during the development.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe CfsSubset variable selection with the BestFirst evaluator method (Witten et al. 2005 ) was next applied on the training set to identify the most significant among the 320 descriptors.", [["the QSPR models", "TEST", 78, 93], ["Organic Materials", "TREATMENT", 189, 206], ["Corrosion Inhibitors", "TREATMENT", 210, 230], ["The CfsSubset variable selection", "TREATMENT", 258, 290], ["Organic Materials", "OBSERVATION", 189, 206]]], ["Thus, the concentration along with seven descriptors was selected as the most important parameter for the model development.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe selected descriptors include number of oxygen (D026), structural information content order-1 index (D282), Geary topological structure autocorrelation length-8 weighted by atomic Sanderson electronegativities (D470), Moran topological structure autocorrelation length-7 weighted by atomic polarizabilities (D509), lowest eigenvalue from Burden matrix weighted by van der Waals order-6 (D545), highest eigenvalue from Burden matrix weighted by van der Waals order-4 (D575), number of group Ar-CHDX (D741), and the concentration (C in mM).Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe description of the selected descriptors will be briefly discussed below (Todeschini and Consonni 2009) .Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesA combination of the descriptors offers a unified representation of the compound and high selective power.", [["oxygen", "CHEMICAL", 254, 260], ["oxygen", "CHEMICAL", 254, 260], ["Ar-CHDX", "CHEMICAL", 704, 711], ["oxygen", "SIMPLE_CHEMICAL", 254, 260], ["Ar-CHDX", "SIMPLE_CHEMICAL", 704, 711], ["Organic Materials", "TREATMENT", 142, 159], ["Corrosion Inhibitors", "TREATMENT", 163, 183], ["oxygen (D026)", "TREATMENT", 254, 267], ["length", "TEST", 366, 372], ["length", "TEST", 476, 482], ["the concentration (C in mM)", "TREATMENT", 724, 751], ["Organic Materials", "TREATMENT", 770, 787], ["Corrosion Inhibitors", "TREATMENT", 791, 811], ["Organic Materials", "TREATMENT", 965, 982], ["Corrosion Inhibitors", "TREATMENT", 986, 1006], ["Enalos", "TREATMENT", 1016, 1022], ["the compound", "PROBLEM", 1102, 1114], ["Organic Materials", "OBSERVATION", 142, 159], ["Organic Materials", "OBSERVATION", 770, 787], ["Organic Materials", "OBSERVATION", 965, 982]]], ["Descriptors D026 and D741 indicate the number of oxygen atoms and Ar-CHDX groups that may be present in the compound.", [["oxygen", "CHEMICAL", 49, 55], ["Ar-", "CHEMICAL", 66, 69], ["oxygen", "CHEMICAL", 49, 55], ["Ar-CHDX", "CHEMICAL", 66, 73], ["oxygen atoms", "SIMPLE_CHEMICAL", 49, 61], ["Ar-CHDX", "SIMPLE_CHEMICAL", 66, 73], ["D741", "TREATMENT", 21, 25], ["oxygen atoms", "TREATMENT", 49, 61], ["Ar-CHDX groups", "TREATMENT", 66, 80], ["oxygen atoms", "OBSERVATION", 49, 61], ["may be", "UNCERTAINTY", 86, 92]]], ["Descriptor D282 encodes the structural information content order-1 index.", [["D282", "DNA", 11, 15]]], ["This descriptor represents a graph theoretical invariant, which considers the molecular graph as being a source of different probability distributions, to which the information theory is applied (Todeschini and Consonni 2009 ).", [["a graph theoretical invariant", "PROBLEM", 27, 56], ["theoretical invariant", "OBSERVATION", 35, 56]]], ["D470 encodes information as described by Geary topological structure autocorrelation length-8 weighted by atomic Sanderson electronegativities.", [["D470", "DNA", 0, 4]]], ["D509 encodes information regarding the atomic polarizabilities combined with Moran topological structure autocorrelation length-7.", [["D509", "DNA", 0, 4], ["the atomic polarizabilities", "PROBLEM", 35, 62]]], ["Moran coefficient (value range between 1 and C1) indicates the spatial autocorrelation and is associated with atomic properties, the number of atoms, and the topological distance between them.", [["Moran coefficient (value range", "TEST", 0, 30]]], ["Descriptors D545 and D575 represent the lowest eigenvalue from Burden matrix (Burden 1989 ) weighted by van der Waals order-6 and the highest eigenvalue from Burden matrix weighted by van der Waals order-4, respectively (Burden et al. 2009 ).", [["D575", "TREATMENT", 21, 25]]], ["Burden descriptors weighted by van der Waals have been shown to be very selective descriptors and in turn useful for similarity searching (Todeschini and Consonni 2009) .Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe above descriptors are associated with different weights that affect the corrosion inhibition across compounds.", [["Organic Materials", "TREATMENT", 188, 205], ["Corrosion Inhibitors", "TREATMENT", 209, 229], ["different weights", "PROBLEM", 299, 316], ["the corrosion inhibition across compounds", "PROBLEM", 329, 370], ["Organic Materials", "OBSERVATION", 188, 205]]], ["Therefore, according to the positive or negative impact of each descriptor, novel compounds with specified properties may be designed.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesAfter comparison with the results from other methodologies (Melagraki and Afantitis 2013) , it was concluded that the kNN approach yielded an accurate and powerful model that reliably predicts the efficiency of corrosion inhibition.", [["Organic Materials", "TREATMENT", 152, 169], ["Corrosion Inhibitors", "TREATMENT", 173, 193], ["the kNN approach", "PROBLEM", 335, 351], ["corrosion inhibition", "TREATMENT", 432, 452], ["Organic Materials", "OBSERVATION", 152, 169], ["corrosion inhibition", "OBSERVATION", 432, 452]]], ["Then, one may safely conclude that the selected descriptors encode the structural characteristics of the substances related to corrosion inhibition.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe experimental vs. predicted corrosion inhibition values for the training set and test set compounds are shown in Fig. 3 .", [["corrosion", "DISEASE", 127, 136], ["corrosion inhibition", "TREATMENT", 127, 147], ["Organic Materials", "TREATMENT", 166, 183], ["Corrosion Inhibitors", "TREATMENT", 187, 207], ["the training set", "TEST", 298, 314], ["test set compounds", "TEST", 319, 337], ["Organic Materials", "OBSERVATION", 166, 183]]], ["Outliers have been indicated and presented in the original article (Melagraki and Afantitis 2013) .Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe Enalos Model Acceptability Criteria KNIME node has been applied to the data (Fig. 4 ) and the model passed Tropsha's requirements for predictive ability.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesR 2 is the determination coefficient between experimental and predicted values and model prediction on the test set (R 2 pred ).", [["Organic Materials", "TREATMENT", 117, 134], ["Corrosion Inhibitors", "TREATMENT", 138, 158], ["Enalos KNIME Nodes", "TREATMENT", 168, 186], ["The Enalos Model", "TREATMENT", 186, 202], ["KNIME node", "PROBLEM", 226, 236], ["Organic Materials", "TREATMENT", 361, 378], ["Corrosion Inhibitors", "TREATMENT", 382, 402], ["the test set", "TEST", 533, 545], ["Organic Materials", "OBSERVATION", 117, 134], ["node", "OBSERVATION", 232, 236], ["Organic Materials", "OBSERVATION", 361, 378]]], ["The model was particularly stable with respect to the inclusion/exclusion of compounds measured by the leave-oneout (LOO) cross validation procedure (R 2 LOO D 0.73).", [["cross validation procedure", "TREATMENT", 122, 148], ["stable", "OBSERVATION_MODIFIER", 27, 33]]], ["Another measure of robustness and statistical significance of a QSPR model is the Y-randomization test, which further validated our approach.", [["a QSPR model", "TEST", 62, 74], ["the Y-randomization test", "TEST", 78, 102]]], ["An additional validation test was conducted to evaluate the predictive power of the method independently of the partitioning of the dataset (Melagraki and Afantitis 2013) .", [["An additional validation test", "TEST", 0, 29]]], ["The distribution of the root mean squared error (RMSE) values is shown in Fig. 5 .", [["root", "ANATOMY", 24, 28], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["root", "OBSERVATION_MODIFIER", 24, 28]]], ["The applicability domain cutoff value was estimated to be 3.774 and 0.183 for similarity (Mouchlis et al. 2012 ) and leverage (Afantitis et al. 2008 ) calculations, respectively.", [["The applicability domain cutoff value", "TEST", 0, 37]]], ["Similarity calculations for all compounds in the test set had values which range between 0.015 and 1.23.", [["Similarity calculations", "TEST", 0, 23], ["the test set", "TEST", 45, 57]]], ["However, the leverage predicted response of a simple pyridine (0.378) resulted from a significant model extrapolation, and it is the only prediction that may be considered unreliable.Identification of Organic Materials as Corrosion Inhibitors Based on Enalos KNIME NodesThe present approach, due to its high predictive power and the minimal requirement of only 2D structure information of a compound, could be a very useful tool for the determination of the corrosion inhibition.", [["pyridine", "CHEMICAL", 53, 61], ["pyridine", "CHEMICAL", 53, 61], ["pyridine", "SIMPLE_CHEMICAL", 53, 61], ["a simple pyridine", "TREATMENT", 44, 61], ["a significant model extrapolation", "PROBLEM", 84, 117], ["Organic Materials", "TREATMENT", 201, 218], ["Corrosion Inhibitors", "TREATMENT", 222, 242], ["its high predictive power", "PROBLEM", 299, 324], ["the corrosion inhibition", "TREATMENT", 454, 478], ["significant", "OBSERVATION_MODIFIER", 86, 97], ["model", "OBSERVATION_MODIFIER", 98, 103], ["extrapolation", "OBSERVATION", 104, 117], ["may be considered", "UNCERTAINTY", 154, 171], ["Organic Materials", "OBSERVATION", 201, 218], ["minimal", "OBSERVATION_MODIFIER", 333, 340]]], ["Moreover, this modeling method considerably decreases the time and cost required to experimentally design corrosion inhibitors.", [["this modeling method", "PROBLEM", 10, 30], ["corrosion inhibitors", "TREATMENT", 106, 126], ["decreases", "OBSERVATION_MODIFIER", 44, 53]]], ["Also, the method may be applied to the screening of regular or virtual chemical databases, thus seeking new organic compounds with specific properties.", [["the method", "TREATMENT", 6, 16], ["the screening", "TEST", 35, 48]]], ["For this purpose, the applicability domain will be an invaluable tool for discarding \"divergent\" chemical structures.KNIME-Based Design and Prediction of Compound StructuresThe broad applicability of KNIME in the area of medicinal and pharmaceutical chemistry has also rendered it a valuable tool for structure prediction and analysis.", [["KNIME", "CHEMICAL", 200, 205], ["KNIME", "SIMPLE_CHEMICAL", 200, 205], ["Compound Structures", "PROBLEM", 154, 173], ["structure prediction", "TEST", 301, 321], ["analysis", "TEST", 326, 334], ["Compound Structures", "OBSERVATION", 154, 173], ["broad", "OBSERVATION_MODIFIER", 177, 182], ["medicinal", "ANATOMY", 221, 230]]], ["Thus, KNIME workflows have been implemented over the years to perform drug design, virtual screening, molecular modeling, QSAR, QSPR, structure classification, and clustering applications among others.KNIME-Based Design and Prediction of Compound StructuresIn this section, we present two KNIME applications regarding the prediction of yellow fever inhibitors and a knowledge-based method for the de novo design of novel compounds.Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisYellow fever (YF) is an acute infection, which is transmitted by arthropods and mosquitoes to humans (Agnihotri et al. 2012) , and is caused by the mosquitoborne yellow fever flavivirus (YFV).", [["fever", "DISEASE", 343, 348], ["Yellow Fever", "DISEASE", 445, 457], ["AnalysisYellow fever", "DISEASE", 519, 539], ["YF", "DISEASE", 541, 543], ["acute infection", "DISEASE", 551, 566], ["yellow fever flavivirus", "DISEASE", 689, 712], ["YFV", "DISEASE", 714, 717], ["humans", "ORGANISM", 621, 627], ["mosquitoborne yellow fever flavivirus", "ORGANISM", 675, 712], ["YFV", "ORGANISM", 714, 717], ["humans", "SPECIES", 621, 627], ["yellow fever flavivirus", "SPECIES", 689, 712], ["humans", "SPECIES", 621, 627], ["yellow fever flavivirus", "SPECIES", 689, 712], ["YFV", "SPECIES", 714, 717], ["virtual screening", "TEST", 83, 100], ["molecular modeling", "TEST", 102, 120], ["QSAR", "TEST", 122, 126], ["QSPR", "PROBLEM", 128, 132], ["Compound Structures", "PROBLEM", 238, 257], ["yellow fever inhibitors", "PROBLEM", 336, 359], ["novel compounds", "PROBLEM", 415, 430], ["Yellow Fever Inhibitors", "PROBLEM", 445, 468], ["ChEMBL Database", "TEST", 474, 489], ["fever", "PROBLEM", 534, 539], ["YF", "PROBLEM", 541, 543], ["an acute infection", "PROBLEM", 548, 566], ["the mosquitoborne yellow fever flavivirus", "PROBLEM", 671, 712], ["Compound Structures", "OBSERVATION", 238, 257], ["Yellow Fever", "OBSERVATION", 445, 457], ["acute", "OBSERVATION_MODIFIER", 551, 556], ["infection", "OBSERVATION", 557, 566]]], ["The family of flaviviruses also includes other RNA viruses, such as the hepatitis C virus (HCV), the dengue virus (DENV), the West Nile virus (WNV), the Japanese encephalitis virus (JEV), and the bovine viral diarrhea virus (BVDV) among others (Agnihotri et al. 2012; Julander 2013) .Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisYFV is a major health risk in particular regions of South America and Africa since almost 200,000 new infections and 30,000 deaths are observed every year (Chatelain et al. 2013) ; importantly, the fatality rate may reach 60 % in severe cases.Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisCurrently, several regular antiviral drugs have been tested against YF disease, but no chemotherapeutic medication has been developed to specifically target YFV.", [["hepatitis C", "DISEASE", 72, 83], ["dengue", "DISEASE", 101, 107], ["Japanese encephalitis", "DISEASE", 153, 174], ["JEV", "DISEASE", 182, 185], ["bovine viral diarrhea virus", "DISEASE", 196, 223], ["Yellow Fever", "DISEASE", 298, 310], ["infections", "DISEASE", 482, 492], ["deaths", "DISEASE", 504, 510], ["YF disease", "DISEASE", 787, 797], ["hepatitis C virus", "ORGANISM", 72, 89], ["HCV", "ORGANISM", 91, 94], ["dengue virus", "ORGANISM", 101, 113], ["DENV", "ORGANISM", 115, 119], ["West Nile virus", "ORGANISM", 126, 141], ["WNV", "ORGANISM", 143, 146], ["Japanese encephalitis virus", "ORGANISM", 153, 180], ["JEV", "ORGANISM", 182, 185], ["bovine viral diarrhea virus", "ORGANISM", 196, 223], ["BVDV", "ORGANISM", 225, 229], ["YF", "ORGANISM", 787, 789], ["YFV", "ORGANISM", 876, 879], ["hepatitis C virus", "SPECIES", 72, 89], ["dengue virus", "SPECIES", 101, 113], ["West Nile virus", "SPECIES", 126, 141], ["Japanese encephalitis virus", "SPECIES", 153, 180], ["bovine", "SPECIES", 196, 202], ["viral diarrhea virus", "SPECIES", 203, 223], ["hepatitis C virus", "SPECIES", 72, 89], ["HCV", "SPECIES", 91, 94], ["dengue virus", "SPECIES", 101, 113], ["DENV", "SPECIES", 115, 119], ["West Nile virus", "SPECIES", 126, 141], ["WNV", "SPECIES", 143, 146], ["Japanese encephalitis virus", "SPECIES", 153, 180], ["JEV", "SPECIES", 182, 185], ["bovine viral diarrhea virus", "SPECIES", 196, 223], ["BVDV", "SPECIES", 225, 229], ["YF", "SPECIES", 787, 789], ["YFV", "SPECIES", 876, 879], ["flaviviruses", "PROBLEM", 14, 26], ["other RNA viruses", "PROBLEM", 41, 58], ["the hepatitis C virus", "PROBLEM", 68, 89], ["HCV", "PROBLEM", 91, 94], ["the dengue virus", "PROBLEM", 97, 113], ["DENV", "PROBLEM", 115, 119], ["the West Nile virus (WNV", "PROBLEM", 122, 146], ["the Japanese encephalitis virus (JEV)", "PROBLEM", 149, 186], ["the bovine viral diarrhea virus", "PROBLEM", 192, 223], ["Yellow Fever Inhibitors", "PROBLEM", 298, 321], ["ChEMBL Database", "TEST", 327, 342], ["new infections", "PROBLEM", 478, 492], ["the fatality rate", "TEST", 574, 591], ["Yellow Fever Inhibitors", "PROBLEM", 637, 660], ["ChEMBL Database", "TEST", 666, 681], ["several regular antiviral drugs", "TREATMENT", 730, 761], ["YF disease", "PROBLEM", 787, 797], ["chemotherapeutic medication", "TREATMENT", 806, 833], ["flaviviruses", "OBSERVATION", 14, 26], ["viruses", "OBSERVATION", 51, 58], ["Yellow Fever", "OBSERVATION", 298, 310], ["new", "OBSERVATION_MODIFIER", 478, 481], ["infections", "OBSERVATION", 482, 492], ["Yellow Fever", "OBSERVATION", 637, 649], ["no", "UNCERTAINTY", 803, 805]]], ["An anti-YFV vaccine (17D) is used to prevent the infection; however, it has been observed to cause systemic infections and side effects in some patients (Julander 2013) .Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisTherefore, computational approaches, such as virtual screening and modeling are particularly suitable to assist the discovery of new anti-YFV compounds.", [["17D", "CHEMICAL", 21, 24], ["infection", "DISEASE", 49, 58], ["infections", "DISEASE", 108, 118], ["anti-YFV", "SIMPLE_CHEMICAL", 3, 11], ["patients", "ORGANISM", 144, 152], ["anti-YFV", "SIMPLE_CHEMICAL", 399, 407], ["patients", "SPECIES", 144, 152], ["An anti-YFV vaccine (17D)", "TREATMENT", 0, 25], ["the infection", "PROBLEM", 45, 58], ["systemic infections", "PROBLEM", 99, 118], ["side effects", "PROBLEM", 123, 135], ["Yellow Fever Inhibitors", "PROBLEM", 184, 207], ["ChEMBL Database", "TEST", 213, 228], ["Classification Analysis", "TEST", 243, 266], ["virtual screening", "TEST", 311, 328], ["new anti-YFV compounds", "PROBLEM", 395, 417], ["infection", "OBSERVATION", 49, 58], ["systemic", "OBSERVATION_MODIFIER", 99, 107], ["infections", "OBSERVATION", 108, 118], ["Yellow Fever", "OBSERVATION", 184, 196]]], ["In this context, Moorthy and Poongavanam collected a number of compounds from the literature that were found (experimentally or computationally) to inhibit the YFV and employed them for the development of KNIME classification models using the Naive Bayes approach (Narayana Moorthy and Poongavanam 2015) .Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisFor this purpose, a set of 379 YFV inhibitors were collected from the ChEMBL database (https://www.ebi.ac.uk/chembl/).", [["YFV", "ORGANISM", 160, 163], ["YFV", "ORGANISM", 432, 435], ["YFV", "SPECIES", 160, 163], ["YFV", "SPECIES", 432, 435], ["Yellow Fever Inhibitors", "PROBLEM", 319, 342], ["ChEMBL Database", "TEST", 348, 363], ["Classification Analysis", "TEST", 378, 401], ["YFV inhibitors", "TREATMENT", 432, 446], ["Yellow Fever", "OBSERVATION", 319, 331]]], ["After the initial treatment of the data (namely, salt removal, 3D structure generation, and energy minimization of the structures), 30 two-dimensional descriptors of the compounds were calculated with the CDK tool as implemented in KNIME (Berthold et al. 2008; Beisken et al. 2013) .", [["CDK", "PROTEIN", 205, 208], ["the data", "TEST", 31, 39], ["salt removal", "TREATMENT", 49, 61], ["3D structure generation", "TREATMENT", 63, 86], ["energy minimization of the structures", "TREATMENT", 92, 129], ["the CDK tool", "TEST", 201, 213]]], ["The first 12 models refer to individual datasets, while models 13-16 were developed from a combined dataset, which contained 309 compounds.", [["individual datasets", "TEST", 29, 48], ["models", "TEST", 56, 62]]], ["Before the development of the models, the dataset was partitioned into training (65 %) and test (35 %) set based on a sampling consideration that distributes the inhibitors and noninhibitors evenly between sets.", [["test", "TEST", 91, 95], ["the inhibitors", "TREATMENT", 158, 172], ["noninhibitors", "TREATMENT", 177, 190]]], ["The inhibitor definition was restricted to specific activity criteria (i.e., IC50 \u00c4 10 M for inhibitors; IC50 > 10 M for noninhibitors).", [["The inhibitor definition", "TREATMENT", 0, 24], ["IC50", "TEST", 77, 81], ["inhibitors", "TREATMENT", 93, 103], ["IC50", "TEST", 105, 109]]], ["The quality of models was investigated through various activity thresholds (10, 30, 50, and 100 M) and statistical parameters, such as the sensitivity, specificity, G-mean, Matthew's correlation coefficient (MCC), and overall accuracy.Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisPrincipal component analysis (PCA) revealed that the dataset does not contain distinct clusters and its diversity is adequately represented by the training set.", [["statistical parameters", "TEST", 103, 125], ["the sensitivity", "TEST", 135, 150], ["specificity", "TEST", 152, 163], ["G", "TEST", 165, 166], ["Yellow Fever Inhibitors", "PROBLEM", 249, 272], ["ChEMBL Database", "TEST", 278, 293], ["PCA", "TEST", 361, 364], ["Yellow Fever", "OBSERVATION", 249, 261], ["distinct", "OBSERVATION_MODIFIER", 409, 417], ["clusters", "OBSERVATION", 418, 426]]], ["Additionally, it was shown that the majority of inhibitors is highly affected by the topological polar surface area (TPSA) and polar bonds.", [["surface area", "ANATOMY", 103, 115], ["TPSA", "SIMPLE_CHEMICAL", 117, 121], ["inhibitors", "TREATMENT", 48, 58], ["TPSA", "TEST", 117, 121], ["polar", "OBSERVATION_MODIFIER", 97, 102], ["surface", "OBSERVATION_MODIFIER", 103, 110], ["polar bonds", "OBSERVATION", 127, 138]]], ["This indicated the more hydrophobic nature of noninhibitors compared to inhibitors.Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisThe BestFirst attribute selection module of Weka was employed to select a set of 24 physicochemical descriptors in order to construct the Naive Bayes classification models for YFV inhibition.", [["YFV", "ORGANISM", 355, 358], ["YFV", "SPECIES", 355, 358], ["noninhibitors", "TREATMENT", 46, 59], ["Yellow Fever Inhibitors", "PROBLEM", 97, 120], ["ChEMBL Database", "TEST", 126, 141], ["Classification Analysis", "TEST", 156, 179], ["a set of 24 physicochemical descriptors", "TREATMENT", 251, 290], ["YFV inhibition", "TREATMENT", 355, 369], ["more hydrophobic", "OBSERVATION_MODIFIER", 19, 35], ["Yellow Fever", "OBSERVATION", 97, 109]]], ["It was shown that the six datasets (activity cutoff 30 M) perform equally well with an overall accuracy for the test set being >75 %.Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisThe model quality (based on MCC) was higher for all datasets except for one, which performed poorly.", [["the test set", "TEST", 108, 120], ["Yellow Fever Inhibitors", "PROBLEM", 147, 170], ["ChEMBL Database", "TEST", 176, 191], ["Classification Analysis", "TEST", 206, 229], ["Yellow Fever", "OBSERVATION", 147, 159], ["quality", "OBSERVATION_MODIFIER", 239, 246]]], ["Models derived from all datasets were statistically significant with MCC and G-mean values >0.7.", [["all datasets", "TEST", 20, 32], ["MCC", "TEST", 69, 72], ["G", "TEST", 77, 78]]], ["The significance of the dataset was also verified by the high F-score values (>0.8), while sensitivity and specificity parameters were >0.75 for most models.", [["the dataset", "TEST", 20, 31], ["specificity parameters", "TEST", 107, 129]]], ["The F-score is calculated through the following equation:Prediction of Yellow Fever Inhibitors from ChEMBL Database Through KNIME Classification AnalysisAlso, the predictive ability of the scheme was investigated by combining all the datasets into one.", [["Fever", "DISEASE", 78, 83], ["The F-score", "TEST", 0, 11], ["Yellow Fever Inhibitors", "PROBLEM", 71, 94], ["ChEMBL Database", "TEST", 100, 115]]], ["It was observed that an activity cutoff of 50 M yields a relatively good accuracy.", [["an activity cutoff", "TEST", 21, 39]]], ["Despite that models developed by different activity thresholds (10 or 30 M) were successful in distinguishing inhibitors (>90 %) from noninhibitors ( 65 %), they lacked a balanced class distribution (predicting adequately both classes instead of predicting accurately only one), which clearly affects the quality of the model.", [["inhibitors", "TEST", 110, 120], ["noninhibitors", "TEST", 134, 147]]], ["That is, it predicted 92 % of inhibitors and 78 % of noninhibitors with a MCC coefficient of 0.71, and a G-mean score (0.84), which reflects the high quality.", [["inhibitors", "TEST", 30, 40], ["noninhibitors", "TEST", 53, 66], ["a MCC coefficient", "TEST", 72, 89], ["a G-mean score", "TEST", 103, 117], ["high quality", "OBSERVATION", 145, 157]]], ["Finally, the best YFV inhibition model (at 50 M) was implemented into KNIME workflow to become freely available for use in medicinal chemistry applications.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachEarly attempts to develop successful de novo design programs for compounds have been seriously hampered by the unfeasible synthesis of the proposed structures (Boda and Johnson 2006; Lewis and Leach 1994; Schneider and Fechner 2005; Gillet and Johnson 1998) .", [["YFV", "ORGANISM", 18, 21], ["YFV", "SPECIES", 18, 21], ["medicinal chemistry applications", "TREATMENT", 123, 155], ["the Reaction Vectors", "TREATMENT", 215, 235], ["successful de novo design programs", "TREATMENT", 270, 304]]], ["More recent approaches that may facilitate synthetic routes generate a fixed set of transformations, which are in turn applied to starting structures to generate new molecules Schneider 2006, 2007; Lameijer et al. 2006; Sch\u00fcrer et al. 2005; Vinkers et al. 2003) .", [["a fixed set of transformations", "PROBLEM", 69, 99]]], ["However, these methods are usually restricted by the limited number of \"reactions\" that can be performed.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachReaction-like methodologies have been used in QSAR and data mining studies.", [["the Reaction Vectors", "TREATMENT", 164, 184], ["data mining studies", "TEST", 248, 267]]], ["For instance, the \"matched molecular pairs\" scheme (Leach et al. 2006 ) evaluates the change of a property with respect to a single structural change.", [["a single structural change", "PROBLEM", 123, 149]]], ["Similar approaches perform clustering of molecule pairs according to descriptor difference vectors, which are constructed by subtracting the vector representation of the \"product\" molecule from the vector representation of the \"reactant\" molecule (Sheridan et al. 2006) .", [["clustering of molecule pairs", "PROBLEM", 27, 55], ["the \"reactant\" molecule", "PROBLEM", 223, 246]]], ["Therefore, the pairs of molecules which belong to the same cluster represent similar transformations.", [["similar transformations", "OBSERVATION", 77, 100]]], ["Thus, changes in activities associated with the pairs may be used to estimate the effect of a particular transformation on activity.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachA knowledge-based approach regarding the de novo design of compounds based on reaction vectors has been proposed by Patel et al. (Patel et al. 2009 ).", [["reaction vectors", "TREATMENT", 298, 314]]], ["The method of reaction vectors is related to the descriptor difference vectors approach (Sheridan et al. 2006 ) and characterizes the structural changes, which occur at the reaction center.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachThe authors' flexible procedure enabled the automatic collection of everincreasing data on reactions, which are available in several databases.", [["The method of reaction vectors", "TREATMENT", 0, 30], ["the structural changes", "PROBLEM", 130, 152], ["the Reaction Vectors Approach", "TREATMENT", 248, 277], ["The authors' flexible procedure", "TREATMENT", 277, 308], ["reaction vectors", "OBSERVATION", 14, 30]]], ["Reaction vectors could be applied to novel starting molecules through a structure generation algorithm to predict new structures.", [["Reaction vectors", "TREATMENT", 0, 16], ["a structure generation algorithm", "TEST", 70, 102]]], ["Each applied transformation is derived from a reactions database, and since it is associated with a reaction from the literature, one may be confident toward the synthetic feasibility of the proposed molecules.", [["a reactions database", "PROBLEM", 44, 64], ["a reaction", "PROBLEM", 98, 108]]], ["The vectors are automatically collected from a set of reactions, which is not restricted by size or reaction type, therefore without involving any complex reaction strategy.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachThe principle of the method is the utilization of the information taken from a set of reactions (parent reactions) in deriving reaction vectors.", [["any complex reaction strategy", "PROBLEM", 143, 172], ["the Reaction Vectors Approach", "TREATMENT", 232, 261], ["reactions (parent reactions", "TREATMENT", 347, 374], ["vectors", "ANATOMY", 4, 11], ["size", "OBSERVATION_MODIFIER", 92, 96], ["reaction type", "OBSERVATION", 100, 113], ["without involving", "UNCERTAINTY", 125, 142]]], ["Reaction vectors are used to describe the reaction environment as well as changes at the reaction center.", [["Reaction vectors", "TREATMENT", 0, 16]]], ["Then, the reaction vectors are extracted from the knowledge base and may be applied to input starting materials in order to predict new product compounds for synthesis.", [["the reaction vectors", "TREATMENT", 6, 26], ["synthesis", "PROBLEM", 158, 167]]], ["In some cases, successful predictions may require the operation of a reaction vector to a second starting molecule.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachIn the past years, reaction vectors have been used to search and classify chemical reactions (Broughton et al. 2003) .", [["the operation", "TREATMENT", 50, 63], ["a reaction vector", "TREATMENT", 67, 84], ["a second starting molecule", "TREATMENT", 88, 114], ["the Reaction Vectors", "TREATMENT", 174, 194], ["reaction vectors", "TREATMENT", 222, 238]]], ["As already mentioned, a reaction vector represents the changes that occur during a reaction.", [["a reaction vector", "PROBLEM", 22, 39], ["a reaction", "PROBLEM", 81, 91]]], ["This is described in a descriptor scheme that is enhanced in the products (positive descriptors, they represent bonds gained in products) and is diminished from the reactants (negative descriptors, they represent bonds lost from reactants).", [["enhanced", "OBSERVATION_MODIFIER", 49, 57], ["diminished", "OBSERVATION_MODIFIER", 145, 155], ["reactants", "OBSERVATION_MODIFIER", 165, 174]]], ["In de novo design, the practical role of reaction vectors is to propose synthetic ways to new compounds by achieving a balance between specificity and generality.", [["reaction vectors", "TREATMENT", 41, 57]]], ["Namely, the reaction vectors should be specific enough in order to avoid their application in environments which disfavor the course of a reaction, but encoding part of the environment will hamper their ability to generate novel structures.", [["the reaction vectors", "TREATMENT", 8, 28], ["a reaction", "PROBLEM", 136, 146]]], ["The reaction vectors employed by Patel et al. are modifications of the original descriptors developed by Carhart et al. (1985) .", [["The reaction vectors", "TREATMENT", 0, 20]]], ["More detailed information on reaction vectors can be found in Patel et al. and references therein (Patel et al. 2009 ).De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachThe authors revealed that many reactions in the Lilly database are incomplete, and they implemented a reaction cleaning algorithm to overcome this drawback.", [["reaction vectors", "TREATMENT", 29, 45], ["the Reaction Vectors Approach", "TREATMENT", 178, 207], ["many reactions", "PROBLEM", 233, 247], ["a reaction cleaning algorithm", "TREATMENT", 307, 336], ["many", "OBSERVATION_MODIFIER", 233, 237], ["reactions", "OBSERVATION", 238, 247]]], ["The reaction cleaning algorithm is applied to the reactions before calculating the atom pair descriptors for the reactants and products.", [["The reaction cleaning algorithm", "TREATMENT", 0, 31], ["the reactions", "PROBLEM", 46, 59], ["calculating the atom pair descriptors", "TREATMENT", 67, 104], ["the reactants", "TREATMENT", 109, 122]]], ["The reaction vector is next calculated as follows:De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors Approachwhere D is the reaction vector, P is the product vector (the sum of the vectors of individual products), and R is the reactant vector (the sum of the vectors of individual reactants).", [["P", "DNA", 170, 171], ["The reaction vector", "TREATMENT", 0, 19], ["the Reaction Vectors", "TREATMENT", 109, 129], ["reactant vector", "OBSERVATION", 256, 271]]], ["Internal validation was achieved by generating 90 % of the known parent products for each reaction in a dataset containing 5695 reactions and 2866 reaction vectors.", [["Internal validation", "TEST", 0, 19], ["the known parent products", "TREATMENT", 55, 80], ["each reaction", "PROBLEM", 85, 98]]], ["The external validation involved the syntheses of the intermediate of the antithrombotic drug (S)-(C)-clopidogrel bisulfate (Wang et al. 2007 ) and the antidepressant venlafaxine (Kavitha and Rangappa 2004) .", [["S)-(C)-clopidogrel bisulfate", "CHEMICAL", 95, 123], ["antidepressant", "CHEMICAL", 152, 166], ["venlafaxine", "CHEMICAL", 167, 178], ["(S)-(C)-clopidogrel bisulfate", "CHEMICAL", 94, 123], ["venlafaxine", "CHEMICAL", 167, 178], ["(S)-(C)-clopidogrel bisulfate", "SIMPLE_CHEMICAL", 94, 123], ["venlafaxine", "SIMPLE_CHEMICAL", 167, 178], ["The external validation", "TEST", 0, 23], ["clopidogrel bisulfate", "TREATMENT", 102, 123], ["the antidepressant venlafaxine", "TREATMENT", 148, 178]]], ["The reaction vectors procedure was successful in reproducing the known synthetic routes for both drugs; however, it was suggested that this approach also yields quite a few alternative products.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachThe applicability of the algorithm to de novo design was demonstrated in three cases: (1) the ability of a reaction vector to generate novel and diverse products as regards the parent reaction, (2) prediction of analogs of a lead compound, and (3) application to the enumeration of a compound library.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachIn the first case, 10 reactants were randomly selected from the smaller (2866 vectors/5695 reactions) dataset and were input to the de novo design tool.", [["The reaction vectors procedure", "TREATMENT", 0, 30], ["both drugs", "TREATMENT", 92, 102], ["the Reaction Vectors Approach", "TREATMENT", 253, 282], ["a reaction vector", "TREATMENT", 387, 404], ["novel and diverse products", "TREATMENT", 417, 443], ["the parent reaction", "PROBLEM", 455, 474], ["a lead compound", "PROBLEM", 505, 520], ["the Reaction Vectors", "TREATMENT", 642, 662], ["compound library", "OBSERVATION", 566, 582], ["smaller", "OBSERVATION_MODIFIER", 735, 742]]], ["Products were generated employing the 16,859 reaction vectors from the larger dataset.", [["larger", "OBSERVATION_MODIFIER", 71, 77]]], ["Structures containing more functional groups than others usually yielded more solutions, therefore, the number of products that were created lies within 0 and 44.", [["more", "OBSERVATION_MODIFIER", 22, 26], ["functional", "OBSERVATION_MODIFIER", 27, 37], ["groups", "OBSERVATION_MODIFIER", 38, 44]]], ["Moreover, the average similarities between predicted compounds and products of the parent reactions vary significantly (0.15-0.96).", [["the parent reactions", "PROBLEM", 79, 99], ["compounds", "OBSERVATION_MODIFIER", 53, 62]]], ["It is therefore suggested that the diversity of the products depends on both the starting molecule and the entries in the reaction database.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachNext, the predictive power of the algorithm in lead optimization cases was explored by considering drugs as starting compounds and generating products after single-step transformations.", [["the products", "TREATMENT", 48, 60], ["drugs", "TREATMENT", 327, 332], ["single-step transformations", "TREATMENT", 385, 412]]], ["The procedure was based on penicillin G, Prozac, and aspirin (starting structures) and was performed with the larger set of reaction vectors (16,859) and the 5839 reagent set as described above.", [["penicillin", "CHEMICAL", 27, 37], ["Prozac", "CHEMICAL", 41, 47], ["aspirin", "CHEMICAL", 53, 60], ["penicillin G", "CHEMICAL", 27, 39], ["Prozac", "CHEMICAL", 41, 47], ["aspirin", "CHEMICAL", 53, 60], ["penicillin G", "SIMPLE_CHEMICAL", 27, 39], ["Prozac", "SIMPLE_CHEMICAL", 41, 47], ["aspirin", "SIMPLE_CHEMICAL", 53, 60], ["The procedure", "TREATMENT", 0, 13], ["penicillin G", "TREATMENT", 27, 39], ["Prozac", "TREATMENT", 41, 47], ["aspirin", "TREATMENT", 53, 60]]], ["Penicillin G was associated with the most potential products (24), while 20 and 12 products were generated for Prozac and aspirin, respectively.", [["Penicillin", "CHEMICAL", 0, 10], ["Prozac", "CHEMICAL", 111, 117], ["aspirin", "CHEMICAL", 122, 129], ["Penicillin G", "CHEMICAL", 0, 12], ["Prozac", "CHEMICAL", 111, 117], ["aspirin", "CHEMICAL", 122, 129], ["Penicillin G", "SIMPLE_CHEMICAL", 0, 12], ["Prozac", "SIMPLE_CHEMICAL", 111, 117], ["aspirin", "SIMPLE_CHEMICAL", 122, 129], ["Penicillin G", "TREATMENT", 0, 12], ["Prozac", "TREATMENT", 111, 117], ["aspirin", "TREATMENT", 122, 129]]], ["The reaction vector methodology was shown to realize the generation of synthetically accessible molecules that share close structural similarities with a parent compound.", [["synthetically accessible molecules", "PROBLEM", 71, 105]]], ["Thus, this approach could be particularly valuable in structure-activity relationship (SAR) studies by proposing structures for synthesis that explore sufficiently the conformational space around a known lead compound.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachFinally, the proposed methodology can be used to construct a virtual library of products by listing all possible products from a single reaction employing a specific set of reagents.", [["this approach", "TREATMENT", 6, 19], ["synthesis", "PROBLEM", 128, 137], ["the conformational space", "PROBLEM", 164, 188], ["a known lead compound", "PROBLEM", 196, 217], ["the Reaction Vectors", "TREATMENT", 277, 297], ["a virtual library of products", "TREATMENT", 365, 394], ["a single reaction", "PROBLEM", 433, 450], ["lead compound", "OBSERVATION", 204, 217]]], ["For instance, the authors used 6-bromoquinoxalin-2-one as starting material, 628 boronic acids as the reagents (extracted from the ACD), and a Suzuki coupling reaction to construct an enumerated library with 292 compounds.", [["6-bromoquinoxalin-2-one", "CHEMICAL", 31, 54], ["boronic acids", "CHEMICAL", 81, 94], ["6-bromoquinoxalin-2-one", "CHEMICAL", 31, 54], ["boronic acids", "CHEMICAL", 81, 94], ["6-bromoquinoxalin-2-one", "SIMPLE_CHEMICAL", 31, 54], ["628 boronic acids", "SIMPLE_CHEMICAL", 77, 94], ["bromoquinoxalin", "TREATMENT", 33, 48], ["boronic acids", "TREATMENT", 81, 94], ["the reagents", "TREATMENT", 98, 110], ["a Suzuki coupling reaction", "PROBLEM", 141, 167], ["ACD", "ANATOMY", 131, 134]]], ["It was shown that this scheme may be used to direct a parallel synthesis route according to a single reaction with varying reagents.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachMoreover, the way the reaction vector methodology recognizes the environment of a reaction is clearly demonstrated.", [["this scheme", "TREATMENT", 18, 29], ["a parallel synthesis route", "TREATMENT", 52, 78], ["a single reaction with varying reagents", "TREATMENT", 92, 131], ["the Reaction Vectors", "TREATMENT", 191, 211], ["a reaction", "PROBLEM", 300, 310]]], ["For the transformation that is applied, there is a literature precedence, and thus a high level of confidence is achieved regarding the completion of the reaction.", [["the reaction", "PROBLEM", 150, 162]]], ["However, this requires that complete coverage of a generic reaction has been obtained through adequate examples in the reaction database.De Novo Design of Synthetically Feasible Compounds Through the Reaction Vectors ApproachThe approach has been implemented in KNIME and this allows the facile customization of the procedure for a variety of applications.", [["a generic reaction", "PROBLEM", 49, 67], ["the Reaction Vectors Approach", "TREATMENT", 196, 225], ["the procedure", "TREATMENT", 312, 325], ["a variety of applications", "TREATMENT", 330, 355]]]], "PMC7092930": [["IntroductionPatients suffering from infection with severe acute respiratory syndrome coronavirus (SARS-CoV) [1] often have appreciable levels of virus-specific antibody [2], [3], [4], [5].", [["infection", "DISEASE", 36, 45], ["acute respiratory syndrome coronavirus", "DISEASE", 58, 96], ["SARS", "DISEASE", 98, 102], ["[3]", "SIMPLE_CHEMICAL", 174, 177], ["[4]", "SIMPLE_CHEMICAL", 179, 182], ["severe acute respiratory syndrome coronavirus", "SPECIES", 51, 96], ["SARS-CoV", "SPECIES", 98, 106], ["infection", "PROBLEM", 36, 45], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 51, 96], ["appreciable levels of virus", "PROBLEM", 123, 150], ["specific antibody", "TEST", 151, 168], ["infection", "OBSERVATION", 36, 45], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome coronavirus", "OBSERVATION", 64, 96]]], ["This situation is similar to that encountered in other viral diseases such as chronic hepatitis C or HIV, where the infection persists despite the presence of antibodies [6], [7], [8], [9], [10].", [["viral diseases", "DISEASE", 55, 69], ["chronic hepatitis C", "DISEASE", 78, 97], ["infection", "DISEASE", 116, 125], ["HIV", "ORGANISM", 101, 104], ["[7]", "SIMPLE_CHEMICAL", 175, 178], ["[8]", "SIMPLE_CHEMICAL", 180, 183], ["[9]", "SIMPLE_CHEMICAL", 185, 188], ["antibodies", "PROTEIN", 159, 169], ["HIV", "SPECIES", 101, 104], ["HIV", "SPECIES", 101, 104], ["other viral diseases", "PROBLEM", 49, 69], ["chronic hepatitis C", "PROBLEM", 78, 97], ["HIV", "PROBLEM", 101, 104], ["the infection", "PROBLEM", 112, 125], ["antibodies", "TEST", 159, 169], ["viral diseases", "OBSERVATION", 55, 69], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["hepatitis", "OBSERVATION", 86, 95], ["infection", "OBSERVATION", 116, 125]]], ["One of the mechanisms proposed originally by Dulbecco et al. [11] to account for apparent inhibition of virus neutralization was that the serum of infected individuals might contain non-neutralizing antibodies.", [["serum", "ANATOMY", 138, 143], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["individuals", "ORGANISM", 156, 167], ["non-neutralizing antibodies", "PROTEIN", 182, 209], ["virus neutralization", "PROBLEM", 104, 124], ["the serum", "TEST", 134, 143], ["infected individuals", "PROBLEM", 147, 167], ["non-neutralizing antibodies", "PROBLEM", 182, 209], ["virus", "OBSERVATION", 104, 109], ["infected", "OBSERVATION", 147, 155], ["non-neutralizing antibodies", "OBSERVATION", 182, 209]]], ["When combined with the corresponding virus, the non-neutralizing antibody could presumably interfere with the attachment of neutralizing antibody, thereby diminishing its neutralizing activity.", [["non-neutralizing antibody", "PROTEIN", 48, 73], ["neutralizing antibody", "PROTEIN", 124, 145], ["the corresponding virus", "PROBLEM", 19, 42], ["the non-neutralizing antibody", "PROBLEM", 44, 73], ["neutralizing antibody", "PROBLEM", 124, 145], ["virus", "OBSERVATION", 37, 42], ["neutralizing antibody", "OBSERVATION", 124, 145], ["neutralizing activity", "OBSERVATION", 171, 192]]], ["Massey and Schochetman subsequently showed that non-neutralizing antibody binds to virus and sterically blocks the binding of neutralizing antibodies [12].", [["non-neutralizing antibody", "PROTEIN", 48, 73], ["neutralizing antibodies", "PROTEIN", 126, 149], ["Schochetman", "TEST", 11, 22], ["non-neutralizing antibody binds to virus", "PROBLEM", 48, 88], ["neutralizing antibodies", "PROBLEM", 126, 149]]], ["Recently, we found two Epitopes I and II, within a short peptide between the hypervariable regions I and II of the hepatitis C virus E2 protein.", [["hepatitis C", "DISEASE", 115, 126], ["E2", "CHEMICAL", 133, 135], ["hepatitis C virus", "ORGANISM", 115, 132], ["E2", "ORGANISM", 133, 135], ["Epitopes I and II", "PROTEIN", 23, 40], ["hypervariable regions I and II", "PROTEIN", 77, 107], ["hepatitis C virus E2 protein", "PROTEIN", 115, 143], ["hepatitis C virus", "SPECIES", 115, 132], ["hepatitis C virus", "SPECIES", 115, 132], ["a short peptide", "PROBLEM", 49, 64], ["the hepatitis C virus E2 protein", "TREATMENT", 111, 143], ["Epitopes", "OBSERVATION", 23, 31], ["hypervariable", "OBSERVATION", 77, 90], ["hepatitis", "OBSERVATION", 115, 124]]], ["Epitope I, but not Epitope II, was implicated in virus neutralization.", [["Epitope I", "GENE_OR_GENE_PRODUCT", 0, 9], ["Epitope II", "GENE_OR_GENE_PRODUCT", 19, 29], ["Epitope I", "PROTEIN", 0, 9], ["Epitope II", "PROTEIN", 19, 29], ["Epitope I", "TREATMENT", 0, 9], ["virus neutralization", "TREATMENT", 49, 69]]], ["The binding of a non-neutralizing antibody to Epitope II disrupted virus neutralization mediated by antibody binding at Epitope I [9], [13].IntroductionHere, we have investigated whether or not a similar occurrence, namely the presence of non-neutralizing antibody along with neutralizing antibody, could account for the observation that SARS-CoV survives despite a vigorous antibody response by the host.", [["Epitope II", "CHEMICAL", 46, 56], ["SARS", "DISEASE", 338, 342], ["Epitope II", "GENE_OR_GENE_PRODUCT", 46, 56], ["SARS-CoV", "ORGANISM", 338, 346], ["non-neutralizing antibody", "PROTEIN", 17, 42], ["Epitope II", "PROTEIN", 46, 56], ["non-neutralizing antibody", "PROTEIN", 239, 264], ["neutralizing antibody", "PROTEIN", 276, 297], ["SARS-CoV", "SPECIES", 338, 346], ["a non-neutralizing antibody", "TREATMENT", 15, 42], ["Epitope II disrupted virus neutralization", "TREATMENT", 46, 87], ["non-neutralizing antibody", "PROBLEM", 239, 264], ["neutralizing antibody", "PROBLEM", 276, 297], ["SARS", "PROBLEM", 338, 342], ["CoV survives", "PROBLEM", 343, 355], ["non-neutralizing antibody", "OBSERVATION", 239, 264]]], ["We have characterized three previously isolated monoclonal antibodies (mAbs) that recognize the spike protein of SARS-CoV between residues 491 and 510 [14].", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 113, 121], ["monoclonal antibodies", "PROTEIN", 48, 69], ["mAbs", "PROTEIN", 71, 75], ["spike protein", "PROTEIN", 96, 109], ["SARS-CoV", "PROTEIN", 113, 121], ["SARS-CoV", "SPECIES", 113, 121], ["three previously isolated monoclonal antibodies (mAbs", "PROBLEM", 22, 75], ["the spike protein of SARS", "PROBLEM", 92, 117], ["CoV between residues", "TEST", 118, 138], ["monoclonal antibodies", "OBSERVATION", 48, 69]]], ["We found that the two neutralizing mAbs, 341C and 540C, could act synergistically to inhibit SARS-CoV infection in vitro, while the non-neutralizing antibody, 240C, disrupted the neutralizing activity of both 341C and 540C.", [["SARS-CoV infection", "DISEASE", 93, 111], ["SARS-CoV", "ORGANISM", 93, 101], ["neutralizing mAbs", "PROTEIN", 22, 39], ["non-neutralizing antibody", "PROTEIN", 132, 157], ["240C", "PROTEIN", 159, 163], ["SARS-CoV", "SPECIES", 93, 101], ["the two neutralizing mAbs", "TREATMENT", 14, 39], ["SARS", "PROBLEM", 93, 97], ["CoV infection", "PROBLEM", 98, 111], ["the non-neutralizing antibody", "TEST", 128, 157], ["CoV", "OBSERVATION_MODIFIER", 98, 101], ["infection", "OBSERVATION", 102, 111], ["neutralizing activity", "OBSERVATION", 179, 200]]], ["These findings suggest that this epitope cluster may provide a viral escape mechanism whereby the neutralization of virus is thwarted by an interfering, non-neutralizing antibody.Materials and methods", [["non-neutralizing antibody", "PROTEIN", 153, 178], ["this epitope cluster", "PROBLEM", 28, 48], ["a viral escape mechanism", "PROBLEM", 61, 85], ["the neutralization of virus", "PROBLEM", 94, 121], ["an interfering, non-neutralizing antibody", "PROBLEM", 137, 178], ["interfering", "OBSERVATION", 140, 151]]]], "PMC5640845": [["INTRODUCTIONFlaviviruses are taxonomically classified in the genus Flavivirus and family Flaviviridae.", [["Flaviviridae", "TREATMENT", 89, 101], ["genus Flavivirus", "OBSERVATION", 61, 77]]], ["These viruses comprise over 70 different pathogens, such as Japanese encephalitis virus (JEV), Zika virus (ZIKV), dengue virus (DENV), West Nile virus (WNV), and yellow fever virus (YFV).", [["Japanese encephalitis virus (JEV), Zika virus (ZIKV), dengue virus (DENV)", "DISEASE", 60, 133], ["West Nile virus (WNV)", "DISEASE", 135, 156], ["yellow fever", "DISEASE", 162, 174], ["Japanese encephalitis virus", "ORGANISM", 60, 87], ["JEV", "ORGANISM", 89, 92], ["Zika virus", "ORGANISM", 95, 105], ["ZIKV", "GENE_OR_GENE_PRODUCT", 107, 111], ["dengue virus", "ORGANISM", 114, 126], ["DENV", "ORGANISM", 128, 132], ["West Nile virus", "ORGANISM", 135, 150], ["WNV", "ORGANISM", 152, 155], ["yellow fever virus", "ORGANISM", 162, 180], ["YFV", "ORGANISM", 182, 185], ["Japanese encephalitis virus", "SPECIES", 60, 87], ["Zika virus", "SPECIES", 95, 105], ["dengue virus", "SPECIES", 114, 126], ["West Nile virus", "SPECIES", 135, 150], ["yellow fever virus", "SPECIES", 162, 180], ["Japanese encephalitis virus", "SPECIES", 60, 87], ["JEV", "SPECIES", 89, 92], ["Zika virus", "SPECIES", 95, 105], ["ZIKV", "SPECIES", 107, 111], ["dengue virus", "SPECIES", 114, 126], ["DENV", "SPECIES", 128, 132], ["West Nile virus", "SPECIES", 135, 150], ["WNV", "SPECIES", 152, 155], ["yellow fever virus", "SPECIES", 162, 180], ["YFV", "SPECIES", 182, 185], ["These viruses", "PROBLEM", 0, 13], ["70 different pathogens", "PROBLEM", 28, 50], ["Japanese encephalitis virus (JEV)", "PROBLEM", 60, 93], ["Zika virus (ZIKV)", "PROBLEM", 95, 112], ["dengue virus (DENV", "PROBLEM", 114, 132], ["West Nile virus (WNV", "PROBLEM", 135, 155], ["yellow fever virus", "PROBLEM", 162, 180], ["viruses", "OBSERVATION", 6, 13], ["70 different", "OBSERVATION_MODIFIER", 28, 40], ["pathogens", "OBSERVATION", 41, 50]]], ["Most flaviviruses are arthropod borne and cause public health problems worldwide (1).", [["flaviviruses", "DISEASE", 5, 17], ["arthropod borne", "DISEASE", 22, 37], ["Most flaviviruses", "PROBLEM", 0, 17]]], ["The development and usage of vaccines against some flaviviruses, such as JEV, YFV, and tick-borne encephalitis virus (TBEV), have decreased the rates of morbidity and mortality from infections caused by these viruses (2); however, flavivirus-induced diseases are still pandemic, and few therapies beyond intensive supportive care are currently available.INTRODUCTIONFlaviviruses have an approximately 11-kb positive-stranded RNA genome containing a single open reading frame (ORF) flanked by untranslated regions (UTRs) at both termini.", [["flaviviruses", "DISEASE", 51, 63], ["tick-borne encephalitis", "DISEASE", 87, 110], ["TBEV", "DISEASE", 118, 122], ["infections", "DISEASE", 182, 192], ["flavivirus-induced diseases", "DISEASE", 231, 258], ["JEV", "ORGANISM", 73, 76], ["YFV", "ORGANISM", 78, 81], ["tick-borne encephalitis virus", "ORGANISM", 87, 116], ["TBEV", "ORGANISM", 118, 122], ["11-kb positive-stranded RNA genome", "DNA", 401, 435], ["open reading frame", "DNA", 456, 474], ["ORF", "DNA", 476, 479], ["untranslated regions", "DNA", 492, 512], ["UTRs", "DNA", 514, 518], ["tick-borne encephalitis virus", "SPECIES", 87, 116], ["JEV", "SPECIES", 73, 76], ["YFV", "SPECIES", 78, 81], ["tick-borne encephalitis virus", "SPECIES", 87, 116], ["TBEV", "SPECIES", 118, 122], ["vaccines", "TREATMENT", 29, 37], ["some flaviviruses", "PROBLEM", 46, 63], ["JEV", "PROBLEM", 73, 76], ["YFV", "PROBLEM", 78, 81], ["tick-borne encephalitis virus", "PROBLEM", 87, 116], ["morbidity", "PROBLEM", 153, 162], ["infections", "PROBLEM", 182, 192], ["these viruses", "PROBLEM", 203, 216], ["flavivirus", "PROBLEM", 231, 241], ["induced diseases", "PROBLEM", 242, 258], ["pandemic", "PROBLEM", 269, 277], ["few therapies", "TREATMENT", 283, 296], ["intensive supportive care", "TREATMENT", 304, 329], ["stranded RNA genome", "PROBLEM", 416, 435], ["a single open reading frame", "PROBLEM", 447, 474], ["infections", "OBSERVATION", 182, 192], ["viruses", "OBSERVATION", 209, 216], ["stranded", "OBSERVATION_MODIFIER", 416, 424], ["RNA genome", "OBSERVATION", 425, 435], ["termini", "OBSERVATION_MODIFIER", 528, 535]]], ["The ORF encodes three structural proteins, including the capsid (C), membrane (premembrane [prM] and membrane [M]), and envelope (E), and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (3).", [["membrane", "ANATOMY", 69, 77], ["membrane", "ANATOMY", 101, 109], ["capsid (C)", "GENE_OR_GENE_PRODUCT", 57, 67], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["membrane", "CELLULAR_COMPONENT", 101, 109], ["NS1", "GENE_OR_GENE_PRODUCT", 168, 171], ["NS2A", "GENE_OR_GENE_PRODUCT", 173, 177], ["NS2B", "GENE_OR_GENE_PRODUCT", 179, 183], ["NS3", "GENE_OR_GENE_PRODUCT", 185, 188], ["NS4A", "GENE_OR_GENE_PRODUCT", 190, 194], ["NS4B", "GENE_OR_GENE_PRODUCT", 196, 200], ["ORF", "DNA", 4, 7], ["structural proteins", "PROTEIN", 22, 41], ["capsid (C)", "PROTEIN", 57, 67], ["premembrane", "PROTEIN", 79, 90], ["prM", "PROTEIN", 92, 95], ["membrane [M]", "PROTEIN", 101, 113], ["envelope (E)", "PROTEIN", 120, 132], ["nonstructural proteins", "PROTEIN", 144, 166], ["NS1", "PROTEIN", 168, 171], ["NS2A", "PROTEIN", 173, 177], ["NS2B", "PROTEIN", 179, 183], ["NS3", "PROTEIN", 185, 188], ["NS4A", "PROTEIN", 190, 194], ["NS4B", "PROTEIN", 196, 200], ["NS5", "PROTEIN", 206, 209], ["The ORF encodes three structural proteins", "PROBLEM", 0, 41], ["the capsid (C), membrane (premembrane [prM] and membrane [M", "TEST", 53, 112], ["seven nonstructural proteins", "TEST", 138, 166], ["NS1", "TEST", 168, 171], ["NS2A", "TEST", 173, 177], ["NS2B", "TEST", 179, 183], ["NS3", "TEST", 185, 188], ["NS4A", "TREATMENT", 190, 194], ["NS4B", "TEST", 196, 200], ["three structural", "OBSERVATION_MODIFIER", 16, 32], ["proteins", "OBSERVATION", 33, 41], ["NS3", "ANATOMY", 185, 188], ["NS4A", "ANATOMY", 190, 194]]], ["These seven nonstructural proteins participate in viral replication, virion assembly, and virus escape from immune surveillance.INTRODUCTIONTo date, no specific antivirals with activity against flaviviruses are available.", [["virion", "CELLULAR_COMPONENT", 69, 75], ["nonstructural proteins", "PROTEIN", 12, 34], ["These seven nonstructural proteins", "PROBLEM", 0, 34], ["viral replication", "TREATMENT", 50, 67], ["virion assembly", "TREATMENT", 69, 84], ["virus escape", "PROBLEM", 90, 102], ["immune surveillance", "TEST", 108, 127], ["specific antivirals", "TREATMENT", 152, 171], ["flaviviruses", "PROBLEM", 194, 206], ["nonstructural proteins", "OBSERVATION", 12, 34], ["viral replication", "OBSERVATION", 50, 67]]], ["Since flaviviruses are similar in structure and pathogenesis, we first utilized JEV as the prototype to screen the drug library and subsequently validated the antiviral activities with ZIKV, WNV, and DENV type 2 (DENV-2).", [["JEV", "ORGANISM", 80, 83], ["ZIKV", "ORGANISM", 185, 189], ["WNV", "ORGANISM", 191, 194], ["DENV type 2", "ORGANISM", 200, 211], ["DENV-2", "ORGANISM", 213, 219], ["JEV", "SPECIES", 80, 83], ["ZIKV", "SPECIES", 185, 189], ["WNV", "SPECIES", 191, 194], ["DENV type 2", "SPECIES", 200, 211], ["DENV", "SPECIES", 213, 217], ["flaviviruses", "PROBLEM", 6, 18], ["ZIKV", "PROBLEM", 185, 189], ["WNV", "PROBLEM", 191, 194], ["flaviviruses", "OBSERVATION", 6, 18], ["similar", "OBSERVATION_MODIFIER", 23, 30]]], ["The hit drugs identified in this study offer potential new therapies for the treatment of flavivirus infection and disease.Screening of an FDA-approved drug library for inhibitors of JEV infection. ::: RESULTSRecombinant viral particles (RVPs) with the luciferase-reporting replicon enveloped by the JEV structural proteins were used to select inhibitors, with a focus on those that inhibit virus entry and replication, by a high-throughput screening (HTS) assay (4, 5).", [["flavivirus infection", "DISEASE", 90, 110], ["JEV infection", "DISEASE", 183, 196], ["flavivirus", "ORGANISM", 90, 100], ["JEV", "ORGANISM", 183, 186], ["RVPs", "GENE_OR_GENE_PRODUCT", 238, 242], ["luciferase", "GENE_OR_GENE_PRODUCT", 253, 263], ["JEV", "ORGANISM", 300, 303], ["luciferase", "PROTEIN", 253, 263], ["JEV structural proteins", "PROTEIN", 300, 323], ["flavivirus", "SPECIES", 90, 100], ["JEV", "SPECIES", 183, 186], ["JEV", "SPECIES", 300, 303], ["The hit drugs", "TREATMENT", 0, 13], ["this study", "TEST", 28, 38], ["new therapies", "TREATMENT", 55, 68], ["the treatment", "TREATMENT", 73, 86], ["flavivirus infection", "PROBLEM", 90, 110], ["disease", "PROBLEM", 115, 122], ["an FDA", "TEST", 136, 142], ["JEV infection", "PROBLEM", 183, 196], ["RESULTSRecombinant viral particles", "TEST", 202, 236], ["RVPs", "TEST", 238, 242], ["the luciferase", "TEST", 249, 263], ["replicon", "TREATMENT", 274, 282], ["the JEV structural proteins", "PROBLEM", 296, 323], ["flavivirus", "OBSERVATION", 90, 100], ["JEV infection", "OBSERVATION", 183, 196], ["viral particles", "OBSERVATION", 221, 236]]], ["The number of genomic RNA copies of RVP was determined to be 8.4 \u00d7 106 copies/ml by using a standard curve generated with plasmids carrying the infectious clone.", [["plasmids", "ANATOMY", 122, 130], ["clone", "ANATOMY", 155, 160], ["clone", "CELL", 155, 160], ["genomic RNA copies", "RNA", 14, 32], ["plasmids", "DNA", 122, 130], ["RVP", "TEST", 36, 39], ["a standard curve", "TEST", 90, 106], ["plasmids", "TREATMENT", 122, 130], ["the infectious clone", "PROBLEM", 140, 160], ["infectious clone", "OBSERVATION", 144, 160]]], ["The HTS assay conditions, including the seeding cell density and RVP dose, were optimized to be 10,000 cells per 96-well plate and 20 \u03bcl (16 copies/cell) RVP for the infective dose, respectively.", [["cell", "ANATOMY", 48, 52], ["cells", "ANATOMY", 103, 108], ["cell", "ANATOMY", 148, 152], ["cell", "CELL", 48, 52], ["cells", "CELL", 103, 108], ["The HTS assay conditions", "TEST", 0, 24], ["the seeding cell density", "TEST", 36, 60], ["RVP dose", "TEST", 65, 73], ["RVP", "TEST", 154, 157], ["the infective dose", "TREATMENT", 162, 180], ["seeding cell density", "OBSERVATION", 40, 60], ["infective", "OBSERVATION", 166, 175]]], ["Under the optimized conditions, the signal-to-basal (S/B) ratio, coefficient of variation (CV), and Z\u2032 factor were 38,374, 2.8%, and 0.89, respectively, which demonstrated that the assay was robust and suitable for the large-scale screening of compounds.Screening of an FDA-approved drug library for inhibitors of JEV infection. ::: RESULTSA schematic of the HTS assay is depicted in Fig. 1B.", [["JEV infection", "DISEASE", 314, 327], ["1B.", "CHEMICAL", 389, 392], ["Z\u2032 factor", "GENE_OR_GENE_PRODUCT", 100, 109], ["JEV", "ORGANISM", 314, 317], ["Z\u2032 factor", "PROTEIN", 100, 109], ["JEV", "SPECIES", 314, 317], ["1B.", "SPECIES", 389, 392], ["the signal", "TEST", 32, 42], ["Z\u2032 factor", "TEST", 100, 109], ["the assay", "TEST", 177, 186], ["the large-scale screening", "TEST", 215, 240], ["an FDA", "TEST", 267, 273], ["JEV infection", "PROBLEM", 314, 327], ["the HTS assay", "TEST", 355, 368], ["JEV infection", "OBSERVATION", 314, 327]]], ["After three rounds of screening, five hits with a selective index (SI; which is equal to the 50% cytotoxic concentration [CC50[/50% inhibitory concentration [IC50]) of >10 were selected.", [["screening", "TEST", 22, 31], ["CC50", "TEST", 122, 126], ["inhibitory concentration", "TEST", 132, 156], ["IC50", "TEST", 158, 162]]], ["The CC50 values of the hit drugs exhibited in Fig. 1B were similar to those previously published for diverse cell systems but determined using different toxicity assays (6\u201313).", [["cell", "ANATOMY", 109, 113], ["toxicity", "DISEASE", 153, 161], ["1B", "GENE_OR_GENE_PRODUCT", 51, 53], ["cell", "CELL", 109, 113], ["The CC50 values", "TEST", 0, 15], ["the hit drugs", "TREATMENT", 19, 32], ["diverse cell systems", "PROBLEM", 101, 121], ["different toxicity assays", "PROBLEM", 143, 168], ["hit drugs", "OBSERVATION", 23, 32]]], ["Three of the hit drugs, manidipine, cilnidipine, and benidipine hydrochloride, were dihydropyridine (DHP) voltage-gated Ca2+ channel (VGCC) antagonists, while pimecrolimus is an inhibitor of inflammatory cytokine secretion and nelfinavir mesylate is an HIV-1 protease blocker.", [["manidipine", "CHEMICAL", 24, 34], ["cilnidipine", "CHEMICAL", 36, 47], ["benidipine hydrochloride", "CHEMICAL", 53, 77], ["dihydropyridine", "CHEMICAL", 84, 99], ["DHP", "CHEMICAL", 101, 104], ["Ca2", "CHEMICAL", 120, 123], ["pimecrolimus", "CHEMICAL", 159, 171], ["nelfinavir mesylate", "CHEMICAL", 227, 246], ["manidipine", "CHEMICAL", 24, 34], ["cilnidipine", "CHEMICAL", 36, 47], ["benidipine hydrochloride", "CHEMICAL", 53, 77], ["dihydropyridine", "CHEMICAL", 84, 99], ["DHP", "CHEMICAL", 101, 104], ["Ca2+", "CHEMICAL", 120, 124], ["pimecrolimus", "CHEMICAL", 159, 171], ["nelfinavir mesylate", "CHEMICAL", 227, 246], ["manidipine", "SIMPLE_CHEMICAL", 24, 34], ["cilnidipine", "SIMPLE_CHEMICAL", 36, 47], ["benidipine hydrochloride", "SIMPLE_CHEMICAL", 53, 77], ["dihydropyridine", "SIMPLE_CHEMICAL", 84, 99], ["DHP", "SIMPLE_CHEMICAL", 101, 104], ["Ca2+ channel", "SIMPLE_CHEMICAL", 120, 132], ["VGCC", "SIMPLE_CHEMICAL", 134, 138], ["pimecrolimus", "SIMPLE_CHEMICAL", 159, 171], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 227, 246], ["HIV-1", "ORGANISM", 253, 258], ["Ca2+ channel", "PROTEIN", 120, 132], ["inflammatory cytokine", "PROTEIN", 191, 212], ["HIV-1", "SPECIES", 253, 258], ["HIV-1", "SPECIES", 253, 258], ["the hit drugs", "TREATMENT", 9, 22], ["manidipine", "TREATMENT", 24, 34], ["cilnidipine", "TREATMENT", 36, 47], ["benidipine hydrochloride", "TREATMENT", 53, 77], ["dihydropyridine (DHP)", "TREATMENT", 84, 105], ["voltage", "TEST", 106, 113], ["gated Ca2+ channel (VGCC) antagonists", "TREATMENT", 114, 151], ["pimecrolimus", "TREATMENT", 159, 171], ["inflammatory cytokine secretion", "PROBLEM", 191, 222], ["nelfinavir mesylate", "TREATMENT", 227, 246], ["an HIV-1 protease blocker", "TREATMENT", 250, 275], ["inflammatory", "OBSERVATION_MODIFIER", 191, 203]]], ["All five drugs exhibited a dose-dependent inhibition of JEV RVP infection (Fig. 1C).", [["JEV RVP infection", "DISEASE", 56, 73], ["JEV", "ORGANISM", 56, 59], ["JEV", "SPECIES", 56, 59], ["All five drugs", "TREATMENT", 0, 14], ["JEV RVP infection", "PROBLEM", 56, 73], ["JEV RVP infection", "OBSERVATION", 56, 73]]], ["To validate the antiviral effect, hit drugs were purchased from other commercial sources and tested.", [["the antiviral effect", "TREATMENT", 12, 32], ["hit drugs", "TREATMENT", 34, 43], ["antiviral effect", "OBSERVATION", 16, 32]]], ["In the reconfirmation screen, all hit drugs showed antiviral and cytotoxic effects similar to those found in the primary screen.Validation of hit drugs. ::: RESULTSTo verify the results obtained by the luciferase reporter assays, we also investigated the antiviral effect of the five hit drugs on wild-type JEV strain AT31.", [["luciferase", "GENE_OR_GENE_PRODUCT", 202, 212], ["JEV", "ORGANISM", 307, 310], ["strain AT31", "ORGANISM", 311, 322], ["luciferase", "PROTEIN", 202, 212], ["JEV strain AT31", "SPECIES", 307, 322], ["the reconfirmation screen", "TEST", 3, 28], ["all hit drugs", "TREATMENT", 30, 43], ["antiviral", "TREATMENT", 51, 60], ["cytotoxic effects", "PROBLEM", 65, 82], ["the luciferase reporter assays", "TEST", 198, 228], ["the five hit drugs", "TREATMENT", 275, 293]]], ["As expected from the HTS assay, all five drugs robustly inhibited virus production, with a reduction of approximately 4 to 5 log units at the highest concentration and an approximately 1-log-unit decrease with 2.5 \u03bcM the drugs (Fig. 2B).", [["the HTS assay", "TEST", 17, 30], ["all five drugs", "TREATMENT", 32, 46], ["a reduction", "TREATMENT", 89, 100], ["the drugs", "TREATMENT", 217, 226]]], ["A sharp decrease in JEV RNA levels was also detected (Fig. 2C).", [["JEV", "ORGANISM", 20, 23], ["JEV RNA", "RNA", 20, 27], ["JEV", "SPECIES", 20, 23], ["A sharp decrease in JEV RNA levels", "PROBLEM", 0, 34], ["sharp", "OBSERVATION_MODIFIER", 2, 7], ["decrease", "OBSERVATION_MODIFIER", 8, 16], ["JEV RNA levels", "OBSERVATION", 20, 34]]], ["The attenuated RNA levels in the high-dose, middle-dose, and low-dose groups were all above 40%.", [["The attenuated RNA levels", "PROBLEM", 0, 25], ["low-dose groups", "TREATMENT", 61, 76], ["attenuated", "OBSERVATION_MODIFIER", 4, 14], ["RNA", "OBSERVATION_MODIFIER", 15, 18], ["levels", "OBSERVATION_MODIFIER", 19, 25]]], ["In particular, in the manidipine-treated group, the inhibitory effect was at least 80% compared to that for the control, which showed a strong inhibition of viral replication.", [["manidipine", "CHEMICAL", 22, 32], ["manidipine", "CHEMICAL", 22, 32], ["manidipine", "SIMPLE_CHEMICAL", 22, 32], ["the manidipine", "TREATMENT", 18, 32], ["viral replication", "TREATMENT", 157, 174], ["viral replication", "OBSERVATION", 157, 174]]], ["Consistent with the inhibition of virus replication and production, expression of the viral structural protein prM was hardly detectable following treatment with the drugs at the high concentration (Fig. 2D).", [["prM", "GENE_OR_GENE_PRODUCT", 111, 114], ["viral structural protein", "PROTEIN", 86, 110], ["prM", "PROTEIN", 111, 114], ["virus replication", "TREATMENT", 34, 51], ["the viral structural protein prM", "PROBLEM", 82, 114], ["the drugs", "TREATMENT", 162, 171], ["virus", "OBSERVATION", 34, 39], ["viral structural", "OBSERVATION", 86, 102], ["protein prM", "OBSERVATION", 103, 114]]], ["Overall, the results in Fig. 2 confirmed that the five hit drugs inhibited JEV infection in a dose-dependent manner in vitro.Drugs inhibit JEV infection during viral RNA synthesis. ::: RESULTSBecause RVPs, which have a natural virus-like envelope on the outside and a replicon on the inside, permitted the quantification of JEV productive entry and replication, a time-of-addition experiment was performed to investigate whether the hit drugs blocked the entry step or the replication step.", [["JEV infection", "DISEASE", 75, 88], ["JEV infection", "DISEASE", 139, 152], ["JEV", "ORGANISM", 75, 78], ["JEV", "ORGANISM", 139, 142], ["RVPs", "GENE_OR_GENE_PRODUCT", 200, 204], ["JEV", "ORGANISM", 324, 327], ["viral RNA", "RNA", 160, 169], ["RVPs", "PROTEIN", 200, 204], ["JEV", "SPECIES", 75, 78], ["JEV", "SPECIES", 139, 142], ["JEV", "SPECIES", 324, 327], ["the five hit drugs", "PROBLEM", 46, 64], ["JEV infection", "PROBLEM", 75, 88], ["Drugs", "TREATMENT", 125, 130], ["JEV infection", "PROBLEM", 139, 152], ["viral RNA synthesis", "PROBLEM", 160, 179], ["RVPs", "PROBLEM", 200, 204], ["a natural virus", "PROBLEM", 217, 232], ["a replicon", "TREATMENT", 266, 276], ["the hit drugs", "PROBLEM", 429, 442], ["JEV infection", "OBSERVATION", 75, 88], ["JEV infection", "OBSERVATION", 139, 152], ["viral RNA synthesis", "OBSERVATION", 160, 179], ["natural virus", "OBSERVATION", 219, 232]]], ["As shown in Fig. 3B, no suppression of luciferase activity by any of the hit drugs was observed when they were used as treatments before infection or during infection or as a virucide, suggesting that these drugs do not inhibit JEV infection either by inactivating the virus directly or by blocking JEV entry.", [["infection", "DISEASE", 137, 146], ["infection", "DISEASE", 157, 166], ["JEV infection", "DISEASE", 228, 241], ["luciferase", "GENE_OR_GENE_PRODUCT", 39, 49], ["JEV", "ORGANISM", 228, 231], ["JEV", "ORGANISM", 299, 302], ["luciferase", "PROTEIN", 39, 49], ["JEV", "SPECIES", 228, 231], ["JEV", "SPECIES", 299, 302], ["luciferase activity", "PROBLEM", 39, 58], ["the hit drugs", "TREATMENT", 69, 82], ["infection", "PROBLEM", 137, 146], ["infection", "PROBLEM", 157, 166], ["these drugs", "TREATMENT", 201, 212], ["JEV infection", "PROBLEM", 228, 241], ["the virus", "PROBLEM", 265, 274], ["no", "UNCERTAINTY", 21, 23]]], ["However, these drugs exerted fully inhibitory effects when they were added at 1 h postinfection, suggesting that viral replication was the stage at which these drugs showed inhibitory activity.Drugs inhibit JEV infection during viral RNA synthesis. ::: RESULTSTo confirm this suggestion, we investigated the inhibitory effects of these drugs on the JEV replicon.", [["JEV infection", "DISEASE", 207, 220], ["JEV", "ORGANISM", 207, 210], ["JEV", "ORGANISM", 349, 352], ["viral RNA", "RNA", 228, 237], ["JEV", "SPECIES", 207, 210], ["JEV", "SPECIES", 349, 352], ["these drugs", "TREATMENT", 9, 20], ["viral replication", "PROBLEM", 113, 130], ["Drugs", "TREATMENT", 193, 198], ["JEV infection", "PROBLEM", 207, 220], ["these drugs", "TREATMENT", 330, 341], ["the JEV replicon", "TREATMENT", 345, 361], ["viral replication", "OBSERVATION", 113, 130], ["inhibitory activity", "OBSERVATION", 173, 192], ["JEV infection", "OBSERVATION", 207, 220]]], ["The highest concentration of manidipine and nelfinavir mesylate tested in baby hamster kidney (BHK-21) cells was adjusted to 5 \u03bcM and 10 \u03bcM, respectively.", [["hamster kidney", "ANATOMY", 79, 93], ["BHK-21) cells", "ANATOMY", 95, 108], ["manidipine", "CHEMICAL", 29, 39], ["nelfinavir mesylate", "CHEMICAL", 44, 63], ["manidipine", "CHEMICAL", 29, 39], ["nelfinavir mesylate", "CHEMICAL", 44, 63], ["manidipine", "SIMPLE_CHEMICAL", 29, 39], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 44, 63], ["baby hamster kidney", "CELL", 74, 93], ["BHK-21) cells", "CELL", 95, 108], ["baby hamster kidney (BHK-21) cells", "CELL_LINE", 74, 108], ["hamster", "SPECIES", 79, 86], ["hamster", "SPECIES", 79, 86], ["manidipine", "TREATMENT", 29, 39], ["nelfinavir mesylate", "TREATMENT", 44, 63], ["BHK", "TEST", 95, 98], ["kidney", "ANATOMY", 87, 93]]], ["It was shown that all five drugs inhibited JEV RNA synthesis in a dose-dependent manner, while neither drug inhibited the initial translation of replicon RNA (5, 14) (Fig. 3C), confirming that these drugs inhibited JEV infection at the stage of replication.Hit drugs exhibit broad-spectrum antiflavivirus activity. ::: RESULTSIn order to determine whether the antiviral activity of the five hit drugs extended to other flaviviruses, we explored their antiviral effect against ZIKV.", [["JEV infection", "DISEASE", 215, 228], ["JEV", "ORGANISM", 43, 46], ["JEV", "ORGANISM", 215, 218], ["ZIKV", "ORGANISM", 476, 480], ["JEV RNA", "RNA", 43, 50], ["replicon RNA", "RNA", 145, 157], ["JEV", "SPECIES", 43, 46], ["JEV", "SPECIES", 215, 218], ["ZIKV", "SPECIES", 476, 480], ["all five drugs", "TREATMENT", 18, 32], ["JEV RNA synthesis", "TREATMENT", 43, 60], ["replicon RNA", "TREATMENT", 145, 157], ["these drugs", "TREATMENT", 193, 204], ["JEV infection", "PROBLEM", 215, 228], ["Hit drugs", "TREATMENT", 257, 266], ["the five hit drugs", "TREATMENT", 382, 400], ["other flaviviruses", "PROBLEM", 413, 431], ["ZIKV", "PROBLEM", 476, 480]]], ["Similar to the findings for JEV, the ZIKV titer was decreased by multiple log units when ZIKV was treated with a high concentration of each of the drugs (Fig. 4A).", [["JEV", "DISEASE", 28, 31], ["JEV", "ORGANISM", 28, 31], ["ZIKV", "ORGANISM", 37, 41], ["JEV", "SPECIES", 28, 31], ["ZIKV", "SPECIES", 37, 41], ["ZIKV", "SPECIES", 89, 93], ["JEV", "PROBLEM", 28, 31], ["the ZIKV titer", "TREATMENT", 33, 47], ["ZIKV", "PROBLEM", 89, 93], ["the drugs", "TREATMENT", 143, 152]]], ["Moreover, ZIKV exhibited a higher sensitivity to the two calcium channels inhibitors manidipine and cilnidipine than JEV, with no plaque formation being observed at 10 \u03bcM.", [["plaque", "ANATOMY", 130, 136], ["ZIKV", "CHEMICAL", 10, 14], ["calcium", "CHEMICAL", 57, 64], ["manidipine", "CHEMICAL", 85, 95], ["cilnidipine", "CHEMICAL", 100, 111], ["calcium", "CHEMICAL", 57, 64], ["manidipine", "CHEMICAL", 85, 95], ["cilnidipine", "CHEMICAL", 100, 111], ["calcium", "SIMPLE_CHEMICAL", 57, 64], ["manidipine", "SIMPLE_CHEMICAL", 85, 95], ["cilnidipine", "SIMPLE_CHEMICAL", 100, 111], ["JEV", "ORGANISM", 117, 120], ["plaque", "PATHOLOGICAL_FORMATION", 130, 136], ["ZIKV", "SPECIES", 10, 14], ["JEV", "SPECIES", 117, 120], ["ZIKV", "PROBLEM", 10, 14], ["a higher sensitivity", "PROBLEM", 25, 45], ["the two calcium channels inhibitors", "TREATMENT", 49, 84], ["manidipine", "TREATMENT", 85, 95], ["cilnidipine", "TREATMENT", 100, 111], ["JEV", "TREATMENT", 117, 120], ["plaque formation", "PROBLEM", 130, 146], ["no", "UNCERTAINTY", 127, 129], ["plaque", "OBSERVATION", 130, 136]]], ["Consistent with this result, sharp decreases in the level of replication of ZIKV RNA and the level of expression of viral protein were also detected (Fig. 4A).", [["ZIKV", "GENE_OR_GENE_PRODUCT", 76, 80], ["ZIKV RNA", "RNA", 76, 84], ["viral protein", "PROTEIN", 116, 129], ["ZIKV", "SPECIES", 76, 80], ["sharp decreases", "PROBLEM", 29, 44], ["ZIKV RNA", "PROBLEM", 76, 84], ["viral protein", "PROBLEM", 116, 129], ["sharp", "OBSERVATION_MODIFIER", 29, 34], ["decreases", "OBSERVATION_MODIFIER", 35, 44], ["replication", "OBSERVATION", 61, 72], ["ZIKV RNA", "OBSERVATION", 76, 84], ["viral protein", "OBSERVATION", 116, 129]]], ["Notably, treatment with 5 \u03bcM manidipine produced a 95% inhibition of viral replication, translation, and viral yields.", [["manidipine", "CHEMICAL", 29, 39], ["manidipine", "CHEMICAL", 29, 39], ["manidipine", "SIMPLE_CHEMICAL", 29, 39], ["manidipine", "TREATMENT", 29, 39], ["viral replication", "TREATMENT", 69, 86]]], ["Taken together, these results indicate that the hit drugs could effectively inhibit ZIKV infection.Hit drugs exhibit broad-spectrum antiflavivirus activity. ::: RESULTSSince these drugs exhibited their anti-JEV effects at the stage of viral replication, we further tested the effects against WNV and DENV-2 by using WNV and DENV-2 replicons.", [["infection", "DISEASE", 89, 98], ["ZIKV", "ORGANISM", 84, 88], ["anti-JEV", "CANCER", 202, 210], ["WNV", "ORGANISM", 292, 295], ["DENV-2", "ORGANISM", 300, 306], ["WNV", "ORGANISM", 316, 319], ["DENV-2", "ORGANISM", 324, 330], ["WNV and DENV-2 replicons", "DNA", 316, 340], ["ZIKV", "SPECIES", 84, 88], ["WNV", "SPECIES", 292, 295], ["DENV-2", "SPECIES", 300, 306], ["WNV", "SPECIES", 316, 319], ["DENV-2", "SPECIES", 324, 330], ["the hit drugs", "TREATMENT", 44, 57], ["ZIKV infection", "PROBLEM", 84, 98], ["Hit drugs", "TREATMENT", 99, 108], ["broad-spectrum antiflavivirus activity", "TREATMENT", 117, 155], ["these drugs", "TREATMENT", 174, 185], ["viral replication", "TREATMENT", 235, 252], ["WNV", "PROBLEM", 292, 295], ["DENV", "PROBLEM", 300, 304], ["WNV", "PROBLEM", 316, 319], ["DENV", "PROBLEM", 324, 328], ["viral replication", "OBSERVATION", 235, 252]]], ["Similar to the results for JEV, a dose-dependent reduction in the level of WNV replication was observed with the drug treatments.", [["JEV", "DISEASE", 27, 30], ["JEV", "ORGANISM", 27, 30], ["WNV", "ORGANISM", 75, 78], ["JEV", "SPECIES", 27, 30], ["WNV", "SPECIES", 75, 78], ["JEV", "PROBLEM", 27, 30], ["a dose-dependent reduction", "TREATMENT", 32, 58], ["WNV replication", "TREATMENT", 75, 90], ["the drug treatments", "TREATMENT", 109, 128], ["dependent", "OBSERVATION_MODIFIER", 39, 48], ["reduction", "OBSERVATION_MODIFIER", 49, 58], ["WNV replication", "OBSERVATION", 75, 90]]], ["The same phenotype was observed for DENV-2 for all drugs except nelfinavir mesylate, which showed no effect at the concentrations tested (Fig. 4B and C).", [["nelfinavir mesylate", "CHEMICAL", 64, 83], ["nelfinavir mesylate", "CHEMICAL", 64, 83], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 64, 83], ["DENV", "PROBLEM", 36, 40], ["all drugs", "TREATMENT", 47, 56], ["nelfinavir mesylate", "TREATMENT", 64, 83], ["the concentrations", "TEST", 111, 129]]], ["Together, these results indicate that the five hit drugs are excellent candidates for broad-spectrum antiflavivirus treatment.Antiviral effect of calcium inhibitors. ::: RESULTSSince three hit drugs, manidipine, cilnidipine, and benidipine hydrochloride, were DHP VGCC inhibitors, we asked whether other calcium antagonists could block JEV infection.", [["calcium", "CHEMICAL", 146, 153], ["manidipine", "CHEMICAL", 200, 210], ["cilnidipine", "CHEMICAL", 212, 223], ["benidipine hydrochloride", "CHEMICAL", 229, 253], ["DHP", "CHEMICAL", 260, 263], ["calcium", "CHEMICAL", 304, 311], ["JEV infection", "DISEASE", 336, 349], ["calcium", "CHEMICAL", 146, 153], ["manidipine", "CHEMICAL", 200, 210], ["cilnidipine", "CHEMICAL", 212, 223], ["benidipine hydrochloride", "CHEMICAL", 229, 253], ["DHP", "CHEMICAL", 260, 263], ["calcium", "CHEMICAL", 304, 311], ["antiflavivirus", "SIMPLE_CHEMICAL", 101, 115], ["calcium", "SIMPLE_CHEMICAL", 146, 153], ["manidipine", "SIMPLE_CHEMICAL", 200, 210], ["cilnidipine", "SIMPLE_CHEMICAL", 212, 223], ["benidipine hydrochloride", "SIMPLE_CHEMICAL", 229, 253], ["DHP", "SIMPLE_CHEMICAL", 260, 263], ["VGCC", "SIMPLE_CHEMICAL", 264, 268], ["calcium", "SIMPLE_CHEMICAL", 304, 311], ["JEV", "ORGANISM", 336, 339], ["JEV", "SPECIES", 336, 339], ["the five hit drugs", "PROBLEM", 38, 56], ["broad-spectrum antiflavivirus treatment", "TREATMENT", 86, 125], ["Antiviral effect", "TREATMENT", 126, 142], ["calcium inhibitors", "TREATMENT", 146, 164], ["three hit drugs", "TREATMENT", 183, 198], ["manidipine", "TREATMENT", 200, 210], ["cilnidipine", "TREATMENT", 212, 223], ["benidipine hydrochloride", "TREATMENT", 229, 253], ["DHP VGCC inhibitors", "TREATMENT", 260, 279], ["calcium antagonists", "TREATMENT", 304, 323], ["block JEV infection", "PROBLEM", 330, 349], ["JEV", "OBSERVATION_MODIFIER", 336, 339], ["infection", "OBSERVATION", 340, 349]]], ["To address this question, we employed four different classes of inhibitors.", [["inhibitors", "TREATMENT", 64, 74]]], ["Verapamil, a prototype phenylalkylamine (PAA) VGCC inhibitor (15), exhibited a dose-dependent inhibition of JEV on both African Green monkey kidney (Vero) and human hepatocellular carcinoma (Huh-7) cells (Fig. 5), which was consistent with the inhibitory effects of the DHP inhibitors, suggesting that calcium channels play an important role in JEV infection.", [["kidney", "ANATOMY", 141, 147], ["Vero", "ANATOMY", 149, 153], ["hepatocellular carcinoma (Huh-7) cells", "ANATOMY", 165, 203], ["Verapamil", "CHEMICAL", 0, 9], ["phenylalkylamine", "CHEMICAL", 23, 39], ["PAA", "CHEMICAL", 41, 44], ["hepatocellular carcinoma", "DISEASE", 165, 189], ["DHP", "CHEMICAL", 270, 273], ["calcium", "CHEMICAL", 302, 309], ["JEV infection", "DISEASE", 345, 358], ["Verapamil", "CHEMICAL", 0, 9], ["phenylalkylamine", "CHEMICAL", 23, 39], ["PAA", "CHEMICAL", 41, 44], ["DHP", "CHEMICAL", 270, 273], ["calcium", "CHEMICAL", 302, 309], ["Verapamil", "SIMPLE_CHEMICAL", 0, 9], ["phenylalkylamine", "SIMPLE_CHEMICAL", 23, 39], ["PAA", "SIMPLE_CHEMICAL", 41, 44], ["VGCC", "SIMPLE_CHEMICAL", 46, 50], ["JEV", "ORGANISM", 108, 111], ["Green monkey kidney", "ORGANISM", 128, 147], ["Vero", "CELL", 149, 153], ["human", "ORGANISM", 159, 164], ["hepatocellular carcinoma (Huh-7) cells", "CELL", 165, 203], ["DHP", "SIMPLE_CHEMICAL", 270, 273], ["calcium", "SIMPLE_CHEMICAL", 302, 309], ["JEV", "ORGANISM", 345, 348], ["human hepatocellular carcinoma (Huh-7) cells", "CELL_LINE", 159, 203], ["Green monkey", "SPECIES", 128, 140], ["human", "SPECIES", 159, 164], ["JEV", "SPECIES", 108, 111], ["African Green monkey", "SPECIES", 120, 140], ["human", "SPECIES", 159, 164], ["JEV", "SPECIES", 345, 348], ["Verapamil", "TREATMENT", 0, 9], ["a prototype phenylalkylamine (PAA) VGCC inhibitor", "TREATMENT", 11, 60], ["JEV", "PROBLEM", 108, 111], ["human hepatocellular carcinoma", "PROBLEM", 159, 189], ["Huh", "TEST", 191, 194], ["the DHP inhibitors", "TREATMENT", 266, 284], ["calcium channels", "PROBLEM", 302, 318], ["JEV infection", "PROBLEM", 345, 358], ["kidney", "ANATOMY", 141, 147], ["hepatocellular", "ANATOMY", 165, 179], ["carcinoma", "OBSERVATION", 180, 189], ["consistent with", "UNCERTAINTY", 224, 239], ["JEV infection", "OBSERVATION", 345, 358]]], ["Cyclosporine and 2-aminobiphenyl borate (2-APB), which inhibit the efflux of Ca2+ from the mitochondrial and endoplasmic reticulum (ER) pool, respectively (16\u201319), were also found to block JEV infection effectively.", [["mitochondrial", "ANATOMY", 91, 104], ["endoplasmic reticulum", "ANATOMY", 109, 130], ["ER", "ANATOMY", 132, 134], ["Cyclosporine", "CHEMICAL", 0, 12], ["2-aminobiphenyl borate", "CHEMICAL", 17, 39], ["2-APB", "CHEMICAL", 41, 46], ["Ca2", "CHEMICAL", 77, 80], ["JEV infection", "DISEASE", 189, 202], ["Cyclosporine", "CHEMICAL", 0, 12], ["2-aminobiphenyl borate", "CHEMICAL", 17, 39], ["2-APB", "CHEMICAL", 41, 46], ["Ca2+", "CHEMICAL", 77, 81], ["Cyclosporine", "SIMPLE_CHEMICAL", 0, 12], ["2-aminobiphenyl borate", "SIMPLE_CHEMICAL", 17, 39], ["2-APB", "SIMPLE_CHEMICAL", 41, 46], ["Ca2+", "SIMPLE_CHEMICAL", 77, 81], ["mitochondrial", "CELLULAR_COMPONENT", 91, 104], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 109, 130], ["ER", "GENE_OR_GENE_PRODUCT", 132, 134], ["JEV", "ORGANISM", 189, 192], ["Ca2", "PROTEIN", 77, 80], ["ER", "PROTEIN", 132, 134], ["JEV", "SPECIES", 189, 192], ["Cyclosporine", "TREATMENT", 0, 12], ["2-aminobiphenyl borate (2-APB)", "TREATMENT", 17, 47], ["block JEV infection", "PROBLEM", 183, 202], ["mitochondrial", "ANATOMY", 91, 104], ["endoplasmic reticulum", "ANATOMY", 109, 130], ["JEV infection", "OBSERVATION", 189, 202]]], ["Similarly, treatment with the cell-permeant Ca2+ chelator 1,2-bis-(o-aminophenoxy)-ethane-N,N,N\u2032,N\u2032-tetraacetic acid, tetraacetoxymethyl ester (BAPTA-AM), could also suppress JEV infection.", [["cell", "ANATOMY", 30, 34], ["Ca2", "CHEMICAL", 44, 47], ["1,2-bis-(o-aminophenoxy)-ethane-N,N,N\u2032,N\u2032-tetraacetic acid", "CHEMICAL", 58, 116], ["tetraacetoxymethyl ester", "CHEMICAL", 118, 142], ["BAPTA", "CHEMICAL", 144, 149], ["AM", "CHEMICAL", 150, 152], ["JEV infection", "DISEASE", 175, 188], ["Ca2+", "CHEMICAL", 44, 48], ["1,2-bis-(o-aminophenoxy)-ethane-N,N,N\u2032,N\u2032-tetraacetic acid", "CHEMICAL", 58, 116], ["tetraacetoxymethyl ester", "CHEMICAL", 118, 142], ["BAPTA-AM", "CHEMICAL", 144, 152], ["cell", "CELL", 30, 34], ["Ca2+ chelator 1,2-bis-(o-aminophenoxy)-ethane-N,N,N\u2032,N\u2032-tetraacetic acid", "SIMPLE_CHEMICAL", 44, 116], ["tetraacetoxymethyl ester", "SIMPLE_CHEMICAL", 118, 142], ["BAPTA-AM", "SIMPLE_CHEMICAL", 144, 152], ["JEV", "ORGANISM", 175, 178], ["JEV", "SPECIES", 175, 178], ["the cell-permeant Ca2+ chelator", "TREATMENT", 26, 57], ["bis", "TEST", 62, 65], ["ethane", "TREATMENT", 83, 89], ["N\u2032", "TREATMENT", 94, 96], ["N\u2032-tetraacetic acid", "TREATMENT", 97, 116], ["tetraacetoxymethyl ester (BAPTA", "TREATMENT", 118, 149], ["JEV infection", "PROBLEM", 175, 188], ["JEV infection", "OBSERVATION", 175, 188]]], ["Taken together, we concluded that intracellular Ca2+ is essential for JEV infection and cytoplasmic calcium is a potent target for antiflavivirus treatment.Selection and characterization of manidipine-resistant JEV. ::: RESULTSTo identify the viral target of the calcium channel inhibitor, we selected a manidipine-resistant virus by serially passaging JEV in the presence of manidipine.", [["intracellular", "ANATOMY", 34, 47], ["cytoplasmic", "ANATOMY", 88, 99], ["Ca2", "CHEMICAL", 48, 51], ["infection", "DISEASE", 74, 83], ["calcium", "CHEMICAL", 100, 107], ["manidipine", "CHEMICAL", 190, 200], ["JEV", "DISEASE", 211, 214], ["calcium", "CHEMICAL", 263, 270], ["manidipine", "CHEMICAL", 304, 314], ["JEV", "DISEASE", 353, 356], ["manidipine", "CHEMICAL", 376, 386], ["Ca2+", "CHEMICAL", 48, 52], ["calcium", "CHEMICAL", 100, 107], ["manidipine", "CHEMICAL", 190, 200], ["calcium", "CHEMICAL", 263, 270], ["manidipine", "CHEMICAL", 304, 314], ["manidipine", "CHEMICAL", 376, 386], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 47], ["Ca2+", "SIMPLE_CHEMICAL", 48, 52], ["JEV", "ORGANISM", 70, 73], ["cytoplasmic", "ORGANISM_SUBSTANCE", 88, 99], ["calcium", "SIMPLE_CHEMICAL", 100, 107], ["antiflavivirus", "SIMPLE_CHEMICAL", 131, 145], ["manidipine", "SIMPLE_CHEMICAL", 190, 200], ["JEV", "ORGANISM", 211, 214], ["calcium", "SIMPLE_CHEMICAL", 263, 270], ["manidipine", "SIMPLE_CHEMICAL", 304, 314], ["JEV", "ORGANISM", 353, 356], ["manidipine", "SIMPLE_CHEMICAL", 376, 386], ["Ca2", "PROTEIN", 48, 51], ["JEV", "SPECIES", 70, 73], ["JEV", "SPECIES", 211, 214], ["JEV", "SPECIES", 353, 356], ["intracellular Ca2", "TEST", 34, 51], ["JEV infection", "PROBLEM", 70, 83], ["cytoplasmic calcium", "TEST", 88, 107], ["antiflavivirus treatment", "TREATMENT", 131, 155], ["manidipine", "TREATMENT", 190, 200], ["the calcium channel inhibitor", "TREATMENT", 259, 288], ["a manidipine", "TREATMENT", 302, 314], ["resistant virus", "PROBLEM", 315, 330], ["manidipine", "TREATMENT", 376, 386], ["essential for", "UNCERTAINTY", 56, 69], ["JEV infection", "OBSERVATION", 70, 83], ["viral target", "OBSERVATION", 243, 255]]], ["Viruses from passage 20 (P20) showed robust resistance compared with the wild type (WT) (Fig. 6A).", [["Viruses", "PROBLEM", 0, 7], ["robust resistance", "PROBLEM", 37, 54], ["robust resistance", "OBSERVATION", 37, 54]]], ["When JEV from P20 was treated with 5 \u03bcM or 10 \u03bcM manidipine, the viral titer was about 10- and 100-fold higher than that of the WT, respectively.Selection and characterization of manidipine-resistant JEV. ::: RESULTSIndividual virus clones were isolated, and two isolates were randomly selected and amplified.", [["manidipine", "CHEMICAL", 49, 59], ["manidipine", "CHEMICAL", 179, 189], ["JEV", "DISEASE", 200, 203], ["manidipine", "CHEMICAL", 49, 59], ["manidipine", "CHEMICAL", 179, 189], ["JEV", "ORGANISM", 5, 8], ["manidipine", "SIMPLE_CHEMICAL", 49, 59], ["manidipine", "SIMPLE_CHEMICAL", 179, 189], ["JEV", "ORGANISM", 200, 203], ["JEV", "SPECIES", 5, 8], ["JEV", "SPECIES", 200, 203], ["10 \u03bcM manidipine", "TREATMENT", 43, 59], ["the viral titer", "TEST", 61, 76], ["manidipine", "TREATMENT", 179, 189], ["RESULTSIndividual virus clones", "PROBLEM", 209, 239], ["two isolates", "TREATMENT", 259, 271], ["virus clones", "OBSERVATION", 227, 239]]], ["An amino acid substitution was observed in two isolated clones, resulting in a glutamine (Q)-to-arginine (R) switch at amino acid position 130 in transmembrane domain 3 (TMD3) of NS4B, i.e., position 2401 of the translated polyprotein in the JEV infectious cDNA clone (Fig. 6B).", [["clones", "ANATOMY", 56, 62], ["amino acid", "CHEMICAL", 3, 13], ["glutamine", "CHEMICAL", 79, 88], ["arginine", "CHEMICAL", 96, 104], ["amino acid", "CHEMICAL", 119, 129], ["amino acid", "CHEMICAL", 3, 13], ["glutamine", "CHEMICAL", 79, 88], ["arginine", "CHEMICAL", 96, 104], ["amino acid", "CHEMICAL", 119, 129], ["amino acid", "AMINO_ACID", 3, 13], ["clones", "CELL", 56, 62], ["glutamine", "AMINO_ACID", 79, 88], ["amino acid", "AMINO_ACID", 119, 129], ["position 130", "AMINO_ACID", 130, 142], ["transmembrane domain 3", "GENE_OR_GENE_PRODUCT", 146, 168], ["TMD3", "GENE_OR_GENE_PRODUCT", 170, 174], ["NS4B", "GENE_OR_GENE_PRODUCT", 179, 183], ["JEV", "ORGANISM", 242, 245], ["glutamine (Q)-to-arginine (R) switch", "PROTEIN", 79, 115], ["amino acid position 130", "PROTEIN", 119, 142], ["transmembrane domain 3", "PROTEIN", 146, 168], ["TMD3", "PROTEIN", 170, 174], ["NS4B", "PROTEIN", 179, 183], ["position 2401", "PROTEIN", 191, 204], ["JEV infectious cDNA clone", "DNA", 242, 267], ["JEV", "SPECIES", 242, 245], ["An amino acid substitution", "TREATMENT", 0, 26], ["a glutamine", "TREATMENT", 77, 88], ["arginine (R) switch at amino acid position", "TREATMENT", 96, 138], ["NS4B", "TREATMENT", 179, 183], ["polyprotein", "TREATMENT", 223, 234], ["amino", "OBSERVATION", 3, 8], ["acid substitution", "OBSERVATION", 9, 26], ["isolated clones", "OBSERVATION", 47, 62]]], ["Sequence alignment of NS4B indicated that Q130 was conserved in all flaviviruses except YFV, which possessed a lysine at that position (Fig. 6B).", [["lysine", "CHEMICAL", 111, 117], ["lysine", "CHEMICAL", 111, 117], ["Q130", "GENE_OR_GENE_PRODUCT", 42, 46], ["YFV", "ORGANISM", 88, 91], ["NS4B", "PROTEIN", 22, 26], ["Q130", "DNA", 42, 46], ["YFV", "SPECIES", 88, 91], ["Sequence alignment of NS4B", "TEST", 0, 26], ["YFV", "PROBLEM", 88, 91], ["a lysine", "TREATMENT", 109, 117]]], ["The conserved Q130 of NS4B may account for the sensitivity of JEV, ZIKV, WNV, and DENV-2 to manidipine, as described above (Fig. 4), while YFV showed resistance to the drug (data not shown).Selection and characterization of manidipine-resistant JEV. ::: RESULTSTo confirm that the Q130R mutation did confer manidipine resistance and to investigate the role of Q130 in NS4B function, we produced JEV clones with the Q130R, Q130K, Q130E, or Q130A mutation by introducing the desired mutations into the infectious cDNA clone and rescuing the mutant viruses.", [["JEV", "DISEASE", 62, 65], ["manidipine", "CHEMICAL", 92, 102], ["manidipine", "CHEMICAL", 224, 234], ["JEV", "DISEASE", 245, 248], ["manidipine", "CHEMICAL", 307, 317], ["manidipine", "CHEMICAL", 92, 102], ["manidipine", "CHEMICAL", 224, 234], ["manidipine", "CHEMICAL", 307, 317], ["Q130", "GENE_OR_GENE_PRODUCT", 14, 18], ["NS4B", "GENE_OR_GENE_PRODUCT", 22, 26], ["JEV", "ORGANISM", 62, 65], ["ZIKV", "GENE_OR_GENE_PRODUCT", 67, 71], ["WNV", "ORGANISM", 73, 76], ["DENV-2", "ORGANISM", 82, 88], ["manidipine", "SIMPLE_CHEMICAL", 92, 102], ["YFV", "ORGANISM", 139, 142], ["manidipine", "SIMPLE_CHEMICAL", 224, 234], ["JEV", "ORGANISM", 245, 248], ["Q130R", "GENE_OR_GENE_PRODUCT", 281, 286], ["manidipine", "SIMPLE_CHEMICAL", 307, 317], ["Q130", "GENE_OR_GENE_PRODUCT", 360, 364], ["NS4B", "GENE_OR_GENE_PRODUCT", 368, 372], ["JEV", "ORGANISM", 395, 398], ["Q130R", "GENE_OR_GENE_PRODUCT", 415, 420], ["mutant viruses", "ORGANISM", 539, 553], ["Q130", "DNA", 14, 18], ["NS4B", "PROTEIN", 22, 26], ["Q130R", "DNA", 281, 286], ["Q130", "DNA", 360, 364], ["NS4B", "PROTEIN", 368, 372], ["infectious cDNA clone", "DNA", 500, 521], ["JEV", "SPECIES", 62, 65], ["ZIKV", "SPECIES", 67, 71], ["WNV", "SPECIES", 73, 76], ["DENV-2", "SPECIES", 82, 88], ["YFV", "SPECIES", 139, 142], ["JEV", "SPECIES", 245, 248], ["JEV", "SPECIES", 395, 398], ["NS4B", "TREATMENT", 22, 26], ["the sensitivity", "TEST", 43, 58], ["JEV", "PROBLEM", 62, 65], ["ZIKV", "PROBLEM", 67, 71], ["WNV", "PROBLEM", 73, 76], ["DENV", "PROBLEM", 82, 86], ["manidipine", "TREATMENT", 92, 102], ["manidipine", "TREATMENT", 224, 234], ["the Q130R mutation", "PROBLEM", 277, 295], ["manidipine resistance", "TREATMENT", 307, 328], ["JEV clones", "TREATMENT", 395, 405], ["the infectious cDNA clone", "PROBLEM", 496, 521], ["the mutant viruses", "PROBLEM", 535, 553]]], ["To investigate the biological properties of the mutant viruses, we first examined the growth kinetics of the rescued viruses.", [["the mutant viruses", "PROBLEM", 44, 62], ["the rescued viruses", "PROBLEM", 105, 124], ["viruses", "OBSERVATION", 55, 62], ["rescued viruses", "OBSERVATION", 109, 124]]], ["As shown in Fig. 6C, all mutant viruses had an accumulation of infectious virions and reached the highest titer at 60 h postinfection.", [["virions", "ANATOMY", 74, 81], ["mutant viruses", "ORGANISM", 25, 39], ["all mutant viruses", "PROBLEM", 21, 39], ["infectious virions", "PROBLEM", 63, 81], ["viruses", "OBSERVATION", 32, 39], ["accumulation", "OBSERVATION_MODIFIER", 47, 59], ["infectious virions", "OBSERVATION", 63, 81]]], ["Infection of the Q130R and Q130K mutant viruses resulted in growth curves similar to the growth curve for the WT (Fig. 6C), while the Q130E and Q130A mutants produced smaller amounts of viruses between 24 and 60 h.", [["Q130R", "GENE_OR_GENE_PRODUCT", 17, 22], ["Q130K", "GENE_OR_GENE_PRODUCT", 27, 32], ["Fig. 6C", "ORGANISM", 114, 121], ["Q130E", "GENE_OR_GENE_PRODUCT", 134, 139], ["Q130A", "GENE_OR_GENE_PRODUCT", 144, 149], ["Q130E and Q130A mutants", "PROTEIN", 134, 157], ["Infection of the Q130R and Q130K mutant viruses", "PROBLEM", 0, 47], ["growth curves", "TEST", 60, 73], ["the growth curve", "TEST", 85, 101], ["the WT", "TEST", 106, 112], ["smaller amounts of viruses", "PROBLEM", 167, 193], ["viruses", "OBSERVATION", 40, 47], ["smaller", "OBSERVATION_MODIFIER", 167, 174]]], ["Analysis of the plaque morphology revealed that the plaques of the Q130R, Q130K, and Q130E mutants were similar to the plaques of the WT, whereas the plaques of the Q130A mutant were smaller than those of the WT.Selection and characterization of manidipine-resistant JEV. ::: RESULTSWe next investigated the sensitivity of the four mutant viruses to manidipine.", [["plaque", "ANATOMY", 16, 22], ["plaques", "ANATOMY", 52, 59], ["plaques", "ANATOMY", 119, 126], ["plaques", "ANATOMY", 150, 157], ["manidipine", "CHEMICAL", 246, 256], ["JEV", "DISEASE", 267, 270], ["manidipine", "CHEMICAL", 350, 360], ["manidipine", "CHEMICAL", 246, 256], ["manidipine", "CHEMICAL", 350, 360], ["plaque", "PATHOLOGICAL_FORMATION", 16, 22], ["plaques", "PATHOLOGICAL_FORMATION", 52, 59], ["Q130R", "GENE_OR_GENE_PRODUCT", 67, 72], ["Q130K", "GENE_OR_GENE_PRODUCT", 74, 79], ["Q130E", "GENE_OR_GENE_PRODUCT", 85, 90], ["plaques", "PATHOLOGICAL_FORMATION", 119, 126], ["plaques", "PATHOLOGICAL_FORMATION", 150, 157], ["Q130A", "GENE_OR_GENE_PRODUCT", 165, 170], ["manidipine", "SIMPLE_CHEMICAL", 246, 256], ["JEV", "ORGANISM", 267, 270], ["manidipine", "SIMPLE_CHEMICAL", 350, 360], ["Q130A mutant", "PROTEIN", 165, 177], ["JEV", "SPECIES", 267, 270], ["the plaque morphology", "TEST", 12, 33], ["the plaques", "PROBLEM", 48, 59], ["manidipine", "TREATMENT", 246, 256], ["manidipine", "TREATMENT", 350, 360], ["plaque", "OBSERVATION", 16, 22], ["plaques", "OBSERVATION", 52, 59], ["plaques", "OBSERVATION", 119, 126], ["plaques", "OBSERVATION", 150, 157], ["smaller", "OBSERVATION_MODIFIER", 183, 190]]], ["As shown in Fig. 6D, the Q130R and Q130K mutant viruses were resistant to manidipine.", [["manidipine", "CHEMICAL", 74, 84], ["manidipine", "CHEMICAL", 74, 84], ["Q130R", "GENE_OR_GENE_PRODUCT", 25, 30], ["Q130K", "GENE_OR_GENE_PRODUCT", 35, 40], ["manidipine", "SIMPLE_CHEMICAL", 74, 84], ["Q130K mutant viruses", "PROBLEM", 35, 55], ["manidipine", "TREATMENT", 74, 84]]], ["At a 10 \u03bcM concentration, manidipine efficiently inhibited WT JEV infection and reduced the viral yields by approximately 4 log units, while the Q130R and Q130K mutant viruses were resistant to manidipine and the viral titer decreased less than 2 log units.", [["manidipine", "CHEMICAL", 26, 36], ["JEV infection", "DISEASE", 62, 75], ["manidipine", "CHEMICAL", 194, 204], ["manidipine", "CHEMICAL", 26, 36], ["manidipine", "CHEMICAL", 194, 204], ["manidipine", "SIMPLE_CHEMICAL", 26, 36], ["WT JEV", "ORGANISM", 59, 65], ["Q130R", "GENE_OR_GENE_PRODUCT", 145, 150], ["Q130K mutant viruses", "ORGANISM", 155, 175], ["manidipine", "SIMPLE_CHEMICAL", 194, 204], ["JEV", "SPECIES", 62, 65], ["a 10 \u03bcM concentration", "TREATMENT", 3, 24], ["manidipine", "TREATMENT", 26, 36], ["WT JEV infection", "PROBLEM", 59, 75], ["Q130K mutant viruses", "PROBLEM", 155, 175], ["manidipine", "TREATMENT", 194, 204], ["the viral titer", "TEST", 209, 224], ["JEV infection", "OBSERVATION", 62, 75]]], ["The Q130A mutant virus demonstrated moderate resistance and a slightly higher than 2-log-unit decrease in titer, while the Q130E mutant virus showed no resistance to manidipine.Selection and characterization of manidipine-resistant JEV. ::: RESULTSTaken together, it could be concluded that Q130 not only is critical for conferring manidipine sensitivity but also is important for JEV replication.", [["manidipine", "CHEMICAL", 166, 176], ["manidipine", "CHEMICAL", 211, 221], ["JEV", "DISEASE", 232, 235], ["Q130", "CHEMICAL", 291, 295], ["manidipine", "CHEMICAL", 332, 342], ["manidipine", "CHEMICAL", 166, 176], ["manidipine", "CHEMICAL", 211, 221], ["manidipine", "CHEMICAL", 332, 342], ["Q130A mutant virus", "ORGANISM", 4, 22], ["Q130E mutant virus", "ORGANISM", 123, 141], ["manidipine", "SIMPLE_CHEMICAL", 166, 176], ["manidipine", "SIMPLE_CHEMICAL", 211, 221], ["JEV", "ORGANISM", 232, 235], ["Q130", "SIMPLE_CHEMICAL", 291, 295], ["manidipine", "SIMPLE_CHEMICAL", 332, 342], ["JEV", "ORGANISM", 381, 384], ["JEV", "SPECIES", 232, 235], ["JEV", "SPECIES", 381, 384], ["The Q130A mutant virus", "TEST", 0, 22], ["moderate resistance", "PROBLEM", 36, 55], ["titer", "TEST", 106, 111], ["the Q130E mutant virus", "PROBLEM", 119, 141], ["manidipine", "TREATMENT", 166, 176], ["manidipine", "TREATMENT", 211, 221], ["manidipine sensitivity", "PROBLEM", 332, 354], ["JEV replication", "TREATMENT", 381, 396], ["moderate", "OBSERVATION_MODIFIER", 36, 44], ["resistance", "OBSERVATION", 45, 55], ["slightly", "OBSERVATION_MODIFIER", 62, 70], ["higher", "OBSERVATION_MODIFIER", 71, 77], ["no resistance", "OBSERVATION", 149, 162]]], ["The replacement of glutamine with basic amino acids conferred resistance to manidipine without an apparent loss of growth.In vivo efficacy of manidipine. ::: RESULTSAs manidipine exhibited the strongest inhibitory activities on JEV replication as well as ZIKV infection when its activities were compared with those of the five hit drugs (Fig. 2 and 4A), we further examined the protective effect of manidipine against JEV-induced lethality in a mouse model.", [["glutamine", "CHEMICAL", 19, 28], ["amino acids", "CHEMICAL", 40, 51], ["manidipine", "CHEMICAL", 76, 86], ["manidipine", "CHEMICAL", 142, 152], ["manidipine", "CHEMICAL", 168, 178], ["ZIKV infection", "DISEASE", 255, 269], ["manidipine", "CHEMICAL", 399, 409], ["JEV", "DISEASE", 418, 421], ["glutamine", "CHEMICAL", 19, 28], ["amino acids", "CHEMICAL", 40, 51], ["manidipine", "CHEMICAL", 76, 86], ["manidipine", "CHEMICAL", 142, 152], ["manidipine", "CHEMICAL", 168, 178], ["manidipine", "CHEMICAL", 399, 409], ["glutamine", "AMINO_ACID", 19, 28], ["basic", "SIMPLE_CHEMICAL", 34, 39], ["amino acids", "AMINO_ACID", 40, 51], ["manidipine", "SIMPLE_CHEMICAL", 76, 86], ["manidipine", "SIMPLE_CHEMICAL", 142, 152], ["manidipine", "SIMPLE_CHEMICAL", 168, 178], ["JEV", "ORGANISM", 228, 231], ["ZIKV", "ORGANISM", 255, 259], ["manidipine", "SIMPLE_CHEMICAL", 399, 409], ["JEV", "ORGANISM", 418, 421], ["mouse", "ORGANISM", 445, 450], ["mouse", "SPECIES", 445, 450], ["JEV", "SPECIES", 228, 231], ["ZIKV", "SPECIES", 255, 259], ["JEV", "SPECIES", 418, 421], ["mouse", "SPECIES", 445, 450], ["The replacement of glutamine", "TREATMENT", 0, 28], ["basic amino acids", "TREATMENT", 34, 51], ["manidipine", "TREATMENT", 76, 86], ["an apparent loss of growth", "PROBLEM", 95, 121], ["manidipine", "TREATMENT", 142, 152], ["RESULTSAs manidipine", "TREATMENT", 158, 178], ["JEV replication", "TREATMENT", 228, 243], ["ZIKV infection", "PROBLEM", 255, 269], ["manidipine", "TREATMENT", 399, 409], ["JEV", "PROBLEM", 418, 421], ["replacement", "OBSERVATION", 4, 15]]], ["As anticipated, mice in the JEV-infected vehicle-treated group started to show symptoms, including limb paralysis, restriction of movement, piloerection, body stiffening, and whole-body tremor, from day 5 postinfection.", [["limb", "ANATOMY", 99, 103], ["body", "ANATOMY", 154, 158], ["body", "ANATOMY", 181, 185], ["JEV-infected", "DISEASE", 28, 40], ["limb paralysis", "DISEASE", 99, 113], ["piloerection", "DISEASE", 140, 152], ["tremor", "DISEASE", 186, 192], ["mice", "ORGANISM", 16, 20], ["JEV", "ORGANISM", 28, 31], ["limb", "ORGANISM_SUBDIVISION", 99, 103], ["body", "ORGANISM_SUBDIVISION", 154, 158], ["body", "ORGANISM_SUBDIVISION", 181, 185], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["JEV", "SPECIES", 28, 31], ["symptoms", "PROBLEM", 79, 87], ["limb paralysis", "PROBLEM", 99, 113], ["body stiffening", "PROBLEM", 154, 169], ["whole-body tremor", "PROBLEM", 175, 192], ["limb", "ANATOMY", 99, 103], ["paralysis", "OBSERVATION", 104, 113]]], ["Within 21 days postinfection, most mice in the JEV-infected group succumbed to the infection, with the mortality rate being 73% (4 out of 15 animals survived).", [["JEV-infected", "DISEASE", 47, 59], ["infection", "DISEASE", 83, 92], ["mice", "ORGANISM", 35, 39], ["JEV", "ORGANISM", 47, 50], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["JEV", "SPECIES", 47, 50], ["postinfection", "PROBLEM", 15, 28], ["the infection", "PROBLEM", 79, 92], ["the mortality rate", "TEST", 99, 117], ["infected", "OBSERVATION", 51, 59], ["infection", "OBSERVATION", 83, 92]]], ["Manidipine treatment following JEV infection reduced the mortality rate to 20% (12 out of 15 animals survived) (Fig. 7A).", [["Manidipine", "CHEMICAL", 0, 10], ["JEV infection", "DISEASE", 31, 44], ["Manidipine", "CHEMICAL", 0, 10], ["Manidipine", "SIMPLE_CHEMICAL", 0, 10], ["JEV", "ORGANISM", 31, 34], ["JEV", "SPECIES", 31, 34], ["Manidipine treatment", "TREATMENT", 0, 20], ["JEV infection", "PROBLEM", 31, 44], ["the mortality rate", "TEST", 53, 71]]], ["Mice treated with manidipine alone or treated with manidipine and infected with JEV showed little abnormal behavior, similar to the findings for the mice in the vehicle-treated group.", [["manidipine", "CHEMICAL", 18, 28], ["manidipine", "CHEMICAL", 51, 61], ["abnormal behavior", "DISEASE", 98, 115], ["manidipine", "CHEMICAL", 18, 28], ["manidipine", "CHEMICAL", 51, 61], ["Mice", "ORGANISM", 0, 4], ["manidipine", "SIMPLE_CHEMICAL", 18, 28], ["manidipine", "SIMPLE_CHEMICAL", 51, 61], ["JEV", "ORGANISM", 80, 83], ["mice", "ORGANISM", 149, 153], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 149, 153], ["JEV", "SPECIES", 80, 83], ["mice", "SPECIES", 149, 153], ["manidipine", "TREATMENT", 18, 28], ["manidipine", "TREATMENT", 51, 61], ["JEV", "PROBLEM", 80, 83], ["little abnormal behavior", "PROBLEM", 91, 115]]], ["These results suggest that manidipine provided effective protection against JEV-induced mortality.In vivo efficacy of manidipine. ::: RESULTSTo further relate these protective effects to the viral load and histopathological changes in the mouse brains, the viral titer was determined and mouse brain sections were collected and assayed at day 5 and day 21 postinfection, since mice started to show symptoms of JEV infection from day 5 postinfection and most of the surviving mice had recovered at day 21.", [["brains", "ANATOMY", 245, 251], ["brain sections", "ANATOMY", 294, 308], ["manidipine", "CHEMICAL", 27, 37], ["JEV", "DISEASE", 76, 79], ["manidipine", "CHEMICAL", 118, 128], ["JEV infection", "DISEASE", 410, 423], ["manidipine", "CHEMICAL", 27, 37], ["manidipine", "CHEMICAL", 118, 128], ["manidipine", "SIMPLE_CHEMICAL", 27, 37], ["JEV", "ORGANISM", 76, 79], ["manidipine", "SIMPLE_CHEMICAL", 118, 128], ["mouse", "ORGANISM", 239, 244], ["brains", "DEVELOPING_ANATOMICAL_STRUCTURE", 245, 251], ["mouse", "ORGANISM", 288, 293], ["brain sections", "MULTI-TISSUE_STRUCTURE", 294, 308], ["mice", "ORGANISM", 377, 381], ["JEV", "ORGANISM", 410, 413], ["mice", "ORGANISM", 475, 479], ["mouse", "SPECIES", 239, 244], ["mouse", "SPECIES", 288, 293], ["mice", "SPECIES", 377, 381], ["mice", "SPECIES", 475, 479], ["JEV", "SPECIES", 76, 79], ["mouse", "SPECIES", 239, 244], ["mouse", "SPECIES", 288, 293], ["mice", "SPECIES", 377, 381], ["JEV", "SPECIES", 410, 413], ["mice", "SPECIES", 475, 479], ["manidipine", "TREATMENT", 27, 37], ["JEV", "PROBLEM", 76, 79], ["manidipine", "TREATMENT", 118, 128], ["the viral load", "TEST", 187, 201], ["histopathological changes in the mouse brains", "PROBLEM", 206, 251], ["the viral titer", "TEST", 253, 268], ["mouse brain sections", "TEST", 288, 308], ["symptoms", "PROBLEM", 398, 406], ["JEV infection", "PROBLEM", 410, 423], ["viral load", "OBSERVATION", 191, 201], ["mouse brains", "ANATOMY", 239, 251], ["JEV", "OBSERVATION_MODIFIER", 410, 413], ["infection", "OBSERVATION", 414, 423]]], ["The results indicated that, during the progression of the disease, manidipine treatment significantly reduced the viral load in infected mice compared to that in infected mice not receiving treatment, while no plaques formed in either the manidipine- or vehicle-treated group, and viral loads were undetectable in each group on day 21 postinfection (Fig. 7B).", [["plaques", "ANATOMY", 210, 217], ["manidipine", "CHEMICAL", 67, 77], ["plaques", "DISEASE", 210, 217], ["manidipine", "CHEMICAL", 239, 249], ["manidipine", "CHEMICAL", 67, 77], ["manidipine", "CHEMICAL", 239, 249], ["manidipine", "SIMPLE_CHEMICAL", 67, 77], ["mice", "ORGANISM", 137, 141], ["mice", "ORGANISM", 171, 175], ["plaques", "PATHOLOGICAL_FORMATION", 210, 217], ["manidipine", "SIMPLE_CHEMICAL", 239, 249], ["vehicle", "SIMPLE_CHEMICAL", 254, 261], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 171, 175], ["mice", "SPECIES", 137, 141], ["mice", "SPECIES", 171, 175], ["the disease", "PROBLEM", 54, 65], ["manidipine treatment", "TREATMENT", 67, 87], ["the viral load", "PROBLEM", 110, 124], ["treatment", "TREATMENT", 190, 199], ["plaques", "PROBLEM", 210, 217], ["viral loads", "TEST", 281, 292], ["disease", "OBSERVATION", 58, 65], ["viral load", "OBSERVATION", 114, 124], ["no", "UNCERTAINTY", 207, 209], ["plaques", "OBSERVATION", 210, 217]]], ["As JEV was rapidly cleared from the blood after inoculation and was present in the lymphatic system during the preclinical phase, the effects of manidipine on infection of serum and the spleen were evaluated at earlier time points to detect whether the drug reduced the peripheral viral loads (20, 21).", [["blood", "ANATOMY", 36, 41], ["lymphatic system", "ANATOMY", 83, 99], ["serum", "ANATOMY", 172, 177], ["spleen", "ANATOMY", 186, 192], ["manidipine", "CHEMICAL", 145, 155], ["infection", "DISEASE", 159, 168], ["manidipine", "CHEMICAL", 145, 155], ["JEV", "ORGANISM", 3, 6], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["lymphatic system", "MULTI-TISSUE_STRUCTURE", 83, 99], ["manidipine", "SIMPLE_CHEMICAL", 145, 155], ["serum", "ORGANISM_SUBSTANCE", 172, 177], ["spleen", "ORGAN", 186, 192], ["JEV", "SPECIES", 3, 6], ["JEV", "PROBLEM", 3, 6], ["inoculation", "PROBLEM", 48, 59], ["manidipine", "TREATMENT", 145, 155], ["infection of serum and the spleen", "PROBLEM", 159, 192], ["the peripheral viral loads", "TEST", 266, 292], ["lymphatic system", "ANATOMY", 83, 99], ["infection", "OBSERVATION", 159, 168], ["spleen", "ANATOMY", 186, 192], ["peripheral", "ANATOMY_MODIFIER", 270, 280], ["viral loads", "OBSERVATION", 281, 292]]], ["As shown in Fig. 7C, manidipine had little effect on peripheral JEV infection, which indicated that manidipine protected the mice against JEV-induced lethality by decreasing the viral load in the brain.", [["brain", "ANATOMY", 196, 201], ["manidipine", "CHEMICAL", 21, 31], ["peripheral JEV infection", "DISEASE", 53, 77], ["manidipine", "CHEMICAL", 100, 110], ["JEV", "DISEASE", 138, 141], ["manidipine", "CHEMICAL", 21, 31], ["manidipine", "CHEMICAL", 100, 110], ["manidipine", "SIMPLE_CHEMICAL", 21, 31], ["peripheral JEV", "ORGANISM", 53, 67], ["manidipine", "SIMPLE_CHEMICAL", 100, 110], ["mice", "ORGANISM", 125, 129], ["JEV", "ORGANISM", 138, 141], ["brain", "ORGAN", 196, 201], ["mice", "SPECIES", 125, 129], ["JEV", "SPECIES", 64, 67], ["mice", "SPECIES", 125, 129], ["JEV", "SPECIES", 138, 141], ["manidipine", "TREATMENT", 21, 31], ["peripheral JEV infection", "PROBLEM", 53, 77], ["manidipine", "TREATMENT", 100, 110], ["JEV", "PROBLEM", 138, 141], ["induced lethality", "PROBLEM", 142, 159], ["the viral load in the brain", "PROBLEM", 174, 201], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["JEV infection", "OBSERVATION", 64, 77], ["viral load", "OBSERVATION", 178, 188], ["brain", "ANATOMY", 196, 201]]], ["Similarly, apparent damage in the brain, including meningitis, perivascular cuffing, vacuolar degeneration, and glial nodules, was observed in the JEV-infected and vehicle-treated group on day 5 postinfection, while manidipine treatment remarkably alleviated these phenomena (Fig. 7D).", [["brain", "ANATOMY", 34, 39], ["perivascular", "ANATOMY", 63, 75], ["vacuolar", "ANATOMY", 85, 93], ["glial nodules", "ANATOMY", 112, 125], ["meningitis", "DISEASE", 51, 61], ["JEV-infected", "DISEASE", 147, 159], ["manidipine", "CHEMICAL", 216, 226], ["manidipine", "CHEMICAL", 216, 226], ["brain", "ORGAN", 34, 39], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 75], ["vacuolar", "CELLULAR_COMPONENT", 85, 93], ["glial nodules", "PATHOLOGICAL_FORMATION", 112, 125], ["JEV", "ORGANISM", 147, 150], ["manidipine", "SIMPLE_CHEMICAL", 216, 226], ["JEV", "SPECIES", 147, 150], ["apparent damage in the brain", "PROBLEM", 11, 39], ["meningitis", "PROBLEM", 51, 61], ["perivascular cuffing", "PROBLEM", 63, 83], ["vacuolar degeneration", "PROBLEM", 85, 106], ["glial nodules", "PROBLEM", 112, 125], ["manidipine treatment", "TREATMENT", 216, 236], ["these phenomena", "PROBLEM", 259, 274], ["damage", "OBSERVATION", 20, 26], ["brain", "ANATOMY", 34, 39], ["meningitis", "OBSERVATION", 51, 61], ["perivascular", "ANATOMY_MODIFIER", 63, 75], ["cuffing", "OBSERVATION", 76, 83], ["vacuolar degeneration", "OBSERVATION", 85, 106], ["glial", "OBSERVATION_MODIFIER", 112, 117], ["nodules", "OBSERVATION", 118, 125], ["JEV", "OBSERVATION_MODIFIER", 147, 150], ["infected", "OBSERVATION_MODIFIER", 151, 159]]], ["These results indicate that the alleviation of histopathological changes was accompanied by a reduction in the viral load as well as a reduction in the rate of mortality, further confirming the curative effects of manidipine on viral encephalitis.DISCUSSIONAmong the five hit drugs, manidipine, cilnidipine, and benidipine hydrochloride were VGCC inhibitors.", [["manidipine", "CHEMICAL", 214, 224], ["viral encephalitis", "DISEASE", 228, 246], ["manidipine", "CHEMICAL", 283, 293], ["cilnidipine", "CHEMICAL", 295, 306], ["benidipine hydrochloride", "CHEMICAL", 312, 336], ["manidipine", "CHEMICAL", 214, 224], ["manidipine", "CHEMICAL", 283, 293], ["cilnidipine", "CHEMICAL", 295, 306], ["benidipine hydrochloride", "CHEMICAL", 312, 336], ["manidipine", "SIMPLE_CHEMICAL", 214, 224], ["manidipine", "SIMPLE_CHEMICAL", 283, 293], ["cilnidipine", "SIMPLE_CHEMICAL", 295, 306], ["benidipine hydrochloride", "SIMPLE_CHEMICAL", 312, 336], ["VGCC", "SIMPLE_CHEMICAL", 342, 346], ["the alleviation of histopathological changes", "PROBLEM", 28, 72], ["a reduction in the viral load", "PROBLEM", 92, 121], ["manidipine", "TREATMENT", 214, 224], ["viral encephalitis", "PROBLEM", 228, 246], ["the five hit drugs", "TREATMENT", 263, 281], ["manidipine", "TREATMENT", 283, 293], ["cilnidipine", "TREATMENT", 295, 306], ["benidipine hydrochloride", "TREATMENT", 312, 336], ["VGCC inhibitors", "TREATMENT", 342, 357], ["reduction", "OBSERVATION_MODIFIER", 94, 103], ["viral load", "OBSERVATION", 111, 121], ["reduction", "OBSERVATION_MODIFIER", 135, 144], ["viral encephalitis", "OBSERVATION", 228, 246]]], ["It has been well documented in the literature that Ca2+ inhibitors serve to inhibit virus infection at the stage of either entry (15, 22) or replication (18) and even at the stage of budding (23).", [["Ca2", "CHEMICAL", 51, 54], ["infection", "DISEASE", 90, 99], ["Ca2+", "CHEMICAL", 51, 55], ["Ca2+", "SIMPLE_CHEMICAL", 51, 55], ["Ca2+ inhibitors", "TREATMENT", 51, 66], ["virus infection", "PROBLEM", 84, 99]]], ["To this end, we first reviewed all 21 calcium inhibitors included in the current library of FDA-approved drugs and found that, in addition to the four DHP VGCC inhibitors listed in Fig. 1B, two other calcium inhibitors, i.e., flunarizine dihydrochloride and lomerizine hydrochloride, were also identified to be primary candidates with levels of inhibition of >90%.", [["calcium", "CHEMICAL", 38, 45], ["DHP", "CHEMICAL", 151, 154], ["calcium", "CHEMICAL", 200, 207], ["flunarizine", "CHEMICAL", 226, 237], ["lomerizine hydrochloride", "CHEMICAL", 258, 282], ["calcium", "CHEMICAL", 38, 45], ["DHP", "CHEMICAL", 151, 154], ["calcium", "CHEMICAL", 200, 207], ["flunarizine dihydrochloride", "CHEMICAL", 226, 253], ["lomerizine hydrochloride", "CHEMICAL", 258, 282], ["calcium", "SIMPLE_CHEMICAL", 38, 45], ["DHP", "SIMPLE_CHEMICAL", 151, 154], ["VGCC", "SIMPLE_CHEMICAL", 155, 159], ["1B", "GENE_OR_GENE_PRODUCT", 186, 188], ["calcium", "SIMPLE_CHEMICAL", 200, 207], ["flunarizine dihydrochloride", "SIMPLE_CHEMICAL", 226, 253], ["lomerizine hydrochloride", "SIMPLE_CHEMICAL", 258, 282], ["all 21 calcium inhibitors", "TREATMENT", 31, 56], ["drugs", "TREATMENT", 105, 110], ["the four DHP VGCC inhibitors", "TREATMENT", 142, 170], ["calcium inhibitors", "TREATMENT", 200, 218], ["flunarizine dihydrochloride", "TREATMENT", 226, 253], ["lomerizine hydrochloride", "TREATMENT", 258, 282], ["levels of inhibition", "TEST", 335, 355]]], ["Similarly, three calcium channel antagonists, nisoldipine, felodipine, and nicardipine hydrochloride, showed levels of inhibition of 75%, 72%, and 66%, respectively, in the primary screen.", [["calcium", "CHEMICAL", 17, 24], ["nisoldipine", "CHEMICAL", 46, 57], ["felodipine", "CHEMICAL", 59, 69], ["nicardipine", "CHEMICAL", 75, 86], ["calcium", "CHEMICAL", 17, 24], ["nisoldipine", "CHEMICAL", 46, 57], ["felodipine", "CHEMICAL", 59, 69], ["nicardipine hydrochloride", "CHEMICAL", 75, 100], ["calcium channel antagonists", "SIMPLE_CHEMICAL", 17, 44], ["nisoldipine", "SIMPLE_CHEMICAL", 46, 57], ["felodipine", "SIMPLE_CHEMICAL", 59, 69], ["nicardipine", "SIMPLE_CHEMICAL", 75, 86], ["three calcium channel antagonists", "TREATMENT", 11, 44], ["nisoldipine", "TREATMENT", 46, 57], ["felodipine", "TREATMENT", 59, 69], ["nicardipine hydrochloride", "TREATMENT", 75, 100], ["inhibition", "TEST", 119, 129]]], ["Together, 9 of the 21 calcium inhibitors in the library, accounting for nearly half of the calcium inhibitors, exhibited levels of flavivirus inhibition of greater than 50%, suggesting that calcium, especially the calcium channel, is a potential antiviral target.", [["calcium", "CHEMICAL", 22, 29], ["calcium", "CHEMICAL", 91, 98], ["calcium", "CHEMICAL", 190, 197], ["calcium", "CHEMICAL", 214, 221], ["calcium", "CHEMICAL", 22, 29], ["calcium", "CHEMICAL", 91, 98], ["calcium", "CHEMICAL", 190, 197], ["calcium", "CHEMICAL", 214, 221], ["calcium", "SIMPLE_CHEMICAL", 22, 29], ["calcium", "SIMPLE_CHEMICAL", 91, 98], ["calcium", "SIMPLE_CHEMICAL", 190, 197], ["calcium", "SIMPLE_CHEMICAL", 214, 221], ["the 21 calcium inhibitors", "TREATMENT", 15, 40], ["the calcium inhibitors", "TREATMENT", 87, 109], ["levels of flavivirus inhibition", "PROBLEM", 121, 152], ["calcium", "TEST", 190, 197], ["the calcium channel", "TEST", 210, 229], ["flavivirus", "OBSERVATION", 131, 141], ["antiviral target", "OBSERVATION", 246, 262]]], ["To address this, another type of VGCC inhibitor, verapamil, an FDA-approved drug not yet included in the drug library used in this study, was investigated.", [["verapamil", "CHEMICAL", 49, 58], ["verapamil", "CHEMICAL", 49, 58], ["VGCC", "GENE_OR_GENE_PRODUCT", 33, 37], ["verapamil", "SIMPLE_CHEMICAL", 49, 58], ["VGCC inhibitor", "TREATMENT", 33, 47], ["verapamil", "TREATMENT", 49, 58], ["an FDA", "TREATMENT", 60, 66], ["this study", "TEST", 126, 136]]], ["Likewise, a Ca2+ chelator, BAPTA-AM, as well as the Ca2+ inhibitors 2-APB and cyclosporine, targeting ER and the mitochondrial Ca2+ channel, respectively, were employed to investigate the response of JEV infection to the decrease in intracellular Ca2+ levels.", [["mitochondrial", "ANATOMY", 113, 126], ["intracellular", "ANATOMY", 233, 246], ["Ca2", "CHEMICAL", 12, 15], ["BAPTA", "CHEMICAL", 27, 32], ["Ca2", "CHEMICAL", 52, 55], ["2-APB", "CHEMICAL", 68, 73], ["cyclosporine", "CHEMICAL", 78, 90], ["Ca2", "CHEMICAL", 127, 130], ["JEV infection", "DISEASE", 200, 213], ["Ca2", "CHEMICAL", 247, 250], ["Ca2+", "CHEMICAL", 12, 16], ["BAPTA-AM", "CHEMICAL", 27, 35], ["Ca2+", "CHEMICAL", 52, 56], ["2-APB", "CHEMICAL", 68, 73], ["cyclosporine", "CHEMICAL", 78, 90], ["Ca2+", "CHEMICAL", 127, 131], ["Ca2+", "CHEMICAL", 247, 251], ["Ca2+ chelator", "SIMPLE_CHEMICAL", 12, 25], ["BAPTA-AM", "SIMPLE_CHEMICAL", 27, 35], ["Ca2+", "SIMPLE_CHEMICAL", 52, 56], ["2-APB", "SIMPLE_CHEMICAL", 68, 73], ["cyclosporine", "SIMPLE_CHEMICAL", 78, 90], ["ER", "GENE_OR_GENE_PRODUCT", 102, 104], ["mitochondrial", "CELLULAR_COMPONENT", 113, 126], ["Ca2+", "SIMPLE_CHEMICAL", 127, 131], ["JEV", "ORGANISM", 200, 203], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 233, 246], ["Ca2+", "SIMPLE_CHEMICAL", 247, 251], ["ER", "PROTEIN", 102, 104], ["mitochondrial Ca2+ channel", "PROTEIN", 113, 139], ["Ca2", "PROTEIN", 247, 250], ["JEV", "SPECIES", 200, 203], ["a Ca2+ chelator", "TREATMENT", 10, 25], ["BAPTA", "TEST", 27, 32], ["the Ca2+ inhibitors", "TREATMENT", 48, 67], ["cyclosporine", "TREATMENT", 78, 90], ["JEV infection", "PROBLEM", 200, 213], ["intracellular Ca2+ levels", "TEST", 233, 258], ["JEV infection", "OBSERVATION", 200, 213], ["decrease", "OBSERVATION_MODIFIER", 221, 229], ["intracellular Ca2", "OBSERVATION", 233, 250]]], ["In line with the activities of the three hit DHP VGCC inhibitor drugs, the additional Ca2+ inhibitors exerted anti-JEV activity, which indicated that Ca2+ is indispensable for JEV infection.", [["DHP", "CHEMICAL", 45, 48], ["Ca2", "CHEMICAL", 86, 89], ["Ca2", "CHEMICAL", 150, 153], ["JEV infection", "DISEASE", 176, 189], ["DHP", "CHEMICAL", 45, 48], ["Ca2+", "CHEMICAL", 86, 90], ["Ca2+", "CHEMICAL", 150, 154], ["DHP", "SIMPLE_CHEMICAL", 45, 48], ["VGCC", "SIMPLE_CHEMICAL", 49, 53], ["Ca2+", "SIMPLE_CHEMICAL", 86, 90], ["anti-JEV", "CANCER", 110, 118], ["Ca2+", "SIMPLE_CHEMICAL", 150, 154], ["JEV", "ORGANISM", 176, 179], ["Ca2", "PROTEIN", 150, 153], ["JEV", "SPECIES", 176, 179], ["DHP VGCC inhibitor drugs", "TREATMENT", 45, 69], ["the additional Ca2+ inhibitors", "TREATMENT", 71, 101], ["Ca2", "TEST", 150, 153], ["JEV infection", "PROBLEM", 176, 189], ["indispensable for", "UNCERTAINTY", 158, 175], ["JEV infection", "OBSERVATION", 176, 189]]], ["Thus, Ca2+ inhibitors might be utilized as effective treatments for flavivirus infection.DISCUSSIONAs the hit drugs exerted full inhibitory activity when they were added posttreatment, we believe that Ca2+ is important for flavivirus genome replication.", [["Ca2", "CHEMICAL", 6, 9], ["flavivirus infection", "DISEASE", 68, 88], ["Ca2", "CHEMICAL", 201, 204], ["Ca2+", "CHEMICAL", 6, 10], ["Ca2+", "CHEMICAL", 201, 205], ["Ca2+", "SIMPLE_CHEMICAL", 6, 10], ["flavivirus", "ORGANISM", 68, 78], ["Ca2+", "SIMPLE_CHEMICAL", 201, 205], ["Ca2", "PROTEIN", 6, 9], ["Ca2", "PROTEIN", 201, 204], ["flavivirus", "SPECIES", 223, 233], ["Ca2+ inhibitors", "TREATMENT", 6, 21], ["effective treatments", "TREATMENT", 43, 63], ["flavivirus infection", "PROBLEM", 68, 88], ["flavivirus genome replication", "TREATMENT", 223, 252], ["flavivirus", "OBSERVATION", 68, 78]]], ["Furthermore, selection and genetic analysis of drug-resistant viruses revealed that NS4B is the viral target of manidipine.", [["manidipine", "CHEMICAL", 112, 122], ["manidipine", "CHEMICAL", 112, 122], ["NS4B", "GENE_OR_GENE_PRODUCT", 84, 88], ["manidipine", "SIMPLE_CHEMICAL", 112, 122], ["NS4B", "PROTEIN", 84, 88], ["selection", "TEST", 13, 22], ["genetic analysis", "TEST", 27, 43], ["drug-resistant viruses", "PROBLEM", 47, 69], ["NS4B", "PROBLEM", 84, 88], ["manidipine", "TREATMENT", 112, 122], ["NS4B", "OBSERVATION", 84, 88], ["viral target", "OBSERVATION", 96, 108]]], ["NS4B is part of the viral replication complex and is supposed to anchor the viral replicase to the ER membrane (24).", [["ER membrane", "ANATOMY", 99, 110], ["ER", "GENE_OR_GENE_PRODUCT", 99, 101], ["membrane", "CELLULAR_COMPONENT", 102, 110], ["NS4B", "PROTEIN", 0, 4], ["viral replication complex", "PROTEIN", 20, 45], ["viral replicase", "PROTEIN", 76, 91], ["ER", "PROTEIN", 99, 101], ["NS4B", "TREATMENT", 0, 4], ["the viral replication complex", "TREATMENT", 16, 45], ["viral replication", "OBSERVATION", 20, 37], ["viral replicase", "OBSERVATION", 76, 91]]], ["Meanwhile, the N-terminal 125-amino-acid domain of DENV NS4B was indicated to be responsible for inhibition of the immune response (25).", [["125-amino-acid", "CHEMICAL", 26, 40], ["amino-acid", "CHEMICAL", 30, 40], ["amino", "AMINO_ACID", 30, 35], ["DENV NS4B", "ORGANISM", 51, 60], ["N-terminal 125-amino-acid domain", "PROTEIN", 15, 47], ["DENV NS4B", "PROTEIN", 51, 60], ["DENV", "SPECIES", 51, 55], ["the N-terminal", "TEST", 11, 25], ["DENV NS4B", "PROBLEM", 51, 60], ["DENV NS4B", "OBSERVATION", 51, 60]]], ["Notably, several structurally distinct compounds have been identified to inhibit flavivirus replication by intensively targeting the TMD of NS4B (26\u201332).", [["flavivirus", "ORGANISM", 81, 91], ["NS4B", "PROTEIN", 140, 144], ["26\u201332", "PROTEIN", 146, 151], ["flavivirus", "SPECIES", 81, 91], ["several structurally distinct compounds", "PROBLEM", 9, 48], ["flavivirus replication", "TREATMENT", 81, 103], ["several", "OBSERVATION_MODIFIER", 9, 16], ["structurally", "OBSERVATION_MODIFIER", 17, 29], ["distinct", "OBSERVATION_MODIFIER", 30, 38], ["compounds", "OBSERVATION", 39, 48]]], ["It is thus conceivable that inhibitors targeting TMD of NS4B would perturb its function, leading to the suppression of viral RNA replication.", [["NS4B", "GENE_OR_GENE_PRODUCT", 56, 60], ["NS4B", "PROTEIN", 56, 60], ["inhibitors", "TREATMENT", 28, 38], ["TMD of NS4B", "PROBLEM", 49, 60], ["viral RNA replication", "TREATMENT", 119, 140], ["viral RNA replication", "OBSERVATION", 119, 140]]], ["In this study, the replacement of Q130 of NS4B with a basic amino acid conferred the resistance effect without suppressing JEV replication, suggesting that position 130 could tolerate a basic amino acid and that the basic amino acid might be involved in the interplay of NS4B with host proteins rather than viral proteins.DISCUSSIONMoreover, the efficacy and toxicity of manidipine were monitored in vivo, with manidipine demonstrating effective antiviral activity with favorable biocompatibility.", [["amino acid", "CHEMICAL", 60, 70], ["amino acid", "CHEMICAL", 192, 202], ["amino acid", "CHEMICAL", 222, 232], ["toxicity", "DISEASE", 359, 367], ["manidipine", "CHEMICAL", 371, 381], ["manidipine", "CHEMICAL", 411, 421], ["amino acid", "CHEMICAL", 60, 70], ["amino acid", "CHEMICAL", 192, 202], ["amino acid", "CHEMICAL", 222, 232], ["manidipine", "CHEMICAL", 371, 381], ["manidipine", "CHEMICAL", 411, 421], ["Q130", "GENE_OR_GENE_PRODUCT", 34, 38], ["NS4B", "GENE_OR_GENE_PRODUCT", 42, 46], ["amino acid", "AMINO_ACID", 60, 70], ["JEV", "ORGANISM", 123, 126], ["amino acid", "AMINO_ACID", 192, 202], ["amino acid", "AMINO_ACID", 222, 232], ["NS4B", "GENE_OR_GENE_PRODUCT", 271, 275], ["manidipine", "SIMPLE_CHEMICAL", 371, 381], ["manidipine", "SIMPLE_CHEMICAL", 411, 421], ["Q130", "PROTEIN", 34, 38], ["NS4B", "PROTEIN", 42, 46], ["position 130", "PROTEIN", 156, 168], ["NS4B", "PROTEIN", 271, 275], ["host proteins", "PROTEIN", 281, 294], ["viral proteins", "PROTEIN", 307, 321], ["JEV", "SPECIES", 123, 126], ["this study", "TEST", 3, 13], ["the replacement of Q130 of NS4B", "TREATMENT", 15, 46], ["a basic amino acid", "TREATMENT", 52, 70], ["the resistance effect", "PROBLEM", 81, 102], ["suppressing JEV replication", "TREATMENT", 111, 138], ["a basic amino acid", "TREATMENT", 184, 202], ["the basic amino acid", "TREATMENT", 212, 232], ["NS4B", "TREATMENT", 271, 275], ["host proteins", "TREATMENT", 281, 294], ["viral proteins", "PROBLEM", 307, 321], ["manidipine", "TREATMENT", 371, 381], ["manidipine", "TREATMENT", 411, 421], ["antiviral activity", "OBSERVATION", 446, 464]]], ["However, the dose used in this study was higher than the dose typically used clinically, representing one of the scenarios most commonly encountered in drug repurposing (33, 34).", [["this study", "TEST", 26, 36]]], ["As manidipine was approved for use for the long-term treatment of hypertension (35, 36), pulse-dose treatment with manidipine over the shorter period of time required for the treatment of virus infection might be relatively safe.", [["manidipine", "CHEMICAL", 3, 13], ["hypertension", "DISEASE", 66, 78], ["manidipine", "CHEMICAL", 115, 125], ["infection", "DISEASE", 194, 203], ["manidipine", "CHEMICAL", 3, 13], ["manidipine", "CHEMICAL", 115, 125], ["manidipine", "SIMPLE_CHEMICAL", 3, 13], ["manidipine", "SIMPLE_CHEMICAL", 115, 125], ["manidipine", "TREATMENT", 3, 13], ["the long-term treatment", "TREATMENT", 39, 62], ["hypertension", "PROBLEM", 66, 78], ["pulse-dose treatment", "TREATMENT", 89, 109], ["manidipine", "TREATMENT", 115, 125], ["virus infection", "PROBLEM", 188, 203], ["hypertension", "OBSERVATION", 66, 78], ["virus", "OBSERVATION", 188, 193]]], ["Moreover, use of a combination of manidipine with other Ca2+ inhibitors might improve its therapeutic efficacy, reduce its toxicity, and reduce the risk of resistance development (37\u201339).DISCUSSIONBesides the three VGCC inhibitors, two hit drugs, pimecrolimus and nelfinavir mesylate, showed equivalent inhibitory activities on the replication of JEV, ZIKV, WNV, and DENV-2.", [["manidipine", "CHEMICAL", 34, 44], ["Ca2", "CHEMICAL", 56, 59], ["toxicity", "DISEASE", 123, 131], ["pimecrolimus", "CHEMICAL", 247, 259], ["nelfinavir mesylate", "CHEMICAL", 264, 283], ["manidipine", "CHEMICAL", 34, 44], ["Ca2+", "CHEMICAL", 56, 60], ["pimecrolimus", "CHEMICAL", 247, 259], ["nelfinavir mesylate", "CHEMICAL", 264, 283], ["manidipine", "SIMPLE_CHEMICAL", 34, 44], ["Ca2+", "SIMPLE_CHEMICAL", 56, 60], ["VGCC", "SIMPLE_CHEMICAL", 215, 219], ["pimecrolimus", "SIMPLE_CHEMICAL", 247, 259], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 264, 283], ["JEV", "ORGANISM", 347, 350], ["ZIKV", "GENE_OR_GENE_PRODUCT", 352, 356], ["WNV", "ORGANISM", 358, 361], ["DENV-2", "ORGANISM", 367, 373], ["JEV", "SPECIES", 347, 350], ["ZIKV", "SPECIES", 352, 356], ["WNV", "SPECIES", 358, 361], ["DENV-2", "SPECIES", 367, 373], ["manidipine", "TREATMENT", 34, 44], ["other Ca2+ inhibitors", "TREATMENT", 50, 71], ["its toxicity", "PROBLEM", 119, 131], ["resistance development", "PROBLEM", 156, 178], ["the three VGCC inhibitors", "TREATMENT", 205, 230], ["two hit drugs", "TREATMENT", 232, 245], ["pimecrolimus", "TREATMENT", 247, 259], ["nelfinavir mesylate", "TREATMENT", 264, 283], ["ZIKV", "PROBLEM", 352, 356], ["DENV", "PROBLEM", 367, 371]]], ["Although there has been no report on the use of pimecrolimus for the treatment of infectious diseases, we showed that it had a robust effect against JEV with an SI of >32.", [["pimecrolimus", "CHEMICAL", 48, 60], ["infectious diseases", "DISEASE", 82, 101], ["JEV", "DISEASE", 149, 152], ["pimecrolimus", "CHEMICAL", 48, 60], ["pimecrolimus", "SIMPLE_CHEMICAL", 48, 60], ["JEV", "ORGANISM", 149, 152], ["JEV", "SPECIES", 149, 152], ["pimecrolimus", "TREATMENT", 48, 60], ["infectious diseases", "PROBLEM", 82, 101], ["JEV", "PROBLEM", 149, 152], ["an SI", "TEST", 158, 163], ["infectious", "OBSERVATION", 82, 92]]], ["The maximum plasma concentration (Cmax) of nelfinavir mesylate achieved with an adult dose was 3 to 4 \u03bcg/ml (40), which was comparable to the IC50 reported here.", [["plasma", "ANATOMY", 12, 18], ["nelfinavir mesylate", "CHEMICAL", 43, 62], ["nelfinavir mesylate", "CHEMICAL", 43, 62], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 43, 62], ["The maximum plasma concentration", "TREATMENT", 0, 32], ["nelfinavir mesylate", "TREATMENT", 43, 62]]], ["Notably, nelfinavir mesylate was confirmed to inhibit herpes simplex virus 1 (HSV-1) and the replication of several other herpesviruses by interfering directly or indirectly with the later steps of virus formation, such as glycoprotein maturation or virion release, other than functioning in herpesviruses protease (41, 42).", [["nelfinavir mesylate", "CHEMICAL", 9, 28], ["herpes simplex virus", "DISEASE", 54, 74], ["nelfinavir mesylate", "CHEMICAL", 9, 28], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 9, 28], ["herpes simplex virus 1", "ORGANISM", 54, 76], ["HSV-1", "ORGANISM", 78, 83], ["herpesviruses", "ORGANISM", 122, 135], ["glycoprotein", "GENE_OR_GENE_PRODUCT", 223, 235], ["virion", "CELLULAR_COMPONENT", 250, 256], ["herpesviruses protease", "PROTEIN", 292, 314], ["herpes simplex virus 1", "SPECIES", 54, 76], ["HSV-1", "SPECIES", 78, 83], ["herpes simplex virus 1", "SPECIES", 54, 76], ["HSV-1", "SPECIES", 78, 83], ["nelfinavir mesylate", "TREATMENT", 9, 28], ["herpes simplex virus", "PROBLEM", 54, 74], ["virus formation", "PROBLEM", 198, 213], ["glycoprotein maturation", "TREATMENT", 223, 246], ["virion release", "TREATMENT", 250, 264], ["herpesviruses protease", "TREATMENT", 292, 314]]], ["Whether nelfinavir mesylate inhibits flavivirus by interference with the virus protease or by other off-target effects is unknown.", [["nelfinavir mesylate", "CHEMICAL", 8, 27], ["flavivirus", "DISEASE", 37, 47], ["nelfinavir mesylate", "CHEMICAL", 8, 27], ["nelfinavir mesylate", "SIMPLE_CHEMICAL", 8, 27], ["flavivirus", "ORGANISM", 37, 47], ["virus protease", "PROTEIN", 73, 87], ["nelfinavir mesylate", "TREATMENT", 8, 27], ["flavivirus", "PROBLEM", 37, 47], ["the virus protease", "TREATMENT", 69, 87]]], ["Understanding of the mechanism of the antiflavivirus effects of these drugs might uncover novel targets of the drugs, providing further insight into the pathogenesis of flaviviruses.DISCUSSIONAbove all, the findings reported here provide novel insights into the molecular mechanisms underlying flavivirus infection and offer new and promising therapeutic possibilities for combating infections caused by flaviviruses.Cells and viruses. ::: MATERIALS AND METHODSBHK-21, SH-SY5Y (human neuroblastoma), Vero, and Huh-7 cells were cultured in Dulbecco modified Eagle medium (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA).", [["Cells", "ANATOMY", 417, 422], ["METHODSBHK-21", "ANATOMY", 454, 467], ["SH-SY5Y", "ANATOMY", 469, 476], ["neuroblastoma", "ANATOMY", 484, 497], ["Vero", "ANATOMY", 500, 504], ["Huh-7 cells", "ANATOMY", 510, 521], ["fetal bovine serum", "ANATOMY", 618, 636], ["flaviviruses", "DISEASE", 169, 181], ["flavivirus infection", "DISEASE", 294, 314], ["infections", "DISEASE", 383, 393], ["flaviviruses", "DISEASE", 404, 416], ["flavivirus", "ORGANISM", 294, 304], ["Cells", "CELL", 417, 422], ["METHODSBHK-21", "CELL", 454, 467], ["SH-SY5Y", "CELL", 469, 476], ["human", "ORGANISM", 478, 483], ["neuroblastoma", "CELL", 484, 497], ["Vero", "CELL", 500, 504], ["Huh-7 cells", "CELL", 510, 521], ["bovine", "ORGANISM", 624, 630], ["serum", "ORGANISM_SUBSTANCE", 631, 636], ["Gibco", "ORGANISM_SUBSTANCE", 638, 643], ["SH-SY5Y (human neuroblastoma), Vero, and Huh-7 cells", "CELL_LINE", 469, 521], ["human", "SPECIES", 478, 483], ["bovine", "SPECIES", 624, 630], ["human", "SPECIES", 478, 483], ["Huh-7", "SPECIES", 510, 515], ["bovine", "SPECIES", 624, 630], ["these drugs", "TREATMENT", 64, 75], ["the drugs", "TREATMENT", 107, 116], ["flaviviruses", "PROBLEM", 169, 181], ["underlying flavivirus infection", "PROBLEM", 283, 314], ["combating infections", "PROBLEM", 373, 393], ["flaviviruses", "PROBLEM", 404, 416], ["viruses", "PROBLEM", 427, 434], ["MATERIALS", "TEST", 440, 449], ["METHODSBHK", "TEST", 454, 464], ["human neuroblastoma", "PROBLEM", 478, 497], ["Vero", "TEST", 500, 504], ["Huh", "TEST", 510, 513], ["fetal bovine serum", "TEST", 618, 636], ["flaviviruses", "OBSERVATION", 169, 181], ["flavivirus infection", "OBSERVATION", 294, 314], ["flaviviruses", "OBSERVATION", 404, 416], ["viruses", "OBSERVATION", 427, 434], ["neuroblastoma", "OBSERVATION", 484, 497]]], ["JEV strain AT31, the WNV replicon, and the DENV-2 replicon expressing Renilla luciferase (Rluc) were kindly provided by Bo Zhang, Wuhan Institute of Virology, Chinese Academy of Sciences (CAS), China.", [["JEV strain AT31", "ORGANISM", 0, 15], ["WNV replicon", "ORGANISM", 21, 33], ["DENV-2 replicon", "ORGANISM", 43, 58], ["Renilla", "ORGANISM", 70, 77], ["luciferase", "GENE_OR_GENE_PRODUCT", 78, 88], ["Rluc", "GENE_OR_GENE_PRODUCT", 90, 94], ["DENV-2 replicon", "DNA", 43, 58], ["Renilla luciferase", "DNA", 70, 88], ["Rluc", "PROTEIN", 90, 94], ["JEV", "SPECIES", 0, 3], ["WNV", "SPECIES", 21, 24], ["DENV-2", "SPECIES", 43, 49], ["JEV strain AT31", "TREATMENT", 0, 15], ["the WNV replicon", "TREATMENT", 17, 33], ["the DENV", "TREATMENT", 39, 47]]], ["JEV replicon recombinant viral particles (RVPs) were generated as previously described (4, 5).", [["JEV replicon recombinant viral particles", "ORGANISM", 0, 40], ["RVPs", "GENE_OR_GENE_PRODUCT", 42, 46], ["JEV", "SPECIES", 0, 3], ["JEV replicon recombinant viral particles", "TREATMENT", 0, 40], ["viral particles", "OBSERVATION", 25, 40]]], ["ZIKV strain H/PF/2013, kindly provided by the European Virus Archive Goes Global, was propagated and titrated in Vero cells.Optimization of HTS assay conditions. ::: MATERIALS AND METHODSThe cell density and RVP dose were optimized for the HTS assay.", [["Vero cells", "ANATOMY", 113, 123], ["cell", "ANATOMY", 191, 195], ["Vero cells", "CELL", 113, 123], ["cell", "CELL", 191, 195], ["Vero cells", "CELL_LINE", 113, 123], ["ZIKV", "SPECIES", 0, 4], ["H/PF/2013", "SPECIES", 12, 21], ["HTS assay conditions", "TEST", 140, 160], ["METHODSThe cell density", "TREATMENT", 180, 203], ["RVP dose", "TREATMENT", 208, 216], ["the HTS assay", "TEST", 236, 249], ["Vero cells", "OBSERVATION", 113, 123], ["cell density", "OBSERVATION", 191, 203]]], ["Vero cells at different densities (2,500 to 12,500 cells per well) were infected with from 1.25 to 20 \u03bcl RVPs (1 to 16 copies per well).", [["Vero cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 51, 56], ["Vero cells", "CELL", 0, 10], ["cells", "CELL", 51, 56], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells at different densities", "PROBLEM", 0, 33], ["different", "OBSERVATION_MODIFIER", 14, 23], ["densities", "OBSERVATION_MODIFIER", 24, 33]]], ["The appropriate cell density as well as the RVP dose was selected by comparing the S/B ratio, CV, and Z\u2032 values under different conditions as previously described (43).", [["cell", "ANATOMY", 16, 20], ["cell", "CELL", 16, 20], ["Z\u2032", "GENE_OR_GENE_PRODUCT", 102, 104], ["the RVP dose", "TREATMENT", 40, 52], ["the S/B ratio", "TEST", 79, 92], ["CV", "TEST", 94, 96], ["appropriate cell density", "OBSERVATION", 4, 28]]], ["Methyl-\u03b2-cyclodextrin and dimethyl sulfoxide (DMSO) were used as positive and negative controls, respectively.HTS assay of an FDA-approved compound library. ::: MATERIALS AND METHODSA library of 1,018 FDA-approved drugs was purchased from Selleck Chemicals (Houston, TX, USA).", [["Methyl-\u03b2-cyclodextrin", "CHEMICAL", 0, 21], ["dimethyl sulfoxide", "CHEMICAL", 26, 44], ["DMSO", "CHEMICAL", 46, 50], ["Methyl-\u03b2-cyclodextrin", "CHEMICAL", 0, 21], ["dimethyl sulfoxide", "CHEMICAL", 26, 44], ["DMSO", "CHEMICAL", 46, 50], ["Methyl-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 0, 21], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 26, 44], ["DMSO", "SIMPLE_CHEMICAL", 46, 50], ["Methyl-\u03b2-cyclodextrin", "TREATMENT", 0, 21], ["dimethyl sulfoxide (DMSO)", "TREATMENT", 26, 51], ["HTS assay", "TEST", 110, 119]]], ["The compounds were stored as 10 mM stock solutions in DMSO at 4\u00b0C until use.", [["DMSO", "CHEMICAL", 54, 58], ["DMSO", "CHEMICAL", 54, 58], ["DMSO", "SIMPLE_CHEMICAL", 54, 58]]], ["The first round of the HTS assay was carried out as shown in Fig. 1A.", [["1A.", "CHEMICAL", 66, 69], ["the HTS assay", "TEST", 19, 32]]], ["The criteria used to identify the primary candidates were no apparent cytotoxicity and an average level of inhibition of >90% in duplicate wells.", [["apparent cytotoxicity", "PROBLEM", 61, 82], ["no apparent", "UNCERTAINTY", 58, 69], ["cytotoxicity", "OBSERVATION", 70, 82]]], ["The criteria of dose-dependent inhibition and cell viability of >80% were applied for the reconfirmation screen.", [["cell", "ANATOMY", 46, 50], ["cell", "CELL", 46, 50], ["dose-dependent inhibition", "TREATMENT", 16, 41], ["cell viability", "TEST", 46, 60], ["the reconfirmation screen", "TEST", 86, 111]]], ["Furthermore, the CC50 of each compound was calculated, and those compounds displaying SIs over 10 were considered hits in this study.Identification of antiviral effects of five hit drugs. ::: MATERIALS AND METHODSThe antiviral effects of the drugs were evaluated by quantitative reverse transcription-PCR (qRT-PCR), immunofluorescence assay (IFA), and plaque assay as previously reported (44\u201347).", [["plaque", "ANATOMY", 352, 358], ["this study", "TEST", 122, 132], ["five hit drugs", "TREATMENT", 172, 186], ["METHODSThe antiviral effects", "TREATMENT", 206, 234], ["the drugs", "TREATMENT", 238, 247], ["quantitative reverse transcription", "TEST", 266, 300], ["PCR", "TEST", 301, 304], ["qRT", "TEST", 306, 309], ["PCR", "TEST", 310, 313], ["immunofluorescence assay", "TEST", 316, 340], ["plaque assay", "TEST", 352, 364], ["antiviral effects", "OBSERVATION", 151, 168], ["plaque", "OBSERVATION", 352, 358]]], ["The experimental timeline is depicted in Fig. 2A.Identification of antiviral effects of five hit drugs. ::: MATERIALS AND METHODSTo ensure the effectiveness of the hit drugs in flavivirus replication, BHK-21 cells transfected with the JEV, WNV, or DENV-2 replicon were incubated with each drug at the concentrations indicated above, and the luciferase activities were determined 24 h, 48 h, or 72 h later, respectively.Time-of-addition experiment. ::: MATERIALS AND METHODSTo evaluate which stage of the JEV life cycle was inhibited by each hit, a time-of-addition experiment was performed as previously described (43).", [["BHK-21 cells", "ANATOMY", 201, 213], ["2A", "GENE_OR_GENE_PRODUCT", 46, 48], ["flavivirus", "ORGANISM", 177, 187], ["BHK-21 cells", "CELL", 201, 213], ["JEV", "ORGANISM", 235, 238], ["WNV", "ORGANISM", 240, 243], ["DENV-2 replicon", "ORGANISM", 248, 263], ["luciferase", "GENE_OR_GENE_PRODUCT", 341, 351], ["JEV", "ORGANISM", 504, 507], ["BHK-21 cells", "CELL_LINE", 201, 213], ["JEV, WNV, or DENV-2 replicon", "DNA", 235, 263], ["luciferase", "PROTEIN", 341, 351], ["flavivirus", "SPECIES", 177, 187], ["BHK-21", "SPECIES", 201, 207], ["JEV", "SPECIES", 235, 238], ["WNV", "SPECIES", 240, 243], ["DENV-2", "SPECIES", 248, 254], ["JEV", "SPECIES", 504, 507], ["five hit drugs", "TREATMENT", 88, 102], ["METHODSTo", "TREATMENT", 122, 131], ["the hit drugs", "TREATMENT", 160, 173], ["flavivirus replication", "TREATMENT", 177, 199], ["BHK", "TEST", 201, 204], ["WNV", "PROBLEM", 240, 243], ["DENV-2 replicon", "TREATMENT", 248, 263], ["the luciferase activities", "TEST", 337, 362], ["METHODSTo evaluate", "TEST", 466, 484], ["antiviral effects", "OBSERVATION", 67, 84]]], ["Vero cells were infected with 20 \u03bcl RVPs for 1 h (0 to 1 h).", [["Vero cells", "ANATOMY", 0, 10], ["Vero cells", "CELL", 0, 10], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["infected", "OBSERVATION_MODIFIER", 16, 24]]], ["The test compounds were incubated with the cells for 1 h before infection (\u22121 to 0 h), during infection (0 to 1 h), and for 23 h postinfection (1 to 24 h) (Fig. 3A).", [["cells", "ANATOMY", 43, 48], ["infection", "DISEASE", 64, 73], ["infection", "DISEASE", 94, 103], ["cells", "CELL", 43, 48], ["The test compounds", "TEST", 0, 18], ["infection", "PROBLEM", 64, 73], ["infection", "PROBLEM", 94, 103], ["infection", "OBSERVATION", 94, 103]]], ["To exclude a possible direct inactivating effect of the drugs, RVPs were incubated with each drug at 37\u00b0C for 1 h, and the mixtures were diluted 25-fold to infect Vero cells.", [["Vero cells", "ANATOMY", 163, 173], ["RVPs", "SIMPLE_CHEMICAL", 63, 67], ["Vero cells", "CELL", 163, 173], ["Vero cells", "CELL_LINE", 163, 173], ["the drugs", "TREATMENT", 52, 61], ["RVPs", "TREATMENT", 63, 67], ["the mixtures", "TREATMENT", 119, 131], ["Vero cells", "OBSERVATION", 163, 173]]], ["Twenty-four hours later, the luciferase activities were determined as described above (Fig. 3A).Manidipine-resistant virus. ::: MATERIALS AND METHODSManidipine-resistant virus was generated by passaging of JEV on Vero cells in the presence of manidipine.", [["Vero cells", "ANATOMY", 213, 223], ["Manidipine", "CHEMICAL", 96, 106], ["METHODSManidipine", "CHEMICAL", 142, 159], ["manidipine", "CHEMICAL", 243, 253], ["Manidipine", "CHEMICAL", 96, 106], ["METHODSManidipine", "CHEMICAL", 142, 159], ["manidipine", "CHEMICAL", 243, 253], ["luciferase", "GENE_OR_GENE_PRODUCT", 29, 39], ["Manidipine", "SIMPLE_CHEMICAL", 96, 106], ["METHODSManidipine", "SIMPLE_CHEMICAL", 142, 159], ["virus", "ORGANISM", 170, 175], ["JEV", "ORGANISM", 206, 209], ["Vero cells", "CELL", 213, 223], ["manidipine", "SIMPLE_CHEMICAL", 243, 253], ["luciferase", "PROTEIN", 29, 39], ["Vero cells", "CELL_LINE", 213, 223], ["JEV", "SPECIES", 206, 209], ["the luciferase activities", "TEST", 25, 50], ["Manidipine", "TREATMENT", 96, 106], ["resistant virus", "PROBLEM", 107, 122], ["METHODSManidipine", "TEST", 142, 159], ["resistant virus", "PROBLEM", 160, 175], ["Vero cells", "TREATMENT", 213, 223], ["manidipine", "TREATMENT", 243, 253], ["resistant virus", "OBSERVATION", 107, 122], ["resistant virus", "OBSERVATION", 160, 175]]], ["Passages 1 to 10 used 5 \u03bcM manidipine, and passages 11 to 20 used 10 \u03bcM manidipine.", [["manidipine", "CHEMICAL", 27, 37], ["manidipine", "CHEMICAL", 72, 82], ["manidipine", "CHEMICAL", 27, 37], ["manidipine", "CHEMICAL", 72, 82], ["manidipine", "SIMPLE_CHEMICAL", 72, 82], ["manidipine", "TREATMENT", 27, 37], ["manidipine", "TREATMENT", 72, 82]]], ["As a control, WT virus was passaged in the presence of 2% DMSO in parallel.", [["DMSO", "CHEMICAL", 58, 62], ["DMSO", "CHEMICAL", 58, 62], ["WT virus", "ORGANISM", 14, 22], ["DMSO", "SIMPLE_CHEMICAL", 58, 62], ["WT virus", "PROBLEM", 14, 22]]], ["Passaging was terminated at passage 20, when no further improvement in resistance was detected.", [["resistance", "PROBLEM", 71, 81], ["improvement", "OBSERVATION_MODIFIER", 56, 67], ["resistance", "OBSERVATION", 71, 81]]], ["Two manidipine-resistant virus isolates were plaque purified and amplified in the presence of manidipine.", [["plaque", "ANATOMY", 45, 51], ["manidipine", "CHEMICAL", 4, 14], ["manidipine", "CHEMICAL", 94, 104], ["manidipine", "CHEMICAL", 4, 14], ["manidipine", "CHEMICAL", 94, 104], ["manidipine", "SIMPLE_CHEMICAL", 4, 14], ["manidipine", "SIMPLE_CHEMICAL", 94, 104], ["Two manidipine", "TREATMENT", 0, 14], ["resistant virus isolates", "PROBLEM", 15, 39], ["plaque", "PROBLEM", 45, 51], ["manidipine", "TREATMENT", 94, 104], ["manidipine", "OBSERVATION_MODIFIER", 4, 14], ["resistant", "OBSERVATION_MODIFIER", 15, 24], ["virus isolates", "OBSERVATION", 25, 39], ["plaque", "OBSERVATION_MODIFIER", 45, 51]]], ["Viral RNA was extracted, amplified, and purified for sequencing.", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["RNA", "OBSERVATION", 6, 9]]], ["An infectious cDNA clone of JEV, strain AT31 (pMWJEAT), kindly provided by T. Wakita, Tokyo Metropolitan Institute for Neuroscience, was used to recover WT and mutant viruses as described previously (4).", [["JEV", "ORGANISM", 28, 31], ["infectious cDNA clone", "DNA", 3, 24], ["JEV", "SPECIES", 28, 31], ["T. Wakita", "SPECIES", 75, 84], ["An infectious cDNA clone of JEV", "PROBLEM", 0, 31], ["mutant viruses", "PROBLEM", 160, 174], ["infectious", "OBSERVATION", 3, 13], ["viruses", "OBSERVATION", 167, 174]]], ["Virus titers and manidipine sensitivities were determined by plaque assay in Vero cells.Manidipine administration to JEV-infected mice. ::: MATERIALS AND METHODSAdult female BALB/c mice (age, 4 weeks) were kept in the Laboratory Animal Center of Wuhan Institute of Virology, CAS (Wuhan, China).", [["plaque", "ANATOMY", 61, 67], ["Vero cells", "ANATOMY", 77, 87], ["manidipine", "CHEMICAL", 17, 27], ["Manidipine", "CHEMICAL", 88, 98], ["JEV-infected", "DISEASE", 117, 129], ["manidipine", "CHEMICAL", 17, 27], ["Manidipine", "CHEMICAL", 88, 98], ["Virus", "ORGANISM", 0, 5], ["manidipine", "SIMPLE_CHEMICAL", 17, 27], ["Vero cells", "CELL", 77, 87], ["Manidipine", "SIMPLE_CHEMICAL", 88, 98], ["JEV", "ORGANISM", 117, 120], ["mice", "ORGANISM", 130, 134], ["BALB/c mice", "ORGANISM", 174, 185], ["Vero cells", "CELL_LINE", 77, 87], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 181, 185], ["JEV", "SPECIES", 117, 120], ["mice", "SPECIES", 181, 185], ["Virus titers", "TEST", 0, 12], ["manidipine sensitivities", "TEST", 17, 41], ["plaque assay", "TEST", 61, 73], ["Manidipine administration", "TREATMENT", 88, 113], ["plaque", "OBSERVATION", 61, 67], ["Vero cells", "OBSERVATION", 77, 87]]], ["The mice were randomly divided into four groups (30 mice per group): a JEV-infected and vehicle (2% Tween 80 plus 5% DMSO in phosphate-buffered saline [PBS])-treated group, a manidipine-treated group, a JEV-infected and manidipine-treated group, and a vehicle-treated group.", [["JEV-infected", "DISEASE", 71, 83], ["DMSO", "CHEMICAL", 117, 121], ["phosphate", "CHEMICAL", 125, 134], ["manidipine", "CHEMICAL", 175, 185], ["JEV-infected", "DISEASE", 203, 215], ["manidipine", "CHEMICAL", 220, 230], ["Tween 80", "CHEMICAL", 100, 108], ["DMSO", "CHEMICAL", 117, 121], ["phosphate", "CHEMICAL", 125, 134], ["manidipine", "CHEMICAL", 175, 185], ["manidipine", "CHEMICAL", 220, 230], ["mice", "ORGANISM", 4, 8], ["mice", "ORGANISM", 52, 56], ["JEV", "ORGANISM", 71, 74], ["DMSO", "SIMPLE_CHEMICAL", 117, 121], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 125, 150], ["manidipine", "SIMPLE_CHEMICAL", 175, 185], ["JEV", "ORGANISM", 203, 206], ["manidipine", "SIMPLE_CHEMICAL", 220, 230], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 52, 56], ["JEV", "SPECIES", 71, 74], ["JEV", "SPECIES", 203, 206], ["a JEV-infected and vehicle", "TREATMENT", 69, 95], ["DMSO in phosphate", "TREATMENT", 117, 134], ["buffered saline", "TREATMENT", 135, 150], ["a manidipine", "TREATMENT", 173, 185], ["a JEV", "TREATMENT", 201, 206], ["manidipine", "TREATMENT", 220, 230], ["infected", "OBSERVATION", 75, 83]]], ["For infection, mice were infected intraperitoneally with 5 \u00d7 106 PFU of JEV strain AT31.", [["intraperitoneally", "ANATOMY", 34, 51], ["infection", "DISEASE", 4, 13], ["mice", "ORGANISM", 15, 19], ["JEV", "ORGANISM", 72, 75], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["JEV", "SPECIES", 72, 75], ["infection", "PROBLEM", 4, 13], ["JEV strain AT31", "TREATMENT", 72, 87], ["infection", "OBSERVATION", 4, 13]]], ["For the manidipine and vehicle treatments, mice were injected intraperitoneally with 25 mg/kg of body weight manidipine or PBS with 2% Tween 80 and 5% DMSO, respectively.", [["body", "ANATOMY", 97, 101], ["manidipine", "CHEMICAL", 8, 18], ["manidipine", "CHEMICAL", 109, 119], ["DMSO", "CHEMICAL", 151, 155], ["manidipine", "CHEMICAL", 8, 18], ["manidipine", "CHEMICAL", 109, 119], ["Tween 80", "CHEMICAL", 135, 143], ["DMSO", "CHEMICAL", 151, 155], ["manidipine", "SIMPLE_CHEMICAL", 8, 18], ["mice", "ORGANISM", 43, 47], ["body", "ORGANISM_SUBDIVISION", 97, 101], ["manidipine", "SIMPLE_CHEMICAL", 109, 119], ["DMSO", "SIMPLE_CHEMICAL", 151, 155], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["the manidipine", "TREATMENT", 4, 18], ["vehicle treatments", "TREATMENT", 23, 41], ["body weight manidipine", "TREATMENT", 97, 119], ["PBS", "TREATMENT", 123, 126]]], ["Treatments were administered twice a day for the first 2 days and then consecutively administered once a day for up to 21 days.", [["Treatments", "TREATMENT", 0, 10]]], ["Five mice from each group were sacrificed on days 1, 3, and 5 postinfection.", [["mice", "ORGANISM", 5, 9], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 5, 9]]], ["Serum, spleen tissue, and brain tissue samples were collected for viral titer determination and histopathology investigation.", [["Serum", "ANATOMY", 0, 5], ["spleen tissue", "ANATOMY", 7, 20], ["brain tissue samples", "ANATOMY", 26, 46], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["spleen tissue", "TISSUE", 7, 20], ["brain tissue samples", "TISSUE", 26, 46], ["Serum, spleen tissue", "TEST", 0, 20], ["brain tissue samples", "TEST", 26, 46], ["viral titer determination", "TEST", 66, 91], ["histopathology investigation", "TEST", 96, 124], ["spleen tissue", "ANATOMY", 7, 20], ["brain tissue", "ANATOMY", 26, 38]]], ["Fifteen mice were monitored daily for morbidity and mortality.", [["mice", "ORGANISM", 8, 12], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["morbidity", "PROBLEM", 38, 47], ["mortality", "PROBLEM", 52, 61]]], ["The mice that showed neurological signs of disease were euthanized according to the Regulations for the Administration of Affairs Concerning Experimental Animals in China.", [["neurological", "ANATOMY", 21, 33], ["neurological signs of disease", "DISEASE", 21, 50], ["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["neurological signs of disease", "PROBLEM", 21, 50], ["disease", "OBSERVATION", 43, 50]]]], "618eceeb14d79e9bd86451e044949e819f51a822": [["In a retrospective cohort of 1014 Chinese patients, AI et al. [12] found detection rates for throat swab and CT scan of 59% and 88%, respectively.", [["throat swab", "ANATOMY", 93, 104], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["detection rates", "TEST", 73, 88], ["throat swab", "TEST", 93, 104], ["CT scan", "TEST", 109, 116]]], ["Taking RT-PCR result as a reference, chest CT showed sensitivity of 96.5%, specificity of 25.4%, positive predictive value of 65.3% and negative predictive value of 83.3%.", [["chest", "ANATOMY", 37, 42], ["chest CT", "TEST", 37, 45], ["sensitivity", "TEST", 53, 64], ["specificity", "TEST", 75, 86], ["chest", "ANATOMY", 37, 42]]], ["CT performance seemed to be even slightly better among older patients (i.e. >60 years) and females.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["CT performance", "TEST", 0, 14]]]], "fe25d46c0b8003a0499ad62274db84f24d5f05e2": [["IntroductionLife expectancy for Cystic Fibrosis (CF) patients has increased dramatically over the last 40 years [1] .", [["Cystic Fibrosis", "DISEASE", 32, 47], ["CF", "DISEASE", 49, 51], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Cystic Fibrosis", "PROBLEM", 32, 47], ["Cystic", "OBSERVATION_MODIFIER", 32, 38], ["Fibrosis", "OBSERVATION", 39, 47], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["dramatically", "OBSERVATION_MODIFIER", 76, 88]]], ["However, progressive pulmonary damage with eventual respiratory failure is still the major cause of morbidity and mortality in CF [2] and bacterial infection is generally thought to be the major cause of clinical deterioration [3] .", [["pulmonary", "ANATOMY", 21, 30], ["respiratory", "ANATOMY", 52, 63], ["pulmonary damage", "DISEASE", 21, 37], ["respiratory failure", "DISEASE", 52, 71], ["bacterial infection", "DISEASE", 138, 157], ["pulmonary", "ORGAN", 21, 30], ["progressive pulmonary damage", "PROBLEM", 9, 37], ["eventual respiratory failure", "PROBLEM", 43, 71], ["morbidity", "PROBLEM", 100, 109], ["mortality in CF", "PROBLEM", 114, 129], ["bacterial infection", "PROBLEM", 138, 157], ["clinical deterioration", "PROBLEM", 204, 226], ["progressive", "OBSERVATION_MODIFIER", 9, 20], ["pulmonary", "ANATOMY", 21, 30], ["damage", "OBSERVATION", 31, 37], ["respiratory failure", "OBSERVATION", 52, 71], ["morbidity", "OBSERVATION", 100, 109], ["bacterial", "OBSERVATION_MODIFIER", 138, 147], ["infection", "OBSERVATION", 148, 157]]], ["Recently, evidence from literature shows that respiratory viruses lead to pulmonary exacerbation and disease progression [4] [5] [6] [7] and an increase in bacterial adherence to the CF airways [8, 9] from in vitro studies.", [["pulmonary", "ANATOMY", 74, 83], ["CF airways", "ANATOMY", 183, 193], ["respiratory viruses", "DISEASE", 46, 65], ["pulmonary exacerbation", "DISEASE", 74, 96], ["pulmonary", "ORGAN", 74, 83], ["[4] [5] [6] [7]", "SIMPLE_CHEMICAL", 121, 136], ["airways", "MULTI-TISSUE_STRUCTURE", 186, 193], ["respiratory viruses", "PROBLEM", 46, 65], ["pulmonary exacerbation", "PROBLEM", 74, 96], ["disease progression", "PROBLEM", 101, 120], ["an increase in bacterial adherence", "PROBLEM", 141, 175], ["the CF airways", "TEST", 179, 193], ["vitro studies", "TEST", 209, 222], ["respiratory viruses", "OBSERVATION", 46, 65], ["pulmonary", "ANATOMY", 74, 83], ["exacerbation", "OBSERVATION", 84, 96], ["increase", "OBSERVATION_MODIFIER", 144, 152], ["bacterial adherence", "OBSERVATION", 156, 175], ["airways", "ANATOMY", 186, 193]]], ["This results in prolonged hospitalizations [10] of CF patients infected by viruses but their true impact on CF may yet have been underestimated by previous studies for a number of reasons: Firstly, respiratory viruses may trigger bacterial infections [11] [12] [13] and so the presence of bacteria does not necessarily exclude viral infections.", [["respiratory viruses", "DISEASE", 198, 217], ["bacterial infections", "DISEASE", 230, 250], ["viral infections", "DISEASE", 327, 343], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["viruses", "PROBLEM", 75, 82], ["respiratory viruses", "PROBLEM", 198, 217], ["bacterial infections", "PROBLEM", 230, 250], ["bacteria", "PROBLEM", 289, 297], ["viral infections", "PROBLEM", 327, 343], ["viruses", "OBSERVATION", 75, 82], ["bacteria", "OBSERVATION", 289, 297], ["does not necessarily exclude", "UNCERTAINTY", 298, 326], ["viral", "OBSERVATION_MODIFIER", 327, 332], ["infections", "OBSERVATION", 333, 343]]], ["Secondly, many previous studies used tissue culture and immunofluorescence techniques which are relatively insensitive methods for viral detection, but these were the techniques used in most published studies in CF [6, 7, 11, 14] .IntroductionThirdly, few studies have used sensitive methods such as molecular based technique for viral detection [12, [15] [16] [17] .IntroductionFinally, many previous studies were poorly designed with a small study sample and used invalidated criteria to define pulmonary exacerbations, therefore providing biased results.", [["tissue", "ANATOMY", 37, 43], ["pulmonary", "ANATOMY", 497, 506], ["pulmonary exacerbations", "DISEASE", 497, 520], ["tissue", "TISSUE", 37, 43], ["[15] [16] [17]", "SIMPLE_CHEMICAL", 351, 365], ["pulmonary", "ORGAN", 497, 506], ["tissue culture", "TEST", 37, 51], ["immunofluorescence techniques", "TEST", 56, 85], ["viral detection", "TEST", 131, 146], ["viral detection", "TEST", 330, 345], ["many previous studies", "TEST", 388, 409], ["a small study sample", "TEST", 436, 456], ["pulmonary exacerbations", "PROBLEM", 497, 520], ["pulmonary", "ANATOMY", 497, 506], ["exacerbations", "OBSERVATION", 507, 520]]], ["Identifying respiratory viruses in CF is important in clinical decision making and is potentially important as new anti-virals are becoming readily available [18] .PatientsThis was a prospective study conducted for 17 months between December 2002 and May 2004 involving patients with CF below the age of 18 years from four CF centres, namely University Hospital of Wales in Cardiff, Royal Gwent Hospital in Newport, and Singleton Hospital in Swansea and Neville Hall Hospital in Abergavenney.Sample collectionNasal swabs were obtained from the patients whenever they developed symptoms suggestive of respiratory exacerbations and whenever they attended for routine outpatient assessment on a 2 monthly basis.", [["Nasal swabs", "ANATOMY", 509, 520], ["respiratory", "ANATOMY", 600, 611], ["respiratory viruses", "DISEASE", 12, 31], ["CF", "DISEASE", 35, 37], ["respiratory exacerbations", "DISEASE", 600, 625], ["Patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 270, 278], ["Nasal swabs", "ORGANISM_SUBSTANCE", 509, 520], ["patients", "ORGANISM", 544, 552], ["Patients", "SPECIES", 164, 172], ["patients", "SPECIES", 270, 278], ["patients", "SPECIES", 544, 552], ["respiratory viruses in CF", "PROBLEM", 12, 37], ["a prospective study", "TEST", 181, 200], ["Sample collection", "TEST", 492, 509], ["Nasal swabs", "TEST", 509, 520], ["symptoms", "PROBLEM", 577, 585], ["respiratory exacerbations", "PROBLEM", 600, 625], ["routine outpatient assessment", "TEST", 657, 686], ["respiratory viruses", "OBSERVATION", 12, 31], ["Nasal", "ANATOMY", 509, 514], ["suggestive of", "UNCERTAINTY", 586, 599], ["respiratory exacerbations", "OBSERVATION", 600, 625]]], ["Each nasal swab was obtained by inserting a sterile cotton swab into one of the nostrils to a depth of 2 to 3 cm.", [["nasal swab", "ANATOMY", 5, 15], ["swab", "ANATOMY", 59, 63], ["nostrils", "ANATOMY", 80, 88], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 5, 15], ["nostrils", "ORGAN", 80, 88], ["cotton", "SPECIES", 52, 58], ["Each nasal swab", "TEST", 0, 15], ["a sterile cotton swab", "TREATMENT", 42, 63], ["nasal", "ANATOMY", 5, 10], ["swab", "OBSERVATION", 11, 15], ["nostrils", "ANATOMY", 80, 88], ["2 to 3 cm", "OBSERVATION_MODIFIER", 103, 112]]], ["The swab was then subjected into 0.5 ml of guanidium thiocyanate lysis buffer.", [["swab", "ANATOMY", 4, 8], ["guanidium thiocyanate", "CHEMICAL", 43, 64], ["guanidium thiocyanate", "CHEMICAL", 43, 64], ["swab", "ORGANISM_SUBSTANCE", 4, 8], ["guanidium thiocyanate", "SIMPLE_CHEMICAL", 43, 64], ["The swab", "TEST", 0, 8], ["guanidium thiocyanate lysis buffer", "TREATMENT", 43, 77]]], ["It was transported with ice packs to the laboratory and then stored at \u221280\u00b0C until undergoing nucleic acid extraction on a later date.", [["nucleic acid", "CHEMICAL", 94, 106], ["ice packs", "TREATMENT", 24, 33], ["nucleic acid extraction", "TREATMENT", 94, 117]]], ["A paired sputum/cough swab sample was also obtained at the same time for bacteriology and was analysed by the National Public Health Service (NPHS) of Wales.Virus identificationRespiratory virus nucleic acid materials were extracted from the nasal swabs using silica slurry as described by Boom et al. [19] .", [["sputum", "ANATOMY", 9, 15], ["swab sample", "ANATOMY", 22, 33], ["nasal swabs", "ANATOMY", 242, 253], ["nucleic acid", "CHEMICAL", 195, 207], ["silica", "CHEMICAL", 260, 266], ["silica", "CHEMICAL", 260, 266], ["Virus identificationRespiratory virus", "ORGANISM", 157, 194], ["nasal swabs", "ORGANISM_SUBSTANCE", 242, 253], ["Virus identificationRespiratory virus", "SPECIES", 157, 194], ["Virus identificationRespiratory virus", "SPECIES", 157, 194], ["A paired sputum/cough swab sample", "TEST", 0, 33], ["Virus identificationRespiratory virus nucleic acid materials", "PROBLEM", 157, 217], ["the nasal swabs using silica slurry", "TREATMENT", 238, 273], ["acid materials", "OBSERVATION", 203, 217], ["nasal", "ANATOMY", 242, 247]]], ["Extracted materials were amplified at 'real-time' using Nucleic Acid Sequence Based Amplification (NASBA) in conjunction with molecular beacons [20] [21] [22] [23] .", [["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 144, 163], ["Extracted materials", "PROBLEM", 0, 19], ["Nucleic Acid Sequence", "TREATMENT", 56, 77]]], ["The panel of respiratory viruses studied included influenza A, influenza B, respiratory syncytial virus (RSV), parainfluenza viruses (PIV) types 1 to 4, rhinovirus and coronavirus.", [["respiratory viruses", "DISEASE", 13, 32], ["influenza A", "DISEASE", 50, 61], ["influenza B", "DISEASE", 63, 74], ["respiratory syncytial virus (RSV), parainfluenza viruses", "DISEASE", 76, 132], ["rhinovirus and coronavirus", "DISEASE", 153, 179], ["influenza A", "ORGANISM", 50, 61], ["influenza B,", "ORGANISM", 63, 75], ["respiratory syncytial virus", "ORGANISM", 76, 103], ["RSV", "ORGANISM", 105, 108], ["parainfluenza viruses", "ORGANISM", 111, 132], ["rhinovirus", "ORGANISM", 153, 163], ["coronavirus", "ORGANISM", 168, 179], ["influenza B", "SPECIES", 63, 74], ["respiratory syncytial virus", "SPECIES", 76, 103], ["(RSV", "SPECIES", 104, 108], ["parainfluenza viruses", "SPECIES", 111, 132], ["coronavirus", "SPECIES", 168, 179], ["influenza A", "SPECIES", 50, 61], ["respiratory syncytial virus", "SPECIES", 76, 103], ["RSV", "SPECIES", 105, 108], ["PIV", "SPECIES", 134, 137], ["The panel", "TEST", 0, 9], ["respiratory viruses", "TEST", 13, 32], ["influenza", "PROBLEM", 50, 59], ["influenza B", "PROBLEM", 63, 74], ["respiratory syncytial virus", "PROBLEM", 76, 103], ["parainfluenza viruses (PIV) types", "PROBLEM", 111, 144], ["rhinovirus", "PROBLEM", 153, 163], ["coronavirus", "PROBLEM", 168, 179], ["respiratory viruses", "OBSERVATION", 13, 32], ["respiratory syncytial", "ANATOMY", 76, 97], ["parainfluenza viruses", "OBSERVATION", 111, 132], ["coronavirus", "OBSERVATION", 168, 179]]], ["The sequences of primers and molecular beacons used in 'real-time' NASBA assays are shown in Table 1 .", [["' NASBA assays", "TEST", 65, 79]]], ["Analysis of results was undertaken using the NucliSens\u00ae Easy Q Analyser (BioM\u00e9rieux Ltd) isothermically at 41\u00b0C and results were available within 120 min.", [["C", "SIMPLE_CHEMICAL", 110, 111]]], ["The NASBA assays have been found to be highly sensitive with the Tissue Culture Infective Dose being between 1 to 1 in 10 \u2212 5 virus input (TCID 50 ) and 100 to 0.1 copies of synthetic RNA.", [["synthetic RNA", "RNA", 174, 187], ["The NASBA assays", "TEST", 0, 16], ["the Tissue Culture Infective Dose", "TREATMENT", 61, 94], ["synthetic RNA", "TREATMENT", 174, 187]]], ["The assays are also specific with no background signal detected with a cross-reacting panel including a range of respiratory viruses and a lysis buffer negative control.", [["respiratory viruses", "DISEASE", 113, 132], ["The assays", "TEST", 0, 10], ["background signal", "PROBLEM", 37, 54], ["a cross-reacting panel", "TEST", 69, 91], ["respiratory viruses", "PROBLEM", 113, 132], ["a lysis buffer negative control", "TREATMENT", 137, 168], ["respiratory viruses", "OBSERVATION", 113, 132]]], ["The cutoff threshold for a positive result was defined as 20% above the negative control wild-type signal [22] .Bacterial isolationBacterial isolation in this study was performed by the NPHS of Wales and the methods were based on the 'Antibiotic treatment for CF' published in the CF Trust Report in 2002 (www.cftrust.org.uk) and the standard operating procedures (BSOP 57) from the 'National Standard Procedure on the Investigation of Bronchoalveolar Lavage, Sputum and Associated Specimens' issued by the Standards Unit, Evaluations and Standards Laboratory Specialist and Reference Microbiology Division (www.hpa.org.uk).Definition of an exacerbationIn this study, each patient (and parents) had been provided with a symptom diary card which comprised of upper and lower respiratory symptoms including runny nose, blocked nose, sore throat, hoarse voice, fever/shivering, cough (daytime and nighttime), wheeze (daytime and night-time), shortness of breath and school absenteeism [24] .", [["respiratory", "ANATOMY", 774, 785], ["nose", "ANATOMY", 825, 829], ["runny nose", "DISEASE", 805, 815], ["sore throat", "DISEASE", 831, 842], ["hoarse voice", "DISEASE", 844, 856], ["fever", "DISEASE", 858, 863], ["shivering", "DISEASE", 864, 873], ["cough", "DISEASE", 875, 880], ["wheeze", "DISEASE", 906, 912], ["shortness of breath", "DISEASE", 939, 958], ["patient", "ORGANISM", 673, 680], ["upper", "ORGANISM_SUBDIVISION", 758, 763], ["nose", "ORGANISM_SUBDIVISION", 811, 815], ["nose", "ORGANISM_SUBDIVISION", 825, 829], ["patient", "SPECIES", 673, 680], ["The cutoff threshold", "TEST", 0, 20], ["Bacterial isolationBacterial isolation", "PROBLEM", 112, 150], ["this study", "TEST", 154, 164], ["the methods", "TREATMENT", 204, 215], ["the 'Antibiotic treatment", "TREATMENT", 230, 255], ["Bronchoalveolar Lavage", "TEST", 436, 458], ["an exacerbationIn this study", "TEST", 638, 666], ["upper and lower respiratory symptoms", "PROBLEM", 758, 794], ["runny nose", "PROBLEM", 805, 815], ["blocked nose", "PROBLEM", 817, 829], ["sore throat", "PROBLEM", 831, 842], ["hoarse voice", "PROBLEM", 844, 856], ["fever", "PROBLEM", 858, 863], ["shivering", "PROBLEM", 864, 873], ["cough", "PROBLEM", 875, 880], ["wheeze", "PROBLEM", 906, 912], ["shortness of breath", "PROBLEM", 939, 958], ["isolationBacterial isolation", "OBSERVATION", 122, 150], ["Bronchoalveolar Lavage", "OBSERVATION", 436, 458], ["upper", "ANATOMY_MODIFIER", 758, 763], ["lower", "ANATOMY_MODIFIER", 768, 773], ["respiratory", "ANATOMY", 774, 785], ["nose", "ANATOMY", 825, 829], ["sore throat", "ANATOMY", 831, 842]]], ["Patients and parents had been asked to score their symptoms using the diary card regularly.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["their symptoms", "PROBLEM", 45, 59]]], ["The symptoms were scored as 0 for no symptoms, 1 for mild symptoms, 2 for moderate symptoms and 3 for severe symptoms for each criterion.", [["The symptoms", "PROBLEM", 0, 12], ["symptoms", "PROBLEM", 37, 45], ["mild symptoms", "PROBLEM", 53, 66], ["moderate symptoms", "PROBLEM", 74, 91], ["severe symptoms", "PROBLEM", 102, 117]]], ["Each patient above the age of 5 years was also provided with a mini-Wright Peak Flow Meter and was asked to record their best of three readings every morning and evening.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["The definition of a respiratory exacerbation was when the symptom score totalled to 4 or more, or if peak expiratory flow fell by more than 50 l/min from the child's usual best value, or if the parent subjectively felt that the child was developing a cold [25] .", [["respiratory", "ANATOMY", 20, 31], ["child", "ORGANISM", 228, 233], ["a respiratory exacerbation", "PROBLEM", 18, 44], ["the symptom score", "TEST", 54, 71], ["peak expiratory flow", "TEST", 101, 121], ["respiratory", "OBSERVATION_MODIFIER", 20, 31], ["exacerbation", "OBSERVATION", 32, 44]]], ["Under these circumstances, the parents or patients were encouraged to contact the investigators to have a nasal swab taken.Definition of an exacerbationPatients and parents were reminded regularly throughout the study by telephone and by letters to contact the investigators in the event of a respiratory exacerbation and to record their peak expiratory flows and symptom scores.EthicsThe study protocol was approved by the Committee of Ethics of each individual hospital and research funding was granted by the Welsh Office of Research and Development (WORD).", [["nasal swab", "ANATOMY", 106, 116], ["respiratory", "ANATOMY", 293, 304], ["respiratory exacerbation", "DISEASE", 293, 317], ["patients", "ORGANISM", 42, 50], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 106, 116], ["Patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 42, 50], ["Patients", "SPECIES", 152, 160], ["a nasal swab", "TEST", 104, 116], ["a respiratory exacerbation", "PROBLEM", 291, 317], ["symptom scores", "PROBLEM", 364, 378], ["nasal", "ANATOMY", 106, 111], ["exacerbation", "OBSERVATION", 140, 152], ["respiratory", "ANATOMY", 293, 304], ["exacerbation", "OBSERVATION", 305, 317]]], ["Informed consent was obtained from at least one parent at the beginning of the study and children and parents information sheets were also provided for clarity.StatisticsThe statistical analysis of this study was performed using the software package GraphPad InStat Version 3.0 for Windows (GraphPad software, San Diego, CA) and the author, FC.", [["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97], ["the study", "TEST", 75, 84], ["this study", "TEST", 198, 208]]], ["Chisquare test and Fisher's exact test were used to compare the incidence of respiratory viral infections between routine and exacerbation samples.", [["samples", "ANATOMY", 139, 146], ["respiratory viral infections", "DISEASE", 77, 105], ["Chisquare test", "TEST", 0, 14], ["Fisher's exact test", "TEST", 19, 38], ["respiratory viral infections", "PROBLEM", 77, 105], ["exacerbation samples", "PROBLEM", 126, 146], ["respiratory", "ANATOMY", 77, 88], ["viral infections", "OBSERVATION", 89, 105]]], ["Fisher's exact test was also used to compare the reasons used to define respiratory exacerbations between the virus positive and virus negative groups.", [["respiratory", "ANATOMY", 72, 83], ["Fisher's exact test", "TEST", 0, 19], ["respiratory exacerbations", "PROBLEM", 72, 97], ["the virus positive", "PROBLEM", 106, 124]]], ["Chi-square test was again used to study the correlation between respiratory viruses and bacteria.", [["respiratory viruses", "DISEASE", 64, 83], ["Chi-square test", "TEST", 0, 15], ["respiratory viruses", "PROBLEM", 64, 83], ["bacteria", "PROBLEM", 88, 96], ["respiratory", "ANATOMY", 64, 75], ["viruses", "OBSERVATION", 76, 83]]], ["P-value of b0.05 was taken to be statistically significant.Patient demographicsThere were 151 patients with CF under the care of these four centres who were all invited to participate in the study.", [["CF", "DISEASE", 108, 110], ["patients", "ORGANISM", 94, 102], ["Patient", "SPECIES", 59, 66], ["patients", "SPECIES", 94, 102], ["P-value", "TEST", 0, 7], ["the study", "TEST", 187, 196]]], ["Of these 151 patients, 71 (and parents) kindly agreed to enrol.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["There was a male predominance, in total, 53 boys (74.6%) and 18 girls (25.4%) participated with a median age of 9 years.", [["boys", "SPECIES", 44, 48], ["girls", "SPECIES", 64, 69], ["male", "OBSERVATION_MODIFIER", 12, 16], ["predominance", "OBSERVATION_MODIFIER", 17, 29]]], ["46% of the study population were homozygous for delta F508 and 49% were heterozygotes for this genetic mutation.", [["delta F508", "GENE_OR_GENE_PRODUCT", 48, 58], ["the study population", "TEST", 7, 27], ["delta F508", "TEST", 48, 58], ["heterozygotes", "PROBLEM", 72, 85], ["this genetic mutation", "PROBLEM", 90, 111]]], ["69% had an FEV 1 predicted of greater than 80%.", [["an FEV", "TEST", 8, 14]]], ["21% and 10% of the study population were colonised with Pseudomonas aeruginosa and Staphylococcus aureus, respectively ( Table 2 ).", [["Pseudomonas aeruginosa and Staphylococcus aureus", "DISEASE", 56, 104], ["Pseudomonas aeruginosa", "ORGANISM", 56, 78], ["Staphylococcus aureus", "ORGANISM", 83, 104], ["Pseudomonas aeruginosa", "SPECIES", 56, 78], ["Staphylococcus aureus", "SPECIES", 83, 104], ["Pseudomonas aeruginosa", "SPECIES", 56, 78], ["Staphylococcus aureus", "SPECIES", 83, 104], ["the study population", "TEST", 15, 35], ["Pseudomonas aeruginosa", "PROBLEM", 56, 78], ["Staphylococcus aureus", "PROBLEM", 83, 104], ["Staphylococcus aureus", "OBSERVATION", 83, 104]]], ["The demographics of those who did not participate in this study (n = 71) were similar to those who joined the study.Prevalence of respiratory virusesThere were 165 reported cases of respiratory exacerbations from 71 volunteers over the 17 month study period.", [["respiratory", "ANATOMY", 182, 193], ["respiratory viruses", "DISEASE", 130, 149], ["respiratory exacerbations", "DISEASE", 182, 207], ["volunteers", "ORGANISM", 216, 226], ["this study", "TEST", 53, 63], ["the study", "TEST", 106, 115], ["respiratory viruses", "PROBLEM", 130, 149], ["respiratory exacerbations", "PROBLEM", 182, 207], ["respiratory viruses", "OBSERVATION", 130, 149], ["respiratory", "ANATOMY", 182, 193], ["exacerbations", "OBSERVATION", 194, 207]]], ["The maximum number of reports was 8 from one child.", [["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["138 samples were obtained from 165 reported exacerbation cases.", [["samples", "ANATOMY", 4, 11], ["samples", "CANCER", 4, 11], ["exacerbation cases", "PROBLEM", 44, 62]]], ["The discrepancies in numbers arose when 4 volunteers refused nasal swabs to be taken; 4 were not at home to have samples collected and 2 were asleep at the point of sample collection.", [["nasal swabs", "ANATOMY", 61, 72], ["samples", "ANATOMY", 113, 120], ["sample", "ANATOMY", 165, 171], ["volunteers", "ORGANISM", 42, 52], ["The discrepancies in numbers", "PROBLEM", 0, 28], ["nasal swabs", "TREATMENT", 61, 72], ["samples", "TEST", 113, 120], ["sample collection", "PROBLEM", 165, 182]]], ["17 samples were missed.", [["samples", "ANATOMY", 3, 10], ["samples", "CANCER", 3, 10]]], ["The median number of samples taken from each patient was 2 with a range between 0 and 8.", [["samples", "ANATOMY", 21, 28], ["samples", "CANCER", 21, 28], ["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["Respiratory viruses were detected by 'real-time' NASBA in 63 of 138 cases (46%); in six cases (4.3%) two viruses were detected, and in three cases (2.2%) three were detected (Table 3) .", [["Respiratory viruses", "PROBLEM", 0, 19], ["NASBA", "TEST", 49, 54], ["two viruses", "PROBLEM", 101, 112], ["viruses", "OBSERVATION", 12, 19]]], ["Influenza A, influenza B, PIV 4 and rhinovirus were the major viruses detected.Prevalence of respiratory viruses272 routine samples were collected from the patients.", [["samples", "ANATOMY", 124, 131], ["Influenza A", "DISEASE", 0, 11], ["influenza B", "DISEASE", 13, 24], ["respiratory viruses", "DISEASE", 93, 112], ["Influenza A", "ORGANISM", 0, 11], ["influenza B", "ORGANISM", 13, 24], ["PIV 4", "ORGANISM", 26, 31], ["rhinovirus", "ORGANISM", 36, 46], ["samples", "CANCER", 124, 131], ["patients", "ORGANISM", 156, 164], ["Influenza", "SPECIES", 0, 9], ["patients", "SPECIES", 156, 164], ["Influenza A", "SPECIES", 0, 11], ["Influenza", "PROBLEM", 0, 9], ["influenza B", "TREATMENT", 13, 24], ["PIV", "TREATMENT", 26, 29], ["rhinovirus", "PROBLEM", 36, 46], ["respiratory viruses", "PROBLEM", 93, 112], ["routine samples", "TEST", 116, 131], ["viruses", "OBSERVATION", 62, 69], ["respiratory", "ANATOMY", 93, 104]]], ["The median number of routine sample collected from each patient was 4 with a range between 2 and 6.", [["sample", "ANATOMY", 29, 35], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["routine sample", "TEST", 21, 35], ["median", "OBSERVATION_MODIFIER", 4, 10], ["number", "OBSERVATION_MODIFIER", 11, 17]]], ["Alternative routine sample was analysed in this study due to the financial constraint.", [["Alternative routine sample", "TEST", 0, 26], ["this study", "TEST", 43, 53]]], ["There were 23 (16.9%) samples positive for respiratory viruses from 136 routine collections (Table 3) .", [["samples", "ANATOMY", 22, 29], ["respiratory viruses", "DISEASE", 43, 62], ["samples", "CANCER", 22, 29], ["samples", "TEST", 22, 29], ["respiratory viruses", "PROBLEM", 43, 62], ["respiratory viruses", "OBSERVATION", 43, 62]]], ["PIV 4 and rhinovirus were the major viruses detected.Prevalence of respiratory virusesThere were significantly more respiratory viruses detected from exacerbation samples than from routine samples (p-value = 0.001).", [["samples", "ANATOMY", 163, 170], ["samples", "ANATOMY", 189, 196], ["respiratory viruses", "DISEASE", 67, 86], ["PIV 4", "ORGANISM", 0, 5], ["rhinovirus", "ORGANISM", 10, 20], ["PIV", "TREATMENT", 0, 3], ["rhinovirus", "PROBLEM", 10, 20], ["respiratory viruses", "PROBLEM", 67, 86], ["significantly more respiratory viruses", "PROBLEM", 97, 135], ["exacerbation samples", "PROBLEM", 150, 170], ["routine samples", "TEST", 181, 196], ["p-value", "TEST", 198, 205], ["rhinovirus", "OBSERVATION", 10, 20], ["major", "OBSERVATION_MODIFIER", 30, 35], ["viruses", "OBSERVATION", 36, 43], ["respiratory viruses", "OBSERVATION", 67, 86], ["significantly", "OBSERVATION_MODIFIER", 97, 110], ["more", "OBSERVATION_MODIFIER", 111, 115], ["respiratory viruses", "OBSERVATION", 116, 135]]], ["In particular, there were significantly more #51 patients out of 71 in the SNOT population were greater than 5 years of age who were able to perform lung function. ## 40 out of 80 patients who declined to join the study were greater than 5 years of age who were able to perform lung function test.Prevalence of respiratory virusesinfluenza A (p = 0.011), influenza B (p = 0.002) and rhinoviruses (p = 0.0027) detectable from exacerbation samples (Table 3) Influenza A was detected in eleven exacerbation samples and only on two occasions from routine samples (p = 0.011).", [["lung", "ANATOMY", 149, 153], ["lung", "ANATOMY", 278, 282], ["samples", "ANATOMY", 504, 511], ["samples", "ANATOMY", 551, 558], ["influenza B", "DISEASE", 355, 366], ["patients", "ORGANISM", 49, 57], ["lung", "ORGAN", 149, 153], ["patients", "ORGANISM", 180, 188], ["lung", "ORGAN", 278, 282], ["influenza B", "ORGANISM", 355, 366], ["rhinoviruses", "ORGANISM", 383, 395], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 180, 188], ["the study", "TEST", 210, 219], ["lung function test", "TEST", 278, 296], ["influenza B", "TEST", 355, 366], ["rhinoviruses", "PROBLEM", 383, 395], ["exacerbation samples", "PROBLEM", 425, 445], ["Influenza A", "PROBLEM", 456, 467], ["eleven exacerbation samples", "PROBLEM", 484, 511], ["routine samples", "TEST", 543, 558], ["lung", "ANATOMY", 149, 153], ["lung", "ANATOMY", 278, 282], ["respiratory virusesinfluenza", "OBSERVATION", 311, 339]]], ["Similarly, influenza B was detectable from eleven exacerbation samples compared to none from routine samples (p = 0.002).", [["samples", "ANATOMY", 63, 70], ["samples", "ANATOMY", 101, 108], ["influenza B", "DISEASE", 11, 22], ["influenza B", "ORGANISM", 11, 22], ["influenza B", "PROBLEM", 11, 22], ["eleven exacerbation samples", "PROBLEM", 43, 70], ["routine samples", "TEST", 93, 108]]], ["Rhinoviruses were also more commonly found in exacerbation samples (p = 0.027).", [["samples", "ANATOMY", 59, 66], ["Rhinoviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Rhinoviruses", "PROBLEM", 0, 12], ["exacerbation samples", "PROBLEM", 46, 66]]], ["PIV 4 was isolated from nasal specimens on 16 occasions, with 11 from exacerbation and 5 from routine samples.", [["nasal specimens", "ANATOMY", 24, 39], ["samples", "ANATOMY", 102, 109], ["PIV 4", "CELL", 0, 5], ["nasal specimens", "MULTI-TISSUE_STRUCTURE", 24, 39], ["PIV", "TREATMENT", 0, 3], ["nasal specimens", "TEST", 24, 39], ["exacerbation", "PROBLEM", 70, 82], ["routine samples", "TEST", 94, 109], ["nasal", "ANATOMY", 24, 29]]], ["The difference between the two sample types was not significant (p = 0.13).The association of upper respiratory tract symptoms and viral infectionsOf the 138 episodes of respiratory exacerbations, the summated symptom score was used on 92 occasions (67%) to define respiratory exacerbations; peak flow fall by greater than 50 l/min from usual best was used on 25 occasions (18%) and subjective evaluation was used on 21 occasions (15%) to define the other episodes of respiratory exacerbations.The association of upper respiratory tract symptoms and viral infectionsWhen the exacerbation nasal swab samples were divided into virus positive group (where at least one virus was identified from a nasal swab, [n = 50, 36%])and virus negative group ([n = 88, 64%], where no virus was identified from a nasal swab), there were significantly more patients in the virus positive group using the summated symptom score to define exacerbations; 39 of 50 episodes (78%) of exacerbations in the virus positive group in comparison to 53 of 88 episodes (60%) in the virus negative group (p = 0.04).", [["sample", "ANATOMY", 31, 37], ["upper respiratory tract", "ANATOMY", 94, 117], ["respiratory", "ANATOMY", 170, 181], ["respiratory", "ANATOMY", 265, 276], ["respiratory", "ANATOMY", 468, 479], ["upper respiratory tract", "ANATOMY", 513, 536], ["nasal swab samples", "ANATOMY", 588, 606], ["nasal swab", "ANATOMY", 694, 704], ["nasal swab", "ANATOMY", 798, 808], ["upper respiratory tract symptoms", "DISEASE", 94, 126], ["respiratory exacerbations", "DISEASE", 170, 195], ["respiratory exacerbations", "DISEASE", 265, 290], ["respiratory exacerbations", "DISEASE", 468, 493], ["upper respiratory tract symptoms", "DISEASE", 513, 545], ["viral infections", "DISEASE", 550, 566], ["exacerbations", "DISEASE", 963, 976], ["upper respiratory", "ORGANISM_SUBDIVISION", 94, 111], ["tract", "ORGANISM_SUBDIVISION", 112, 117], ["upper", "ORGANISM_SUBDIVISION", 513, 518], ["respiratory tract", "ORGANISM_SUBDIVISION", 519, 536], ["nasal swab samples", "CANCER", 588, 606], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 694, 704], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 798, 808], ["patients", "ORGANISM", 841, 849], ["patients", "SPECIES", 841, 849], ["upper respiratory tract symptoms", "PROBLEM", 94, 126], ["viral infectionsOf", "PROBLEM", 131, 149], ["respiratory exacerbations", "PROBLEM", 170, 195], ["the summated symptom score", "PROBLEM", 197, 223], ["respiratory exacerbations", "PROBLEM", 265, 290], ["peak flow fall", "PROBLEM", 292, 306], ["subjective evaluation", "TEST", 383, 404], ["respiratory exacerbations", "PROBLEM", 468, 493], ["upper respiratory tract symptoms", "PROBLEM", 513, 545], ["viral infections", "PROBLEM", 550, 566], ["the exacerbation nasal swab samples", "TEST", 571, 606], ["one virus", "PROBLEM", 662, 671], ["a nasal swab", "TEST", 692, 704], ["virus", "TEST", 724, 729], ["virus", "PROBLEM", 770, 775], ["a nasal swab", "TEST", 796, 808], ["the summated symptom score", "PROBLEM", 884, 910], ["exacerbations", "PROBLEM", 921, 934], ["exacerbations in the virus", "PROBLEM", 963, 989], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["not", "UNCERTAINTY", 48, 51], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["upper", "ANATOMY_MODIFIER", 94, 99], ["respiratory tract", "ANATOMY", 100, 117], ["viral", "OBSERVATION_MODIFIER", 131, 136], ["respiratory exacerbations", "OBSERVATION", 170, 195], ["respiratory", "ANATOMY", 265, 276], ["exacerbations", "OBSERVATION", 277, 290], ["respiratory", "ANATOMY", 468, 479], ["exacerbations", "OBSERVATION", 480, 493], ["upper", "ANATOMY_MODIFIER", 513, 518], ["respiratory tract", "ANATOMY", 519, 536], ["viral", "OBSERVATION_MODIFIER", 550, 555], ["infections", "OBSERVATION", 556, 566], ["nasal", "ANATOMY", 694, 699]]], ["The mean symptom score during respiratory exacerbations in the virus positive group was 7 compared to that of 6 for the virus negative group, though the difference was not significant.", [["respiratory", "ANATOMY", 30, 41], ["respiratory exacerbations", "DISEASE", 30, 55], ["The mean symptom score", "PROBLEM", 0, 22], ["respiratory exacerbations", "PROBLEM", 30, 55], ["respiratory", "OBSERVATION_MODIFIER", 30, 41], ["exacerbations", "OBSERVATION", 42, 55]]], ["There was no difference in the proportion of patients using peak expiratory flow reduction or using subjective evaluation to define an exacerbation between the two groups.The association of upper respiratory tract symptoms and viral infectionsThere was a significantly higher proportion of patients in the virus positive group complaining of upper respiratory tract symptoms such as a runny nose (77% versus 38%, p-value = 0.0003) and sore throat (62% versus 38%, p-value = 0.03) during exacerbations.", [["upper respiratory tract", "ANATOMY", 190, 213], ["upper respiratory tract", "ANATOMY", 342, 365], ["upper respiratory tract symptoms", "DISEASE", 190, 222], ["viral infections", "DISEASE", 227, 243], ["upper respiratory tract symptoms", "DISEASE", 342, 374], ["runny nose", "DISEASE", 385, 395], ["sore throat", "DISEASE", 435, 446], ["patients", "ORGANISM", 45, 53], ["upper", "ORGANISM_SUBDIVISION", 190, 195], ["respiratory tract", "ORGANISM_SUBDIVISION", 196, 213], ["patients", "ORGANISM", 290, 298], ["upper", "ORGANISM_SUBDIVISION", 342, 347], ["respiratory tract", "ORGANISM_SUBDIVISION", 348, 365], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 290, 298], ["peak expiratory flow reduction", "TREATMENT", 60, 90], ["subjective evaluation", "TEST", 100, 121], ["an exacerbation between the two groups", "PROBLEM", 132, 170], ["upper respiratory tract symptoms", "PROBLEM", 190, 222], ["viral infections", "PROBLEM", 227, 243], ["upper respiratory tract symptoms", "PROBLEM", 342, 374], ["a runny nose", "PROBLEM", 383, 395], ["p-value", "TEST", 413, 420], ["sore throat", "PROBLEM", 435, 446], ["p-value", "TEST", 464, 471], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["exacerbation", "OBSERVATION", 135, 147], ["upper", "ANATOMY_MODIFIER", 190, 195], ["respiratory tract", "ANATOMY", 196, 213], ["viral", "OBSERVATION_MODIFIER", 227, 232], ["infections", "OBSERVATION", 233, 243], ["upper", "ANATOMY_MODIFIER", 342, 347], ["respiratory tract", "ANATOMY", 348, 365], ["sore throat", "ANATOMY", 435, 446]]], ["The frequencies in lower respiratory tract complaints were similar between the two groups.The association of upper respiratory tract symptoms and viral infectionsA subgroup analysis was performed comparing the samples that were positive for either influenza A, influenza B or both and the group that was positive for other viral infections.", [["lower respiratory tract", "ANATOMY", 19, 42], ["upper respiratory tract", "ANATOMY", 109, 132], ["samples", "ANATOMY", 210, 217], ["lower respiratory tract complaints", "DISEASE", 19, 53], ["upper respiratory tract symptoms", "DISEASE", 109, 141], ["viral infections", "DISEASE", 146, 162], ["influenza A", "DISEASE", 248, 259], ["influenza B", "DISEASE", 261, 272], ["viral infections", "DISEASE", 323, 339], ["lower", "ORGANISM_SUBDIVISION", 19, 24], ["respiratory tract", "ORGANISM_SUBDIVISION", 25, 42], ["upper respiratory", "ORGANISM_SUBDIVISION", 109, 126], ["tract", "ORGANISM_SUBDIVISION", 127, 132], ["influenza A", "ORGANISM", 248, 259], ["influenza B", "ORGANISM", 261, 272], ["The frequencies in lower respiratory tract complaints", "PROBLEM", 0, 53], ["upper respiratory tract symptoms", "PROBLEM", 109, 141], ["viral infections", "PROBLEM", 146, 162], ["A subgroup analysis", "TEST", 162, 181], ["the samples", "TEST", 206, 217], ["influenza A", "PROBLEM", 248, 259], ["influenza B", "PROBLEM", 261, 272], ["other viral infections", "PROBLEM", 317, 339], ["lower", "ANATOMY_MODIFIER", 19, 24], ["respiratory tract", "ANATOMY", 25, 42], ["upper", "ANATOMY_MODIFIER", 109, 114], ["respiratory tract", "ANATOMY", 115, 132], ["viral", "OBSERVATION_MODIFIER", 146, 151], ["infections", "OBSERVATION", 152, 162], ["viral infections", "OBSERVATION", 323, 339]]], ["Of the 50 virus positive exacerbation samples (accounting for 63 respiratory viruses detected), 18 (36%) were positive for influenza A, B or both.", [["samples", "ANATOMY", 38, 45], ["samples", "CANCER", 38, 45], ["B", "CANCER", 136, 137], ["the 50 virus positive exacerbation samples", "PROBLEM", 3, 45], ["respiratory viruses", "TEST", 65, 84], ["influenza", "PROBLEM", 123, 132]]], ["4 of the 18 samples were excluded from analysis because they also had other respiratory viruses identified in addition to influenza virus.", [["samples", "ANATOMY", 12, 19], ["respiratory viruses", "DISEASE", 76, 95], ["influenza", "DISEASE", 122, 131], ["samples", "CANCER", 12, 19], ["influenza virus", "ORGANISM", 122, 137], ["influenza virus", "SPECIES", 122, 137], ["the 18 samples", "TEST", 5, 19], ["analysis", "TEST", 39, 47], ["other respiratory viruses", "PROBLEM", 70, 95], ["influenza virus", "PROBLEM", 122, 137], ["respiratory viruses", "OBSERVATION", 76, 95], ["influenza virus", "OBSERVATION", 122, 137]]], ["One of the 14 remaining samples contained both influenza A and B viruses.", [["samples", "ANATOMY", 24, 31], ["influenza A and B viruses", "DISEASE", 47, 72], ["samples", "CANCER", 24, 31], ["influenza A", "ORGANISM", 47, 58], ["B viruses", "ORGANISM", 63, 72], ["B viruses", "SPECIES", 63, 72], ["both influenza A and B viruses", "PROBLEM", 42, 72], ["both", "OBSERVATION_MODIFIER", 42, 46], ["influenza", "OBSERVATION", 47, 56]]], ["32 samples (64%) were positive for other respiratory viruses only.", [["samples", "ANATOMY", 3, 10], ["respiratory viruses", "DISEASE", 41, 60], ["samples", "CANCER", 3, 10], ["other respiratory viruses", "PROBLEM", 35, 60], ["respiratory viruses", "OBSERVATION", 41, 60]]], ["The reasons used to report respiratory exacerbations were similar between the influenza and other viral groups.", [["respiratory", "ANATOMY", 27, 38], ["respiratory exacerbations", "DISEASE", 27, 52], ["influenza", "DISEASE", 78, 87], ["respiratory exacerbations", "PROBLEM", 27, 52], ["the influenza and other viral groups", "PROBLEM", 74, 110]]], ["Summated symptom score was the major reason used to define respiratory exacerbations in both groups (79% in the influenza group and 81% in the other viral group).", [["respiratory", "ANATOMY", 59, 70], ["respiratory exacerbations", "DISEASE", 59, 84], ["influenza", "DISEASE", 112, 121], ["Summated symptom score", "PROBLEM", 0, 22], ["respiratory exacerbations", "PROBLEM", 59, 84], ["respiratory", "ANATOMY", 59, 70], ["exacerbations", "OBSERVATION", 71, 84]]], ["However, there were significantly more upper respiratory symptom complaints including runny nose (p-value = 0.02), blocked nose (p-value = 0.01), sore throat (p-value = 0.01), hoarse voice (p-value = 0.0002) and fever/ shivery episodes (p-value = 0.0002) in the influenza group compare to the other viral group.", [["respiratory", "ANATOMY", 45, 56], ["runny nose", "DISEASE", 86, 96], ["sore throat", "DISEASE", 146, 157], ["fever", "DISEASE", 212, 217], ["influenza", "DISEASE", 262, 271], ["nose", "ORGAN", 123, 127], ["significantly more upper respiratory symptom complaints", "PROBLEM", 20, 75], ["runny nose", "PROBLEM", 86, 96], ["p-value", "TEST", 98, 105], ["blocked nose", "PROBLEM", 115, 127], ["p-value", "TEST", 129, 136], ["sore throat", "PROBLEM", 146, 157], ["p-value", "TEST", 159, 166], ["hoarse voice", "PROBLEM", 176, 188], ["p-value", "TEST", 190, 197], ["fever/ shivery episodes", "PROBLEM", 212, 235], ["p-value", "TEST", 237, 244], ["the influenza group", "PROBLEM", 258, 277], ["significantly", "OBSERVATION_MODIFIER", 20, 33], ["upper", "ANATOMY_MODIFIER", 39, 44], ["respiratory", "ANATOMY", 45, 56], ["nose", "ANATOMY", 123, 127], ["sore throat", "ANATOMY", 146, 157]]], ["There was no difference in the lower respiratory symptom complaints between the groups.Relationship between bacteria and respiratory virusesThere were 274 paired sputum samples/cough swabs analysed for bacterial isolation (138 exacerbation and 136 routine), consisting of 84 (31%) cough swabs and 190 (69%) sputum samples.", [["respiratory", "ANATOMY", 37, 48], ["sputum samples", "ANATOMY", 162, 176], ["sputum samples", "ANATOMY", 307, 321], ["respiratory viruses", "DISEASE", 121, 140], ["cough", "DISEASE", 281, 286], ["respiratory viruses", "ORGANISM", 121, 140], ["sputum samples", "CANCER", 307, 321], ["the lower respiratory symptom complaints", "PROBLEM", 27, 67], ["Relationship between bacteria", "PROBLEM", 87, 116], ["respiratory viruses", "PROBLEM", 121, 140], ["paired sputum samples", "TEST", 155, 176], ["cough swabs", "TEST", 177, 188], ["bacterial isolation (138 exacerbation", "PROBLEM", 202, 239], ["cough swabs", "TEST", 281, 292], ["sputum samples", "TEST", 307, 321], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["lower", "OBSERVATION_MODIFIER", 31, 36], ["respiratory symptom", "OBSERVATION", 37, 56], ["bacteria", "OBSERVATION", 108, 116], ["respiratory viruses", "OBSERVATION", 121, 140]]], ["69 of 274 specimens (25%) were positive for bacteria accounting for a total of 86 isolates.", [["specimens", "ANATOMY", 10, 19], ["specimens", "CANCER", 10, 19], ["specimens", "TEST", 10, 19], ["bacteria", "PROBLEM", 44, 52]]], ["8 of 84 (10%) cough swab specimens were positive and 61 of 190 sputum samples (32%) were positive.", [["swab specimens", "ANATOMY", 20, 34], ["sputum samples", "ANATOMY", 63, 77], ["cough", "DISEASE", 14, 19], ["sputum samples", "CANCER", 63, 77], ["cough swab specimens", "TEST", 14, 34], ["sputum samples", "TEST", 63, 77]]], ["P. aeruginosa and S. aureus were the major bacteria isolated accounting for 54% and 23% of all bacteria identified, respectively.Relationship between bacteria and respiratory virusesOf the 74 nasal swabs (exacerbation and routine samples) that were positive for at least one respiratory virus, 19 (26%) of the paired sputum/cough swab samples were positive for bacteria.", [["nasal swabs", "ANATOMY", 192, 203], ["samples", "ANATOMY", 230, 237], ["sputum", "ANATOMY", 317, 323], ["swab samples", "ANATOMY", 330, 342], ["cough", "DISEASE", 324, 329], ["P. aeruginosa", "ORGANISM", 0, 13], ["S. aureus", "ORGANISM", 18, 27], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 192, 203], ["P. aeruginosa", "SPECIES", 0, 13], ["S. aureus", "SPECIES", 18, 27], ["P. aeruginosa", "SPECIES", 0, 13], ["S. aureus", "SPECIES", 18, 27], ["P. aeruginosa", "PROBLEM", 0, 13], ["S. aureus", "PROBLEM", 18, 27], ["the major bacteria", "PROBLEM", 33, 51], ["all bacteria", "PROBLEM", 91, 103], ["bacteria", "PROBLEM", 150, 158], ["respiratory virusesOf the 74 nasal swabs (exacerbation", "PROBLEM", 163, 217], ["routine samples", "TEST", 222, 237], ["one respiratory virus", "PROBLEM", 271, 292], ["the paired sputum/cough swab samples", "TEST", 306, 342], ["bacteria", "PROBLEM", 361, 369], ["aureus", "OBSERVATION", 21, 27], ["bacteria", "OBSERVATION_MODIFIER", 150, 158], ["respiratory virusesOf", "OBSERVATION", 163, 184], ["respiratory virus", "ANATOMY", 275, 292]]], ["Similarly, there were 200 nasal swab samples with no viruses identified, 50 (25%) of them were positive for bacteria.", [["nasal swab samples", "ANATOMY", 26, 44], ["nasal swab samples", "TEST", 26, 44], ["viruses", "PROBLEM", 53, 60], ["bacteria", "PROBLEM", 108, 116], ["no", "UNCERTAINTY", 50, 52], ["viruses", "OBSERVATION", 53, 60], ["positive for", "UNCERTAINTY", 95, 107], ["bacteria", "OBSERVATION", 108, 116]]], ["Hence there was no statistical difference between the viral and non-viral groups in terms of bacteria isolation (p = 0.909).", [["statistical difference", "PROBLEM", 19, 41], ["the viral and non-viral groups", "PROBLEM", 50, 80], ["bacteria isolation", "PROBLEM", 93, 111], ["no", "UNCERTAINTY", 16, 18], ["viral", "OBSERVATION", 54, 59], ["bacteria isolation", "OBSERVATION", 93, 111]]], ["There was also no difference in Pseudomonas isolation between the viral and non-viral groups.Relationship between bacteria and respiratory virusesWhen nasal swab samples were considered in terms of routine/asymptomatic (n = 136) and exacerbation (n = 138) collections, once again no difference was found between the two groups in terms of bacterial infection status (p = 0.728).", [["nasal swab samples", "ANATOMY", 151, 169], ["respiratory viruses", "DISEASE", 127, 146], ["infection", "DISEASE", 349, 358], ["respiratory viruses", "ORGANISM", 127, 146], ["nasal swab samples", "ORGANISM_SUBSTANCE", 151, 169], ["difference in Pseudomonas isolation", "PROBLEM", 18, 53], ["the viral and non-viral groups", "PROBLEM", 62, 92], ["Relationship between bacteria", "PROBLEM", 93, 122], ["respiratory viruses", "PROBLEM", 127, 146], ["nasal swab samples", "TEST", 151, 169], ["exacerbation (n = 138) collections", "PROBLEM", 233, 267], ["bacterial infection status", "PROBLEM", 339, 365], ["no", "UNCERTAINTY", 15, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28], ["Pseudomonas", "OBSERVATION", 32, 43], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["non-viral groups", "OBSERVATION", 76, 92], ["bacteria", "OBSERVATION", 114, 122], ["respiratory viruses", "OBSERVATION", 127, 146], ["bacterial", "OBSERVATION_MODIFIER", 339, 348], ["infection", "OBSERVATION", 349, 358]]], ["Bacteria were found in 33 (24.3%) routine samples and 36 (26.1%) exacerbation samples.DiscussionThis is a novel study using 'real-time' NASBA to examine the role of respiratory viruses in CF.", [["samples", "ANATOMY", 42, 49], ["samples", "ANATOMY", 78, 85], ["respiratory viruses", "DISEASE", 165, 184], ["CF", "DISEASE", 188, 190], ["Bacteria", "CELL", 0, 8], ["Bacteria", "PROBLEM", 0, 8], ["routine samples", "TEST", 34, 49], ["exacerbation samples", "PROBLEM", 65, 85], ["a novel study", "TEST", 104, 117], ["respiratory viruses in CF", "PROBLEM", 165, 190], ["respiratory", "ANATOMY", 165, 176], ["viruses", "OBSERVATION", 177, 184]]], ["It has achieved the highest detection rate of 46% amongst all existing literature concerning respiratory viruses in the CF population during reported episodes of respiratory illness.", [["respiratory", "ANATOMY", 162, 173], ["respiratory viruses", "DISEASE", 93, 112], ["respiratory illness", "DISEASE", 162, 181], ["respiratory viruses", "PROBLEM", 93, 112], ["respiratory illness", "PROBLEM", 162, 181], ["highest", "OBSERVATION_MODIFIER", 20, 27], ["respiratory viruses", "OBSERVATION", 93, 112], ["respiratory illness", "OBSERVATION", 162, 181]]], ["Our results compare favourably with previous studies and this may be that earlier studies relied heavily on repeated serological testing, either alone [11] or in combination with viral isolation [4, 6, 7, 12, 26] .", [["previous studies", "TEST", 36, 52], ["earlier studies", "TEST", 74, 89], ["repeated serological testing", "TEST", 108, 136], ["viral isolation", "TREATMENT", 179, 194]]], ["These traditional methods are relatively insensitive and may have underestimated the prevalence of viruses in CF.DiscussionWe have also achieved a viral detection rate of 18.3% from routine nasal samples and this is comparable to the seroconversion rate of 12.3% as reported by Wang et al. [7] .", [["nasal samples", "ANATOMY", 190, 203], ["CF", "DISEASE", 110, 112], ["nasal samples", "CANCER", 190, 203], ["viruses in CF", "PROBLEM", 99, 112], ["a viral detection rate", "TEST", 145, 167], ["routine nasal samples", "TEST", 182, 203], ["the seroconversion rate", "TEST", 230, 253], ["viruses", "OBSERVATION", 99, 106]]], ["This value is also similar to the seroconversion rate of 16.2% from asymptomatic samples achieved by Ramsey et al. [6] .", [["samples", "ANATOMY", 81, 88], ["the seroconversion rate", "TEST", 30, 53], ["asymptomatic samples", "PROBLEM", 68, 88]]], ["Amongst stable asthmatic children, Johnston et al. [25] found a viral detection rate of 12% by PCR.", [["asthmatic", "DISEASE", 15, 24], ["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33], ["a viral detection rate", "TEST", 62, 84], ["stable", "OBSERVATION_MODIFIER", 8, 14], ["asthmatic", "OBSERVATION", 15, 24]]], ["Therefore, a laboratory method with a higher sensitivity for viral detection used in this study has not increased the detection rate in asymptomatic samples, implying that the high detection rate in exacerbation samples is unlikely to be due to false positive results.DiscussionPIV 4 has been reported as a cause of severe respiratory infections in previously healthy children and can lead to an increased risk of hospital admission [27, 28] To our knowledge, this is the first study showing that PIV4 can be detectable in CF.", [["samples", "ANATOMY", 149, 156], ["respiratory", "ANATOMY", 323, 334], ["respiratory infections", "DISEASE", 323, 345], ["samples", "CANCER", 149, 156], ["children", "ORGANISM", 368, 376], ["PIV4", "GENE_OR_GENE_PRODUCT", 497, 501], ["PIV4", "PROTEIN", 497, 501], ["children", "SPECIES", 368, 376], ["a laboratory method", "TEST", 11, 30], ["viral detection", "TEST", 61, 76], ["this study", "TEST", 85, 95], ["the high detection rate", "PROBLEM", 172, 195], ["exacerbation samples", "PROBLEM", 199, 219], ["false positive results", "PROBLEM", 245, 267], ["severe respiratory infections", "PROBLEM", 316, 345], ["the first study", "TEST", 468, 483], ["PIV4", "TREATMENT", 497, 501], ["severe", "OBSERVATION_MODIFIER", 316, 322], ["respiratory", "ANATOMY", 323, 334], ["infections", "OBSERVATION", 335, 345]]], ["The lack of data regarding PIV4 in CF may be that it was not actively sought in previous studies and may also be due to the lack of knowledge of this virus.", [["CF", "DISEASE", 35, 37], ["PIV4", "GENE_OR_GENE_PRODUCT", 27, 31], ["PIV4", "TREATMENT", 27, 31], ["previous studies", "TEST", 80, 96], ["this virus", "PROBLEM", 145, 155]]], ["This study shows that PIV4 can be isolated in CF and could lead to pulmonary exacerbation but further studies will be required to fully define the exact role of PIV 4 in CF exacerbations.DiscussionThis study demonstrates that influenza A and B viruses are major viruses in causing respiratory exacerbations in CF and both viruses are more commonly detected during pulmonary exacerbations.", [["pulmonary", "ANATOMY", 67, 76], ["respiratory", "ANATOMY", 281, 292], ["pulmonary", "ANATOMY", 364, 373], ["PIV4", "CHEMICAL", 22, 26], ["influenza A and B viruses", "DISEASE", 226, 251], ["respiratory exacerbations", "DISEASE", 281, 306], ["CF", "DISEASE", 310, 312], ["pulmonary exacerbations", "DISEASE", 364, 387], ["PIV4", "SIMPLE_CHEMICAL", 22, 26], ["pulmonary", "ORGAN", 67, 76], ["PIV 4", "GENE_OR_GENE_PRODUCT", 161, 166], ["influenza A and B viruses", "ORGANISM", 226, 251], ["pulmonary", "ORGAN", 364, 373], ["PIV4", "PROTEIN", 22, 26], ["influenza A", "SPECIES", 226, 237], ["B viruses", "SPECIES", 242, 251], ["This study", "TEST", 0, 10], ["PIV4", "TREATMENT", 22, 26], ["pulmonary exacerbation", "PROBLEM", 67, 89], ["further studies", "TEST", 94, 109], ["PIV", "TREATMENT", 161, 164], ["CF exacerbations", "PROBLEM", 170, 186], ["This study", "TEST", 197, 207], ["influenza A and B viruses", "PROBLEM", 226, 251], ["major viruses", "PROBLEM", 256, 269], ["respiratory exacerbations in CF", "PROBLEM", 281, 312], ["both viruses", "PROBLEM", 317, 329], ["pulmonary exacerbations", "PROBLEM", 364, 387], ["pulmonary", "ANATOMY", 67, 76], ["exacerbation", "OBSERVATION", 77, 89], ["influenza", "OBSERVATION", 226, 235], ["respiratory exacerbations", "OBSERVATION", 281, 306], ["viruses", "OBSERVATION", 322, 329], ["pulmonary", "ANATOMY", 364, 373], ["exacerbations", "OBSERVATION", 374, 387]]], ["22 of 88 (23%) viruses found in this study are influenza viruses (A and B).", [["influenza viruses", "DISEASE", 47, 64], ["influenza viruses", "ORGANISM", 47, 64], ["viruses", "PROBLEM", 15, 22], ["this study", "TEST", 32, 42], ["influenza viruses", "PROBLEM", 47, 64], ["influenza viruses", "OBSERVATION", 47, 64]]], ["This figure is consistent with majority of the previous studies which showed that influenza virus represented between 12 to 27% of all viruses detected.", [["influenza virus", "DISEASE", 82, 97], ["influenza virus", "ORGANISM", 82, 97], ["influenza virus", "SPECIES", 82, 97], ["the previous studies", "TEST", 43, 63], ["influenza virus", "PROBLEM", 82, 97], ["all viruses", "PROBLEM", 131, 142], ["consistent with", "UNCERTAINTY", 15, 30], ["influenza virus", "OBSERVATION", 82, 97], ["viruses", "OBSERVATION", 135, 142]]], ["In relation to influenza vaccination, the uptake rate was up to 70% during the 2003/4 season [24] (but we did not have the data for our study population during 2002/2003) and the significance is that the influenza detection rate in our study could easily have been higher had the vaccination uptake not been this high.DiscussionPrevious studies have shown that RSV were also important viruses in CF exacerbations [4, 10] and represented 9 to 58% of all viruses in CF with the highest incidence in young children.", [["influenza", "DISEASE", 15, 24], ["influenza", "DISEASE", 204, 213], ["CF exacerbations", "DISEASE", 396, 412], ["CF", "DISEASE", 464, 466], ["RSV", "ORGANISM", 361, 364], ["children", "ORGANISM", 503, 511], ["children", "SPECIES", 503, 511], ["RSV", "SPECIES", 361, 364], ["influenza vaccination", "TREATMENT", 15, 36], ["the uptake rate", "TEST", 38, 53], ["our study population", "TEST", 132, 152], ["the influenza detection rate", "TEST", 200, 228], ["our study", "TEST", 232, 241], ["the vaccination uptake", "PROBLEM", 276, 298], ["DiscussionPrevious studies", "TEST", 318, 344], ["RSV", "PROBLEM", 361, 364], ["CF exacerbations", "PROBLEM", 396, 412], ["influenza", "OBSERVATION", 15, 24], ["RSV", "OBSERVATION", 361, 364], ["viruses", "OBSERVATION", 453, 460]]], ["In our study, only 7 of 88 (8%) reported viruses were RSV and this low detection rate may be due to nasal swabs used for sample collection having a 20 to 30% lower detection rate than nasopharyngeal aspirate for RSV [29] .", [["nasal swabs", "ANATOMY", 100, 111], ["sample", "ANATOMY", 121, 127], ["nasopharyngeal aspirate", "ANATOMY", 184, 207], ["RSV", "ORGANISM", 54, 57], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 184, 207], ["RSV", "ORGANISM", 212, 215], ["RSV", "SPECIES", 54, 57], ["RSV", "SPECIES", 212, 215], ["our study", "TEST", 3, 12], ["viruses", "PROBLEM", 41, 48], ["RSV", "PROBLEM", 54, 57], ["this low detection rate", "PROBLEM", 62, 85], ["nasal swabs", "PROBLEM", 100, 111], ["sample collection", "TEST", 121, 138], ["nasopharyngeal aspirate", "TEST", 184, 207], ["RSV", "PROBLEM", 212, 215]]], ["RSV is a relatively labile virus and the amount of virus in a small-volume nasal swab specimen may be a lot less than that in a sample obtained by aspiration.", [["nasal swab specimen", "ANATOMY", 75, 94], ["sample", "ANATOMY", 128, 134], ["RSV", "DISEASE", 0, 3], ["RSV", "ORGANISM", 0, 3], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["a relatively labile virus", "PROBLEM", 7, 32], ["virus", "PROBLEM", 51, 56], ["a small-volume nasal swab specimen", "TEST", 60, 94], ["aspiration", "PROBLEM", 147, 157], ["relatively", "OBSERVATION_MODIFIER", 9, 19], ["labile virus", "OBSERVATION", 20, 32], ["amount", "OBSERVATION_MODIFIER", 41, 47], ["virus", "OBSERVATION", 51, 56], ["small", "OBSERVATION_MODIFIER", 62, 67], ["aspiration", "OBSERVATION", 147, 157]]], ["In addition, RSV more commonly infects the lower airways and sampling from the upper airways by nasal swabs could have underestimated its true prevalence [30] .The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inDecember 2003 and could have potentially missed 2 months' worth of valuable specimens.", [["lower airways", "ANATOMY", 43, 56], ["upper airways", "ANATOMY", 79, 92], ["nasal swabs", "ANATOMY", 96, 107], ["specimens", "ANATOMY", 345, 354], ["RSV", "DISEASE", 241, 244], ["RSV", "ORGANISM", 13, 16], ["lower airways", "MULTI-TISSUE_STRUCTURE", 43, 56], ["upper airways", "ORGAN", 79, 92], ["nasal swabs", "ORGAN", 96, 107], ["RSV", "ORGANISM", 241, 244], ["specimens", "CANCER", 345, 354], ["RSV", "SPECIES", 13, 16], ["RSV", "SPECIES", 241, 244], ["RSV", "PROBLEM", 13, 16], ["nasal swabs", "TEST", 96, 107], ["RSV", "PROBLEM", 241, 244], ["our study", "TEST", 249, 258], ["valuable specimens", "TEST", 336, 354], ["RSV", "OBSERVATION", 13, 16], ["lower", "ANATOMY_MODIFIER", 43, 48], ["airways", "ANATOMY", 49, 56], ["upper", "ANATOMY_MODIFIER", 79, 84], ["airways", "ANATOMY", 85, 92], ["nasal", "ANATOMY", 96, 101]]], ["Lastly, 90% of the RSV infections reported were amongst children between the ages of 0 to 4 years [31] so the median age of 9 years in the study population may account for the low RSV detection rate.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inHowever, following a review of the case histories of the volunteers, there were 53 occasions where respiratory exacerbations and diminished peak flows that were not reported.", [["respiratory", "ANATOMY", 407, 418], ["RSV infections", "DISEASE", 19, 33], ["RSV", "DISEASE", 280, 283], ["respiratory exacerbations", "DISEASE", 407, 432], ["RSV", "ORGANISM", 19, 22], ["children", "ORGANISM", 56, 64], ["RSV", "ORGANISM", 180, 183], ["RSV", "ORGANISM", 280, 283], ["volunteers", "ORGANISM", 365, 375], ["children", "SPECIES", 56, 64], ["RSV", "SPECIES", 19, 22], ["RSV", "SPECIES", 180, 183], ["RSV", "SPECIES", 280, 283], ["the RSV infections", "PROBLEM", 15, 33], ["the low RSV detection rate", "PROBLEM", 172, 198], ["RSV", "PROBLEM", 280, 283], ["our study", "TEST", 288, 297], ["respiratory exacerbations", "PROBLEM", 407, 432], ["diminished peak flows", "PROBLEM", 437, 458], ["RSV", "ANATOMY", 19, 22], ["infections", "OBSERVATION", 23, 33], ["may account for", "UNCERTAINTY", 156, 171], ["low RSV", "OBSERVATION", 176, 183], ["respiratory", "ANATOMY", 407, 418], ["exacerbations", "OBSERVATION", 419, 432], ["diminished", "OBSERVATION_MODIFIER", 437, 447], ["peak flows", "OBSERVATION", 448, 458]]], ["Therefore, the total number of cases of respiratory exacerbation was 218 over 17 months, giving an exacerbation rate per patient per year of 2.05 and this was comparable to that reported by previous studies [5] [6] [7] 12, 13, 16, 26, 32, 33] .The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inIt has been more than 20 years since Wang et al. [7] described the relationship between respiratory viral infections and the deterioration in clinical status in CF.", [["respiratory", "ANATOMY", 40, 51], ["respiratory exacerbation", "DISEASE", 40, 64], ["RSV", "DISEASE", 325, 328], ["respiratory viral infections", "DISEASE", 441, 469], ["CF", "DISEASE", 514, 516], ["patient", "ORGANISM", 121, 128], ["RSV", "ORGANISM", 325, 328], ["patient", "SPECIES", 121, 128], ["RSV", "SPECIES", 325, 328], ["respiratory exacerbation", "PROBLEM", 40, 64], ["an exacerbation rate", "PROBLEM", 96, 116], ["RSV", "PROBLEM", 325, 328], ["our study", "TEST", 333, 342], ["respiratory viral infections", "PROBLEM", 441, 469], ["the deterioration in clinical status in CF", "PROBLEM", 474, 516], ["respiratory", "ANATOMY", 40, 51], ["exacerbation", "OBSERVATION", 52, 64], ["respiratory", "ANATOMY", 441, 452], ["viral infections", "OBSERVATION", 453, 469]]], ["Viruses were identified through repeated serology and nasal lavage for viral isolation in 49 patients with CF (mean age 13.7 years) over 2 years.", [["nasal lavage", "ANATOMY", 54, 66], ["CF", "DISEASE", 107, 109], ["nasal lavage", "MULTI-TISSUE_STRUCTURE", 54, 66], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["Viruses", "PROBLEM", 0, 7], ["repeated serology", "TEST", 32, 49], ["nasal lavage", "TREATMENT", 54, 66], ["viral isolation", "TREATMENT", 71, 86], ["nasal", "ANATOMY", 54, 59], ["lavage", "OBSERVATION", 60, 66]]], ["Although the CF patients had more respiratory illnesses than sibling controls (3.7 versus 1.7/year), there were no differences in virus identification rates (1.7/year).", [["respiratory", "ANATOMY", 34, 45], ["respiratory illnesses", "DISEASE", 34, 55], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["more respiratory illnesses", "PROBLEM", 29, 55], ["differences in virus identification rates", "PROBLEM", 115, 156], ["no", "UNCERTAINTY", 112, 114]]], ["All their viruses were identified by seroconversions; none were detected by viral cultures.", [["All their viruses", "PROBLEM", 0, 17], ["seroconversions", "PROBLEM", 37, 52], ["viral cultures", "TEST", 76, 90], ["viruses", "OBSERVATION", 10, 17]]], ["From a total of 1028 (689 acute episodes versus 339 asymptomatic episodes) serum samples, 105 infections (10.2%) were identified.", [["serum samples", "ANATOMY", 75, 88], ["infections", "DISEASE", 94, 104], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["acute episodes", "PROBLEM", 26, 40], ["asymptomatic episodes", "PROBLEM", 52, 73], ["serum samples", "TEST", 75, 88], ["105 infections", "PROBLEM", 90, 104]]], ["42 of the 105 infections were identified from asymptomatic periods.", [["infections", "DISEASE", 14, 24], ["the 105 infections", "PROBLEM", 6, 24], ["infections", "OBSERVATION", 14, 24], ["asymptomatic", "OBSERVATION_MODIFIER", 46, 58]]], ["Therefore their viral detection rates were 9.1% during acute episodes and 12.3% during asymptomatic episodes, compared to our detection rates of 46% and 18.4%, respectively.", [["their viral detection rates", "TEST", 10, 37], ["acute episodes", "PROBLEM", 55, 69], ["asymptomatic episodes", "PROBLEM", 87, 108], ["our detection rates", "TEST", 122, 141]]], ["Our study also show that rhinoviruses played a major role in exacerbations of CF but in contrast, Wang et al. [7] failed to detect any rhinoviruses.", [["rhinoviruses", "DISEASE", 25, 37], ["CF", "DISEASE", 78, 80], ["rhinoviruses", "DISEASE", 135, 147], ["rhinoviruses", "ORGANISM", 25, 37], ["rhinoviruses", "ORGANISM", 135, 147], ["Our study", "TEST", 0, 9], ["rhinoviruses", "PROBLEM", 25, 37], ["exacerbations of CF", "PROBLEM", 61, 80], ["any rhinoviruses", "PROBLEM", 131, 147], ["rhinoviruses", "OBSERVATION", 25, 37], ["rhinoviruses", "OBSERVATION", 135, 147]]], ["The authors concluded that the high serotypes of rhinoviruses making detection by serology and cultures impossible.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inRamsey et al. [6] prospectively compared the incidence and effect of viral infections on pulmonary function and clinical scores in 15 schoolchildren with CF aged 5-22 years and their unaffected siblings.", [["pulmonary", "ANATOMY", 313, 322], ["RSV", "DISEASE", 196, 199], ["viral infections", "DISEASE", 293, 309], ["CF", "DISEASE", 378, 380], ["rhinoviruses", "ORGANISM", 49, 61], ["RSV", "ORGANISM", 196, 199], ["pulmonary", "ORGAN", 313, 322], ["schoolchildren", "SPECIES", 358, 372], ["RSV", "SPECIES", 196, 199], ["the high serotypes of rhinoviruses", "PROBLEM", 27, 61], ["serology", "TEST", 82, 90], ["cultures", "TEST", 95, 103], ["RSV", "PROBLEM", 196, 199], ["our study", "TEST", 204, 213], ["viral infections on pulmonary function", "PROBLEM", 293, 331], ["viral", "OBSERVATION_MODIFIER", 293, 298], ["infections", "OBSERVATION", 299, 309], ["pulmonary", "ANATOMY", 313, 322]]], ["Over a 2-year period, oropharyngeal cultures and serological tests were taken at regular two monthly intervals and during acute exacerbations for respiratory viruses.", [["oropharyngeal cultures", "ANATOMY", 22, 44], ["respiratory viruses", "DISEASE", 146, 165], ["oropharyngeal cultures", "CELL", 22, 44], ["oropharyngeal cultures", "TEST", 22, 44], ["serological tests", "TEST", 49, 66], ["acute exacerbations", "PROBLEM", 122, 141], ["respiratory viruses", "PROBLEM", 146, 165], ["oropharyngeal", "ANATOMY", 22, 35], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["exacerbations", "OBSERVATION", 128, 141], ["respiratory viruses", "OBSERVATION", 146, 165]]], ["A total of 68 acute respiratory illness (ARI) episodes occurred in the patients with CF and in 19 episodes there was an associated virus identified.", [["respiratory", "ANATOMY", 20, 31], ["acute respiratory illness", "DISEASE", 14, 39], ["ARI", "DISEASE", 41, 44], ["CF", "DISEASE", 85, 87], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["68 acute respiratory illness", "PROBLEM", 11, 39], ["ARI) episodes", "PROBLEM", 41, 54], ["CF", "PROBLEM", 85, 87], ["an associated virus", "PROBLEM", 117, 136], ["total", "OBSERVATION_MODIFIER", 2, 7], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["respiratory illness", "OBSERVATION", 20, 39], ["virus", "OBSERVATION", 131, 136]]], ["This gave a viral detection rate of 27.9% during CF exacerbations and a rate of 27.8% when asymptomatic.", [["CF exacerbations", "DISEASE", 49, 65], ["a viral detection rate", "TEST", 10, 32], ["CF exacerbations", "PROBLEM", 49, 65], ["a rate", "TEST", 70, 76], ["asymptomatic", "PROBLEM", 91, 103]]], ["They were unable to demonstrate any significant adverse effect of viral infections on lung functions in patients with CF.", [["lung", "ANATOMY", 86, 90], ["viral infections", "DISEASE", 66, 82], ["CF", "DISEASE", 118, 120], ["lung", "ORGAN", 86, 90], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["viral infections on lung functions", "PROBLEM", 66, 100], ["CF", "PROBLEM", 118, 120], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["infections", "OBSERVATION", 72, 82], ["lung", "ANATOMY", 86, 90]]], ["However, they found that patients with CF had more frequent viral infections and infections were associated with a significantly slower rate of clinical decline.", [["CF", "DISEASE", 39, 41], ["viral infections", "DISEASE", 60, 76], ["infections", "DISEASE", 81, 91], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["CF", "PROBLEM", 39, 41], ["frequent viral infections", "PROBLEM", 51, 76], ["infections", "PROBLEM", 81, 91], ["clinical decline", "PROBLEM", 144, 160], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["infections", "OBSERVATION", 66, 76], ["infections", "OBSERVATION", 81, 91]]], ["The authors also suggested that viral infections may possibly protect against Pseudomonas acquisition.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inRhinovirus has been found to be a major virus in CF exacerbation in this study.", [["viral infections", "DISEASE", 32, 48], ["RSV", "DISEASE", 183, 186], ["inRhinovirus", "CHEMICAL", 209, 221], ["RSV", "ORGANISM", 183, 186], ["RSV", "SPECIES", 183, 186], ["inRhinovirus", "SPECIES", 209, 221], ["viral infections", "PROBLEM", 32, 48], ["Pseudomonas acquisition", "PROBLEM", 78, 101], ["RSV", "PROBLEM", 183, 186], ["our study", "TEST", 191, 200], ["a major virus in CF exacerbation", "PROBLEM", 243, 275], ["this study", "TEST", 279, 289], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infections", "OBSERVATION", 38, 48], ["virus", "OBSERVATION", 251, 256]]], ["To date only 3 studies have prospectively used molecular based methods to identify viral agents [5, 12, 15, 16] .", [["3 studies", "TEST", 13, 22], ["viral agents", "TREATMENT", 83, 95]]], ["Over a 1-year period, Smyth et al. [15] prospectively investigated 108 patients with CF (mean age of 7.9 years) using a combination of viral culture and immunofluoresence, seroconversion (fourfold increase in titres) and a PCR based method for rhinoviruses.", [["CF", "DISEASE", 85, 87], ["rhinoviruses", "DISEASE", 244, 256], ["patients", "ORGANISM", 71, 79], ["rhinoviruses", "ORGANISM", 244, 256], ["patients", "SPECIES", 71, 79], ["CF", "PROBLEM", 85, 87], ["viral culture", "TEST", 135, 148], ["immunofluoresence", "PROBLEM", 153, 170], ["seroconversion (fourfold increase in titres)", "TREATMENT", 172, 216], ["a PCR", "TEST", 221, 226], ["rhinoviruses", "PROBLEM", 244, 256]]], ["During the study, 76 subjects had 157 reported respiratory exacerbations (1.5 episodes/patient/year compared to 2.05 in our study), and a viral agent was identified in 44 episodes (28%) (with rhinovirus in 25 [15.9%] ), and an equal distribution of other viruses identified almost always on seroconversion.", [["respiratory", "ANATOMY", 47, 58], ["respiratory exacerbations", "DISEASE", 47, 72], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94], ["the study", "TEST", 7, 16], ["respiratory exacerbations", "PROBLEM", 47, 72], ["our study", "TEST", 120, 129], ["a viral agent", "PROBLEM", 136, 149], ["rhinovirus", "TEST", 192, 202], ["other viruses", "PROBLEM", 249, 262], ["equal", "OBSERVATION_MODIFIER", 227, 232], ["distribution", "OBSERVATION_MODIFIER", 233, 245], ["viruses", "OBSERVATION", 255, 262]]], ["They also found that those children in whom a non-rhinovirus was identified had a significantly greater decline in FEV 1 , whereas patients with rhinovirus infection had fewer declines.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inCollinson et al. [5] followed 48 children with CF over a 15 month period using a combination of viral culture and PCR for picornaviruses alone.", [["rhinovirus infection", "DISEASE", 145, 165], ["RSV", "DISEASE", 266, 269], ["CF", "DISEASE", 341, 343], ["children", "ORGANISM", 27, 35], ["FEV 1", "GENE_OR_GENE_PRODUCT", 115, 120], ["patients", "ORGANISM", 131, 139], ["rhinovirus", "ORGANISM", 145, 155], ["RSV", "ORGANISM", 266, 269], ["children", "ORGANISM", 327, 335], ["children", "SPECIES", 27, 35], ["patients", "SPECIES", 131, 139], ["children", "SPECIES", 327, 335], ["FEV 1", "SPECIES", 115, 120], ["RSV", "SPECIES", 266, 269], ["a significantly greater decline in FEV 1", "PROBLEM", 80, 120], ["rhinovirus infection", "PROBLEM", 145, 165], ["RSV", "PROBLEM", 266, 269], ["our study", "TEST", 274, 283], ["viral culture", "TEST", 390, 403], ["PCR", "TEST", 408, 411], ["picornaviruses", "PROBLEM", 416, 430], ["rhinovirus", "OBSERVATION_MODIFIER", 145, 155], ["infection", "OBSERVATION", 156, 165]]], ["Thirty eight children completed the study and there were 147 symptomatic upper respiratory infections (2.7 episodes/child/year), with samples available for 119 episodes.", [["respiratory", "ANATOMY", 79, 90], ["samples", "ANATOMY", 134, 141], ["respiratory infections", "DISEASE", 79, 101], ["children", "ORGANISM", 13, 21], ["children", "SPECIES", 13, 21], ["the study", "TEST", 32, 41], ["symptomatic upper respiratory infections", "PROBLEM", 61, 101], ["symptomatic", "OBSERVATION_MODIFIER", 61, 72], ["upper", "ANATOMY_MODIFIER", 73, 78], ["respiratory", "ANATOMY", 79, 90], ["infections", "OBSERVATION", 91, 101]]], ["Picornaviruses were identified in 51 (43%) of these episodes, of which 21 (18%) were rhinoviruses.", [["rhinoviruses", "DISEASE", 85, 97], ["rhinoviruses", "ORGANISM", 85, 97], ["Picornaviruses", "PROBLEM", 0, 14], ["these episodes", "PROBLEM", 46, 60], ["rhinoviruses", "PROBLEM", 85, 97], ["rhinoviruses", "OBSERVATION", 85, 97]]], ["This study confirmed the importance of this virus in CF exacerbation similar to our findings (15.9%) from exacerbation episodes.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inThere are significantly more patients in the virus positive group using the summated symptom score to define respiratory exacerbations compared to the virus negative group, possibly because the virus positive group had a higher perception and awareness of increased respiratory symptoms.", [["respiratory", "ANATOMY", 346, 357], ["respiratory", "ANATOMY", 503, 514], ["RSV", "DISEASE", 209, 212], ["respiratory exacerbations", "DISEASE", 346, 371], ["respiratory symptoms", "DISEASE", 503, 523], ["RSV", "ORGANISM", 209, 212], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 266, 274], ["RSV", "SPECIES", 209, 212], ["This study", "TEST", 0, 10], ["this virus", "PROBLEM", 39, 49], ["CF exacerbation", "PROBLEM", 53, 68], ["exacerbation episodes", "PROBLEM", 106, 127], ["RSV", "PROBLEM", 209, 212], ["our study", "TEST", 217, 226], ["the summated symptom score", "PROBLEM", 309, 335], ["respiratory exacerbations", "PROBLEM", 346, 371], ["the virus", "TEST", 384, 393], ["the virus positive group", "PROBLEM", 427, 451], ["increased respiratory symptoms", "PROBLEM", 493, 523], ["respiratory", "ANATOMY", 346, 357], ["exacerbations", "OBSERVATION", 358, 371], ["increased", "OBSERVATION_MODIFIER", 493, 502], ["respiratory symptoms", "OBSERVATION", 503, 523]]], ["This suggests that patients with more upper respiratory symptoms were more likely to have a virus isolated from nasal swabs.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inThe difference in symptomology is even more striking when the patients were divided into subgroups of influenza positives and other viral positives.", [["respiratory", "ANATOMY", 44, 55], ["nasal swabs", "ANATOMY", 112, 123], ["RSV", "DISEASE", 205, 208], ["influenza positives", "DISEASE", 335, 354], ["patients", "ORGANISM", 19, 27], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 112, 123], ["RSV", "ORGANISM", 205, 208], ["patients", "ORGANISM", 295, 303], ["influenza", "ORGANISM", 335, 344], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 295, 303], ["RSV", "SPECIES", 205, 208], ["more upper respiratory symptoms", "PROBLEM", 33, 64], ["a virus", "PROBLEM", 90, 97], ["nasal swabs", "PROBLEM", 112, 123], ["RSV", "PROBLEM", 205, 208], ["our study", "TEST", 213, 222], ["symptomology", "PROBLEM", 251, 263], ["influenza positives", "PROBLEM", 335, 354], ["other viral positives", "PROBLEM", 359, 380], ["upper", "ANATOMY_MODIFIER", 38, 43], ["respiratory", "ANATOMY", 44, 55], ["virus", "OBSERVATION", 92, 97]]], ["The influenza subgroup had significantly more upper respiratory tract symptoms during respiratory exacerbations compared to the other virus group, but there was no difference in terms of lower respiratory complaints.", [["upper respiratory tract", "ANATOMY", 46, 69], ["respiratory", "ANATOMY", 86, 97], ["respiratory", "ANATOMY", 193, 204], ["influenza", "DISEASE", 4, 13], ["respiratory tract symptoms", "DISEASE", 52, 78], ["respiratory exacerbations", "DISEASE", 86, 111], ["respiratory complaints", "DISEASE", 193, 215], ["upper", "ORGANISM_SUBDIVISION", 46, 51], ["respiratory tract", "ORGANISM_SUBDIVISION", 52, 69], ["The influenza subgroup", "PROBLEM", 0, 22], ["upper respiratory tract symptoms", "PROBLEM", 46, 78], ["respiratory exacerbations", "PROBLEM", 86, 111], ["lower respiratory complaints", "PROBLEM", 187, 215], ["upper", "ANATOMY_MODIFIER", 46, 51], ["respiratory tract", "ANATOMY", 52, 69], ["no", "UNCERTAINTY", 161, 163], ["respiratory complaints", "OBSERVATION", 193, 215]]], ["This is an important observation as this confirmed that influenza is more likely to infect the upper airways.", [["upper airways", "ANATOMY", 95, 108], ["influenza", "DISEASE", 56, 65], ["upper airways", "MULTI-TISSUE_STRUCTURE", 95, 108], ["influenza", "PROBLEM", 56, 65], ["influenza", "OBSERVATION", 56, 65], ["more likely", "UNCERTAINTY", 69, 80], ["upper", "ANATOMY_MODIFIER", 95, 100], ["airways", "ANATOMY", 101, 108]]], ["In addition, we have recently shown that influenza vaccination does offer protection against its subsequent acquisition in patients with CF [24] contradictory to a recent Cochrane review [34] .", [["influenza", "DISEASE", 41, 50], ["CF", "DISEASE", 137, 139], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["influenza vaccination", "TREATMENT", 41, 62]]], ["The recent development of intranasal vaccination may be an effective and attractive option as this will offer local protection in the upper airways, which can help arresting infection at an early phase before symptom complications arise.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inThe data available for the optimal method for respiratory viral detection is limited.", [["upper airways", "ANATOMY", 134, 147], ["infection", "DISEASE", 174, 183], ["RSV", "DISEASE", 318, 321], ["upper airways", "MULTI-TISSUE_STRUCTURE", 134, 147], ["RSV", "ORGANISM", 318, 321], ["RSV", "SPECIES", 318, 321], ["intranasal vaccination", "TREATMENT", 26, 48], ["local protection in the upper airways", "TREATMENT", 110, 147], ["arresting infection", "PROBLEM", 164, 183], ["symptom complications", "PROBLEM", 209, 230], ["RSV", "PROBLEM", 318, 321], ["our study", "TEST", 326, 335], ["respiratory viral detection", "TEST", 392, 419], ["upper", "ANATOMY_MODIFIER", 134, 139], ["airways", "ANATOMY", 140, 147]]], ["The best sites to collect material for viral detection may differ for different viruses, such as using bronchoalveolar lavage (BAL) to obtain lower airways specimens for RSV [30] and nasal swabs for upper airways sampling for rhinovirus and influenza virus [29] .", [["sites", "ANATOMY", 9, 14], ["bronchoalveolar lavage", "ANATOMY", 103, 125], ["BAL", "ANATOMY", 127, 130], ["airways specimens", "ANATOMY", 148, 165], ["nasal swabs", "ANATOMY", 183, 194], ["upper airways", "ANATOMY", 199, 212], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 103, 125], ["BAL", "MULTI-TISSUE_STRUCTURE", 127, 130], ["airways specimens", "TISSUE", 148, 165], ["RSV", "ORGANISM", 170, 173], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 183, 194], ["upper airways", "MULTI-TISSUE_STRUCTURE", 199, 212], ["rhinovirus", "ORGANISM", 226, 236], ["influenza virus", "ORGANISM", 241, 256], ["influenza virus", "SPECIES", 241, 256], ["RSV", "SPECIES", 170, 173], ["viral detection", "TEST", 39, 54], ["different viruses", "PROBLEM", 70, 87], ["bronchoalveolar lavage", "TEST", 103, 125], ["lower airways specimens", "TEST", 142, 165], ["RSV", "PROBLEM", 170, 173], ["nasal swabs", "TEST", 183, 194], ["upper airways sampling", "PROBLEM", 199, 221], ["rhinovirus", "PROBLEM", 226, 236], ["influenza virus", "PROBLEM", 241, 256], ["airways", "ANATOMY", 148, 155], ["upper", "ANATOMY_MODIFIER", 199, 204], ["airways", "ANATOMY", 205, 212]]], ["The collection of a nasal swab is simple, convenient, relatively painless, does not require any additional devices such as an electrical suction device for obtaining nasopharyngeal aspirates (NPA) or any specialised skill.", [["nasal swab", "ANATOMY", 20, 30], ["nasopharyngeal aspirates", "ANATOMY", 166, 190], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 166, 190], ["a nasal swab", "PROBLEM", 18, 30], ["any additional devices", "TREATMENT", 92, 114], ["an electrical suction device", "TREATMENT", 123, 151], ["nasopharyngeal aspirates", "TEST", 166, 190], ["collection", "OBSERVATION_MODIFIER", 4, 14], ["nasal", "ANATOMY", 20, 25], ["swab", "OBSERVATION", 26, 30], ["nasopharyngeal", "ANATOMY", 166, 180], ["aspirates", "OBSERVATION", 181, 190]]], ["Thus far there is no data comparing the sensitivities and specificities of different sampling techniques incorporating molecular detection methods for viral detection.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inIn future studies, it may be worth obtaining specimens from different respiratory sites using different sampling methods simultaneously as this may increase the diagnostic yield [35, 36] and further establish the impact of respiratory virus in CF.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inThe bacterial isolation rate in this study was low at 25% (69 positive samples from 274), compared to a study by Olesen et al. [17] who achieved a bacterial detection rate of 76%.", [["specimens", "ANATOMY", 321, 330], ["respiratory sites", "ANATOMY", 346, 363], ["RSV", "DISEASE", 248, 251], ["CF", "DISEASE", 520, 522], ["RSV", "DISEASE", 604, 607], ["RSV", "ORGANISM", 248, 251], ["respiratory virus", "ORGANISM", 499, 516], ["RSV", "ORGANISM", 604, 607], ["RSV", "SPECIES", 248, 251], ["RSV", "SPECIES", 604, 607], ["the sensitivities", "TEST", 36, 53], ["different sampling techniques", "TEST", 75, 104], ["viral detection", "TEST", 151, 166], ["RSV", "PROBLEM", 248, 251], ["our study", "TEST", 256, 265], ["different respiratory sites", "PROBLEM", 336, 363], ["different sampling methods", "TREATMENT", 370, 396], ["respiratory virus in CF", "PROBLEM", 499, 522], ["RSV", "PROBLEM", 604, 607], ["our study", "TEST", 612, 621], ["The bacterial isolation rate", "TEST", 632, 660], ["this study", "TEST", 664, 674], ["a study", "TEST", 734, 741], ["a bacterial detection rate", "TEST", 777, 803], ["no", "UNCERTAINTY", 18, 20], ["respiratory virus", "OBSERVATION", 499, 516]]], ["This may be that 30% of the samples obtained for bacterial isolation in this study were cough swabs whereas Olesen et al. used a combination of laryngeal aspirate (20%) and sputum sample (80%) for isolation, which tended to have a higher isolation rate.", [["samples", "ANATOMY", 28, 35], ["laryngeal aspirate", "ANATOMY", 144, 162], ["sputum sample", "ANATOMY", 173, 186], ["cough", "DISEASE", 88, 93], ["samples", "CANCER", 28, 35], ["laryngeal aspirate", "MULTI-TISSUE_STRUCTURE", 144, 162], ["the samples", "TEST", 24, 35], ["bacterial isolation", "TREATMENT", 49, 68], ["this study", "TEST", 72, 82], ["cough swabs", "PROBLEM", 88, 99], ["laryngeal aspirate", "TEST", 144, 162], ["sputum sample", "TEST", 173, 186], ["isolation", "PROBLEM", 197, 206], ["laryngeal", "ANATOMY", 144, 153], ["aspirate", "OBSERVATION", 154, 162]]], ["In the Brompton study [37] , cough swabs had a specificity of 100% compared to sputum samples for bacteria isolation but a sensitivity of only 34%.", [["sputum samples", "ANATOMY", 79, 93], ["the Brompton study", "TEST", 3, 21], ["cough swabs", "TEST", 29, 40], ["sputum samples", "TEST", 79, 93], ["bacteria isolation", "PROBLEM", 98, 116], ["a sensitivity", "TEST", 121, 134]]], ["Another study conducted by Maiya et al. [38] showed a similar sensitivity of 35% with cough swabs compared to sputum samples and cough plates.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inBronchoalveolar lavage or laryngeal aspirate may be superior [39, 40] , but these procedures carry higher risks, costs and require more expertise and these considerations must be taken into account before utilising these procedures for routine screening and research purposes.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inIn this study, there is no change in incidence of bacterial infection during viral infections.", [["sputum samples", "ANATOMY", 110, 124], ["inBronchoalveolar lavage", "ANATOMY", 249, 273], ["laryngeal aspirate", "ANATOMY", 277, 295], ["cough", "DISEASE", 86, 91], ["cough", "DISEASE", 129, 134], ["RSV", "DISEASE", 223, 226], ["RSV", "DISEASE", 608, 611], ["bacterial infection", "DISEASE", 686, 705], ["viral infections", "DISEASE", 713, 729], ["RSV", "ORGANISM", 223, 226], ["inBronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 249, 273], ["laryngeal aspirate", "MULTI-TISSUE_STRUCTURE", 277, 295], ["RSV", "ORGANISM", 608, 611], ["RSV", "SPECIES", 223, 226], ["RSV", "SPECIES", 608, 611], ["Another study", "TEST", 0, 13], ["cough swabs", "TEST", 86, 97], ["sputum samples", "TEST", 110, 124], ["cough plates", "PROBLEM", 129, 141], ["RSV", "PROBLEM", 223, 226], ["our study", "TEST", 231, 240], ["inBronchoalveolar lavage", "TREATMENT", 249, 273], ["laryngeal aspirate", "PROBLEM", 277, 295], ["these procedures", "TEST", 466, 482], ["routine screening", "TEST", 487, 504], ["research purposes", "TEST", 509, 526], ["RSV", "PROBLEM", 608, 611], ["our study", "TEST", 616, 625], ["this study", "TEST", 639, 649], ["bacterial infection", "PROBLEM", 686, 705], ["viral infections", "PROBLEM", 713, 729], ["laryngeal", "ANATOMY", 277, 286], ["no", "UNCERTAINTY", 660, 662], ["change", "OBSERVATION_MODIFIER", 663, 669], ["bacterial", "OBSERVATION_MODIFIER", 686, 695], ["infection", "OBSERVATION", 696, 705], ["viral infections", "OBSERVATION", 713, 729]]], ["Symptomatic viral infections did not increase the likelihood of bacterial infection.", [["viral infections", "DISEASE", 12, 28], ["bacterial infection", "DISEASE", 64, 83], ["Symptomatic viral infections", "PROBLEM", 0, 28], ["bacterial infection", "PROBLEM", 64, 83], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infections", "OBSERVATION", 18, 28], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["infection", "OBSERVATION", 74, 83]]], ["Therefore, the criteria used in this study to define a respiratory exacerbation are poor predictors of bacterial infection.", [["respiratory", "ANATOMY", 55, 66], ["bacterial infection", "DISEASE", 103, 122], ["this study", "TEST", 32, 42], ["a respiratory exacerbation", "PROBLEM", 53, 79], ["bacterial infection", "PROBLEM", 103, 122], ["respiratory", "ANATOMY", 55, 66], ["exacerbation", "OBSERVATION", 67, 79], ["bacterial", "OBSERVATION_MODIFIER", 103, 112], ["infection", "OBSERVATION", 113, 122]]], ["The introduction of additional antibiotics in these situations may be difficult to decide.", [["additional antibiotics", "TREATMENT", 20, 42]]], ["In addition, Ramsey et al. [6] have shown that CF patients colonised with S. aureus did not have an increased risk of viral infection and those colonised with P. aeruginosa were protected from viral infections.", [["viral infection", "DISEASE", 118, 133], ["viral infections", "DISEASE", 193, 209], ["patients", "ORGANISM", 50, 58], ["S. aureus", "ORGANISM", 74, 83], ["P. aeruginosa", "ORGANISM", 159, 172], ["patients", "SPECIES", 50, 58], ["S. aureus", "SPECIES", 74, 83], ["P. aeruginosa", "SPECIES", 159, 172], ["S. aureus", "SPECIES", 74, 83], ["P. aeruginosa", "SPECIES", 159, 172], ["CF", "PROBLEM", 47, 49], ["S. aureus", "PROBLEM", 74, 83], ["viral infection", "PROBLEM", 118, 133], ["P. aeruginosa", "PROBLEM", 159, 172], ["viral infections", "PROBLEM", 193, 209], ["aureus", "OBSERVATION", 77, 83], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["viral", "OBSERVATION_MODIFIER", 118, 123], ["infection", "OBSERVATION", 124, 133], ["viral infections", "OBSERVATION", 193, 209]]], ["Hence, the high proportion of S. aureus and P. aeruginosa found in this study may part explain the lack of association between viruses and bacteria.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inNASBA used in this study for viral identification offers several advantages.", [["RSV", "DISEASE", 229, 232], ["S. aureus", "ORGANISM", 30, 39], ["P. aeruginosa", "ORGANISM", 44, 57], ["RSV", "ORGANISM", 229, 232], ["S. aureus", "SPECIES", 30, 39], ["P. aeruginosa", "SPECIES", 44, 57], ["S. aureus", "SPECIES", 30, 39], ["P. aeruginosa", "SPECIES", 44, 57], ["RSV", "SPECIES", 229, 232], ["S. aureus", "PROBLEM", 30, 39], ["P. aeruginosa", "PROBLEM", 44, 57], ["this study", "TEST", 67, 77], ["viruses", "PROBLEM", 127, 134], ["bacteria", "PROBLEM", 139, 147], ["RSV", "PROBLEM", 229, 232], ["our study", "TEST", 237, 246], ["this study", "TEST", 271, 281], ["viral identification", "TEST", 286, 306], ["aureus", "OBSERVATION", 33, 39]]], ["Firstly, it is developed specifically for RNA target amplification and is particularly suited for the detection of RNA viruses because there is no need for a separate reverse transcription step, unlike PCR.", [["RNA target amplification", "PROBLEM", 42, 66], ["RNA viruses", "PROBLEM", 115, 126], ["PCR", "TEST", 202, 205], ["no", "UNCERTAINTY", 144, 146]]], ["Secondly, the selection criteria for NASBA primers are less stringent, allowing easier primer design in selected less-conserved regions of the gene [41] .", [["NASBA primers", "DNA", 37, 50], ["the selection criteria", "TEST", 10, 32], ["NASBA primers", "TREATMENT", 37, 50]]], ["Thirdly, it is a continuous isothermic process that does not require a thermocycler [42, 43] .", [["a continuous isothermic process", "PROBLEM", 15, 46]]], ["Hence a constant temperature throughout the amplification reaction allows NASBA to amplify the targeted RNA or DNA exponentially at each step of the reaction.", [["DNA", "CELLULAR_COMPONENT", 111, 114], ["targeted RNA", "RNA", 95, 107], ["a constant temperature", "PROBLEM", 6, 28], ["the amplification reaction", "PROBLEM", 40, 66], ["NASBA", "TREATMENT", 74, 79], ["the reaction", "PROBLEM", 145, 157]]], ["The NASBA reaction is also more efficient than PCR methods that are restricted to binary increases per cycle.", [["The NASBA reaction", "PROBLEM", 0, 18], ["PCR methods", "TEST", 47, 58], ["NASBA reaction", "OBSERVATION", 4, 18], ["more efficient", "OBSERVATION_MODIFIER", 27, 41]]], ["Fourthly, background DNA does not interfere with the NASBA reaction, as single-stranded RNA sequences are specifically targeted, unlike PCR where background DNA may cause false positive results [44] .", [["DNA", "CELLULAR_COMPONENT", 21, 24], ["DNA", "CELLULAR_COMPONENT", 157, 160], ["single-stranded RNA sequences", "DNA", 72, 101], ["background DNA", "PROBLEM", 10, 24], ["the NASBA reaction", "PROBLEM", 49, 67], ["single-stranded RNA sequences", "TEST", 72, 101], ["PCR", "TEST", 136, 139], ["false positive results", "PROBLEM", 171, 193]]], ["The closed-tube format of NASBA assay greatly reduces the risk of contamination and thus of false positive results.", [["tube", "TISSUE", 11, 15], ["The closed-tube", "TREATMENT", 0, 15], ["NASBA assay", "TEST", 26, 37], ["contamination", "PROBLEM", 66, 79], ["false positive results", "PROBLEM", 92, 114], ["closed", "OBSERVATION_MODIFIER", 4, 10], ["tube", "OBSERVATION", 11, 15], ["contamination", "OBSERVATION", 66, 79]]], ["Finally, the detection of PCR products requires gel electrophoresis, which necessitates the transfer of resolved nucleic acid to an agarose gel.", [["nucleic acid", "CHEMICAL", 113, 125], ["nucleic acid", "SIMPLE_CHEMICAL", 113, 125], ["agarose", "SIMPLE_CHEMICAL", 132, 139], ["PCR products", "TREATMENT", 26, 38], ["gel electrophoresis", "TREATMENT", 48, 67], ["nucleic acid", "TREATMENT", 113, 125], ["an agarose gel", "TREATMENT", 129, 143]]], ["This is very labour intensive and time-consuming and is not as well suited for diagnostic use compares to 'real-time' NASBA.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inWe did not study the differences in hospitalisation rates between the viral and non-viral group as patients could have been admitted to hospital for non-respiratory reasons as this was not deemed as a robust end-point.", [["RSV", "DISEASE", 205, 208], ["RSV", "ORGANISM", 205, 208], ["patients", "ORGANISM", 332, 340], ["patients", "SPECIES", 332, 340], ["RSV", "SPECIES", 205, 208], ["RSV", "PROBLEM", 205, 208], ["our study", "TEST", 213, 222], ["very", "OBSERVATION_MODIFIER", 8, 12], ["labour", "OBSERVATION", 13, 19]]], ["Similarly, we did not study the use of intravenous antibiotics between the viral and nonviral groups as one of the end-points of the study because it was felt that antibiotics were sometimes administered for reasons other than for pulmonary exacerbations, such as before holidays or school examinations in order to improve lung functions and respiratory reserve.The 2002/03 season [31] between October 2002 and May 2003, was a high season for RSV but our study started inWe did not have the assay identifying human metapneumovirus (hMPV), a virus that has recently been reported and it is closely related taxonomically to RSV [45] .", [["intravenous", "ANATOMY", 39, 50], ["pulmonary", "ANATOMY", 231, 240], ["lung", "ANATOMY", 323, 327], ["respiratory", "ANATOMY", 342, 353], ["pulmonary exacerbations", "DISEASE", 231, 254], ["RSV", "DISEASE", 443, 446], ["human metapneumovirus (hMPV)", "DISEASE", 509, 537], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 50], ["pulmonary", "ORGAN", 231, 240], ["lung", "ORGAN", 323, 327], ["RSV", "ORGANISM", 443, 446], ["human", "ORGANISM", 509, 514], ["metapneumovirus", "ORGANISM", 515, 530], ["hMPV", "ORGANISM", 532, 536], ["RSV", "ORGANISM", 622, 625], ["human", "SPECIES", 509, 514], ["metapneumovirus", "SPECIES", 515, 530], ["RSV", "SPECIES", 443, 446], ["human metapneumovirus", "SPECIES", 509, 530], ["hMPV", "SPECIES", 532, 536], ["RSV", "SPECIES", 622, 625], ["intravenous antibiotics", "TREATMENT", 39, 62], ["the viral and nonviral groups", "TREATMENT", 71, 100], ["the study", "TEST", 129, 138], ["antibiotics", "TREATMENT", 164, 175], ["pulmonary exacerbations", "PROBLEM", 231, 254], ["school examinations", "TEST", 283, 302], ["RSV", "PROBLEM", 443, 446], ["our study", "TEST", 451, 460], ["the assay", "TEST", 487, 496], ["human metapneumovirus", "PROBLEM", 509, 530], ["hMPV", "PROBLEM", 532, 536], ["a virus", "PROBLEM", 539, 546], ["pulmonary", "ANATOMY", 231, 240], ["exacerbations", "OBSERVATION", 241, 254], ["lung", "ANATOMY", 323, 327], ["respiratory reserve", "OBSERVATION", 342, 361], ["metapneumovirus", "OBSERVATION", 515, 530]]], ["This virus possibly accounts for about 10% of unexplained respiratory infections in children during the winter season.", [["respiratory", "ANATOMY", 58, 69], ["respiratory infections", "DISEASE", 58, 80], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["This virus", "PROBLEM", 0, 10], ["unexplained respiratory infections", "PROBLEM", 46, 80], ["respiratory", "ANATOMY", 58, 69], ["infections", "OBSERVATION", 70, 80]]], ["Garcia et al [46] has recently shown that this virus behaves similarly to RSV in CF in that it leads to an increased risk of hospitalisation and exacerbation.ConclusionsOur results provide evidence to support respiratory viruses are commonly found during respiratory exacerbations of CF, particularly influenza A, influenza B and rhinovirus.", [["respiratory", "ANATOMY", 255, 266], ["RSV", "DISEASE", 74, 77], ["CF", "DISEASE", 81, 83], ["respiratory viruses", "DISEASE", 209, 228], ["respiratory exacerbations", "DISEASE", 255, 280], ["CF", "DISEASE", 284, 286], ["influenza A", "DISEASE", 301, 312], ["influenza B", "DISEASE", 314, 325], ["RSV", "ORGANISM", 74, 77], ["influenza A", "ORGANISM", 301, 312], ["influenza B", "ORGANISM", 314, 325], ["rhinovirus", "ORGANISM", 330, 340], ["influenza B and rhinovirus", "SPECIES", 314, 340], ["RSV", "SPECIES", 74, 77], ["influenza A", "SPECIES", 301, 312], ["this virus", "PROBLEM", 42, 52], ["exacerbation", "PROBLEM", 145, 157], ["respiratory viruses", "PROBLEM", 209, 228], ["respiratory exacerbations of CF", "PROBLEM", 255, 286], ["influenza", "PROBLEM", 301, 310], ["influenza B", "PROBLEM", 314, 325], ["rhinovirus", "PROBLEM", 330, 340], ["RSV", "OBSERVATION", 74, 77], ["increased", "OBSERVATION_MODIFIER", 107, 116], ["hospitalisation", "OBSERVATION", 125, 140], ["respiratory viruses", "OBSERVATION", 209, 228]]], ["PIV 4 has been detected for the first time in the CF population but its exact role will need to be further defined.", [["PIV", "TREATMENT", 0, 3]]], ["However, there is little evidence to suggest that viral infections predispose to bacterial infections, contrary to previous reports.ConclusionsAs the role of respiratory viruses in CF becomes a more prominent entity , 'real-time' NASBA in viral detection may play a pivotal role in the future management of CF because of its rapid turn-around of results.", [["viral infections", "DISEASE", 50, 66], ["bacterial infections", "DISEASE", 81, 101], ["respiratory viruses", "DISEASE", 158, 177], ["CF", "DISEASE", 181, 183], ["CF", "DISEASE", 307, 309], ["viral infections", "PROBLEM", 50, 66], ["bacterial infections", "PROBLEM", 81, 101], ["respiratory viruses in CF", "PROBLEM", 158, 183], ["CF", "PROBLEM", 307, 309], ["little evidence to suggest", "UNCERTAINTY", 18, 44], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infections", "OBSERVATION", 56, 66], ["bacterial", "OBSERVATION_MODIFIER", 81, 90], ["infections", "OBSERVATION", 91, 101], ["respiratory viruses", "OBSERVATION", 158, 177], ["more prominent", "OBSERVATION_MODIFIER", 194, 208]]], ["It may provide guidance to clinicians regarding anti-viral administration, thus avoiding the inappropriate use of antibiotics and further support the importance of patient segregation.", [["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["anti-viral administration", "TREATMENT", 48, 73], ["antibiotics", "TREATMENT", 114, 125], ["patient segregation", "PROBLEM", 164, 183]]], ["At the moment, NASBA largely remains as a research tool and for now, clinicians will have to use a matter of judgement and clinical accruement to diagnose viral infection as many currently available diagnostic tools still take days or weeks to provide definitive results.", [["viral infection", "DISEASE", 155, 170], ["NASBA", "TEST", 15, 20], ["viral infection", "PROBLEM", 155, 170], ["diagnostic tools", "TEST", 199, 215]]], ["Hopefully, one day NASBA may become widely available to allow respiratory viral testing to become part of the routine investigation during pulmonary exacerbations of CF.", [["pulmonary", "ANATOMY", 139, 148], ["pulmonary exacerbations", "DISEASE", 139, 162], ["CF", "DISEASE", 166, 168], ["pulmonary", "ORGAN", 139, 148], ["respiratory viral testing", "TEST", 62, 87], ["the routine investigation", "TEST", 106, 131], ["pulmonary exacerbations of CF", "PROBLEM", 139, 168], ["pulmonary", "ANATOMY", 139, 148], ["exacerbations", "OBSERVATION", 149, 162]]], ["In addition, NASBA may also become a very important screening tool for exacerbations in other respiratory illnesses such as chronic obstructive pulmonary disease, asthma and bronchiectasis.", [["respiratory", "ANATOMY", 94, 105], ["pulmonary", "ANATOMY", 144, 153], ["respiratory illnesses", "DISEASE", 94, 115], ["chronic obstructive pulmonary disease", "DISEASE", 124, 161], ["asthma", "DISEASE", 163, 169], ["bronchiectasis", "DISEASE", 174, 188], ["pulmonary", "ORGAN", 144, 153], ["exacerbations", "PROBLEM", 71, 84], ["other respiratory illnesses", "PROBLEM", 88, 115], ["chronic obstructive pulmonary disease", "PROBLEM", 124, 161], ["asthma", "PROBLEM", 163, 169], ["bronchiectasis", "PROBLEM", 174, 188], ["respiratory illnesses", "OBSERVATION", 94, 115], ["chronic", "OBSERVATION_MODIFIER", 124, 131], ["obstructive", "OBSERVATION_MODIFIER", 132, 143], ["pulmonary", "ANATOMY", 144, 153], ["disease", "OBSERVATION", 154, 161], ["asthma", "OBSERVATION", 163, 169], ["bronchiectasis", "OBSERVATION", 174, 188]]]], "9608b3f8e4091417bf35bd49c1522515641a2ed9": [["IntroductionDespite recent therapeutic progress, HCV remains a worldwide health issue with 300,000 deaths per year.", [["HCV", "DISEASE", 49, 52], ["deaths", "DISEASE", 99, 105], ["HCV", "ORGANISM", 49, 52], ["HCV", "SPECIES", 49, 52], ["therapeutic", "OBSERVATION_MODIFIER", 27, 38]]], ["HCV-infected patients develop cirrhosis (27%) and HCC (25%) [1] [2] [3] .", [["HCV-infected", "DISEASE", 0, 12], ["cirrhosis", "DISEASE", 30, 39], ["HCC", "DISEASE", 50, 53], ["HCV", "ORGANISM", 0, 3], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["HCV", "SPECIES", 0, 3], ["HCV", "PROBLEM", 0, 3], ["cirrhosis", "PROBLEM", 30, 39], ["HCC", "TEST", 50, 53], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["cirrhosis", "OBSERVATION", 30, 39]]], ["Earlier than 2011, the standard treatment for HCV infection was the combination of pegylated interferon alpha (pIFNa) and ribavirin (RBV) for 24 or 48 weeks contingent on the HCV genotype [4] , resulting in a sustained virologic response (SVR) rate of 40-50%, but associated with major side effects [5] [6] [7] .", [["HCV infection", "DISEASE", 46, 59], ["pegylated interferon alpha", "CHEMICAL", 83, 109], ["ribavirin", "CHEMICAL", 122, 131], ["RBV", "CHEMICAL", 133, 136], ["ribavirin", "CHEMICAL", 122, 131], ["RBV", "CHEMICAL", 133, 136], ["HCV", "ORGANISM", 46, 49], ["pegylated interferon alpha", "GENE_OR_GENE_PRODUCT", 83, 109], ["pIFNa", "SIMPLE_CHEMICAL", 111, 116], ["ribavirin", "SIMPLE_CHEMICAL", 122, 131], ["RBV", "SIMPLE_CHEMICAL", 133, 136], ["pegylated interferon alpha", "PROTEIN", 83, 109], ["pIFNa", "PROTEIN", 111, 116], ["HCV", "SPECIES", 46, 49], ["HCV", "SPECIES", 175, 178], ["the standard treatment", "TREATMENT", 19, 41], ["HCV infection", "PROBLEM", 46, 59], ["pegylated interferon alpha (pIFNa)", "TREATMENT", 83, 117], ["ribavirin (RBV)", "TREATMENT", 122, 137], ["a sustained virologic response", "PROBLEM", 207, 237], ["SVR", "TEST", 239, 242], ["rate", "TEST", 244, 248], ["infection", "OBSERVATION", 50, 59]]], ["The first two direct-acting antivirals (DAAs)-the protease inhibitors telaprevir and boceprevir-enhanced viral clearance rate by 70% compared to the pIFNa and RBV treatment, but still induced significant side effects [8] [9] .", [["DAAs", "CHEMICAL", 40, 44], ["telaprevir", "CHEMICAL", 70, 80], ["boceprevir", "CHEMICAL", 85, 95], ["RBV", "CHEMICAL", 159, 162], ["telaprevir", "CHEMICAL", 70, 80], ["boceprevir", "CHEMICAL", 85, 95], ["RBV", "CHEMICAL", 159, 162], ["direct-acting antivirals", "SIMPLE_CHEMICAL", 14, 38], ["DAAs", "SIMPLE_CHEMICAL", 40, 44], ["telaprevir", "SIMPLE_CHEMICAL", 70, 80], ["boceprevir", "SIMPLE_CHEMICAL", 85, 95], ["RBV", "SIMPLE_CHEMICAL", 159, 162], ["direct-acting antivirals (DAAs", "TREATMENT", 14, 44], ["the protease inhibitors", "TREATMENT", 46, 69], ["telaprevir", "TREATMENT", 70, 80], ["boceprevir", "TREATMENT", 85, 95], ["enhanced viral clearance rate", "TREATMENT", 96, 125], ["the pIFNa", "TREATMENT", 145, 154], ["RBV treatment", "TREATMENT", 159, 172], ["significant side effects", "PROBLEM", 192, 216]]], ["Then, new FDA-approved DAAs were developed, including the protease inhibitors glecaprevir, grazoprevir and simeprevir, the NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitors daclatasvir and elbasvir [10] .", [["glecaprevir", "CHEMICAL", 78, 89], ["grazoprevir", "CHEMICAL", 91, 102], ["simeprevir", "CHEMICAL", 107, 117], ["sofosbuvir", "CHEMICAL", 149, 159], ["daclatasvir", "CHEMICAL", 184, 195], ["elbasvir", "CHEMICAL", 200, 208], ["glecaprevir", "CHEMICAL", 78, 89], ["grazoprevir", "CHEMICAL", 91, 102], ["simeprevir", "CHEMICAL", 107, 117], ["sofosbuvir", "CHEMICAL", 149, 159], ["daclatasvir", "CHEMICAL", 184, 195], ["elbasvir", "CHEMICAL", 200, 208], ["DAAs", "SIMPLE_CHEMICAL", 23, 27], ["glecaprevir", "SIMPLE_CHEMICAL", 78, 89], ["grazoprevir", "SIMPLE_CHEMICAL", 91, 102], ["simeprevir", "SIMPLE_CHEMICAL", 107, 117], ["sofosbuvir", "SIMPLE_CHEMICAL", 149, 159], ["daclatasvir", "SIMPLE_CHEMICAL", 184, 195], ["elbasvir", "SIMPLE_CHEMICAL", 200, 208], ["NS5B polymerase", "PROTEIN", 123, 138], ["DAAs", "TREATMENT", 23, 27], ["the protease inhibitors glecaprevir", "TREATMENT", 54, 89], ["grazoprevir", "TREATMENT", 91, 102], ["simeprevir", "TREATMENT", 107, 117], ["the NS5B polymerase inhibitor", "TREATMENT", 119, 148], ["sofosbuvir", "TREATMENT", 149, 159], ["the NS5A inhibitors daclatasvir", "TREATMENT", 164, 195], ["elbasvir", "TREATMENT", 200, 208]]], ["DAA resistance, which is associated with the selection of resistance-associated substitutions (RASs) present at baseline or are acquired during treatment [11] , remains a main issue for the treatment of HCV patients [11] .", [["DAA", "CHEMICAL", 0, 3], ["HCV", "DISEASE", 203, 206], ["HCV", "ORGANISM", 203, 206], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["HCV", "SPECIES", 203, 206], ["DAA resistance", "PROBLEM", 0, 14], ["associated substitutions (RASs)", "PROBLEM", 69, 100], ["HCV patients", "TREATMENT", 203, 215]]], ["Given the high number of patients who will need retreatment, an option to circumvent DAA resistance is to include into DAA regimens drugs with high barrier to resistance and with distinct antiviral mechanisms of action.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["retreatment", "TREATMENT", 48, 59], ["circumvent DAA resistance", "TREATMENT", 74, 99], ["DAA regimens drugs", "TREATMENT", 119, 137], ["high barrier to resistance", "TREATMENT", 143, 169], ["distinct antiviral mechanisms", "TREATMENT", 179, 208]]], ["Such a class of candidates are the cyclophilin inhibitors (CypIs).", [["cyclophilin", "GENE_OR_GENE_PRODUCT", 35, 46], ["CypIs", "SIMPLE_CHEMICAL", 59, 64], ["the cyclophilin inhibitors", "TREATMENT", 31, 57]]], ["We and others showed that CypIs inhibit the replication of diverse viruses including HIV-1, HCV, HBV, arteriviruses and coronaviruses [12] [13] [14] [15] .", [["CypIs", "CHEMICAL", 26, 31], ["CypIs", "GENE_OR_GENE_PRODUCT", 26, 31], ["HIV-1", "ORGANISM", 85, 90], ["HCV", "ORGANISM", 92, 95], ["HBV", "ORGANISM", 97, 100], ["arteriviruses", "CANCER", 102, 115], ["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 134, 153], ["CypIs", "PROTEIN", 26, 31], ["HIV-1", "SPECIES", 85, 90], ["HIV-1", "SPECIES", 85, 90], ["HCV", "SPECIES", 92, 95], ["HBV", "SPECIES", 97, 100], ["CypIs", "PROBLEM", 26, 31], ["diverse viruses", "PROBLEM", 59, 74], ["HIV", "TEST", 85, 88], ["HCV", "PROBLEM", 92, 95], ["HBV", "PROBLEM", 97, 100], ["coronaviruses", "PROBLEM", 120, 133], ["diverse viruses", "OBSERVATION", 59, 74]]], ["Their most striking inhibitory effect was demonstrated for HCV [16] [17] [18] [19] [20] [21] [22] .", [["[16] [17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 63, 97], ["HCV", "SPECIES", 59, 62], ["HCV", "PROBLEM", 59, 62]]], ["Specifically, the CypI alisporivir/Debio-025 exhibited high antiviral potency in vitro as well as in HCV-infected patients in phase I, II, and III studies [16] [17] [18] [19] [20] [21] [22] .", [["CypI", "CHEMICAL", 18, 22], ["Debio-025", "CHEMICAL", 35, 44], ["HCV-infected", "DISEASE", 101, 113], ["alisporivir", "CHEMICAL", 23, 34], ["Debio-025", "CHEMICAL", 35, 44], ["CypI alisporivir", "SIMPLE_CHEMICAL", 18, 34], ["Debio-025", "SIMPLE_CHEMICAL", 35, 44], ["HCV", "ORGANISM", 101, 104], ["patients", "ORGANISM", 114, 122], ["[16] [17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 155, 189], ["patients", "SPECIES", 114, 122], ["HCV", "SPECIES", 101, 104], ["Debio", "TEST", 35, 40], ["HCV", "PROBLEM", 101, 104], ["II, and III studies", "TEST", 135, 154], ["antiviral potency", "OBSERVATION", 60, 77]]], ["There are two structurally distinct main classes of CypIs, which are derived from two natural products-cyclosporin A and sanglifehrin A: i) the non-immunosuppressive cyclosporine A (CsA) analogs such as CRV431 (previously named CPI-431-32) [13] ; and ii) the non-immunosuppressive sangliferin analogs such as NV556 (previously named BC556/NVP018) [23] .", [["cyclosporin A", "CHEMICAL", 103, 116], ["sanglifehrin A", "CHEMICAL", 121, 135], ["cyclosporine A", "CHEMICAL", 166, 180], ["CsA", "CHEMICAL", 182, 185], ["CRV431", "CHEMICAL", 203, 209], ["sangliferin", "CHEMICAL", 281, 292], ["NV556", "CHEMICAL", 309, 314], ["CypIs", "CHEMICAL", 52, 57], ["cyclosporin A", "CHEMICAL", 103, 116], ["sanglifehrin A", "CHEMICAL", 121, 135], ["cyclosporine A", "CHEMICAL", 166, 180], ["CsA", "CHEMICAL", 182, 185], ["CRV431", "CHEMICAL", 203, 209], ["CPI-431-32", "CHEMICAL", 228, 238], ["sangliferin", "CHEMICAL", 281, 292], ["NV556", "CHEMICAL", 309, 314], ["CypIs", "SIMPLE_CHEMICAL", 52, 57], ["cyclosporin A", "SIMPLE_CHEMICAL", 103, 116], ["sanglifehrin A", "SIMPLE_CHEMICAL", 121, 135], ["cyclosporine A", "SIMPLE_CHEMICAL", 166, 180], ["CsA", "SIMPLE_CHEMICAL", 182, 185], ["CRV431", "SIMPLE_CHEMICAL", 203, 209], ["sangliferin", "SIMPLE_CHEMICAL", 281, 292], ["NV556", "SIMPLE_CHEMICAL", 309, 314], ["CypIs", "PROTEIN", 52, 57], ["cyclosporin", "TREATMENT", 103, 114], ["the non-immunosuppressive cyclosporine A (CsA) analogs", "TREATMENT", 140, 194], ["the non-immunosuppressive sangliferin analogs", "TREATMENT", 255, 300], ["structurally", "OBSERVATION_MODIFIER", 14, 26], ["distinct", "OBSERVATION_MODIFIER", 27, 35], ["main", "OBSERVATION_MODIFIER", 36, 40], ["classes", "OBSERVATION_MODIFIER", 41, 48], ["CypIs", "OBSERVATION", 52, 57]]], ["Both classes of CypIs neutralize the peptidylprolyl cis-trans isomerase (\"foldase\") activity of members of the cyclophilin family by binding to their enzymatic hydrophobic pockets [13, 23] .", [["CypIs", "CHEMICAL", 16, 21], ["peptidylprolyl", "CHEMICAL", 37, 51], ["CypIs", "CHEMICAL", 16, 21], ["peptidylprolyl", "CHEMICAL", 37, 51], ["CypIs", "SIMPLE_CHEMICAL", 16, 21], ["peptidylprolyl cis-trans isomerase", "GENE_OR_GENE_PRODUCT", 37, 71], ["cyclophilin", "GENE_OR_GENE_PRODUCT", 111, 122], ["CypIs", "PROTEIN", 16, 21], ["peptidylprolyl cis-trans isomerase", "PROTEIN", 37, 71], ["foldase", "PROTEIN", 74, 81], ["cyclophilin family", "PROTEIN", 111, 129], ["CypIs", "TREATMENT", 16, 21], ["the cyclophilin family", "TREATMENT", 107, 129]]], ["Both classes of CypIs show efficacy against HIV-1 and HCV [13, 23] because they block the formation of complexes between cyclophilins-especially the abundant cytosolic cyclophilin A (CypA)-and the respective viral ligands, HIV-1 capsid [24] [25] [26] and HCV NS5A [27] [28] [29] [30] .", [["cytosolic", "ANATOMY", 158, 167], ["CypIs", "CHEMICAL", 16, 21], ["HIV-1 capsid [24] [25] [26", "CHEMICAL", 223, 249], ["CypIs", "SIMPLE_CHEMICAL", 16, 21], ["HIV-1", "ORGANISM", 44, 49], ["HCV", "ORGANISM", 54, 57], ["cyclophilins", "SIMPLE_CHEMICAL", 121, 133], ["cyclophilin A", "GENE_OR_GENE_PRODUCT", 168, 181], ["CypA", "GENE_OR_GENE_PRODUCT", 183, 187], ["HIV-1", "ORGANISM", 223, 228], ["[24] [25] [26]", "SIMPLE_CHEMICAL", 236, 250], ["HCV", "ORGANISM", 255, 258], ["NS5A [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 259, 283], ["CypIs", "PROTEIN", 16, 21], ["cyclophilins", "PROTEIN", 121, 133], ["cytosolic cyclophilin A", "PROTEIN", 158, 181], ["CypA", "PROTEIN", 183, 187], ["viral ligands", "PROTEIN", 208, 221], ["HIV-1", "SPECIES", 44, 49], ["HIV-1", "SPECIES", 223, 228], ["HIV-1", "SPECIES", 44, 49], ["HCV", "SPECIES", 54, 57], ["HIV-1", "SPECIES", 223, 228], ["CypIs", "TEST", 16, 21], ["HIV", "TEST", 44, 47], ["HCV", "PROBLEM", 54, 57], ["cyclophilins", "TREATMENT", 121, 133], ["the respective viral ligands", "PROBLEM", 193, 221], ["HIV", "TEST", 223, 226], ["HCV NS5A", "TEST", 255, 263], ["cytosolic cyclophilin", "OBSERVATION", 158, 179], ["viral ligands", "OBSERVATION", 208, 221]]], ["It has been postulated that the inhibitors disrupt the proper folding of HIV-1 capsid and HCV NS5A and in turn the optimal progression of the viruses through their life cycles and productive infection of CD4+ cells and hepatocytes, respectively.IntroductionAlthough we previously showed and reported that the non-immunosuppressive cyclosporin A and sanglifehrin A or B analogs derived from distinct natural products with highly dissimilar structures-CRV431 and NV556 -block HCV replication in vitro [13, 23] , we asked in the present study whether they could also suppress HCV infection in vivo in humanized-liver chimeric mice.DrugsCRV431 was synthesized in-house by chemical modification of cyclosporin A while NV556 was manufactured by a three-step semi-synthesis from a fermentation product.", [["CD4+ cells", "ANATOMY", 204, 214], ["hepatocytes", "ANATOMY", 219, 230], ["liver", "ANATOMY", 608, 613], ["infection", "DISEASE", 191, 200], ["cyclosporin A", "CHEMICAL", 331, 344], ["sanglifehrin A", "CHEMICAL", 349, 363], ["HCV infection", "DISEASE", 573, 586], ["DrugsCRV431", "CHEMICAL", 628, 639], ["cyclosporin A", "CHEMICAL", 693, 706], ["NV556", "CHEMICAL", 713, 718], ["cyclosporin A", "CHEMICAL", 331, 344], ["sanglifehrin A or B", "CHEMICAL", 349, 368], ["CRV431", "CHEMICAL", 450, 456], ["DrugsCRV431", "CHEMICAL", 628, 639], ["cyclosporin A", "CHEMICAL", 693, 706], ["NV556", "CHEMICAL", 713, 718], ["HIV-1 capsid", "ORGANISM", 73, 85], ["HCV NS5A", "ORGANISM", 90, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 204, 207], ["hepatocytes", "CELL", 219, 230], ["cyclosporin A", "SIMPLE_CHEMICAL", 331, 344], ["sanglifehrin A", "SIMPLE_CHEMICAL", 349, 363], ["B analogs", "SIMPLE_CHEMICAL", 367, 376], ["CRV431", "SIMPLE_CHEMICAL", 450, 456], ["NV556", "SIMPLE_CHEMICAL", 461, 466], ["HCV", "ORGANISM", 474, 477], ["HCV", "ORGANISM", 573, 576], ["liver", "ORGAN", 608, 613], ["mice", "ORGANISM", 623, 627], ["DrugsCRV431", "SIMPLE_CHEMICAL", 628, 639], ["cyclosporin A", "SIMPLE_CHEMICAL", 693, 706], ["NV556", "SIMPLE_CHEMICAL", 713, 718], ["HIV-1 capsid", "PROTEIN", 73, 85], ["HCV NS5A", "PROTEIN", 90, 98], ["CD4+ cells", "CELL_TYPE", 204, 214], ["hepatocytes", "CELL_TYPE", 219, 230], ["HIV-1", "SPECIES", 73, 78], ["mice", "SPECIES", 623, 627], ["HIV-1", "SPECIES", 73, 78], ["HCV", "SPECIES", 90, 93], ["HCV", "SPECIES", 474, 477], ["HCV", "SPECIES", 573, 576], ["mice", "SPECIES", 623, 627], ["the inhibitors", "TREATMENT", 28, 42], ["HIV-1 capsid", "TREATMENT", 73, 85], ["HCV NS5A", "TREATMENT", 90, 98], ["the viruses", "PROBLEM", 138, 149], ["their life cycles", "TREATMENT", 158, 175], ["productive infection of CD4+ cells", "PROBLEM", 180, 214], ["the non-immunosuppressive cyclosporin", "TREATMENT", 305, 342], ["sanglifehrin A", "TREATMENT", 349, 363], ["B analogs", "TREATMENT", 367, 376], ["NV556 -block HCV replication", "TREATMENT", 461, 489], ["HCV infection", "PROBLEM", 573, 586], ["cyclosporin A", "TREATMENT", 693, 706], ["a fermentation product", "TREATMENT", 772, 794], ["viruses", "OBSERVATION", 142, 149], ["productive", "OBSERVATION_MODIFIER", 180, 190], ["infection", "OBSERVATION", 191, 200], ["hepatocytes", "ANATOMY", 219, 230], ["infection", "OBSERVATION", 577, 586], ["liver", "ANATOMY", 608, 613]]], ["Their purity exceeded 95% as determined by HPLC.", [["Their purity", "TEST", 0, 12]]], ["Sofosbuvir was purchased from MedChemExpress.Animal careAnimal housing: individually ventilated cage (IVC) racks are used to house the majority of mice.", [["Sofosbuvir", "CHEMICAL", 0, 10], ["Sofosbuvir", "CHEMICAL", 0, 10], ["Sofosbuvir", "SIMPLE_CHEMICAL", 0, 10], ["IVC", "MULTI-TISSUE_STRUCTURE", 102, 105], ["mice", "ORGANISM", 147, 151], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["Sofosbuvir", "TREATMENT", 0, 10], ["MedChemExpress", "TREATMENT", 30, 44], ["individually ventilated cage (IVC) racks", "TREATMENT", 72, 112], ["IVC", "ANATOMY", 102, 105]]], ["HEPA-filtered air is supplied into each cage at a rate of 60 air changes per hour.", [["HEPA", "TREATMENT", 0, 4], ["filtered air", "OBSERVATION", 5, 17], ["cage", "ANATOMY_MODIFIER", 40, 44], ["air", "OBSERVATION", 61, 64]]], ["Mice are housed in solid bottom cages.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["Static mouse cages are changed at least once a week.", [["mouse", "ORGANISM", 7, 12], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 7, 12], ["Static mouse cages", "TREATMENT", 0, 18]]], ["IVCs are changed at least once every14 days.", [["IVCs", "ANATOMY", 0, 4], ["IVCs", "SIMPLE_CHEMICAL", 0, 4], ["IVCs", "CELL_TYPE", 0, 4], ["IVCs", "TREATMENT", 0, 4]]], ["Certain strains of rodents (e.g., diabetic) are changed into clean cages more frequently as needed.", [["diabetic", "DISEASE", 34, 42], ["rodents", "ORGANISM", 19, 26], ["Certain strains of rodents", "PROBLEM", 0, 26]]], ["Room environment: heating, ventilation and air conditioning performance is routinely assessed as part of facility renovations, system repairs, and at least once every 3 years.", [["ventilation", "TREATMENT", 27, 38], ["air conditioning performance", "TEST", 43, 71], ["system repairs", "TREATMENT", 127, 141]]], ["Each animal room is equipped with a high/low thermo-hygrometer and its own computerized controlled thermostat.", [["a high/low thermo-hygrometer", "TREATMENT", 34, 62]]], ["Animal care staff monitor and record animal provided support in the form of salary for author MH.", [["MH", "DISEASE", 94, 96]]], ["Hepion Pharmaceuticals provided support in the form of salary for authors PM, DU, and RF.", [["Hepion Pharmaceuticals", "TREATMENT", 0, 22], ["DU", "PROBLEM", 78, 80]]], ["These companies provided the drugs and participated in the revision of the manuscript, but did not have any role in the study design, data collection and analysis, or decision to publish the manuscript.", [["the drugs", "TREATMENT", 25, 34], ["the study", "TEST", 116, 125], ["data collection", "TEST", 134, 149], ["analysis", "TEST", 154, 162]]], ["The specific roles of these authors are articulated in the 'author contributions' section.Competing interests:The authors have read the journal's policy and have the following potential competing interests: MH is a paid employee of NeuroVive Pharmaceutical AB (Abliva), and PM, DU, and RF are paid employees of Hepion Pharmaceuticals.", [["MH", "DISEASE", 207, 209], ["Hepion Pharmaceuticals", "TREATMENT", 311, 333]]], ["There are no patents, products in development or marketed products associated with this research to declare.Competing interests:room high/low temperatures and humidity daily on the room activity log.", [["no", "UNCERTAINTY", 10, 12], ["patents", "OBSERVATION", 13, 20], ["low temperatures", "OBSERVATION_MODIFIER", 138, 154]]], ["Temperature settings are consistent with Guide recommendations and are calibrated by the Engineering Department.", [["Temperature settings", "TEST", 0, 20]]], ["Alarm points are set at \u00b1 4\u02daF. High or low temperature alarms are annunciated to the engineer on duty 24 hours a day.", [["Alarm points", "TEST", 0, 12], ["High or low temperature alarms", "PROBLEM", 31, 61], ["low temperature", "OBSERVATION_MODIFIER", 39, 54]]], ["Most of the animal facilities are also equipped with an Edstrom Industries Watchdog environmental monitoring system in addition to the automated building management system (BMS).", [["an Edstrom Industries", "TREATMENT", 53, 74], ["the automated building management system", "TREATMENT", 131, 171]]], ["Humidity levels are not controlled in any of the facilities but are reliably maintained between 30-70% most of the year.", [["Humidity levels", "TEST", 0, 15]]], ["Diet: Food (Teklad LM-485 autoclavable diet) is provided ad libitum to mice in wirebar lids.", [["mice", "ORGANISM", 71, 75], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 71, 75]]], ["Water: our vivarium is equipped with a reverse osmosis (R/O) water purification system and automatic watering distribution system from Edstrom Industries.", [["a reverse osmosis", "TREATMENT", 37, 54], ["water purification system", "TREATMENT", 61, 86], ["automatic watering distribution system", "PROBLEM", 91, 129]]], ["A number of parameters are monitored including conductivity, temperature, pH level and chlorine concentration.", [["chlorine", "CHEMICAL", 87, 95], ["chlorine", "CHEMICAL", 87, 95], ["chlorine", "SIMPLE_CHEMICAL", 87, 95], ["conductivity", "TEST", 47, 59], ["temperature", "TEST", 61, 72], ["pH level", "TEST", 74, 82], ["chlorine concentration", "TREATMENT", 87, 109]]], ["Automatic water delivery systems (room and rack distribution lines) are timed for daily in-line flushing.", [["Automatic water delivery systems", "TREATMENT", 0, 32], ["rack distribution lines", "TREATMENT", 43, 66], ["daily in-line flushing", "TREATMENT", 82, 104]]], ["Quick disconnect drinking valves are sanitized with each cage change or more often if needed.", [["Quick disconnect drinking valves", "TREATMENT", 0, 32]]], ["System sanitation and preventive maintenance is performed by the DAR equipment technicians.Competing interests:Acclimation period: mice are allowed up to 72 hours to stabilize into their new housing environment.", [["mice", "ORGANISM", 131, 135], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135], ["System sanitation", "TREATMENT", 0, 17]]], ["Some experimental paradigms involve examining the behavioral response to novelty and therefore the animal cannot be habituated to the procedure.Competing interests:Animal suffering: In order to minimize suffering, all surgical procedures are carried out under anesthesia using isoflurane (1-4%) in conjunction with ketamine/xylazine ip (90 120 mg/Kg and 10 mg/Kg).", [["isoflurane", "CHEMICAL", 277, 287], ["ketamine", "CHEMICAL", 315, 323], ["xylazine", "CHEMICAL", 324, 332], ["isoflurane", "CHEMICAL", 277, 287], ["ketamine", "CHEMICAL", 315, 323], ["xylazine", "CHEMICAL", 324, 332], ["isoflurane", "SIMPLE_CHEMICAL", 277, 287], ["ketamine", "SIMPLE_CHEMICAL", 315, 323], ["xylazine", "SIMPLE_CHEMICAL", 324, 332], ["Some experimental paradigms", "PROBLEM", 0, 27], ["the procedure", "TREATMENT", 130, 143], ["all surgical procedures", "TREATMENT", 214, 237], ["anesthesia", "TREATMENT", 260, 270], ["isoflurane", "TREATMENT", 277, 287], ["ketamine", "TREATMENT", 315, 323], ["xylazine ip", "TREATMENT", 324, 335]]], ["Mice are monitored every 15 minutes after induction for respiratory and heart rates if the surgical procedure requires more time.", [["respiratory", "ANATOMY", 56, 67], ["heart", "ANATOMY", 72, 77], ["Mice", "ORGANISM", 0, 4], ["heart", "ORGAN", 72, 77], ["Mice", "SPECIES", 0, 4], ["respiratory and heart rates", "PROBLEM", 56, 83], ["the surgical procedure", "TREATMENT", 87, 109], ["heart", "ANATOMY", 72, 77]]], ["Animals are provided buprenorphine (0.05-2.5 mg/Kg s.c.) for 6-12 h followed by flunixine meglumine (2.5 mg/Kg s.c.) as a postoperative analgesic for 2 days post-implantation.", [["buprenorphine", "CHEMICAL", 21, 34], ["flunixine meglumine", "CHEMICAL", 80, 99], ["buprenorphine", "CHEMICAL", 21, 34], ["flunixine meglumine", "CHEMICAL", 80, 99], ["Animals", "ORGANISM", 0, 7], ["buprenorphine", "SIMPLE_CHEMICAL", 21, 34], ["flunixine meglumine", "SIMPLE_CHEMICAL", 80, 99], ["buprenorphine", "TREATMENT", 21, 34], ["flunixine meglumine", "TREATMENT", 80, 99], ["a postoperative analgesic", "TREATMENT", 120, 145]]], ["Mice are observed 2 h, 6 h and 24 h postsurgery with daily monitoring during the course of the study.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["daily monitoring", "TEST", 53, 69], ["the study", "TEST", 91, 100]]], ["Mice are supplied with acidified water supplemented with sulfamethoxazole (or, sulfadiazine) with trimethoprim at a final concentration of 0.65-1.6 mg/mL to reduce chances of opportunistic bacterial colonization.Competing interests:MUP-uPA-SCID/Beige mice were maintained at DAR at TSRI in accordance with protocols approved by the TSRI Ethics Committee, the Institutional Animal Care and Use Committee (Protocol Number: 11-0015).", [["sulfamethoxazole", "CHEMICAL", 57, 73], ["sulfadiazine", "CHEMICAL", 79, 91], ["trimethoprim", "CHEMICAL", 98, 110], ["sulfamethoxazole", "CHEMICAL", 57, 73], ["sulfadiazine", "CHEMICAL", 79, 91], ["trimethoprim", "CHEMICAL", 98, 110], ["Mice", "ORGANISM", 0, 4], ["sulfamethoxazole", "SIMPLE_CHEMICAL", 57, 73], ["sulfadiazine", "SIMPLE_CHEMICAL", 79, 91], ["trimethoprim", "SIMPLE_CHEMICAL", 98, 110], ["MUP-uPA", "GENE_OR_GENE_PRODUCT", 232, 239], ["mice", "ORGANISM", 251, 255], ["MUP", "PROTEIN", 232, 235], ["uPA", "PROTEIN", 236, 239], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 251, 255], ["mice", "SPECIES", 251, 255], ["sulfamethoxazole", "TREATMENT", 57, 73], ["sulfadiazine", "TREATMENT", 79, 91], ["trimethoprim", "TREATMENT", 98, 110], ["opportunistic bacterial colonization", "PROBLEM", 175, 211], ["MUP-uPA", "TREATMENT", 232, 239], ["SCID/Beige mice", "TREATMENT", 240, 255], ["opportunistic bacterial colonization", "OBSERVATION", 175, 211]]], ["This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.", [["This study", "TEST", 0, 10]]], ["The method of sacrifice used for the experimental mice was cervical dislocation.", [["cervical", "ANATOMY", 59, 67], ["cervical dislocation", "DISEASE", 59, 79], ["mice", "ORGANISM", 50, 54], ["cervical", "ORGAN", 59, 67], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["The method of sacrifice", "TREATMENT", 0, 23], ["cervical dislocation", "PROBLEM", 59, 79], ["cervical", "ANATOMY", 59, 67], ["dislocation", "OBSERVATION", 68, 79]]], ["A power calculation was used to determine the sample size (number of mice/group).", [["sample", "ANATOMY", 46, 52], ["mice", "ORGANISM", 69, 73], ["mice", "SPECIES", 69, 73], ["A power calculation", "TEST", 0, 19], ["size", "OBSERVATION_MODIFIER", 53, 57]]], ["10 mice per group were used for each treatment in all experiments.HCV chimeric mouse studyTransgenic mice carrying the uPA gene driven by the major urinary protein promoter were crossed onto a SCID/Beige background (MUP-uPA-SCID/Beige) [31] .", [["urinary", "ANATOMY", 148, 155], ["mice", "ORGANISM", 3, 7], ["HCV", "ORGANISM", 66, 69], ["mouse", "ORGANISM", 79, 84], ["mice", "ORGANISM", 101, 105], ["uPA", "GENE_OR_GENE_PRODUCT", 119, 122], ["MUP-uPA", "GENE_OR_GENE_PRODUCT", 216, 223], ["uPA gene", "DNA", 119, 127], ["major urinary protein promoter", "DNA", 142, 172], ["MUP", "PROTEIN", 216, 219], ["uPA", "PROTEIN", 220, 223], ["mice", "SPECIES", 3, 7], ["mouse", "SPECIES", 79, 84], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 3, 7], ["HCV", "SPECIES", 66, 69], ["mouse", "SPECIES", 79, 84], ["mice", "SPECIES", 101, 105], ["each treatment", "TREATMENT", 32, 46], ["HCV chimeric mouse study", "TEST", 66, 90], ["Transgenic mice carrying the uPA gene", "TREATMENT", 90, 127], ["the major urinary protein promoter", "TREATMENT", 138, 172], ["a SCID/Beige background (MUP-uPA", "TREATMENT", 191, 223], ["urinary protein", "ANATOMY", 148, 163]]], ["These transgenic mice are healthier than former Alb-uPA mice and provide an extended window from age 4 to 12 months for engraftment with human hepatocytes and infection with viral hepatitis viruses derived from serum of infected chimpanzees or from concentrated supernatant of HCV-replicating cell culture [31] .", [["hepatocytes", "ANATOMY", 143, 154], ["serum", "ANATOMY", 211, 216], ["supernatant", "ANATOMY", 262, 273], ["cell", "ANATOMY", 293, 297], ["infection", "DISEASE", 159, 168], ["viral hepatitis viruses", "DISEASE", 174, 197], ["mice", "ORGANISM", 17, 21], ["Alb-uPA", "GENE_OR_GENE_PRODUCT", 48, 55], ["human", "ORGANISM", 137, 142], ["hepatocytes", "CELL", 143, 154], ["viral hepatitis viruses", "ORGANISM", 174, 197], ["serum", "ORGANISM_SUBSTANCE", 211, 216], ["chimpanzees", "ORGANISM", 229, 240], ["HCV", "ORGANISM", 277, 280], ["cell", "CELL", 293, 297], ["Alb", "PROTEIN", 48, 51], ["uPA", "PROTEIN", 52, 55], ["human hepatocytes", "CELL_TYPE", 137, 154], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 56, 60], ["human", "SPECIES", 137, 142], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 56, 60], ["human", "SPECIES", 137, 142], ["HCV", "SPECIES", 277, 280], ["engraftment", "PROBLEM", 120, 131], ["human hepatocytes", "PROBLEM", 137, 154], ["infection", "PROBLEM", 159, 168], ["viral hepatitis viruses", "PROBLEM", 174, 197], ["infected chimpanzees", "PROBLEM", 220, 240], ["HCV", "PROBLEM", 277, 280], ["replicating cell culture", "TEST", 281, 305], ["infection", "OBSERVATION", 159, 168]]], ["MUP-uPA-SCID/Beige mice (gift from A. Kumar) (4 months old) were transplanted with human hepatocytes (10 7 cells/mouse) (we usually obtain~300-500x10 6 hepatocytes per donor, gift from D. Geller) as described previously [31] .", [["hepatocytes", "ANATOMY", 89, 100], ["cells", "ANATOMY", 107, 112], ["hepatocytes", "ANATOMY", 152, 163], ["MUP", "GENE_OR_GENE_PRODUCT", 0, 3], ["uPA", "GENE_OR_GENE_PRODUCT", 4, 7], ["mice", "ORGANISM", 19, 23], ["gift", "ORGANISM", 25, 29], ["A. Kumar", "ORGANISM", 35, 43], ["human", "ORGANISM", 83, 88], ["hepatocytes", "CELL", 89, 100], ["cells", "CELL", 107, 112], ["mouse", "ORGANISM", 113, 118], ["hepatocytes", "CELL", 152, 163], ["MUP", "PROTEIN", 0, 3], ["uPA", "PROTEIN", 4, 7], ["human hepatocytes", "CELL_TYPE", 83, 100], ["mice", "SPECIES", 19, 23], ["human", "SPECIES", 83, 88], ["mouse", "SPECIES", 113, 118], ["mice", "SPECIES", 19, 23], ["human", "SPECIES", 83, 88], ["mouse", "SPECIES", 113, 118], ["human hepatocytes", "TEST", 83, 100], ["hepatocytes", "ANATOMY", 89, 100]]], ["In brief, fresh hepatocytes were transplanted immediately upon arrival within 12-16 hour after isolation.", [["hepatocytes", "ANATOMY", 16, 27], ["hepatocytes", "CELL", 16, 27], ["hepatocytes", "CELL_TYPE", 16, 27], ["hepatocytes", "ANATOMY", 16, 27]]], ["Viable cell counts were determined.", [["cell", "ANATOMY", 7, 11], ["Viable cell", "CELL", 0, 11], ["Viable cell counts", "TEST", 0, 18], ["cell counts", "OBSERVATION", 7, 18]]], ["One cm skin incision was made in the upper left quadrant of the mouse abdomen to visualize the spleen.", [["skin", "ANATOMY", 7, 11], ["left quadrant", "ANATOMY", 43, 56], ["abdomen", "ANATOMY", 70, 77], ["spleen", "ANATOMY", 95, 101], ["skin", "ORGAN", 7, 11], ["mouse", "ORGANISM", 64, 69], ["abdomen", "ORGAN", 70, 77], ["spleen", "ORGAN", 95, 101], ["mouse", "SPECIES", 64, 69], ["mouse", "SPECIES", 64, 69], ["One cm skin incision", "TREATMENT", 0, 20], ["skin", "ANATOMY", 7, 11], ["incision", "OBSERVATION", 12, 20], ["upper", "ANATOMY_MODIFIER", 37, 42], ["left", "ANATOMY_MODIFIER", 43, 47], ["quadrant", "ANATOMY_MODIFIER", 48, 56], ["mouse", "ANATOMY_MODIFIER", 64, 69], ["abdomen", "ANATOMY", 70, 77], ["spleen", "ANATOMY", 95, 101]]], ["Human hepatocytes were injected intra-splenically.", [["hepatocytes", "ANATOMY", 6, 17], ["Human", "ORGANISM", 0, 5], ["hepatocytes", "CELL", 6, 17], ["Human hepatocytes", "CELL_TYPE", 0, 17], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human hepatocytes", "TREATMENT", 0, 17], ["hepatocytes", "ANATOMY", 6, 17]]], ["Incision was then closed with Vetbond tissue adhesive (3M Animal Care Products, St. Paul, MN).", [["tissue", "ANATOMY", 38, 44], ["tissue", "TISSUE", 38, 44], ["Incision", "TREATMENT", 0, 8], ["Vetbond tissue adhesive", "TREATMENT", 30, 53], ["closed", "OBSERVATION", 18, 24], ["Vetbond tissue", "OBSERVATION_MODIFIER", 30, 44], ["adhesive", "OBSERVATION_MODIFIER", 45, 53]]], ["To verify the degree of \"humanization\", blood was weekly collected for human albumin quantification by ELISA (Bethyl Laboratories) according to the manufacturer's protocol.", [["blood", "ANATOMY", 40, 45], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["human", "ORGANISM", 71, 76], ["albumin", "GENE_OR_GENE_PRODUCT", 77, 84], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["human albumin quantification", "TEST", 71, 99], ["the manufacturer's protocol", "TREATMENT", 144, 171]]], ["Mice expressing >300 \u03bcg/mL of human albumin were randomized into groups of 10 mice.", [["Mice", "ORGANISM", 0, 4], ["human", "ORGANISM", 30, 35], ["albumin", "GENE_OR_GENE_PRODUCT", 36, 43], ["mice", "ORGANISM", 78, 82], ["human albumin", "PROTEIN", 30, 43], ["Mice", "SPECIES", 0, 4], ["human", "SPECIES", 30, 35], ["mice", "SPECIES", 78, 82], ["human", "SPECIES", 30, 35], ["mice", "SPECIES", 78, 82], ["human albumin", "TREATMENT", 30, 43]]], ["Note that the expression of the uPA transgene causes damage to the murine liver that is rapidly replaced by clusters of implanted human hepatocytes that can be visualized by human albumin immunostaining [31] .", [["liver", "ANATOMY", 74, 79], ["hepatocytes", "ANATOMY", 136, 147], ["uPA", "GENE_OR_GENE_PRODUCT", 32, 35], ["murine", "ORGANISM", 67, 73], ["liver", "ORGAN", 74, 79], ["human", "ORGANISM", 130, 135], ["hepatocytes", "CELL", 136, 147], ["human", "ORGANISM", 174, 179], ["albumin", "GENE_OR_GENE_PRODUCT", 180, 187], ["uPA transgene", "DNA", 32, 45], ["implanted human hepatocytes", "CELL_TYPE", 120, 147], ["murine", "SPECIES", 67, 73], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 174, 179], ["the uPA transgene", "TREATMENT", 28, 45], ["damage to the murine liver", "PROBLEM", 53, 79], ["implanted human hepatocytes", "PROBLEM", 120, 147], ["human albumin immunostaining", "TEST", 174, 202], ["liver", "ANATOMY", 74, 79], ["implanted human hepatocytes", "OBSERVATION", 120, 147]]], ["MUP-uPA-SCID/Beige mice that had been engrafted with human hepatocytes were infected intravenously (i.v.) with diluted plasma from HCV-infected chimpanzee (100 infectious doses (CID 50 )/mL of genotype 2a HCV) (gift from R. Lanford) or concentrated viruses (genotype 1a, 2a, 3a and 4a) derived from cell culture [16] .", [["hepatocytes", "ANATOMY", 59, 70], ["intravenously", "ANATOMY", 85, 98], ["plasma", "ANATOMY", 119, 125], ["cell", "ANATOMY", 299, 303], ["HCV-infected", "DISEASE", 131, 143], ["MUP", "GENE_OR_GENE_PRODUCT", 0, 3], ["uPA", "GENE_OR_GENE_PRODUCT", 4, 7], ["mice", "ORGANISM", 19, 23], ["human", "ORGANISM", 53, 58], ["hepatocytes", "CELL", 59, 70], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 85, 98], ["plasma", "ORGANISM_SUBSTANCE", 119, 125], ["HCV", "ORGANISM", 131, 134], ["chimpanzee", "ORGANISM", 144, 154], ["HCV", "ORGANISM", 205, 208], ["cell", "CELL", 299, 303], ["MUP", "PROTEIN", 0, 3], ["uPA", "PROTEIN", 4, 7], ["human hepatocytes", "CELL_TYPE", 53, 70], ["mice", "SPECIES", 19, 23], ["human", "SPECIES", 53, 58], ["mice", "SPECIES", 19, 23], ["human", "SPECIES", 53, 58], ["HCV", "SPECIES", 131, 134], ["HCV", "SPECIES", 205, 208], ["R. Lanford", "SPECIES", 221, 231], ["SCID/Beige mice", "TREATMENT", 8, 23], ["human hepatocytes", "TREATMENT", 53, 70], ["HCV", "PROBLEM", 131, 134], ["infected chimpanzee", "TREATMENT", 135, 154], ["genotype 2a HCV)", "PROBLEM", 193, 209], ["concentrated viruses", "PROBLEM", 236, 256], ["cell culture", "TEST", 299, 311], ["SCID", "OBSERVATION", 8, 12]]], ["CRV431 was dissolved in polyethylene glycol 300 molecular weight (PEG-300), NV556 was dissolved in 5% absolute ethanol, 5% Cremophor EL, and 90% sterile saline solution, and sofosbuvir was dissolved in DMSO and subsequently in 95% sterile saline solution.", [["CRV431", "CHEMICAL", 0, 6], ["polyethylene glycol", "CHEMICAL", 24, 43], ["PEG-300", "CHEMICAL", 66, 73], ["NV556", "CHEMICAL", 76, 81], ["ethanol", "CHEMICAL", 111, 118], ["Cremophor EL", "CHEMICAL", 123, 135], ["sofosbuvir", "CHEMICAL", 174, 184], ["DMSO", "CHEMICAL", 202, 206], ["CRV431", "CHEMICAL", 0, 6], ["polyethylene glycol", "CHEMICAL", 24, 43], ["PEG-300", "CHEMICAL", 66, 73], ["NV556", "CHEMICAL", 76, 81], ["ethanol", "CHEMICAL", 111, 118], ["Cremophor", "CHEMICAL", 123, 132], ["sofosbuvir", "CHEMICAL", 174, 184], ["DMSO", "CHEMICAL", 202, 206], ["CRV431", "SIMPLE_CHEMICAL", 0, 6], ["polyethylene glycol", "SIMPLE_CHEMICAL", 24, 43], ["PEG-300", "SIMPLE_CHEMICAL", 66, 73], ["NV556", "SIMPLE_CHEMICAL", 76, 81], ["ethanol", "SIMPLE_CHEMICAL", 111, 118], ["Cremophor EL", "SIMPLE_CHEMICAL", 123, 135], ["saline", "SIMPLE_CHEMICAL", 153, 159], ["sofosbuvir", "SIMPLE_CHEMICAL", 174, 184], ["DMSO", "SIMPLE_CHEMICAL", 202, 206], ["saline", "SIMPLE_CHEMICAL", 239, 245], ["polyethylene glycol", "TREATMENT", 24, 43], ["PEG", "TREATMENT", 66, 69], ["5% absolute ethanol", "TREATMENT", 99, 118], ["5% Cremophor EL", "TREATMENT", 120, 135], ["90% sterile saline solution", "TREATMENT", 141, 168], ["sofosbuvir", "TREATMENT", 174, 184], ["DMSO", "TREATMENT", 202, 206], ["95% sterile saline solution", "TREATMENT", 227, 254]]], ["Drugs were administered once by oral gavage at 50 mg/kg at the indicated time points.", [["oral", "ANATOMY", 32, 36], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["Drugs", "TREATMENT", 0, 5]]], ["Blood was collected retro-orbitally at the indicated time points.Quantification of HCV RNA by Real-Time Reverse Transcription PCRHCV RNA in serum and collected livers was extracted using the acid guanidinium-phenolchloroform method.", [["Blood", "ANATOMY", 0, 5], ["serum", "ANATOMY", 140, 145], ["livers", "ANATOMY", 160, 166], ["acid guanidinium", "CHEMICAL", 191, 207], ["guanidinium-phenolchloroform", "CHEMICAL", 196, 224], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["HCV", "ORGANISM", 83, 86], ["PCRHCV", "GENE_OR_GENE_PRODUCT", 126, 132], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["livers", "ORGAN", 160, 166], ["HCV RNA", "RNA", 83, 90], ["PCRHCV RNA", "RNA", 126, 136], ["HCV", "SPECIES", 83, 86], ["Blood", "TEST", 0, 5], ["HCV RNA", "PROBLEM", 83, 90], ["the acid guanidinium", "TREATMENT", 187, 207], ["phenolchloroform method", "TREATMENT", 208, 231], ["HCV", "OBSERVATION", 83, 86], ["livers", "ANATOMY", 160, 166]]], ["Quantification of HCV RNA was performed using real-time reverse transcription PCR based on TaqMan chemistry, as described previously [32] .CRV431 and NV556 suppress ongoing HCV replication in humanized-liver chimeric miceWe previously demonstrated and reported that two entirely structurally distinct non-immunosuppressive CypIs-the cyclosporin A analog CRV431 and the sanglifehrin analog NV556 (Fig 1) -efficiently inhibit HCV replication in vitro [13, 23] .", [["liver", "ANATOMY", 202, 207], ["CRV431", "CHEMICAL", 139, 145], ["NV556", "CHEMICAL", 150, 155], ["CypIs", "CHEMICAL", 323, 328], ["cyclosporin A", "CHEMICAL", 333, 346], ["CRV431", "CHEMICAL", 354, 360], ["sanglifehrin", "CHEMICAL", 369, 381], ["NV556", "CHEMICAL", 389, 394], ["CRV431", "CHEMICAL", 139, 145], ["NV556", "CHEMICAL", 150, 155], ["cyclosporin A", "CHEMICAL", 333, 346], ["CRV431", "CHEMICAL", 354, 360], ["sanglifehrin", "CHEMICAL", 369, 381], ["NV556", "CHEMICAL", 389, 394], ["HCV", "ORGANISM", 18, 21], ["CRV431", "SIMPLE_CHEMICAL", 139, 145], ["NV556", "SIMPLE_CHEMICAL", 150, 155], ["HCV", "ORGANISM", 173, 176], ["liver", "ORGAN", 202, 207], ["chimeric miceWe", "ORGANISM", 208, 223], ["CypIs", "SIMPLE_CHEMICAL", 323, 328], ["cyclosporin A", "SIMPLE_CHEMICAL", 333, 346], ["CRV431", "SIMPLE_CHEMICAL", 354, 360], ["sanglifehrin", "SIMPLE_CHEMICAL", 369, 381], ["NV556", "SIMPLE_CHEMICAL", 389, 394], ["HCV", "ORGANISM", 424, 427], ["HCV RNA", "RNA", 18, 25], ["HCV", "SPECIES", 18, 21], ["HCV", "SPECIES", 173, 176], ["HCV", "SPECIES", 424, 427], ["HCV RNA", "PROBLEM", 18, 25], ["TaqMan chemistry", "TEST", 91, 107], ["HCV replication", "TREATMENT", 173, 188], ["the cyclosporin A analog CRV431", "TREATMENT", 329, 360], ["the sanglifehrin analog", "TREATMENT", 365, 388], ["HCV replication", "TREATMENT", 424, 439], ["HCV", "OBSERVATION", 18, 21], ["liver", "ANATOMY", 202, 207], ["distinct", "OBSERVATION_MODIFIER", 292, 300], ["non-immunosuppressive CypIs", "OBSERVATION", 301, 328]]], ["The inhibition (nM range) was observed for all HCV genotypes tested [13, 23] .", [["HCV", "SPECIES", 47, 50], ["The inhibition (nM range", "TEST", 0, 24], ["all HCV genotypes", "TEST", 43, 60]]], ["Here, we asked whether CRV431 and NV556 can also reduce HCV replication in vivo.", [["CRV431", "CHEMICAL", 23, 29], ["NV556", "CHEMICAL", 34, 39], ["CRV431", "CHEMICAL", 23, 29], ["NV556", "CHEMICAL", 34, 39], ["CRV431", "GENE_OR_GENE_PRODUCT", 23, 29], ["NV556", "SIMPLE_CHEMICAL", 34, 39], ["HCV", "ORGANISM", 56, 59], ["HCV", "SPECIES", 56, 59], ["HCV replication", "TREATMENT", 56, 71]]], ["To address this possibility, we used a chimeric mouse model, which consists of implanting permissive human hepatocytes into MUP-uPA-SCID/ Beige mice (Fig 1) as developed and described by the Feinstone lab [31] .", [["hepatocytes", "ANATOMY", 107, 118], ["mouse", "ORGANISM", 48, 53], ["human", "ORGANISM", 101, 106], ["hepatocytes", "CELL", 107, 118], ["MUP", "GENE_OR_GENE_PRODUCT", 124, 127], ["uPA", "GENE_OR_GENE_PRODUCT", 128, 131], ["human hepatocytes", "CELL_TYPE", 101, 118], ["MUP", "PROTEIN", 124, 127], ["uPA", "PROTEIN", 128, 131], ["mouse", "SPECIES", 48, 53], ["human", "SPECIES", 101, 106], ["mice", "SPECIES", 144, 148], ["mouse", "SPECIES", 48, 53], ["human", "SPECIES", 101, 106], ["a chimeric mouse model", "TREATMENT", 37, 59], ["implanting permissive human hepatocytes", "TREATMENT", 79, 118], ["Beige mice (Fig", "TREATMENT", 138, 153]]], ["After verifying successful human hepatocyte engraftment by detecting high blood of human albumin (>300 ng/ mL), MUP-uPA-SCID/Beige mice were infected intravenously with HCV.", [["hepatocyte", "ANATOMY", 33, 43], ["blood", "ANATOMY", 74, 79], ["intravenously", "ANATOMY", 150, 163], ["human", "ORGANISM", 27, 32], ["hepatocyte", "CELL", 33, 43], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["human", "ORGANISM", 83, 88], ["albumin", "GENE_OR_GENE_PRODUCT", 89, 96], ["MUP-uPA", "GENE_OR_GENE_PRODUCT", 112, 119], ["mice", "ORGANISM", 131, 135], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 150, 163], ["HCV", "ORGANISM", 169, 172], ["human albumin", "PROTEIN", 83, 96], ["MUP", "PROTEIN", 112, 115], ["uPA", "PROTEIN", 116, 119], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 83, 88], ["mice", "SPECIES", 131, 135], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 83, 88], ["mice", "SPECIES", 131, 135], ["HCV", "SPECIES", 169, 172], ["successful human hepatocyte engraftment", "TREATMENT", 16, 55], ["high blood of human albumin", "PROBLEM", 69, 96], ["MUP-uPA", "TREATMENT", 112, 119], ["SCID/Beige mice", "TREATMENT", 120, 135], ["HCV", "PROBLEM", 169, 172], ["hepatocyte engraftment", "OBSERVATION", 33, 55]]], ["Viral replication was monitored over time by qPCR quantification and CRV431 and NV556 were administered orally at the indicated time points.CRV431 and NV556 suppress ongoing HCV replication in humanized-liver chimeric miceIn vehicle-treated chimeric mice, HCV replicates rapidly and reached a peak of viremia 9 weeks post-infection (Fig 2A) .", [["liver", "ANATOMY", 203, 208], ["CRV431", "CHEMICAL", 69, 75], ["NV556", "CHEMICAL", 80, 85], ["CRV431", "CHEMICAL", 140, 146], ["NV556", "CHEMICAL", 151, 156], ["viremia", "DISEASE", 301, 308], ["CRV431", "CHEMICAL", 69, 75], ["NV556", "CHEMICAL", 80, 85], ["CRV431", "CHEMICAL", 140, 146], ["NV556", "CHEMICAL", 151, 156], ["Viral", "ORGANISM", 0, 5], ["CRV431", "SIMPLE_CHEMICAL", 69, 75], ["NV556", "SIMPLE_CHEMICAL", 80, 85], ["CRV431", "SIMPLE_CHEMICAL", 140, 146], ["NV556", "SIMPLE_CHEMICAL", 151, 156], ["HCV", "ORGANISM", 174, 177], ["liver", "ORGAN", 203, 208], ["chimeric miceIn vehicle", "ORGANISM", 209, 232], ["mice", "ORGANISM", 250, 254], ["HCV", "ORGANISM", 256, 259], ["mice", "SPECIES", 250, 254], ["HCV", "SPECIES", 174, 177], ["mice", "SPECIES", 250, 254], ["HCV", "SPECIES", 256, 259], ["Viral replication", "PROBLEM", 0, 17], ["qPCR quantification", "TEST", 45, 64], ["CRV431", "TEST", 69, 75], ["NV556", "TREATMENT", 80, 85], ["HCV replication in humanized-liver chimeric miceIn vehicle", "TREATMENT", 174, 232], ["HCV", "PROBLEM", 256, 259], ["viremia", "PROBLEM", 301, 308], ["liver", "ANATOMY", 203, 208]]], ["The administration of the NS5B polymerase sofosbuvir (50 mg/ kg) together with HCV (T = 0) totally prevented viral replication in mice (Fig 2C) .", [["sofosbuvir", "CHEMICAL", 42, 52], ["sofosbuvir", "CHEMICAL", 42, 52], ["sofosbuvir", "SIMPLE_CHEMICAL", 42, 52], ["HCV", "ORGANISM", 79, 82], ["mice", "ORGANISM", 130, 134], ["NS5B polymerase", "PROTEIN", 26, 41], ["mice", "SPECIES", 130, 134], ["HCV", "SPECIES", 79, 82], ["mice", "SPECIES", 130, 134], ["the NS5B polymerase sofosbuvir", "TREATMENT", 22, 52], ["HCV (T = 0)", "TREATMENT", 79, 90], ["viral replication", "TREATMENT", 109, 126], ["viral replication", "OBSERVATION", 109, 126]]], ["Similarly, the administration of either CRV431 or NV556 together with the virus completely abolished HCV infection (Fig 2B and 2D ).", [["CRV431", "CHEMICAL", 40, 46], ["NV556", "CHEMICAL", 50, 55], ["HCV infection", "DISEASE", 101, 114], ["CRV431", "CHEMICAL", 40, 46], ["NV556", "CHEMICAL", 50, 55], ["CRV431", "SIMPLE_CHEMICAL", 40, 46], ["NV556", "SIMPLE_CHEMICAL", 50, 55], ["HCV", "ORGANISM", 101, 104], ["HCV", "SPECIES", 101, 104], ["the virus", "PROBLEM", 70, 79], ["HCV infection", "PROBLEM", 101, 114]]], ["Remarkably, CRV431 or NV556 administration (50 mg/kg) 3 or 6 weeks post-infection profoundly inhibited HCV replication 9 or 12 weeks post-infection (Fig 2E and 2F) .", [["CRV431", "CHEMICAL", 12, 18], ["NV556", "CHEMICAL", 22, 27], ["infection", "DISEASE", 72, 81], ["infection", "DISEASE", 138, 147], ["CRV431", "CHEMICAL", 12, 18], ["NV556", "CHEMICAL", 22, 27], ["CRV431", "SIMPLE_CHEMICAL", 12, 18], ["NV556", "SIMPLE_CHEMICAL", 22, 27], ["HCV", "ORGANISM", 103, 106], ["HCV", "SPECIES", 103, 106], ["infection", "PROBLEM", 72, 81], ["HCV replication", "PROBLEM", 103, 118], ["infection", "PROBLEM", 138, 147], ["infection", "OBSERVATION", 72, 81], ["infection", "OBSERVATION", 138, 147]]], ["To our knowledge, no previous studies investigated the inhibitory effect of CypIs in HCV-infected liver-humanized chimeric mice.", [["liver", "ANATOMY", 98, 103], ["CypIs", "CHEMICAL", 76, 81], ["HCV-infected", "DISEASE", 85, 97], ["CypIs", "SIMPLE_CHEMICAL", 76, 81], ["HCV", "ORGANISM", 85, 88], ["liver", "ORGAN", 98, 103], ["mice", "ORGANISM", 123, 127], ["CypIs", "PROTEIN", 76, 81], ["mice", "SPECIES", 123, 127], ["HCV", "SPECIES", 85, 88], ["mice", "SPECIES", 123, 127], ["previous studies", "TEST", 21, 37], ["CypIs", "PROBLEM", 76, 81], ["HCV", "PROBLEM", 85, 88], ["HCV", "OBSERVATION", 85, 88], ["infected", "OBSERVATION", 89, 97], ["liver", "ANATOMY", 98, 103]]], ["Patterns of CRV431 and NV556-mediated viral inhibition were similar to that of sofosbuvir, indicating high potency of the two CypIs.", [["CRV431", "CHEMICAL", 12, 18], ["NV556", "CHEMICAL", 23, 28], ["sofosbuvir", "CHEMICAL", 79, 89], ["CRV431", "CHEMICAL", 12, 18], ["sofosbuvir", "CHEMICAL", 79, 89], ["CRV431", "GENE_OR_GENE_PRODUCT", 12, 18], ["NV556", "GENE_OR_GENE_PRODUCT", 23, 28], ["sofosbuvir", "SIMPLE_CHEMICAL", 79, 89], ["CypIs", "GENE_OR_GENE_PRODUCT", 126, 131], ["CypIs", "PROTEIN", 126, 131], ["CRV431", "TEST", 12, 18], ["NV556", "TEST", 23, 28], ["viral inhibition", "PROBLEM", 38, 54], ["sofosbuvir", "TREATMENT", 79, 89], ["the two CypIs", "PROBLEM", 118, 131], ["sofosbuvir", "OBSERVATION", 79, 89], ["high", "OBSERVATION_MODIFIER", 102, 106], ["potency", "OBSERVATION_MODIFIER", 107, 114], ["two", "OBSERVATION_MODIFIER", 122, 125], ["CypIs", "OBSERVATION", 126, 131]]], ["CRV431-and NV556-mediated inhibitions of HCV RNA levels in livers (collected 12 weeks post-infection) correlate well with those of HCV RNA levels in serum (Fig 2G) , likely reflecting a major neutralization of cyclophilin A in hepatocytes.", [["livers", "ANATOMY", 59, 65], ["serum", "ANATOMY", 149, 154], ["hepatocytes", "ANATOMY", 227, 238], ["CRV431", "CHEMICAL", 0, 6], ["NV556", "CHEMICAL", 11, 16], ["CRV431", "CHEMICAL", 0, 6], ["NV556", "CHEMICAL", 11, 16], ["CRV431", "GENE_OR_GENE_PRODUCT", 0, 6], ["NV556", "SIMPLE_CHEMICAL", 11, 16], ["HCV", "ORGANISM", 41, 44], ["livers", "ORGAN", 59, 65], ["HCV", "ORGANISM", 131, 134], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["cyclophilin A", "GENE_OR_GENE_PRODUCT", 210, 223], ["hepatocytes", "CELL", 227, 238], ["HCV RNA", "RNA", 41, 48], ["HCV RNA", "RNA", 131, 138], ["cyclophilin A", "PROTEIN", 210, 223], ["hepatocytes", "CELL_TYPE", 227, 238], ["HCV", "SPECIES", 41, 44], ["HCV", "SPECIES", 131, 134], ["CRV431", "TEST", 0, 6], ["HCV RNA levels in livers", "PROBLEM", 41, 65], ["HCV RNA levels", "TEST", 131, 145], ["serum", "TEST", 149, 154], ["cyclophilin A in hepatocytes", "PROBLEM", 210, 238], ["HCV", "OBSERVATION", 41, 44], ["livers", "ANATOMY", 59, 65], ["major", "OBSERVATION_MODIFIER", 186, 191], ["neutralization", "OBSERVATION", 192, 206], ["hepatocytes", "ANATOMY", 227, 238]]], ["Human albumin blood levels remained constant over the full period of drug treatments (12 weeks) and among all groups.", [["blood", "ANATOMY", 14, 19], ["Human", "ORGANISM", 0, 5], ["albumin", "GENE_OR_GENE_PRODUCT", 6, 13], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human albumin blood levels", "TEST", 0, 26], ["drug treatments", "TREATMENT", 69, 84]]], ["The CRV431-and NV556-mediated reduction of HCV replication is highly pronounced.", [["NV556", "CHEMICAL", 15, 20], ["CRV431", "GENE_OR_GENE_PRODUCT", 4, 10], ["NV556", "GENE_OR_GENE_PRODUCT", 15, 20], ["HCV", "ORGANISM", 43, 46], ["HCV", "SPECIES", 43, 46], ["The CRV431", "TEST", 0, 10], ["NV556", "TEST", 15, 20], ["HCV replication", "PROBLEM", 43, 58], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["HCV replication", "OBSERVATION", 43, 58], ["highly", "OBSERVATION_MODIFIER", 62, 68], ["pronounced", "OBSERVATION_MODIFIER", 69, 79]]], ["For example, the administration of either CRV431 or NV556 6 weeks post-infection when viral replication is already robust (Fig 2F) suppresses viral loads 12 weeks post-infection (6 weeks post-drug administration) by >100-200-fold.", [["CRV431", "CHEMICAL", 42, 48], ["NV556", "CHEMICAL", 52, 57], ["CRV431", "CHEMICAL", 42, 48], ["NV556", "CHEMICAL", 52, 57], ["viral replication", "PROBLEM", 86, 103], ["robust (Fig 2F)", "TREATMENT", 115, 130], ["viral loads", "PROBLEM", 142, 153]]], ["Specifically, a reduction from 26,231 HCV RNA copies/mL in vehicle-treated mice to 112 and 221 copies/mL in CRV431-and NV556-treated mice, respectively.", [["NV556", "CHEMICAL", 119, 124], ["mice", "ORGANISM", 75, 79], ["CRV431", "SIMPLE_CHEMICAL", 108, 114], ["NV556", "SIMPLE_CHEMICAL", 119, 124], ["mice", "ORGANISM", 133, 137], ["26,231 HCV RNA copies", "RNA", 31, 52], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 133, 137], ["HCV", "SPECIES", 38, 41], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 133, 137], ["a reduction", "PROBLEM", 14, 25], ["CRV431", "TEST", 108, 114], ["reduction", "OBSERVATION_MODIFIER", 16, 25]]], ["Evidently, CRV431-and NV556-mediated suppressions of viral replication 12 weeks post-infection (>100-200-fold or >99% decreases) are statistically significant (Fig 2E and 2F ).", [["CRV431", "CHEMICAL", 11, 17], ["NV556", "CHEMICAL", 22, 27], ["CRV431", "CHEMICAL", 11, 17], ["CRV431", "GENE_OR_GENE_PRODUCT", 11, 17], ["NV556", "SIMPLE_CHEMICAL", 22, 27], ["CRV431", "TEST", 11, 17], ["NV556", "TEST", 22, 27], ["viral replication", "PROBLEM", 53, 70], ["viral replication", "OBSERVATION", 53, 70]]], ["Together these data indicate that the two structurally distinct CypIs-CRV431 and NV556-can totally suppress an established HCV infection in chimeric mice.CRV431 and NV556 suppress ongoing HCV replication in liver-humanized mice independently of the hepatocyte donor originWe then asked whether the suppression of an established HCV infection can be repeated in mice implanted with human hepatocytes derived from several donors.", [["liver", "ANATOMY", 207, 212], ["hepatocyte", "ANATOMY", 249, 259], ["hepatocytes", "ANATOMY", 387, 398], ["CRV431", "CHEMICAL", 70, 76], ["NV556", "CHEMICAL", 81, 86], ["HCV infection", "DISEASE", 123, 136], ["CRV431", "CHEMICAL", 154, 160], ["NV556", "CHEMICAL", 165, 170], ["HCV infection", "DISEASE", 328, 341], ["CRV431", "CHEMICAL", 70, 76], ["NV556", "CHEMICAL", 81, 86], ["CRV431", "CHEMICAL", 154, 160], ["NV556", "CHEMICAL", 165, 170], ["CypIs-CRV431", "SIMPLE_CHEMICAL", 64, 76], ["NV556", "SIMPLE_CHEMICAL", 81, 86], ["HCV", "ORGANISM", 123, 126], ["mice", "ORGANISM", 149, 153], ["CRV431", "SIMPLE_CHEMICAL", 154, 160], ["NV556", "SIMPLE_CHEMICAL", 165, 170], ["HCV", "ORGANISM", 188, 191], ["liver", "ORGAN", 207, 212], ["mice", "ORGANISM", 223, 227], ["hepatocyte", "CELL", 249, 259], ["HCV", "ORGANISM", 328, 331], ["mice", "ORGANISM", 361, 365], ["human", "ORGANISM", 381, 386], ["hepatocytes", "CELL", 387, 398], ["donors", "ORGANISM", 420, 426], ["human hepatocytes", "CELL_TYPE", 381, 398], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 223, 227], ["mice", "SPECIES", 361, 365], ["human", "SPECIES", 381, 386], ["HCV", "SPECIES", 123, 126], ["mice", "SPECIES", 149, 153], ["HCV", "SPECIES", 188, 191], ["mice", "SPECIES", 223, 227], ["HCV", "SPECIES", 328, 331], ["mice", "SPECIES", 361, 365], ["human", "SPECIES", 381, 386], ["NV556", "TEST", 81, 86], ["an established HCV infection", "PROBLEM", 108, 136], ["HCV replication", "TREATMENT", 188, 203], ["the hepatocyte donor originWe", "TREATMENT", 245, 274], ["an established HCV infection", "PROBLEM", 313, 341], ["HCV", "OBSERVATION_MODIFIER", 123, 126], ["infection", "OBSERVATION", 127, 136], ["liver", "ANATOMY", 207, 212], ["hepatocyte", "ANATOMY", 249, 259], ["HCV", "OBSERVATION", 328, 331]]], ["To address this issue, human hepatocytes derived from 3 donors were implanted into MUP-uPA-SCID-Beige mice, which were then infected with HCV, and treated with vehicles, CRV431 and NV556 (50 mg/ kg) six weeks post-infection.", [["hepatocytes", "ANATOMY", 29, 40], ["CRV431", "CHEMICAL", 170, 176], ["NV556", "CHEMICAL", 181, 186], ["CRV431", "CHEMICAL", 170, 176], ["NV556", "CHEMICAL", 181, 186], ["human", "ORGANISM", 23, 28], ["hepatocytes", "CELL", 29, 40], ["donors", "ORGANISM", 56, 62], ["MUP", "GENE_OR_GENE_PRODUCT", 83, 86], ["uPA", "GENE_OR_GENE_PRODUCT", 87, 90], ["mice", "ORGANISM", 102, 106], ["HCV", "ORGANISM", 138, 141], ["CRV431", "SIMPLE_CHEMICAL", 170, 176], ["NV556", "SIMPLE_CHEMICAL", 181, 186], ["human hepatocytes", "CELL_TYPE", 23, 40], ["MUP", "PROTEIN", 83, 86], ["uPA", "PROTEIN", 87, 90], ["human", "SPECIES", 23, 28], ["mice", "SPECIES", 102, 106], ["human", "SPECIES", 23, 28], ["mice", "SPECIES", 102, 106], ["HCV", "SPECIES", 138, 141], ["HCV", "PROBLEM", 138, 141], ["vehicles", "TREATMENT", 160, 168], ["CRV431", "TREATMENT", 170, 176], ["NV556", "TREATMENT", 181, 186]]], ["Blood levels of human albumin were similar between mice implanted with 7x10 6 human hepatocytes derived from the three donors (315 +/-17 ng/mL for donor 1, 352 +/-62 ng/mL for donor 2, and 306 +/-28 ng/mL for donor 3).", [["Blood", "ANATOMY", 0, 5], ["hepatocytes", "ANATOMY", 84, 95], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["human", "ORGANISM", 16, 21], ["albumin", "GENE_OR_GENE_PRODUCT", 22, 29], ["mice", "ORGANISM", 51, 55], ["human", "ORGANISM", 78, 83], ["hepatocytes", "CELL", 84, 95], ["donors", "ORGANISM", 119, 125], ["human albumin", "PROTEIN", 16, 29], ["human hepatocytes", "CELL_TYPE", 78, 95], ["human", "SPECIES", 16, 21], ["mice", "SPECIES", 51, 55], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 16, 21], ["mice", "SPECIES", 51, 55], ["human", "SPECIES", 78, 83], ["Blood levels", "TEST", 0, 12], ["human albumin", "TEST", 16, 29], ["donor", "TEST", 147, 152], ["donor", "TEST", 176, 181]]], ["Thirty mice per donor were randomized in 3 groups (vehicles, CRV431 and NV556 treatments (n = 10 per treatment).", [["CRV431", "CHEMICAL", 61, 67], ["NV556", "CHEMICAL", 72, 77], ["mice", "ORGANISM", 7, 11], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 7, 11], ["CRV431", "TREATMENT", 61, 67], ["NV556 treatments", "TREATMENT", 72, 88]]], ["HCV replicated similarly in vehicles-treated chimeric mice implanted with hepatocytes derived from three donors (Fig 3A) .", [["hepatocytes", "ANATOMY", 74, 85], ["HCV", "ORGANISM", 0, 3], ["mice", "ORGANISM", 54, 58], ["hepatocytes", "CELL", 74, 85], ["donors", "ORGANISM", 105, 111], ["hepatocytes", "CELL_TYPE", 74, 85], ["mice", "SPECIES", 54, 58], ["HCV", "SPECIES", 0, 3], ["mice", "SPECIES", 54, 58], ["HCV", "PROBLEM", 0, 3], ["chimeric mice implanted", "TREATMENT", 45, 68], ["hepatocytes", "ANATOMY", 74, 85]]], ["Importantly, both the administration of CRV431 and NV556 6 weeks post-infection totally suppressed robust ongoing HCV replication 12 weeks post-infections (Fig 3A) .CRV431 and NV556 suppress ongoing HCV replication in liver-humanized mice independently of the hepatocyte donor originThe CRV431-and NV556-mediated inhibitions of HCV replication remain highly pronounced among hepatocyte donors.", [["liver", "ANATOMY", 218, 223], ["hepatocyte", "ANATOMY", 260, 270], ["hepatocyte", "ANATOMY", 375, 385], ["CRV431", "CHEMICAL", 40, 46], ["NV556", "CHEMICAL", 51, 56], ["CRV431", "CHEMICAL", 165, 171], ["NV556", "CHEMICAL", 176, 181], ["CRV431", "CHEMICAL", 40, 46], ["NV556", "CHEMICAL", 51, 56], ["CRV431", "CHEMICAL", 165, 171], ["NV556", "CHEMICAL", 176, 181], ["CRV431", "SIMPLE_CHEMICAL", 40, 46], ["HCV", "ORGANISM", 114, 117], ["CRV431", "GENE_OR_GENE_PRODUCT", 165, 171], ["NV556", "SIMPLE_CHEMICAL", 176, 181], ["HCV", "ORGANISM", 199, 202], ["liver", "ORGAN", 218, 223], ["mice", "ORGANISM", 234, 238], ["hepatocyte", "CELL", 260, 270], ["CRV431", "GENE_OR_GENE_PRODUCT", 287, 293], ["NV556", "GENE_OR_GENE_PRODUCT", 298, 303], ["HCV", "ORGANISM", 328, 331], ["hepatocyte donors", "CELL", 375, 392], ["mice", "SPECIES", 234, 238], ["HCV", "SPECIES", 114, 117], ["HCV", "SPECIES", 199, 202], ["mice", "SPECIES", 234, 238], ["HCV", "SPECIES", 328, 331], ["CRV431", "TREATMENT", 40, 46], ["HCV replication", "TREATMENT", 114, 129], ["HCV replication", "TREATMENT", 199, 214], ["The CRV431", "TEST", 283, 293], ["HCV replication", "TREATMENT", 328, 343], ["liver", "ANATOMY", 218, 223], ["hepatocyte", "ANATOMY", 260, 270], ["HCV", "OBSERVATION", 328, 331]]], ["For example, the administration of either CRV431 or NV556 6 weeks post-infection when viral replication is already robust (Fig 3A) reduces viral loads 12 weeks post-infection (6 weeks post-drug administration) by >150-250-fold.", [["CRV431", "CHEMICAL", 42, 48], ["NV556", "CHEMICAL", 52, 57], ["CRV431", "CHEMICAL", 42, 48], ["NV556", "CHEMICAL", 52, 57], ["viral replication", "PROBLEM", 86, 103], ["viral loads", "PROBLEM", 139, 150]]], ["For donor 1, a reduction from 22,118 HCV RNA copies/mL in vehicle-treated mice to 85 and 133 copies/mL in CRV431-and NV556-treated mice, respectively.", [["NV556", "CHEMICAL", 117, 122], ["vehicle", "SIMPLE_CHEMICAL", 58, 65], ["mice", "ORGANISM", 74, 78], ["CRV431", "SIMPLE_CHEMICAL", 106, 112], ["NV556", "SIMPLE_CHEMICAL", 117, 122], ["mice", "ORGANISM", 131, 135], ["22,118 HCV RNA copies", "RNA", 30, 51], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 131, 135], ["HCV", "SPECIES", 37, 40], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 131, 135], ["a reduction", "TREATMENT", 13, 24], ["CRV431", "TEST", 106, 112]]], ["For donor 2, a reduction from 26,998 HCV RNA copies/mL in vehicle-treated mice to 106 and 159 copies/mL in CRV431and NV556-treated mice, respectively.", [["NV556", "CHEMICAL", 117, 122], ["vehicle", "SIMPLE_CHEMICAL", 58, 65], ["mice", "ORGANISM", 74, 78], ["CRV431and", "SIMPLE_CHEMICAL", 107, 116], ["NV556", "SIMPLE_CHEMICAL", 117, 122], ["mice", "ORGANISM", 131, 135], ["26,998 HCV RNA copies", "RNA", 30, 51], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 131, 135], ["HCV", "SPECIES", 37, 40], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 131, 135], ["a reduction", "TREATMENT", 13, 24]]], ["For donor 3, a reduction from 25,094 HCV RNAFig 2.", [["HCV", "SPECIES", 37, 40], ["a reduction", "TEST", 13, 24], ["HCV RNAFig", "TREATMENT", 37, 47]]], ["CRV431 and NV556 suppress HCV replication in humanized-liver chimeric mice.A-F. MUP-uPA-SCID-Beige mice implanted with fresh human hepatocytes were infected i.v. with diluted plasma from HCVinfected chimpanzee (100 infectious doses (CID 50 )/mL of genotype 2a HCV).", [["liver", "ANATOMY", 55, 60], ["hepatocytes", "ANATOMY", 131, 142], ["plasma", "ANATOMY", 175, 181], ["CRV431", "CHEMICAL", 0, 6], ["NV556", "CHEMICAL", 11, 16], ["CRV431", "CHEMICAL", 0, 6], ["NV556", "CHEMICAL", 11, 16], ["CRV431", "SIMPLE_CHEMICAL", 0, 6], ["NV556", "SIMPLE_CHEMICAL", 11, 16], ["HCV", "ORGANISM", 26, 29], ["liver", "ORGAN", 55, 60], ["mice", "ORGANISM", 70, 74], ["MUP", "GENE_OR_GENE_PRODUCT", 80, 83], ["uPA", "GENE_OR_GENE_PRODUCT", 84, 87], ["mice", "ORGANISM", 99, 103], ["human", "ORGANISM", 125, 130], ["hepatocytes", "CELL", 131, 142], ["plasma", "ORGANISM_SUBSTANCE", 175, 181], ["chimpanzee", "ORGANISM", 199, 209], ["uPA", "PROTEIN", 84, 87], ["human hepatocytes", "CELL_TYPE", 125, 142], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 99, 103], ["human", "SPECIES", 125, 130], ["HCV", "SPECIES", 26, 29], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 99, 103], ["human", "SPECIES", 125, 130], ["HCVinfected chimpanzee", "SPECIES", 187, 209], ["HCV", "SPECIES", 260, 263], ["CRV431", "TEST", 0, 6], ["HCV replication", "TREATMENT", 26, 41], ["Beige mice implanted", "TREATMENT", 93, 113], ["fresh human hepatocytes", "TREATMENT", 119, 142], ["diluted plasma from HCVinfected chimpanzee", "TREATMENT", 167, 209], ["genotype 2a HCV", "PROBLEM", 248, 263], ["liver", "ANATOMY", 55, 60], ["hepatocytes", "ANATOMY", 131, 142]]], ["Drugs (50 mg/kg) were administered orally at the indicated time points.", [["Drugs", "TREATMENT", 0, 5]]], ["CRV431 was dissolved in PEG-300, NV556 in 5% ethanol, 5% Cremophor EL, and 90% saline solution, and sofosbuvir in DMSO and subsequently in 95% saline solution.", [["CRV431", "CHEMICAL", 0, 6], ["PEG-300", "CHEMICAL", 24, 31], ["NV556", "CHEMICAL", 33, 38], ["ethanol", "CHEMICAL", 45, 52], ["Cremophor EL", "CHEMICAL", 57, 69], ["sofosbuvir", "CHEMICAL", 100, 110], ["DMSO", "CHEMICAL", 114, 118], ["CRV431", "CHEMICAL", 0, 6], ["PEG-300", "CHEMICAL", 24, 31], ["NV556", "CHEMICAL", 33, 38], ["ethanol", "CHEMICAL", 45, 52], ["Cremophor", "CHEMICAL", 57, 66], ["sofosbuvir", "CHEMICAL", 100, 110], ["DMSO", "CHEMICAL", 114, 118], ["CRV431", "SIMPLE_CHEMICAL", 0, 6], ["PEG-300", "SIMPLE_CHEMICAL", 24, 31], ["NV556", "SIMPLE_CHEMICAL", 33, 38], ["ethanol", "SIMPLE_CHEMICAL", 45, 52], ["Cremophor EL", "SIMPLE_CHEMICAL", 57, 69], ["saline", "SIMPLE_CHEMICAL", 79, 85], ["sofosbuvir", "SIMPLE_CHEMICAL", 100, 110], ["DMSO", "SIMPLE_CHEMICAL", 114, 118], ["saline", "SIMPLE_CHEMICAL", 143, 149], ["PEG", "TREATMENT", 24, 27], ["ethanol", "TREATMENT", 45, 52], ["5% Cremophor EL", "TREATMENT", 54, 69], ["90% saline solution", "TREATMENT", 75, 94], ["sofosbuvir in DMSO", "TREATMENT", 100, 118], ["95% saline solution", "TREATMENT", 139, 158]]], ["Blood was collected retroorbitally every 3 weeks until week 12 post-HCV infection.", [["Blood", "ANATOMY", 0, 5], ["HCV infection", "DISEASE", 68, 81], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["HCV", "ORGANISM", 68, 71], ["HCV", "SPECIES", 68, 71], ["Blood", "TEST", 0, 5], ["HCV infection", "PROBLEM", 68, 81], ["infection", "OBSERVATION", 72, 81]]], ["For each treatment, 10 mice per group were used.", [["mice", "ORGANISM", 23, 27], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["each treatment", "TREATMENT", 4, 18]]], ["Error bars represent standard deviation (SD) for the 10 mice per group.", [["mice", "ORGANISM", 56, 60], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["standard deviation", "PROBLEM", 21, 39], ["standard deviation", "OBSERVATION", 21, 39]]], ["Statistical analysis was a protected ANOVA with Tukey-Kramer HSD Post-Hoc Test run in R 3.6.3.", [["Statistical analysis", "TEST", 0, 20], ["Test run", "TEST", 74, 82]]], ["G. Same as A except that livers were collected 12 weeks post-infection and HCV RNA levels were quantified as described previously [32] .", [["livers", "ANATOMY", 25, 31], ["G", "GENE_OR_GENE_PRODUCT", 0, 1], ["livers", "ORGAN", 25, 31], ["HCV", "ORGANISM", 75, 78], ["HCV RNA", "RNA", 75, 82], ["HCV", "SPECIES", 75, 78], ["HCV RNA levels", "TEST", 75, 89], ["livers", "ANATOMY", 25, 31]]], ["Data (SD) are expressed as mean of HCV RNA copies per gram of liver collected from 10 mice per treatment.Fig 2.", [["liver", "ANATOMY", 62, 67], ["HCV", "ORGANISM", 35, 38], ["liver", "ORGAN", 62, 67], ["mice", "ORGANISM", 86, 90], ["HCV RNA", "RNA", 35, 42], ["mice", "SPECIES", 86, 90], ["HCV", "SPECIES", 35, 38], ["mice", "SPECIES", 86, 90], ["HCV RNA", "PROBLEM", 35, 42], ["liver", "ANATOMY", 62, 67]]], ["CRV431 and NV556 suppress HCV replication in humanized-liver chimeric mice.https://doi.org/10.1371/journal.pone.0237236.g002 copies/mL in vehicle-treated mice to 97 and 126 copies/mL in CRV431-and NV556-treated mice, respectively.", [["liver", "ANATOMY", 55, 60], ["CRV431", "CHEMICAL", 0, 6], ["NV556", "CHEMICAL", 11, 16], ["NV556", "CHEMICAL", 197, 202], ["CRV431", "CHEMICAL", 0, 6], ["NV556", "CHEMICAL", 11, 16], ["CRV431", "GENE_OR_GENE_PRODUCT", 0, 6], ["NV556", "SIMPLE_CHEMICAL", 11, 16], ["HCV", "ORGANISM", 26, 29], ["liver", "ORGAN", 55, 60], ["mice", "ORGANISM", 154, 158], ["CRV431", "SIMPLE_CHEMICAL", 186, 192], ["NV556", "SIMPLE_CHEMICAL", 197, 202], ["mice", "ORGANISM", 211, 215], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 211, 215], ["HCV", "SPECIES", 26, 29], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 211, 215], ["CRV431", "TEST", 0, 6], ["HCV replication", "TREATMENT", 26, 41], ["CRV431", "TEST", 186, 192], ["liver", "ANATOMY", 55, 60]]], ["We obtained similar profiles of a suppression of viral replications when CRV431 and NV556 were administered 9 or even 12 weeks post-infections (Figs 3B and 4B , respectively).", [["CRV431", "CHEMICAL", 73, 79], ["NV556", "CHEMICAL", 84, 89], ["CRV431", "CHEMICAL", 73, 79], ["NV556", "CHEMICAL", 84, 89], ["viral replications", "TREATMENT", 49, 67], ["CRV431", "TEST", 73, 79]]], ["These data demonstrate that the two totally unrelated structurally CypIs-CRV431 and NV556-suppress ongoing HCV replication in mice with liver reconstituted with human hepatocytes derived three donors.", [["liver", "ANATOMY", 136, 141], ["hepatocytes", "ANATOMY", 167, 178], ["CypIs-CRV431", "GENE_OR_GENE_PRODUCT", 67, 79], ["NV556", "SIMPLE_CHEMICAL", 84, 89], ["HCV", "ORGANISM", 107, 110], ["mice", "ORGANISM", 126, 130], ["liver", "ORGAN", 136, 141], ["human", "ORGANISM", 161, 166], ["hepatocytes", "CELL", 167, 178], ["donors", "ORGANISM", 193, 199], ["NV556", "DNA", 84, 89], ["human hepatocytes", "CELL_TYPE", 161, 178], ["mice", "SPECIES", 126, 130], ["human", "SPECIES", 161, 166], ["HCV", "SPECIES", 107, 110], ["mice", "SPECIES", 126, 130], ["human", "SPECIES", 161, 166], ["These data", "TEST", 0, 10], ["CypIs", "TEST", 67, 72], ["CRV431", "TEST", 73, 79], ["NV556", "TEST", 84, 89], ["ongoing HCV replication", "TREATMENT", 99, 122], ["human hepatocytes", "PROBLEM", 161, 178], ["HCV", "OBSERVATION", 107, 110], ["liver", "ANATOMY", 136, 141]]], ["We observed a similar inhibition of viral replication for different HCV genotypes (GT1a, GT2a, GT3a and GT4a) when CRV431 and NV556 were administered at the peak of viral replication (9 weeks post-infection) (Fig 3B) .", [["CRV431", "CHEMICAL", 115, 121], ["NV556", "CHEMICAL", 126, 131], ["CRV431", "CHEMICAL", 115, 121], ["NV556", "CHEMICAL", 126, 131], ["HCV", "ORGANISM", 68, 71], ["GT1a", "GENE_OR_GENE_PRODUCT", 83, 87], ["GT2a", "GENE_OR_GENE_PRODUCT", 89, 93], ["GT3a", "GENE_OR_GENE_PRODUCT", 95, 99], ["GT4a", "GENE_OR_GENE_PRODUCT", 104, 108], ["NV556", "SIMPLE_CHEMICAL", 126, 131], ["GT1a", "PROTEIN", 83, 87], ["GT2a", "PROTEIN", 89, 93], ["GT3a", "PROTEIN", 95, 99], ["GT4a", "PROTEIN", 104, 108], ["HCV", "SPECIES", 68, 71], ["viral replication", "TREATMENT", 36, 53], ["different HCV genotypes", "TREATMENT", 58, 81], ["GT2a", "TREATMENT", 89, 93], ["CRV431", "TEST", 115, 121], ["NV556", "TREATMENT", 126, 131], ["viral replication", "TREATMENT", 165, 182], ["viral replication", "OBSERVATION", 36, 53], ["viral replication", "OBSERVATION", 165, 182]]], ["This confirms previous studies including ours demonstrating that CypIs-CRV431, NV556 and alisporivir-are pan-genotypic [12-13, 16-19, 23] .Prevention of HCV rebound by CRV431 and NV556 is dose-dependentWe then asked whether CRV431 and NV556 can prevent viral rebound after single dose drug administration.", [["alisporivir", "CHEMICAL", 89, 100], ["HCV", "DISEASE", 153, 156], ["CRV431", "CHEMICAL", 168, 174], ["NV556", "CHEMICAL", 179, 184], ["CRV431", "CHEMICAL", 224, 230], ["NV556", "CHEMICAL", 235, 240], ["CRV431", "CHEMICAL", 71, 77], ["NV556", "CHEMICAL", 79, 84], ["alisporivir", "CHEMICAL", 89, 100], ["CRV431", "CHEMICAL", 168, 174], ["NV556", "CHEMICAL", 179, 184], ["CRV431", "CHEMICAL", 224, 230], ["NV556", "CHEMICAL", 235, 240], ["CypIs-CRV431", "GENE_OR_GENE_PRODUCT", 65, 77], ["NV556", "SIMPLE_CHEMICAL", 79, 84], ["alisporivir", "SIMPLE_CHEMICAL", 89, 100], ["HCV", "ORGANISM", 153, 156], ["CRV431", "SIMPLE_CHEMICAL", 168, 174], ["NV556", "SIMPLE_CHEMICAL", 179, 184], ["CRV431", "SIMPLE_CHEMICAL", 224, 230], ["NV556", "SIMPLE_CHEMICAL", 235, 240], ["HCV", "SPECIES", 153, 156], ["previous studies", "TEST", 14, 30], ["CypIs", "TEST", 65, 70], ["alisporivir", "TEST", 89, 100], ["HCV rebound", "PROBLEM", 153, 164], ["CRV431", "TEST", 168, 174], ["viral rebound", "PROBLEM", 253, 266], ["single dose drug administration", "TREATMENT", 273, 304], ["HCV", "OBSERVATION", 153, 156]]], ["Specifically, HCV-infected chimeric mice received 4 weeks post-infection a single dose of 12.5, 25 and 50 mg/kg of CRV431 or NV556, and viral replication was monitored monthly over a period of 6 months.", [["HCV-infected", "DISEASE", 14, 26], ["CRV431", "CHEMICAL", 115, 121], ["NV556", "CHEMICAL", 125, 130], ["CRV431", "CHEMICAL", 115, 121], ["NV556", "CHEMICAL", 125, 130], ["HCV", "ORGANISM", 14, 17], ["mice", "ORGANISM", 36, 40], ["CRV431", "SIMPLE_CHEMICAL", 115, 121], ["NV556", "SIMPLE_CHEMICAL", 125, 130], ["mice", "SPECIES", 36, 40], ["HCV", "SPECIES", 14, 17], ["mice", "SPECIES", 36, 40], ["HCV", "PROBLEM", 14, 17], ["CRV431", "TREATMENT", 115, 121], ["viral replication", "TREATMENT", 136, 153], ["HCV", "OBSERVATION_MODIFIER", 14, 17], ["infected", "OBSERVATION_MODIFIER", 18, 26], ["viral replication", "OBSERVATION", 136, 153]]], ["We prolonged the period of viral load analysis from 3 months (12 weeks) (Figs 2 and 3) to 6 ( Fig 4A) , 12 ( Fig 4B) and even 15 months (Fig 4C) to permit an eventual occurrence of a viral rebound after an extended period of time after CypI treatment in complementary experimental designs.", [["CypI", "CHEMICAL", 236, 240], ["CypI", "CHEMICAL", 236, 240], ["CypI", "SIMPLE_CHEMICAL", 236, 240], ["viral load analysis", "TEST", 27, 46], ["Figs", "TEST", 73, 77], ["a viral rebound", "PROBLEM", 181, 196], ["CypI treatment", "TREATMENT", 236, 250], ["experimental designs", "OBSERVATION", 268, 288]]], ["Therefore, data in Fig 4 are expressed in \"months post-infection\" rather than \"weeks post-infection\".", [["infection", "DISEASE", 55, 64], ["post-infection", "PROBLEM", 50, 64], ["infection", "OBSERVATION", 55, 64]]], ["In vehicle-treated chimeric mice, viral replication was relatively stable 2 to 6 months post-infection (Fig 4A) .", [["vehicle", "SIMPLE_CHEMICAL", 3, 10], ["mice", "ORGANISM", 28, 32], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["viral replication", "PROBLEM", 34, 51]]], ["A single 12.5 mg/ kg dose of CRV431 or NV556 4 weeks post-infection partially reduced HCV replication 3 months post-drug administration, but viral replication rebound after 5 months (Fig 4A) .", [["CRV431", "CHEMICAL", 29, 35], ["NV556", "CHEMICAL", 39, 44], ["CRV431", "CHEMICAL", 29, 35], ["CRV431", "SIMPLE_CHEMICAL", 29, 35], ["HCV", "ORGANISM", 86, 89], ["HCV", "SPECIES", 86, 89], ["CRV431", "TREATMENT", 29, 35], ["partially reduced HCV replication", "PROBLEM", 68, 101], ["drug administration", "TREATMENT", 116, 135], ["viral replication rebound", "PROBLEM", 141, 166]]], ["A single 25 mg/kg dose of CRV431 or NV556 4 weeks post-infection profoundly suppressed HCV replication 3 months post-drug administration, but viral replication nevertheless rebound after 6 months (Fig 4A) .", [["CRV431", "CHEMICAL", 26, 32], ["NV556", "CHEMICAL", 36, 41], ["CRV431", "CHEMICAL", 26, 32], ["CRV431", "SIMPLE_CHEMICAL", 26, 32], ["HCV", "ORGANISM", 87, 90], ["HCV", "SPECIES", 87, 90], ["CRV431", "TREATMENT", 26, 32], ["HCV replication", "TREATMENT", 87, 102], ["drug administration", "TREATMENT", 117, 136], ["viral replication", "TREATMENT", 142, 159]]], ["In contrast, a single 50 mg/kg dose of CRV431 or NV556 4 weeks post-infection totally suppressed reduced HCV replication 4 months post-drug administration, and most importantly, no viral rebound was observed after 6 months (Fig 4A) .", [["CRV431", "CHEMICAL", 39, 45], ["NV556", "CHEMICAL", 49, 54], ["CRV431", "CHEMICAL", 39, 45], ["CRV431", "SIMPLE_CHEMICAL", 39, 45], ["HCV", "ORGANISM", 105, 108], ["HCV", "SPECIES", 105, 108], ["CRV431", "TREATMENT", 39, 45], ["HCV replication", "TREATMENT", 105, 120], ["drug administration", "TREATMENT", 135, 154], ["viral rebound", "PROBLEM", 181, 194]]], ["These data suggest that a single 50 mg/kg dose suppresses HCV infection in the absence of viral rebound when added 1 month post-infection.Prevention of HCV rebound by CRV431 and NV556 is dose-dependentWe conducted a similar experiment but this time CRV431 and NV556 were added 3 months post-infection when viral replication is maximal and steady (Fig 4B) .", [["HCV infection", "DISEASE", 58, 71], ["HCV", "DISEASE", 152, 155], ["CRV431", "CHEMICAL", 167, 173], ["NV556", "CHEMICAL", 178, 183], ["CRV431", "CHEMICAL", 249, 255], ["NV556", "CHEMICAL", 260, 265], ["CRV431", "CHEMICAL", 167, 173], ["NV556", "CHEMICAL", 178, 183], ["CRV431", "CHEMICAL", 249, 255], ["NV556", "CHEMICAL", 260, 265], ["HCV", "ORGANISM", 58, 61], ["HCV", "ORGANISM", 152, 155], ["CRV431", "SIMPLE_CHEMICAL", 167, 173], ["NV556", "SIMPLE_CHEMICAL", 178, 183], ["NV556", "SIMPLE_CHEMICAL", 260, 265], ["HCV", "SPECIES", 58, 61], ["HCV", "SPECIES", 152, 155], ["HCV infection", "PROBLEM", 58, 71], ["viral rebound", "PROBLEM", 90, 103], ["HCV rebound", "PROBLEM", 152, 163], ["CRV431", "TEST", 167, 173], ["NV556", "TREATMENT", 260, 265], ["viral replication", "PROBLEM", 306, 323], ["infection", "OBSERVATION", 62, 71], ["HCV", "OBSERVATION", 152, 155]]], ["A single low dose of CRV431 or NV556 (25 mg/kg) profoundly reduces viral replication 3 months postdrug administration (6 months post-infection), but again viral rebound occurs 6 months postdrug administration (9 months post-infection) (Fig 4B) .", [["CRV431", "CHEMICAL", 21, 27], ["NV556", "CHEMICAL", 31, 36], ["CRV431", "CHEMICAL", 21, 27], ["NV556", "CHEMICAL", 31, 36], ["CRV431", "SIMPLE_CHEMICAL", 21, 27], ["NV556", "SIMPLE_CHEMICAL", 31, 36], ["A single low dose of CRV431", "TREATMENT", 0, 27], ["NV556", "TREATMENT", 31, 36], ["viral replication", "TREATMENT", 67, 84], ["viral rebound", "PROBLEM", 155, 168]]], ["In contrast, a single high dose of CRV431 or NV556 (50 mg/kg) suppresses viral replication and apparently prevents viral rebound even 9 months post-drug administration (12 months post-infection) (Fig 4B) .", [["CRV431", "CHEMICAL", 35, 41], ["NV556", "CHEMICAL", 45, 50], ["CRV431", "CHEMICAL", 35, 41], ["NV556", "CHEMICAL", 45, 50], ["CRV431", "SIMPLE_CHEMICAL", 35, 41], ["NV556", "SIMPLE_CHEMICAL", 45, 50], ["a single high dose of CRV431", "TREATMENT", 13, 41], ["NV556", "TREATMENT", 45, 50], ["viral replication", "TREATMENT", 73, 90], ["viral rebound", "PROBLEM", 115, 128]]], ["To exclude the possibility that the viral rebound observed after a single low dose of CRV431 or A. MUP-uPA-SCID-Beige mice implanted with fresh human hepatocytes derived from three distinct donors were infected i.v. with diluted plasma from HCV-infected chimpanzee (100 infectious doses (CID 50 )/mL of genotype 2a HCV).", [["hepatocytes", "ANATOMY", 150, 161], ["plasma", "ANATOMY", 229, 235], ["CRV431", "CHEMICAL", 86, 92], ["HCV-infected", "DISEASE", 241, 253], ["CRV431", "SIMPLE_CHEMICAL", 86, 92], ["A. MUP-", "ORGANISM", 96, 103], ["uPA", "GENE_OR_GENE_PRODUCT", 103, 106], ["-SCID-Beige mice", "ORGANISM", 106, 122], ["human", "ORGANISM", 144, 149], ["hepatocytes", "CELL", 150, 161], ["donors", "ORGANISM", 190, 196], ["plasma", "ORGANISM_SUBSTANCE", 229, 235], ["HCV", "ORGANISM", 241, 244], ["chimpanzee", "ORGANISM", 254, 264], ["uPA", "PROTEIN", 103, 106], ["human hepatocytes", "CELL_TYPE", 144, 161], ["mice", "SPECIES", 118, 122], ["human", "SPECIES", 144, 149], ["mice", "SPECIES", 118, 122], ["human", "SPECIES", 144, 149], ["HCV", "SPECIES", 241, 244], ["chimpanzee", "SPECIES", 254, 264], ["HCV", "SPECIES", 315, 318], ["the viral rebound", "PROBLEM", 32, 49], ["a single low dose of CRV431", "TREATMENT", 65, 92], ["SCID", "PROBLEM", 107, 111], ["Beige mice implanted", "TREATMENT", 112, 132], ["fresh human hepatocytes", "TREATMENT", 138, 161], ["HCV", "PROBLEM", 241, 244], ["infected chimpanzee", "TREATMENT", 245, 264], ["genotype 2a HCV", "PROBLEM", 303, 318], ["exclude the possibility", "UNCERTAINTY", 3, 26]]], ["Drugs (50 mg/kg) were administered orally 6 weeks post-infection.", [["Drugs", "TREATMENT", 0, 5]]], ["CRV431 was dissolved in PEG-300 and NV556 in 5% ethanol, 5% Cremophor EL.", [["CRV431", "CHEMICAL", 0, 6], ["PEG-300", "CHEMICAL", 24, 31], ["NV556", "CHEMICAL", 36, 41], ["ethanol", "CHEMICAL", 48, 55], ["Cremophor EL", "CHEMICAL", 60, 72], ["CRV431", "CHEMICAL", 0, 6], ["PEG-300", "CHEMICAL", 24, 31], ["NV556", "CHEMICAL", 36, 41], ["ethanol", "CHEMICAL", 48, 55], ["Cremophor", "CHEMICAL", 60, 69], ["CRV431", "SIMPLE_CHEMICAL", 0, 6], ["PEG-300", "SIMPLE_CHEMICAL", 24, 31], ["NV556", "SIMPLE_CHEMICAL", 36, 41], ["ethanol", "SIMPLE_CHEMICAL", 48, 55], ["Cremophor EL", "SIMPLE_CHEMICAL", 60, 72], ["PEG", "TREATMENT", 24, 27]]], ["Blood was collected retro-orbitally every 3 weeks until week 12 post-HCV infection.", [["Blood", "ANATOMY", 0, 5], ["HCV infection", "DISEASE", 69, 82], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["HCV", "ORGANISM", 69, 72], ["HCV", "SPECIES", 69, 72], ["Blood", "TEST", 0, 5], ["HCV infection", "PROBLEM", 69, 82], ["infection", "OBSERVATION", 73, 82]]], ["B. Same as A except that chimeric mice were infected with concentrated HCV (100 infectious doses (CID 50 )/mL) from different GT (GT1a (H77), GT2a (J6/JFH-1), GT3a (S52) and GT4a (ED43)) [16] and drugs were administered 9 weeks post-infection.", [["mice", "ORGANISM", 34, 38], ["HCV", "ORGANISM", 71, 74], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 34, 38], ["HCV", "SPECIES", 71, 74], ["concentrated HCV", "TREATMENT", 58, 74], ["different GT (GT1a (H77)", "TREATMENT", 116, 140], ["GT2a (J6/JFH", "TREATMENT", 142, 154], ["drugs", "TREATMENT", 196, 201]]], ["Blood was collected retro-orbitally every 3 weeks until week 15 post-infection.", [["Blood", "ANATOMY", 0, 5], ["infection", "DISEASE", 69, 78], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood", "TEST", 0, 5], ["infection", "PROBLEM", 69, 78], ["infection", "OBSERVATION", 69, 78]]], ["Data (SD) are expressed in HCV RNA copies per mL of serum.", [["serum", "ANATOMY", 52, 57], ["HCV", "ORGANISM", 27, 30], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["HCV RNA", "RNA", 27, 34], ["HCV", "SPECIES", 27, 30], ["serum", "TEST", 52, 57]]], ["For each treatment, 10 mice per group were used (n = 10).", [["mice", "ORGANISM", 23, 27], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["each treatment", "TREATMENT", 4, 18]]], ["Asterisks indicate statistical significance (P less than 0.00001) in comparison to vehicles group at the same time point as determined by one-way ANOVA with post-hoc multiple comparisons tests (Tukey).Prevention of HCV rebound by CRV431 and NV556 is dose-dependenthttps://doi.org/10.1371/journal.pone.0237236.g003 NV556 (25 mg/kg) (Fig 4B) results from CRV431-and NV556-resistant variants, a second low dose of CRV431 or NV556 (25 mg/kg) was administered when viral rebound is maximal (9 months post-single dose administration or 12 months post-infection) (Fig 4C) .", [["HCV", "DISEASE", 215, 218], ["CRV431", "CHEMICAL", 230, 236], ["NV556", "CHEMICAL", 241, 246], ["NV556", "CHEMICAL", 314, 319], ["CRV431", "CHEMICAL", 353, 359], ["NV556", "CHEMICAL", 364, 369], ["CRV431", "CHEMICAL", 411, 417], ["NV556", "CHEMICAL", 421, 426], ["CRV431", "CHEMICAL", 230, 236], ["NV556", "CHEMICAL", 241, 246], ["CRV431", "CHEMICAL", 353, 359], ["NV556", "CHEMICAL", 364, 369], ["CRV431", "CHEMICAL", 411, 417], ["NV556", "CHEMICAL", 421, 426], ["HCV", "ORGANISM", 215, 218], ["CRV431", "SIMPLE_CHEMICAL", 230, 236], ["NV556", "SIMPLE_CHEMICAL", 241, 246], ["CRV431", "SIMPLE_CHEMICAL", 353, 359], ["NV556", "SIMPLE_CHEMICAL", 364, 369], ["CRV431", "SIMPLE_CHEMICAL", 411, 417], ["NV556", "SIMPLE_CHEMICAL", 421, 426], ["HCV", "SPECIES", 215, 218], ["CRV431", "SPECIES", 411, 417], ["HCV rebound", "PROBLEM", 215, 226], ["CRV431", "TEST", 230, 236], ["CRV431", "TEST", 353, 359], ["NV556", "TEST", 364, 369], ["a second low dose of CRV431", "TREATMENT", 390, 417], ["NV556", "TREATMENT", 421, 426], ["viral rebound", "PROBLEM", 460, 473], ["single dose administration", "TREATMENT", 500, 526], ["HCV", "OBSERVATION", 215, 218]]], ["The second low dose of CRV431 and NV556 for a second time profoundly reduces viral replication, suggesting that the first viral rebound unlikely originated from CRV431-or NV556-resistant escape variants but rather from the residual pool of wild-type viruses.", [["CRV431", "CHEMICAL", 23, 29], ["NV556", "CHEMICAL", 34, 39], ["CRV431", "CHEMICAL", 161, 167], ["NV556", "CHEMICAL", 171, 176], ["CRV431", "CHEMICAL", 23, 29], ["NV556", "CHEMICAL", 34, 39], ["CRV431", "SIMPLE_CHEMICAL", 23, 29], ["CRV431", "GENE_OR_GENE_PRODUCT", 161, 167], ["NV556", "GENE_OR_GENE_PRODUCT", 171, 176], ["wild-type viruses", "ORGANISM", 240, 257], ["The second low dose of CRV431", "TREATMENT", 0, 29], ["viral replication", "TREATMENT", 77, 94], ["the first viral rebound", "PROBLEM", 112, 135], ["CRV431", "TEST", 161, 167], ["resistant escape variants", "PROBLEM", 177, 202], ["type viruses", "PROBLEM", 245, 257], ["viral replication", "OBSERVATION", 77, 94], ["escape variants", "OBSERVATION", 187, 202], ["type viruses", "OBSERVATION", 245, 257]]], ["This is in accordance with previous studies including ours [16] [17] [18] [19] that CypI present a high barrier to the development of viral resistance.DiscussionAlthough a majority of DAAs-treated patients achieve virological cure, HCV resistance to DAAs has a crucial role in the failure of pIFNa-free treatment regimens.", [["CypI", "CHEMICAL", 84, 88], ["DAAs", "CHEMICAL", 184, 188], ["DAAs", "CHEMICAL", 250, 254], ["pIFNa", "CHEMICAL", 292, 297], ["DAAs", "CHEMICAL", 184, 188], ["[16] [17] [18] [19]", "SIMPLE_CHEMICAL", 59, 78], ["CypI", "SIMPLE_CHEMICAL", 84, 88], ["DAAs", "SIMPLE_CHEMICAL", 184, 188], ["patients", "ORGANISM", 197, 205], ["HCV", "ORGANISM", 232, 235], ["DAAs", "SIMPLE_CHEMICAL", 250, 254], ["pIFNa", "SIMPLE_CHEMICAL", 292, 297], ["patients", "SPECIES", 197, 205], ["HCV", "SPECIES", 232, 235], ["previous studies", "TEST", 27, 43], ["viral resistance", "PROBLEM", 134, 150], ["DAAs", "TREATMENT", 184, 188], ["virological cure", "TREATMENT", 214, 230], ["HCV resistance", "PROBLEM", 232, 246], ["DAAs", "TREATMENT", 250, 254], ["pIFNa", "TREATMENT", 292, 297], ["free treatment regimens", "TREATMENT", 298, 321], ["viral resistance", "OBSERVATION", 134, 150], ["failure", "OBSERVATION", 281, 288]]], ["The presence of viral variants resistant to NS5A inhibitors at baseline is associated with lower rates of HCV cure in certain groups of patients, such as those with genotype 1a or 3, those with cirrhosis, and/or prior non-responders to pIFNa-based regimens [33] .", [["cirrhosis", "DISEASE", 194, 203], ["pIFNa", "CHEMICAL", 236, 241], ["NS5A", "GENE_OR_GENE_PRODUCT", 44, 48], ["patients", "ORGANISM", 136, 144], ["pIFNa", "SIMPLE_CHEMICAL", 236, 241], ["NS5A", "PROTEIN", 44, 48], ["patients", "SPECIES", 136, 144], ["HCV", "SPECIES", 106, 109], ["viral variants", "PROBLEM", 16, 30], ["NS5A inhibitors", "TREATMENT", 44, 59], ["HCV cure", "PROBLEM", 106, 114], ["cirrhosis", "PROBLEM", 194, 203], ["pIFNa-based regimens", "TREATMENT", 236, 256], ["viral variants", "OBSERVATION", 16, 30], ["HCV", "OBSERVATION", 106, 109], ["cirrhosis", "OBSERVATION", 194, 203]]], ["DAA-resistant HCV variants represent the main cause of virological failure.", [["DAA", "CHEMICAL", 0, 3], ["DAA", "SIMPLE_CHEMICAL", 0, 3], ["HCV", "ORGANISM", 14, 17], ["HCV", "SPECIES", 14, 17], ["DAA", "TEST", 0, 3], ["resistant HCV variants", "PROBLEM", 4, 26], ["virological failure", "PROBLEM", 55, 74], ["resistant", "OBSERVATION_MODIFIER", 4, 13], ["HCV variants", "OBSERVATION", 14, 26], ["main", "OBSERVATION_MODIFIER", 41, 45], ["virological failure", "OBSERVATION", 55, 74]]], ["Viruses resistant to protease inhibitors disappear from blood in a few weeks to months, while NS5A inhibitor-resistant viruses remain for years [33] .", [["blood", "ANATOMY", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["NS5A", "GENE_OR_GENE_PRODUCT", 94, 98], ["Viruses", "PROBLEM", 0, 7], ["protease inhibitors", "TREATMENT", 21, 40], ["NS5A inhibitor", "TREATMENT", 94, 108], ["resistant viruses", "PROBLEM", 109, 126]]], ["Re-treatment options are available, but first-line treatment strategies should be optimized to efficiently prevent treatment failure due to HCV resistance [33] .", [["HCV", "ORGANISM", 140, 143], ["HCV", "SPECIES", 140, 143], ["Re-treatment options", "TREATMENT", 0, 20], ["first-line treatment strategies", "TREATMENT", 40, 71], ["treatment failure", "PROBLEM", 115, 132], ["HCV resistance", "PROBLEM", 140, 154]]], ["The failure of one regimen does not imply that the patient cannot be cured from HCV infection since another scheme is always applied, and if it fails (which is very rare), a third one can be used.", [["HCV infection", "DISEASE", 80, 93], ["patient", "ORGANISM", 51, 58], ["HCV", "ORGANISM", 80, 83], ["patient", "SPECIES", 51, 58], ["HCV", "SPECIES", 80, 83], ["The failure", "PROBLEM", 0, 11], ["one regimen", "TREATMENT", 15, 26], ["HCV infection", "PROBLEM", 80, 93], ["failure", "OBSERVATION", 4, 11], ["HCV", "OBSERVATION_MODIFIER", 80, 83], ["infection", "OBSERVATION", 84, 93]]], ["So according to our current knowledge, the existence of multiple regimens allows clearance of infection from any patient.", [["infection", "DISEASE", 94, 103], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["multiple regimens", "TREATMENT", 56, 73], ["infection", "PROBLEM", 94, 103], ["infection", "OBSERVATION", 94, 103]]], ["One of these regimens may include an additional class of drugs with high barrier resistance and with mechanisms of antiviral action distinct from current DAAs.", [["DAAs", "SIMPLE_CHEMICAL", 154, 158], ["these regimens", "TREATMENT", 7, 21], ["drugs", "TREATMENT", 57, 62], ["high barrier resistance", "TREATMENT", 68, 91], ["antiviral action", "TREATMENT", 115, 131], ["current DAAs", "TREATMENT", 146, 158], ["high barrier resistance", "OBSERVATION_MODIFIER", 68, 91], ["antiviral", "OBSERVATION", 115, 124]]], ["We previously demonstrated that the in vitro combination of CypI with NS5A inhibitors provides additive to synergistic anti-HCV activity without detectable cross-resistance [16] .", [["CypI", "CHEMICAL", 60, 64], ["CypI", "SIMPLE_CHEMICAL", 60, 64], ["NS5A", "GENE_OR_GENE_PRODUCT", 70, 74], ["CypI", "PROTEIN", 60, 64], ["NS5A", "PROTEIN", 70, 74], ["CypI with NS5A inhibitors", "TREATMENT", 60, 85], ["synergistic anti-HCV activity", "TREATMENT", 107, 136]]], ["The new in vivo data presented in this study suggest that such a class of drug candidates are the CypIs.", [["CypIs", "GENE_OR_GENE_PRODUCT", 98, 103], ["CypIs", "PROTEIN", 98, 103], ["this study", "TEST", 34, 44], ["the CypIs", "PROBLEM", 94, 103], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Specifically, we showed that a single administration of CRV431 or NV556 (50 mg/kg) when viral replication is robust and well established in humanized-liver MUP-uPA-SCID-Beige mice drastically suppressed viral replication.", [["liver", "ANATOMY", 150, 155], ["CRV431", "CHEMICAL", 56, 62], ["NV556", "CHEMICAL", 66, 71], ["CRV431", "CHEMICAL", 56, 62], ["NV556", "CHEMICAL", 66, 71], ["CRV431", "SIMPLE_CHEMICAL", 56, 62], ["NV556", "SIMPLE_CHEMICAL", 66, 71], ["liver", "ORGAN", 150, 155], ["MUP", "GENE_OR_GENE_PRODUCT", 156, 159], ["uPA", "GENE_OR_GENE_PRODUCT", 160, 163], ["mice", "ORGANISM", 175, 179], ["uPA", "PROTEIN", 160, 163], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["a single administration of CRV431", "TREATMENT", 29, 62], ["NV556", "TREATMENT", 66, 71], ["viral replication", "TREATMENT", 88, 105], ["Beige mice drastically suppressed viral replication", "TREATMENT", 169, 220], ["liver", "ANATOMY", 150, 155]]], ["We obtained similar results for HCV genotype 1a, 2a, 3a and 4a.", [["HCV genotype 1a", "ORGANISM", 32, 47], ["HCV genotype 1a, 2a, 3a and 4a", "PROTEIN", 32, 62], ["HCV", "SPECIES", 32, 35]]], ["Importantly, a single high dose of CRV431 or NV556 (50 mg/kg) prevents viral rebound even after 9 months post-single dose CypI administration, suggesting a high barrier to the development of viral resistance.", [["CRV431", "CHEMICAL", 35, 41], ["NV556", "CHEMICAL", 45, 50], ["CypI", "CHEMICAL", 122, 126], ["CRV431", "CHEMICAL", 35, 41], ["NV556", "CHEMICAL", 45, 50], ["CypI", "CHEMICAL", 122, 126], ["CRV431", "SIMPLE_CHEMICAL", 35, 41], ["NV556", "SIMPLE_CHEMICAL", 45, 50], ["CypI", "SIMPLE_CHEMICAL", 122, 126], ["CRV431", "TREATMENT", 35, 41], ["NV556", "TREATMENT", 45, 50], ["viral rebound", "PROBLEM", 71, 84], ["single dose CypI administration", "TREATMENT", 110, 141], ["viral resistance", "PROBLEM", 191, 207], ["viral resistance", "OBSERVATION", 191, 207]]], ["Supporting this hypothesis, we found that when viral rebound occurs when using a single low dose of CypI (25 mg/kg), the virus remains sensitive to a second low dose of CypI.", [["CypI", "CHEMICAL", 100, 104], ["CypI", "CHEMICAL", 169, 173], ["CypI", "CHEMICAL", 100, 104], ["CypI", "CHEMICAL", 169, 173], ["CypI", "SIMPLE_CHEMICAL", 100, 104], ["CypI", "SIMPLE_CHEMICAL", 169, 173], ["CypI", "PROTEIN", 169, 173], ["viral rebound", "PROBLEM", 47, 60], ["a single low dose of CypI", "TREATMENT", 79, 104], ["the virus", "PROBLEM", 117, 126], ["a second low dose of CypI", "TREATMENT", 148, 173]]], ["Thus, these data together with previous work [16] [17] [18] [19] indicate that CypI display a high barrier to the development of viral resistance.DiscussionCRV431 and NV556 exhibit apparent low toxicity in vivo.", [["CypI", "CHEMICAL", 79, 83], ["DiscussionCRV431", "CHEMICAL", 146, 162], ["NV556", "CHEMICAL", 167, 172], ["toxicity", "DISEASE", 194, 202], ["NV556", "CHEMICAL", 167, 172], ["[16] [17] [18] [19]", "SIMPLE_CHEMICAL", 45, 64], ["CypI", "SIMPLE_CHEMICAL", 79, 83], ["NV556", "SIMPLE_CHEMICAL", 167, 172], ["CypI", "PROTEIN", 79, 83], ["viral resistance", "PROBLEM", 129, 145], ["apparent low toxicity in vivo", "PROBLEM", 181, 210], ["viral resistance", "OBSERVATION", 129, 145], ["low toxicity", "OBSERVATION", 190, 202]]], ["Indeed, we found that a daily oral administration of a high dose of CRV431 or NV556 (50 mg/kg) for extended periods of time (i.e., 14 to 30 weeks treatment) in mice did not induce unanticipated side effects [34] [35] [36] .", [["oral", "ANATOMY", 30, 34], ["CRV431", "CHEMICAL", 68, 74], ["NV556", "CHEMICAL", 78, 83], ["CRV431", "CHEMICAL", 68, 74], ["NV556", "CHEMICAL", 78, 83], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["CRV431", "SIMPLE_CHEMICAL", 68, 74], ["NV556", "SIMPLE_CHEMICAL", 78, 83], ["mice", "ORGANISM", 160, 164], ["mice", "SPECIES", 160, 164], ["mice", "SPECIES", 160, 164], ["a high dose of CRV431", "TREATMENT", 53, 74], ["NV556", "TREATMENT", 78, 83]]], ["This is in accordance with previous work conducted in humans that showed that a daily administration of the CypI alisporivir alone or in combination with ribavirin in HCV-infected patients in phase I, II, and III studies did not induce significant adverse effects [16] [17] [18] [19] [20] [21] [22] .DiscussionOur recent work that show that both CRV431 and NV556 significantly decrease the development of liver fibrosis and hepatocellular carcinoma in non-alcoholic steatohepatitis mouse models [34] [35] [36] , our present data suggest that the two entirely structurally different CypIs-CRV431 and NV556-derived from unrelated natural products, represent attractive partners to current DAA regimens for the treatment of hepatitis C and liver diseases.", [["liver", "ANATOMY", 405, 410], ["hepatocellular carcinoma", "ANATOMY", 424, 448], ["liver", "ANATOMY", 737, 742], ["CypI", "CHEMICAL", 108, 112], ["alisporivir", "CHEMICAL", 113, 124], ["ribavirin", "CHEMICAL", 154, 163], ["HCV-infected", "DISEASE", 167, 179], ["CRV431", "CHEMICAL", 346, 352], ["NV556", "CHEMICAL", 357, 362], ["liver fibrosis", "DISEASE", 405, 419], ["hepatocellular carcinoma", "DISEASE", 424, 448], ["non-alcoholic steatohepatitis", "DISEASE", 452, 481], ["CRV431", "CHEMICAL", 588, 594], ["NV556", "CHEMICAL", 599, 604], ["hepatitis C", "DISEASE", 721, 732], ["liver diseases", "DISEASE", 737, 751], ["alisporivir", "CHEMICAL", 113, 124], ["ribavirin", "CHEMICAL", 154, 163], ["CRV431", "CHEMICAL", 346, 352], ["NV556", "CHEMICAL", 357, 362], ["CRV431", "CHEMICAL", 588, 594], ["humans", "ORGANISM", 54, 60], ["CypI", "SIMPLE_CHEMICAL", 108, 112], ["alisporivir", "SIMPLE_CHEMICAL", 113, 124], ["ribavirin", "SIMPLE_CHEMICAL", 154, 163], ["HCV", "ORGANISM", 167, 170], ["patients", "ORGANISM", 180, 188], ["[16] [17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 264, 298], ["CRV431", "SIMPLE_CHEMICAL", 346, 352], ["NV556", "SIMPLE_CHEMICAL", 357, 362], ["liver", "ORGAN", 405, 410], ["hepatocellular carcinoma", "CANCER", 424, 448], ["mouse", "ORGANISM", 482, 487], ["CypIs", "GENE_OR_GENE_PRODUCT", 582, 587], ["CRV431", "GENE_OR_GENE_PRODUCT", 588, 594], ["NV556", "SIMPLE_CHEMICAL", 599, 604], ["hepatitis C", "ORGANISM", 721, 732], ["liver", "ORGAN", 737, 742], ["NV556", "PROTEIN", 599, 604], ["humans", "SPECIES", 54, 60], ["patients", "SPECIES", 180, 188], ["mouse", "SPECIES", 482, 487], ["humans", "SPECIES", 54, 60], ["HCV", "SPECIES", 167, 170], ["mouse", "SPECIES", 482, 487], ["hepatitis C", "SPECIES", 721, 732], ["the CypI alisporivir", "TREATMENT", 104, 124], ["ribavirin", "TREATMENT", 154, 163], ["HCV", "PROBLEM", 167, 170], ["III studies", "TEST", 209, 220], ["significant adverse effects", "PROBLEM", 236, 263], ["liver fibrosis", "PROBLEM", 405, 419], ["hepatocellular carcinoma", "PROBLEM", 424, 448], ["non-alcoholic steatohepatitis mouse models", "PROBLEM", 452, 494], ["CypIs", "TEST", 582, 587], ["CRV431", "TEST", 588, 594], ["NV556", "TEST", 599, 604], ["current DAA regimens", "TREATMENT", 679, 699], ["hepatitis C", "PROBLEM", 721, 732], ["liver diseases", "PROBLEM", 737, 751], ["liver", "ANATOMY", 405, 410], ["fibrosis", "OBSERVATION", 411, 419], ["hepatocellular", "ANATOMY", 424, 438], ["carcinoma", "OBSERVATION", 439, 448], ["natural products", "OBSERVATION", 628, 644], ["hepatitis", "OBSERVATION", 721, 730], ["liver", "ANATOMY", 737, 742], ["diseases", "OBSERVATION", 743, 751]]]]}